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Glossary 
Amphiphile Chemical compound possessing both hydrophilic and hydrophobic 
properties. 
Biosurfactant Surfactant produced from renewable resources 
Bolaamphiphile Amphiphilic compounds which contain two hydrophilic parts 
linked by a hydrophobic linker. 
Compaction (of pDNA) Formation of a complex between pDNA and a liposomal 
formulation. 
Charge ratio (CR) Term used in transfection experiments to indicate the number of 
positive charges provided by the cationic lipid derivative divided 
by the number of positive charges carried by the pDNA. 
Critical micelle concentration 
(CMC) 
Lowest concentration of surfactants for which micelles are 
formed. 
Fermentation Bioconversion where yeast or bacteria convert certain substrates 
(mostly sugars) into other compounds such as for example 
ethanol, lactic acid or sophorolipids. 
Guinier analysis Method to calculate the particle size of micelles in SAXS analysis. 
In vitro Studies performed with micro-organisms, cells or biological 
molecules outside their biological context. 
In vivo Studies performed with whole living organisms. 
Liposomal formulation Aggregation of amphiphiles into spherical vesicles. 
Lipoplex Complex between pDNA and a liposomal formulation. 
Minimum bactericidal 
concentration (MBC) 
The lowest concentration of test compound in antimicrobial 
evaluation at which no more viability of the test organism can be 
observed; indication of microbial death. 
Minimum inhibitory 
concentration (MIC) 
The lowest concentration of test compound in antimicrobial 
evaluation for which a lack of visible bacterial growth is observed; 
indication of microbial growth inhibition. 
SAXS analysis Small-angle scattering technique where the scattering of X-rays by 
a sample of self-assembled aggregates is recorded at very low 
angles to obtain information on the shape and size of the 
aggregates. 
Surfactant Chemical compound possessing both hydrophilic and hydrophobic 
properties that can lower the surface or interfacial tension. 
Supramolecular aggregate Well defined complex of molecules held together by noncovalent 
bonds. 
Transfection The process of introducing nucleic acids (DNA) into cells. 
Transmission electron 
microscopy (TEM) 
Microscopic technique to visualize small objects (nm scale) by 
transmitting a beam of electrons through a very thin sample. 
Wilhelmy plate method Measurement of the surface tension of a solution with a thin, 
rectangular plate which has optimal wetting properties. 
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1. Introduction and goals 
In the last decades, the transition towards a bio-based economy has been initiated. This transition 
focusses on the use of renewable resources and sustainable technologies as replacements for the 
classical, fossil based chemical industry.1-4 In view of the agreements made at the COP21 conference 
on climate change in Paris (November 2015) which resulted in the first-ever universal, legally binding 
climate deal, this transition is becoming more urgent than before. 
For the further development of a bio-based economy, the implementation of biorefineries will play 
an important role in the future.5-8 Biorefineries focus on the complete utilization and conversion of 
biomass into a variety of valuable products. The production of transportation fuels is seen as the 
driving force for the development of biorefinery units and the accessibility of new chemical platform 
molecules. Therefore, biorefineries mostly combine the production of high-volume transportation 
fuels with the production of low-volume chemicals with a higher added-value. For example, an 
increased production of biodiesel will result in an increased supply of the by-product glycerol. To 
date, the conversion of biomass and its implementation in a biorefinery still faces a lot of challenges. 
The biggest bottleneck is the economic viability of the generated products which can often hardly 
compete with fossil based alternatives, certainly with the current low oil prices of 50 $/barrel. Other 
problems which should be dealt with are related to transport and seasonal variability of biomass.1 
At present, only 8% of all the chemicals produced in Europe are based on renewable resources.9 
Although the application of renewable resources is not a new concept, this mostly comprises the use 
of simple resources or unpurified products for the production of low added-value products such as 
plastics, detergents, surfactants, paper and textile. The application of renewable resources in high 
added-value products, often having a complex structure, faces much more challenges since multiple 
reaction steps are needed to obtain the desired products. When renewable resources are used for 
the production of high-added value products, they are mostly broken down into low molecular 
weight base-chemicals which are subsequently used as building blocks for the synthesis of more 
complex compounds. Due to the high price of these renewable base-chemicals, they can hardly 
compete with fossil based products for high added-value applications. However, these high added-
value applications offer the best perspective for the succesfull implementation of biorefineries. 
When renewable resources with a complex structure would directly be used as building blocks for 
chemical derivatization, the number of reaction steps and the associated production cost can be 
drastically reduced. This approach makes optimal use of the high complexity inherent to these 
compounds and the high oxidation state they already possess. The most critical points to develop an 
economical viable synthesis pathway are the purity and quantity of the renewable feedstock. 
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In this respect, sophorolipid biosurfactants can be regarded as excellent renewable resources for 
chemical derivatization. They are glycolipid biosurfactants, produced by different yeast species via 
fermentation of renewable resources.10-11 Starmerella bombicola is the preferred production 
organism, for which a production up to 400 g/L was reported.10 Sophorolipids consist of sophorose as 
hydrophilic head and a fatty acid (mostly oleic acid) as lipid tail, which gives them an amphiphilic 
character. Sophorolipids lower the surface tension of water from 72.8 to 30-40 mN/m and have a 
critical micelle concentration of 40-100 mg/L.10 Their emulsifying properties can be applied for the 
recovery of oil and hydrocarbons and for the decontamination of soil and water.12-17 Microbial 
production results in the formation of different sophorolipid derivatives with diacetylated C18:1 
sophorolipid lactone 1 and C18:1 sophorolipid acid 2 being the major fermentation compounds 
(Figure 1). Natural sophorolipids possess interesting biological activities, such as anti-cancer, 
antimicrobial, dermatological, immunoregulatory, spermicidal and antiviral activities.18-19 Besides, 
they possess self-assembly properties which results in the formation of nanostructures with 
supramolecular chirality.20-21 Selective production of specific sophorolipid lactone or acid derivatives 
can be obtained with genetically modified S. bombicola strains.22 When feeding pure hydrophobic 
substrates to these modified strains, production of one single sophorolipid derivative can be 
obtained.23 
 
Figure 1. Diacetylated sophorolipid lactone 1 and sophorolipid acid 2 
The incorporation of sophorolipid production in current biorefineries is feasible since they can be 
produced from waste streams such as biodiesel by-product streams.11 However, fermentations using 
these cheap substrates will result in lower yields and a more heterogeneous product compared to 
fermentations using glucose and oleic acid. Therefore, when sophorolipids are considered as building 
blocks for chemical derivatization, the production facility should have as main focus the production 
of sophorolipids and not transportation fuels. 
Sophorolipids are considered as one of the most promising classes of biosurfactants, mainly due to 
their production as a homogenous product in high quantity.10, 24 In contrast to the first generation 
biosurfactants, such as the alkylpolyglucosides (APGs) which are produced chemically from 
renewable resources, sophorolipids belong to the second generation biosurfactants which are 
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produced biotechnologically by micro-organisms. This offers the advantage that they contain a rare 
hydrophilic head (sophorose) in combination with a specific chirality in the lipid tail and at the 
anomeric positions, both features which are not easily accessible via chemical synthesis. The second 
generation biosurfactants include amongst others phospholipids, surfactin, emulsan and other 
glycolipids such as rhamnolipids, trehalose lipids, cellobiose lipids and mannosylerythritol lipids. 
Interest in sophorolipids exponentially increased over the last 20 years, reaching up to 600 citations 
in 2013, 2014 and 2015 (Figure 2). To date, natural sophorolipids are commercialized by different 
companies world-wide. The Japanese company Saraya and the Belgian company Ecover apply 
sophorolipids in their laundry, dishwashing and cleaning products while the former French company 
Soliance, now part of the Swiss company Givaudan, and the Korean company MG Intobio offer 
respectively the products Sopholiance S and Sopholine for cosmetic applications.22 Other companies 
working on the industrial production of sophorolipids are Evonik, DSM and Croda.22, 25 
 
Figure 2. Number of publications (A) and citations (B) per year on sophorolipids. These data 
was retrieved from the Web of Science database with the term “Sophorolipid” as key-word. 
Unfortunately, several disadvantages restrict the application potential of the natural sophorolipids. 
First of all, their production cost is estimated at 2 to 5 €/kg although an up-to-date production price 
is not communicated by the companies.10 Secondly, the sophorolipid microbial production pathway 
limits the fatty acid incorporation to C16 or C18 hydrophobic substrates. This selectivity originates 
from the specificity of the hydroxylation step of the hydrophobic substrates and can be circumvented 
by using already hydroxylated substrates or stearic acid-like substrates for the production of shorter-
chain derivatives.26 For example, the microbial production of C12 sophorolipid compounds was 
successfully accomplished using 12-hydroxydodecanoic acid, 1-dodecanol or 1,12-dodecanediol.26-27 
Secondary alcohols can be used as well, but only the (S)-enantiomers will be incorporated in the 
sophorolipid product. This was confirmed by fermentations using ricinoleic acid having an 
(R)-hydroxyl function, which was not included in the sophorolipid structure.11 
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Chemical modification offers the opportunity to extend the limited set of microbial derivatives to 
other high-added value sectors, in particular the pharmaceutical sector. Compared to the other 
second generation biosurfactants, sophorolipids offer several advantages as building blocks for 
chemical modification towards high-added value products. Sophorolipids are produced by a 
non-pathogenic yeast, in contrast to the rhamnolipids which are produced by the pathogen 
Pseudomonas aeruginosa. Moreover, sophorolipids can be produced in high quantity, in contrast to 
most of the other glycolipids, and the production of one homogenous compound can be 
accomplished, in contrast to the phospholipids. 
At present, chemical and enzymatic modifications of sophorolipids have been mostly limited to the 
sugar head or the lipid tail.19 Cleavage of the double bond, however, has only been described for the 
synthesis of short-chained sophorolipid acids or in ring-opening cross-metathesis reactions.28-29 It was 
never included in a synthetic pathway for the production of a functionalized building block towards 
modified derivatives. 
The goal of this research project is the synthesis of a wide range of innovative sophorolipid 
derivatives with optimized surface-active properties and biological activities by combining the 
fermentation technology with chemical derivatization (Scheme 1). In view of the high production cost 
of the microbialy produced sophorolipids, application of the modified derivatives as detergents will 
not be feasible. Therefore, it is the aim for this project to synthesize innovative derivatives with a 
high added-value which can be applied in the pharmaceutical sector where they can be economically 
competitive. 
 
Scheme 1. Retrosynthetic scheme for the synthesis of innovative sophorolipid derivatives 
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A first goal of this research project is the synthesis of functionalized sophorolipid building blocks 3 
with focus on the synthesis of a sophorolipid aldehyde intermediate. Therefore, an ozonolysis 
reaction will be performed to transform the double bond into a reactive site. This modification will 
reduce the chain length of the sophorolipid derivatives which will increase their hydrophilic 
character. 
A second goal of this research project is the transformation of the sophorolipid building blocks 3 into 
a broad library of innovative sophorolipid derivatives. On the one hand, a nitrogen functionality will 
be introduced. This offers the opportunity to synthesize a whole range of nitrogen containing 
sophorolipid derivatives 4 such as sophorolipid amines, sophorolipid quaternary ammonium salts and 
sophorolipid amine oxides. All these derivatives can possess cationic surfactant properties, 
depending on the pH of the solution which can have a great influence on their solubility and 
biological activity. On the other hand, the sophorolipid building blocks 3 can be used for the synthesis 
of a new class of sophorolipid bolaamphiphiles 5. These compounds contain two hydrophilic parts 
linked by a hydrophobic linker and they can be used for the formation of stable liposomes and 
vesicles. Therefore, they offer perspectives for targeted drug delivery. 
For each class of derivatives, a lot of attention will be payed to the evaluation of their surface-active 
properties and biological activities. All derivatives will be evaluated on their antimicrobial activities 
against both Gram-positive and Gram-negative bacteria. Their self-assembly properties will be 
assessed via the measurement of their critical micelle concentration (CMC) and via small-angle X-ray 
scattering (SAXS) analysis. The derivatives which possess a permanent positive charge will be 
evaluated on their suitability as gene delivery vectors. 
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2. State of the art: Chemical and enzymatic modification of 
sophorolipids 
2.1. Production of natural sophorolipids 
Sophorolipids are produced by a selected number of yeast species.10-11, 30 They were first described by 
Gorin et al. in the early 1960s as an extracellular glycolipid produced by Candida apicola, formerly 
known as Torulopsis apicola. Other producing strains comprise Rhodotorula bogoriensis (formerly 
known as Candida bogoriensis), Starmerella bombicola (formerly known as Torulopsis bombicola and 
Candida bombicola) and Wickerhamiella domericqiae. Starmerella bombicola is the best known and 
preferred producing strain with a production yield of more than 400 g/L. The sophorolipid 
biosynthesis starts with glucose as the hydrophilic carbon source and fatty acids, fatty acid methyl 
esters, triglycerides or alkanes as the hydrophobic carbon source (Scheme 2). All hydrophobic carbon 
sources are converted into fatty acids, which contain in general 16 or 18 carbon atoms with one or 
more double bonds. When no hydrophobic carbon source is present in the fermentation medium, 
fatty acids can be formed de novo via the acetyl-CoA pathway. The fatty acids are subsequently 
oxidized at the terminal () or subterminal (-1) position by a cytochrome P450 monooxygenase 
enzyme. The resulting hydroxylated fatty acids are -glycosidically linked to a first glucose molecule 
at the 1’-position by a glycosyltransferase I. A second glucose molecule is linked to the 2’-position of 
the first one by a glycosyltransferase II, yielding sophorolipid acid 2. Subsequently, the carbohydrate 
head can be acetylated at the 6’- and/or 6”-position by an acetyl-CoA dependent acetyl transferase. 
After excretion in the fermentation medium, lactonization can occur at the 4”-position by an 
extracellular esterase.31 The major microbial product is the diacetylated, -1 hydroxylated, mono-
unsaturated sophorolipid lactone 1. 
Most sophorolipid fermentations are run at a temperature between 25 to 30°C and a pH of 3.5. 
Sophorolipid synthesis starts in the stationary phase under nitrogen-limiting conditions and is very 
dependent on good aeration conditions. The highest yields are obtained when both a hydrophilic and 
a hydrophobic carbon source are present, but fermentation on only one type of carbon source is 
possible. After the fermentation, sophorolipids are extracted with ethyl acetate and washed with 
hexane to remove residual fatty acids. On larger scale, physical separation methods such as 
centrifugation are applied for the isolation. Lactonic sophorolipids were also purified by 
crystallization.32 
The biggest bottleneck for the sophorolipid production process is the variability in the composition of 
the fermentation product. To optimize chemical modification procedures, one single compound is 
preferred as starting compound. If this is not the case, problems can arise along the modification 
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pathway. For example, in the synthesis of sophorolipid alkyl esters via alkaline alcoholysis of 
di-acetylated sophorolipid lactone, the products are precipitated in water after reaction. In some 
cases, precipitation does not occur, possibly due to the presence of a considerable fraction of 
sophorolipid acids or residual fatty acids. Therefore, it is of utmost importance to have access to 
selective organisms for the fermentation process or suitable purification procedures to obtain the 
desired sophorolipid compounds in high purity.22, 33 
 
Scheme 2. Biosynthesis of sophorolipid derivatives 
2.2. Physiological activity 
2.2.1. Biodegradability and toxicity 
The biodegradability of sophorolipids was determined via biological oxygen demand studies and the 
manometric respirometry method (OECD 301C and 301F method).11, 34 They can be classified as 
readily biodegradable since 61% of the product was degraded after only 8 days of cultivation. The 
aquatic toxicity is subdivided in acute and chronic toxicity. The acute toxicity is determined as the 
EC50 after 48 h on Daphnia magna, Tetrahymena thermophila and Pseudokirchneriella subcaptitata. 
State of the art   
8 
 
This EC50 proved to be ten times higher as compared to conventional surfactants.
11, 35 The chronic 
toxicity was determined via a reproduction test on Daphnia magna. The no-observed-effect 
concentration (NOEC) was 11.3 µg/mL, which is also ten times higher as compared to conventional 
surfactants.35 The cytotoxicity was determined by the MTT method with human epidermal 
keratinocytes, displaying a lower cytotoxicity for sophorolipids than for surfactin, arthrofactin, 
pluronic L31, sodium dodecyl sulfate and polyoxyethylene lauryl ether.34 The cytotoxicity was also 
evaluated on normal Chang liver cells, displaying an IC50 value of 81900 µg/mL for crude 
sophorolipids and a higher cell viability for acidic sophorolipids compared to lactonic ones.36 
Sophorolipids are not irritating to skin and eyes, have an oral safety level which is greater than or 
equal to 5 mL/kg body weight and cause no allergic reactions.37 
2.2.2. Dermatological activity 
Sophorolipids inhibit elastase activity, the enzyme which is responsible for the degradation of elastin 
fibres, at a concentration of 50000 µg/mL and also inhibits radical effects towards the hydroxy-
radical at a concentration of 830 µg/mL.37 Diacetylated sophorolipid lactones stimulate the 
metabolism of skin dermis fibroblast cells and hereby the in vitro neosynthesis of collagen.38 
Therefore, they possess restructuring and tissue repairing activity which is higher as compared to 
crude sophorolipid mixtures. Besides moisturizing and skin-conditioning properties, sophorolipid 
lactones proved active to eliminate dandruff.39 Moreover, sophorolipids possess desquamating, 
depigmenting and melanogenesis inhibiting activity.40 The desquamation is achieved by detachment 
of the corneocytes and offers opportunities for the use of sophorolipids against acne and as an anti-
wrinkle product. Sophorolipids induce the secretion of leptin by adipocytes, hereby inducing the 
lipolysis of adipocytes and reducing the subcutaneous deposition of fat.41 
2.2.3. Antimicrobial activity 
Diacetylated sophorolipid lactones synthesized by Starmerella bombicola inhibited the growth of 
Candida, Pichia, Debaryomyces, Saccharomycopsis and Lodderomyces yeasts on n-alkanes.42 Natural 
sophorolipids also inhibited the growth of Candida albicans, Candida Antarctica and Candida 
tropicalis with respectively 30, 32 and 25% at a concentration of 5000 µg/mL, while the inhibition 
with sophorolipid acids was respectively 24, 45 and 40%.43 Kulakovskaya et al. determined the 
minimum inhibitory concentrations (MIC) of sophorolipids against Filobasidiella neoformans, Candida 
tropicalis and Candida albicans as respectively 1000, 15000 and 15000 µg/mL.44 The antibacterial 
activity of sophorolipids against Rhodococcus erythropolis, Bacillus subtilis, Staphylococcus 
epidermidis, Streptococcus agalactiae, Moraxella sp., Pseudomonas putida, Enterobacter aerogenes 
and Escherichia coli was evaluated, displaying a higher activity against Gram-positive bacteria than 
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Gram-negative bacteria.45 The activity was expressed as minimum lethal doses (MLD50) and was 
98 µg/mL for R. erythropolis, B. subtilis, S. agalactiae and Moraxella sp., and >6250 µg/mL for 
S. epidermis, P. putida, E. aerogenes and E. coli. Kulakovskaya et al. determined the MIC values of 
sophorolipids against E. coli, Streptococcus salivarius and Micrococcus luteus as respectively 32000, 
23000 and 23000 mg/mL.44 More antimicrobial activities against other species are described in a 
patent by Gross and Shah.46 Overall, sophorolipid lactones perform better than sophorolipid acids, 
with the lowest MIC values of 10 µg/mL for sophorolipid lactones against Bacillus subtilis and 
Rhodococcus rhodochrous. Sleiman et al. evaluated MIC values of different sophorolipid derivatives 
in sucrose and ethanol vehicles against Escherichia coli and Staphylococcus aureus.47 No significant 
inhibitory activity was observed for most derivatives at a concentration of 512 µg/mL and against S. 
aureus at a concentration of 218 µg/mL for two derivatives in an ethanol vehicle. The antibacterial 
activity of lauryl alcohol based sophorolipids was also evaluated against E. coli and S. aureus, 
respectively displaying a zero percent survival at 3000 µg/mL after 2 h and at 600 µg/mL after 4 h.48 
Both crude and acidic sophorolipids inhibited the growth of Cupriavidus necator and Bacillus subtilis 
at a concentration of 50000 µg/mL.49 They also disrupted biofilms of B. subtilis and a mixed culture of 
B. subtilis and S. aureus at a concentration of 50000 µg/mL. Synergistic effects were observed for 
administration of sophorolipids with the antibiotics tetracycline and cefaclor against respectively S. 
aureus and E. coli.50 Sophorolipids inhibited the motility of the harmful algae Alexandrium 
tamarense, Heterosigma akashiwo and Cochlodinium polykrikoides at concentrations of 10-20 
µg/mL.51 At these concentrations, sophorolipids have low adverse effects on the non-harmful 
microalgae Platymonas helgolandica var. tsingtaoensis, Isochrysis galbana and Nitzschia closterium f. 
minutissima.52 The EC50 for the zooplankton Strombidium sp., Calanus sinicus and Neomysis 
awatschensis was respectively 20, 50 and 150 µg/mL after 96 h. The EC50 for the zooplankton Artemia 
salina was 600 µg/mL after 24 h. The fish Lateolabrax japonicas and Paralichthys olivaceus displayed 
an EC50 of respectively 60 and 110 µg/mL and the relative clearance rate of the mussel Mytilus edulis 
decreased to 80% at a sophorolipid concentration of 20 µg/mL. Synergistic effects were observed for 
the combination of sophorolipids and loess on the motility inhibition and removal of the harmful 
algae C. polykrikoides and A. tamarense.53 It can be concluded that sophorolipids display no 
significant antibacterial activity against clinically relevant bacteria, but are effective in the inhibition 
of harmful algae in concentrations which are not detrimental to most of the tested organisms. 
2.2.4. Anticancer activity 
Sophorolipids induced differentiation of human acute promyelocytic leukemia cell line HL60.54 At a 
concentration of 10 µg/mL, the proliferation of the HL60 cells and the protein kinase C activity was 
inhibited after 2 days and differentiation into monocytes took place. For two other leukemic cell 
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lines, the human myelogenous leukemia cell line K562 and the human basophilic leukemia cell line 
KU812, differentiation into megakaryocytes was also induced at a sophorolipid concentration of 15 
µg/mL. Chen et al. evaluated the anticancer activity of diacetylated sophorolipid lactone on liver 
cancer cell line H7402, lung cancer cell line A549 and leukemia cell lines HL60 and K562 via an MTT 
assay.55 The cell proliferation of all four cell lines was inhibited at concentrations ranging up to 
62.5 µg/mL after 2 days with 0% cell viability at concentrations exceeding 62.5 µg/mL. The 
mechanism of anticancer activity on the liver cancer cell line H7402 was identified as apoptosis.56 The 
condensation of chromatin, nuclear fragmentation and appearance of apoptotic bodies was 
observed. At a sophorolipid concentration of 50 µg/mL, cell viability of both liver cancer cell line 
H7402 and lung cancer cell line A549 was completely inhibited while only a little decrease was 
observed for the normal liver cell lines HL7702 and Chang liver. The anticancer activity of 
diacetylated sophorolipid lactone and sophorolipid acid against human pancreatic cancer cells was 
also evaluated.57 A decreasing cytotoxicity of respectively 40.3 to 3.4% and 49 to 0% was observed 
with increasing concentration from 500 to 2000 µg/mL. No cytotoxicity was observed against healthy 
peripheral blood mononuclear cells. Shao et al. described the anticancer activity of different 
sophorolipid derivatives against the esophageal cancer cell lines KYSE109 and KYSE450.58 
Diacetylated sophorolipid lactone displayed the highest activity with complete inhibition of both cell 
lines at a concentration of 30 µg/mL. The anticancer activity depended on the acetylation and 
unsaturation degree of the derivatives. No inhibition was observed for acidic sophorolipids. 
Evaluation of the anticancer activity on MDA-MB-321 breast cancer cell line demonstrated a higher 
activity for sophorolipid lactones compared to sophorolipid acids, with IC50 values of respectively 
15-20 and 80 µg/mL.59 Sophorolipids also induce differentiation in LN-229 glioma cell lines.60 
Morphological changes were detected at concentrations of 10 µg/mL and 0.4 µg/mL for respectively 
oleic acid and linolenic acid based sophorolipids. 
2.2.5. Immunoregulatory activity 
Sophorolipids possess a pro-inflammatory activity by activating macrophages to induce the release of 
cytokines.40 They also promote wound healing due to the proliferative effect of these cytokines on 
the fibroblasts, the phagocytosis of bacteria, cells and cellular fragments which could obstruct the 
wound by macrophages and their fibrinolytic activity. Sophorolipids can reduce septic shock related 
mortality by inhibition of the nitrogen oxide production of macrophages and modulation of the 
inflammatory response.61 Experiments were performed in in vivo rat models with intravenous and 
intraperitoneal administration of Nembutal to induce septic shock. The survival rate after 36 h with 
and without addition of 5 mg/kg natural sophorolipid mixture was respectively 81.8 and 47.8% for 
the intervenous administration and 67 and 53% for the intraperitoneal administration. Macrophages 
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which were in vitro cultured with lipopolysaccharides showed reduced nitrogen oxide production and 
induced expression of several cytokines. The viability of these macrophages also increased from 56 to 
66% and from 23 to 36% after respectively 36 and 48 h.62 Moreover, sophorolipids at a concentration 
of 100 µg/mL decreased the IgE production in U266 myeloma cells with 63%.63 The effect of dosing 
was evaluated in the in vivo rat models.64 When a single dose was administered, survival increased 
with 28 and 42% after respectively 24 and 72 h while survival increased with 39 and 26% for 
sequential dosing after respectively 24 and 72 h. Increased mortality was observed for treatment 
with purified diacetylated sophorolipids lactone. Sophorolipids also reduced asthma severity in an in 
vivo asthma model with mice, which was demonstrated on the basis of decreased leukocytic infiltrate 
in the lungs and decreased levels of ovalbumin specific IgE in the bronchoalveolar lavage fluid.65 
2.2.6. Spermicidal and antiviral activity 
Sophorolipids are active as spermicidal and antiviral agents.66-67 Natural mixture sophorolipids and 
sophorolipid lactones displayed a minimum effective concentration of respectively 800 and 1000 
µg/mL after 30 seconds of incubation. Sophorolipids at a concentration of 300 µg/mL immobilized 
spermatozoa completely and irreversibly after 2 minutes. Immobilization occurred faster than death 
and the mechanism of action is most likely membrane perturbation and disruption. Sophorolipids 
also displayed some degree of anti-HIV activity, with sophorolipid acids being more potent than 
sophorolipid lactones. Natural mixture sophorolipids and sophorolipid lactones exerted high 
cytotoxicity against human vaginal cells with a 50% effective concentration around 15 µg/mL, while 
sophorolipid acids displayed a 50% effective concentration higher than 100 µg/mL. Natural mixture 
sophorolipids and sophorolipid lactones also induced the production of pro-inflammatory cytokines 
by vaginal epithelial cells. Sophorolipids also displayed anti-herpes virus activity for which the 
Epstein-Bar virus was used as a model organism.68 The EC50 values for diacetylated sophorolipid 
lactone and sophorolipid acid were respectively 37.5 and 79.1 µg/mL (25.8 and 49.2 µM). 
2.3. Modifications in the context of structural characterization 
The first modifications of sophorolipids produced by Candida magnoliae (formerly known as 
Torulopsis magnoliae) are described by Gorin et al. in the context of the characterization of this class 
of biosurfactants (Scheme 3).69 In a first step, the crude sophorolipid product was transformed into 
unsaturated sophorolipid acid 2 and saturated sophorolipid acid 13 through removal of the acetyl 
groups with sodium methoxide. Acid methanolysis of sophorolipid acids 2 and 13 resulted in the 
cleavage of fatty acid methyl esters 14 and 15 which were separated via fractional crystallization. The 
saturated methyl ester 15 was oxidized with chromium trioxide into 17-oxo-stearic acid 16, which 
enabled the determination of the hydroxyl position. The unsaturated methyl ester 14 was oxidized 
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with potassium permanganate and sodium periodate into azelaic acid 17 and 8-hydroxy-pelargonic 
acid 18, which enabled the determination of the double bond. Unsaturated sophorolipid acid 2, on 
the other hand, was oxidized with performic acid followed by alkaline methanolysis into the threo-
9,10-dihydroxy sophorolipid 19. Subsequent oxidation with lead(IV) acetate and reduction with 
sodium borohydride yielded sophorolipid alcohol 20. Partial acid hydrolysis furnished a mixture of 
1,8-S-nonanediol 21, glucose 22, 1,8-S-nonanediol--D-glucopyranoside 23 and sophorose 24. The 
latter two were isolated by chromatography. Sophorolipid alcohol 20 and saturated sophorolipid acid 
13 were methylated into respectively sophorolipid ether 25 and sophorolipid methyl ester 26. Both 
compounds were hydrolyzed into 2,3,4,6-tetra-O-methyl-D-glucose 27 and 3,4,6-tri-O-methyl-D-
glucose 28 which confirmed the 1,2-glycosidic link between the two glucose units. 
 
Scheme 3. Sophorolipid modifications in the context of the structure determination 
Similar modifications were performed by Tulloch et al. for the characterization of diacetylated 
sophorolipid 29 which is produced by Rhodotorula bogoriensis (Scheme 4).70 In a first step, 
sophorolipid 29 was transformed into diacetylated sophorolipid methyl ester 30 with diazomethane. 
Alkaline methanolysis furnished the corresponding methyl ester 31. Acid methanolysis of 
sophorolipid acid 29 resulted in the cleavage of fatty acid methyl ester 32. Oxidation with chromium 
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oxide at room temperature or 100°C yielded respectively methyl 13-oxodocosanoate 33 or 
dodecanedioic acid 34 and tridecanedioic acid 35, which enabled the determination of the hydroxyl 
position. Diacetylated sophorolipid 30 was acetylated with acetic anhydride towards the 
peracetylated sophorolipid 36. Bromination towards -acetobromosophorose 37 was followed by 
the synthesis of -octaacetyl sophorose 38. Diacetylated sophorolipid 39 was further methylated 
towards sophorolipid methyl ester 29 and subsequently hydrolyzed into 2,3,4,6-tetra-O-methyl-D-
glucose 27 and 3,4,6-tri-O-methyl-D-glucose 28 which confirmed the 1,2-glycosidic link between the 
two glucose units. 
 
Scheme 4. Modifications for the structural determination of diacetylated sophorolipid 29 
Modifications starting from diacetylated sophorolipid lactone 40 are described by Tulloch et al. 
(Scheme 5).71 Diacetylated sophorolipid lactone 40 proved to be the major fermentation product and 
was obtained in pure form after crystallization and hydrogenation of the fermentation product 
followed by subsequent chromatography. Tetraphenylurethane sophorolipid 41 was synthesized via 
reaction with phenyl isocyanate. Acetylation of diacetylated sophorolipid lactone 40 was performed 
with acetic anhydride towards the hexaacetylated sophorolipid lactone 42 followed by brominolysis 
towards -bromosophorose hexaacetate derivative 43. Subsequent treatment with silver acetate 
gave the corresponding -acetoxysophorose derivative 44. The -bromosophorose hexaacetate 43 
was converted into -methoxysophorose hexaacetate 45 followed by deacetylation towards 
-methoxysophorose 46 and acetylation towards -methoxysophorose heptaacetate 47. The latter 
compound was also prepared via brominolysis of -sophorose octaacetate 38 towards 
-bromosophorose heptaacetate 37 and subsequent reaction with methanol in the presence of silver 
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carbonate. A third method for the synthesis of -methoxysophorose heptaacetate 47 comprises the 
Koenigs-Knorr reaction of 3,4,6-tri-O-acetyl--D-glucopyranoside 48 and -acetobromoglucose 49 in 
the presence of mercuric cyanide in nitromethane. The brominolysis reaction of hexaacetylated 
sophorolipid lactone 42 also resulted in the cleavage of the linkage between the two glucose units 
and reversion of the anomeric center. 
 
Scheme 5. Modifications of diacetylated sophorolipid lactone 40 
Treatment of the mother liquor after isolation of -bromosophorose hexaacetate 43 with silver 
acetate and subsequent chromatography resulted in the isolation of hexaacetylated -sophorolipid 
lactone 50 and -glucose tetraacetate derivative 51 (Scheme 6). The structure of the latter 
compound was confirmed upon reaction of the acid chloride 52 synthesized from 
17-L-acetoxyoctadecanoic acid and 1,2,3,6-tetra-O-acetyl--D-glucopyranose 53. In this context, acid 
chloride 52 was also coupled with 1,2,3,4-tetra-O-acetyl--D-glucopyranose 54 and 1,2,4,6-tetra-O-
acetyl--D-glucopyranose 56 towards the -glucose tetraacetate derivatives 55 and 57 respectively. 
Isolation and characterization of -glucose tetraacetate derivative 51 demonstrated that the fatty 
acid tail is linked to the C4”-position in the diacetylated sophorolipid lactone 40. 
  State of the art 
15 
 
 
Scheme 6. Isolation of brominolysis side-products 
Next to diacetylated sophorolipid lactone 40, a second major fermentation product was present, i.e. 
diacetylated sophorolipid acid 58. Treatment of sophorolipid acid 58 with diazomethane on the one 
hand, and treatment of sophorolipid lactone 40 with low concentrated sodium methoxide on the 
other hand both resulted in the synthesis of diacetylated sophorolipid methyl ester 59 (Scheme 7). 
Subsequent deacetylation gave sophorolipid methyl ester 60, which was also prepared by 
deacetylation of sophorolipid lactone 40 and by treatment of sophorolipid acid 58 with a methanolic 
hydrogen chloride solution. The syntheses of sophorolipid methyl esters 59 and 60 confirmed that 
the structure of diacetylated sophorolipid acid 58 is similar to that of diacetylated sophorolipid 
lactone 40. Sophorolipid methyl ester 60 was acetylated towards heptaacetylated sophorolipid 
methyl ester 61 followed by brominolysis towards -acetobromosophorose 37. When the reaction 
time was reduced to seven hours, heptaacetylated -sophorolipid methyl ester 62 was obtained, 
which confirmed that brominolysis reaction conditions induced reversion of the anomeric center. 
Deacetylation with sodium methoxide gave -sophorolipid methyl ester 63. 
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Scheme 7. Modifications of diacetylated sophorolipid acid 58 
The unexpected production of diacetylated sophorolipid octadecyl ester 64 via fermentation of 
octadecanol by Starmerella bombicola and subsequent modifications is described by Tulloch and 
Spencer (Scheme 8).72 Alkaline hydrolysis with sodium hydroxide followed by reaction with 
diazomethane in methanol yielded sophorolipid methyl ester 60. Methanolysis with sodium 
methoxide gave sophorolipid octadecyl ester 65 and acetylation resulted in the synthesis of 
heptaacetylated sophorolipid octadecyl ester 66. To confirm the structure of diacetylated 
sophorolipid octadecyl ester 64, synthesis of heptaacetylated sophorolipid octadecyl ester 66 via the 
Koenigs-Knorr reaction was attempted. Octadecyl 17-L-hydroxyoctadecanoate 67 was synthesized 
from 17-L-formyloxyoctadecanoyl chloride and octadecanol and subsequently reacted with 
-acetobromosophorose 37. A mixture of  and  anomers 68 and 66 was obtained which was 
completely converted into heptaacetylated -sophorolipid octadecyl ester 68 upon reaction with 
hydrogen bromide. Synthesis of the heptaacetylated derivative 69 of the desired fermentation 
product, i.e. an octadecyl -sophoroside, was performed via the Koenigs-Knorr reaction of 
octadecanol with -acetobromosophorose 37. Deacetylation gave octadecyl -sophoroside 70. 
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Scheme 8. Modifications of diacetylated sophorolipid octadecyl ester 64 
The first total synthesis of sophorolipid lactone 12 was described by Fürstner et al.73 In a first step, 
two major building blocks were synthesized (Scheme 9). The ring-opening reaction of 
(S)-propenoxide with Grignard reagent 71 yielded the enantiomerically pure alcohol 72. D-glucal 73 
was protected with p-methoxybenzyl chloride and the resulting tri-O-PMB ether 74 was subsequently 
treated with dimethyldioxirane to yield epoxide 75. Alcohol 72 was reacted with epoxide 75 into the 
first building block 76. On the other hand, D-glucose and p-methoxybenzaldehyde dimethylacetal 77 
were coupled via a transacetalization reaction to yield 4,6-O-p-methoxybenzylidene acetal 78. 
Peracetylation towards acetal 79 was followed by selective deprotection of the anomeric center 
yielding reducing sugar 80. Reaction with bromine delivered the second building block 81. The two 
building blocks were coupled via a glycosylation reaction under modified Koenigs-Knorr conditions 
which yielded the desired sophorose glycoside 82 (Scheme 10). Deacetylation into diol 83 was 
followed by protection with p-methoxybenzyl chloride. The resulting PMB ether derivative 84 was 
treated with sodium cyanoborohydride to remove the acetal protecting group. The 
p-methoxybenzylated sophorolipid 85 was esterified with 9-undecynoic acid towards diyne 86. A 
ring-closing metathesis reaction was performed which was catalyzed by a molybdenum catalyst to 
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yield cycloalkyne 87. Protected sophorolipid lactone 88 was obtained via Lindlar hydrogenation and 
subsequent deprotection delivered the desired sophorolipid lactone 12. 
 
Scheme 9. Synthesis of building blocks 76 and 81 
 
Scheme 10. First total synthesis of sophorolipid lactone 12 
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2.4. Modifications towards new derivatives 
2.4.1. Regioselective reactions at the sugar head group 
Regioselective acylations of the sophorolipid head group through the use of enzymes is described by 
Bisht et al. (Scheme 11).74 First, the crude sophorolipid fermentation product needed to be 
transformed into a single pure compound to enable the synthesis of well-defined sophorolipid 
analogues. Therefore, the starting product was subjected to alkaline alcoholysis with sodium 
alkoxides, yielding sophorolipid esters 89. Transformation of the starting product into sophorolipid 
acid was not useful, since this acid is only soluble in water and polar aprotic solvents which are not 
suitable for transesterification reactions with lipase enzymes. The sophorolipid esters 89 were 
subjected to lipase-catalyzed esterifications with an excess of vinyl acetate, vinyl acrylate or succinic 
anhydride. Multiple enzymes were evaluated and the highest conversion was obtained with 
Novozym 435. With this enzyme, selective acylations at both the 6’- and 6”-position of the sugar 
head were obtained, yielding acylated sophorolipid esters 90. Acylation of only one of these positions 
was attempted through variation of the ratio sophorolipid ester/acylating agent. With a ratio of 1:1 
or less, 1,6”-sophorolipid lactone 91 was formed which is an unnatural analogue of the 
1,4”-sophorolipid lactone. This lactone was subsequently used for the regioselective esterification at 
the 6’-position of the sugar head, yielding the monoacrylated sophorolipid lactone 92.  
 
Scheme 11. Regioselective acylation of sophorolipid esters 89 at both the 6’- and 6”-position 
Sophorolipid methyl ester 89a displayed a cytotoxicity of 63 ± 5% against human pancreatic cells at a 
concentration ranging from 500 to 2000 µg/mL.57 Sophorolipid ethyl esters 89b and 90b displayed a 
lower cytotoxicity of respectively 23.6% at 1000 µg/mL and 42.6% at 500 µg/mL. No cytotoxicity was 
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observed against healthy peripheral blood mononuclear cells. Sophorolipid ethyl ester 90b also 
reduced septic shock related mortality in in vivo rat models with 23% and possessed high spermicidal 
and anti-HIV activity comparable to those of nonoxynol-9.64, 67 Unfortunately, high cytotoxicity was 
exerted on human vaginal cells. 
Selective enzyme-catalyzed deacetylation of sophorolipid lactone 1 at the 6’-position was performed 
by Peng et al. with the lipase from Candida rugosa (Scheme 12).75 This mono-acetylated sophorolipid 
lactone 11 was subsequently hydrolyzed into the non-acetylated sophorolipid lactone 12 with the 
cutinase from Humicola insolens. Methacrylate and butyrate groups were introduced at the 6’-
position through an enzyme-catalyzed acylation of the mono-acetylated sophorolipid lactone 11 with 
the respective vinyl acylates. An azide group was introduced in two steps. First, a iodination was 
performed followed by reaction with sodium azide. Methacrylate and azide groups offer the 
opportunity to introduce bioactive groups through click reactions. 
 
Scheme 12. Regioselective functionalization of sophorolipid lactone 1 
More enzyme-mediated regioselective acylations of sophorolipids at the 6’- and/or 6”-position of the 
sugar head are described by Singh et al. (Scheme 13).76 Selective acylation at the 6’-position was 
accomplished through reaction of sophorolipid ethyl ester 89b with excess vinyl acetate and 
Novozym 435, yielding sophorolipid monoacetate 96. A small amount of the corresponding 
sophorolipid diacetate was formed as well. When Lipase PS is used as catalyst, selective acylation at 
the 6”-position is obtained. Vinyl acetate and vinyl methacrylate were used respectively for the 
synthesis of sophorolipid monoacetates 97a and 97b. Enzymatic catalysis was also evaluated for the 
amidation of sophorolipid ethyl ester 89b with a number of primary amines. Different enzymes were 
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evaluated, of which only Novozym 435 was successful for the formation of sophorolipid amides 98 in 
high yield. The regioselective acylations with vinyl acetate and vinyl methacrylate at the 6’- and/or 
6”-positions of the sugar head were extended to the sophorolipid amides, yielding sophorolipid 
diacetate 99 and sophorolipid monoacetates 100 and 101. Also a one-pot synthesis of compound 99b 
was successfully accomplished. 
 
Scheme 13. Regioselective acylation and enzyme-catalyzed amidation of sophorolipid esters 89 
The modification of 2-dodecyl sophorolipid 102, prepared by fermentation with 2-dodecanol as 
substrate, was performed by Recke et al. (Scheme 14).77 The 2-dodecyl sophorolipid 102 was 
transformed into the 2-dodecyl glucolipid 103 via the selective removal of a glucose unit with the 
-glucuronidase enzyme. Subsequently, this glucolipid was acylated at the 6’-position with sebacic 
acid towards glucolipid 104. The free carboxylic acid function offers the opportunity for further 
derivatization towards polyesters. The 2-dodecyl sophorolipid 102 was also acylated at the 6’- and 
6”-position with the unusual fatty acids (R)-3-hydroxydecanoic acid and (S)-17-hydroxystearic acid 
which are obtained via hydrolysis of respectively rhamnolipids and sophorolipids. Acylation with (R)-
3-hydroxydecanoic acid resulted in the synthesis of one major product, i.e. the diacylated 
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sophorolipid 105. On the other hand, acylation with (S)-17-hydroxystearic acid was not complete 
after 48 hours, resulting in the formation of both the mono-acylated sophorolipid 106 and the di-
acylated sophorolipid 107. Longer reaction times were however not evaluated to obtain full 
conversion. 
 
Scheme 14. Acylations at the 6'- and 6”-position of sophorolipid 102 and glucolipid 103 
The emulsion stability, CMC values and reduction of the air-water surface tension () and water-n-
hexadecane interfacial tension () of the derivatives were evaluated. A good stabilization of w/o 
emulsions was achieved with all derivatives. This was not the case for o/w emulsions. CMC, - and -
values were respectively 150-200 mg/L, 27-50 mN/m and 3-7 mN/m. Antimicrobial activities of the 
derivatives were also evaluated. All derivatives showed strong growth inhibition against the Gram-
positive bacteria Bacillus megaterium and Bacillus subtilis, and against the fungus Candida 
magnoliae. Only di-acylated sophorolipid 105 and the mixture of mono-acylated sophorolipid 106 
and di-acylated sophorolipid 107 showed inhibition against the Gram-positive bacteria 
Staphylococcus capitis. No growth inhibition was observed against the Gram-negative bacteria 
Escherichia coli and Pseudomonas aeruginosa, the fungi Eurotium repens, Mycotypha microspora and 
Ustilago maydis, and against the alga Chlorella fusca. Finally, the anti-tumor promoting activity of the 
derivatives was evaluated via a short-term in vitro assay for Epstein-Barr virus activation in Raji cells 
induced by TPA using heptyl-galactosyl-glyceride as a reference compound. Concentrations were 
expressed as mol ratio of compound compared to TPA. At 1000 mol ratio/TPA, only 10-15% 
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activation was observed for the derivatives. All compounds displayed a cell viability of 70% at this 
concentration, which corresponds to a weak cytotoxicity against the Raji cells. 
The enzymatic conversion of crude sophorolipid fermentation product into glucolipid 8 is described 
by Rau et al. (Scheme 15).78-79 In a first step, the crude fermentation product was transformed via 
alkaline hydrolysis into deacetylated sophorolipid acid 2. Different glycosidases were evaluated for 
the specific release of one glucose molecule and the best results were obtained with the 
hesperidinase and naringinase enzyme. A comparison was made for the interfacial activities of 
glucolipid 8 and sophorolipid lactone both at the air-water and water-n-hexadecane interface. In 
both cases, the interfacial activity of the sophorolipid lactone could not be matched by glucolipid 8. 
 
Scheme 15. Deglycosylation of sophorolipid acid 2 
A similar deglycosylation of diacetylated sophorolipid acid 9 is described by Imura et al. (Scheme 
16).80 For this acetylated substrate, no activity was observed with hesperidinase or naringinase as 
was the case for the non-acetylated compound. Selective cleavage of the -1,2-glycosidic bond was 
obtained with invertase, pectinase solution, pectinase and pectolyase. The highest activity for the 
conversion towards acetylated glucolipid acid 108 was obtained with pectolyase. Evaluation of the 
surface active properties of sophorolipid acid 2, glucolipid acid 8, diacetylated sophorolipid acid 9 
and acetylated glucolipid acid 108 showed little variation in CMC value for the different compounds. 
 
Scheme 16. Deglycosylation of diacetylated sophorolipid 9 
2.4.2. Non-selective reactions at the sugar head 
Modifications at the head group of stearic acid based sophorolipids are described by Zerkowski et al. 
(Scheme 17).81 The crude sophorolipid fermentation product is subjected to alkaline hydrolysis and 
alcoholysis, yielding the sophorolipid free acid and the sophorolipid ethyl ester 109a. The 
sophorolipid free acid is transformed into the sophorolipid benzyl ester 109b through esterification 
with benzyl alcohol. Head group modified sophorolipid esters 110 were obtained through coupling of 
protected amino acids possessing a para-aminobenzoic acid linker (Paba) with the carbohydrate 
hydroxyl groups. The presence of a Paba-linker should avoid decoupling of the amino acids under 
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alkaline conditions and an excess of sophorolipid ester is used to favor mono-acylation. Two major 
isomers are obtained for each derivative, most probably the 6’ and 6” adducts. Acidolytic or 
hydrogenolytic deprotection yields the water-soluble sophorolipids 111 with charged head groups. 
CMC values were determined for the derivatives at different pH-values and were 5.3-27.1 mg/L (6-
24 µM) for compounds 111a-e and 54.1-116.7 mg/L (51-110 µM) for compounds 111f-g. The results 
show a significant impact of the modified head groups on the surface tension-lowering properties. 
A patent was published by Inoue et al. on the synthesis of hydroxyalkyl-etherified sophorolipid esters 
(Scheme 18).82 The crude sophorolipid fermentation product was subjected to methanolysis to 
produce sophorolipid methyl ester 89a. After transformation towards sophorolipid esters 89g and 
89h or sophorolipid acid 2, the hydroxyalkyl-etherified sophorolipid esters 112 and 113 were 
produced through reaction with alkylene oxides in the presence of an alkali catalyst. These 
hydroxyalkyl-etherified sophorolipid esters were incorporated in cosmetic compositions to prepare 
powdered compressed cosmetic materials such as face powder, cheek rouge, highlight or eye 
shadow or stick-shaped cosmetic materials such as stick-shaped rouge, lip cream, stick-shaped eye 
shadow or cosmetic pencil.83-84 They were also applied in cosmetics as moisture-retaining and 
moisturizing agents, giving a less sticky and better moisturizing feeling than conventional 
moisturizers such as glycerin, sorbitol and ethylene glycol.85 The hydroxyalkyl-etherified sophorolipid 
esters were formulated as moisturizers in hand cream, cleansing milk, skin lotion, facial pack and lip 
stick. 
 
Scheme 17. Modification at the head group with amino acids towards charged sophorolipid derivatives 
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Scheme 18. Synthesis of hydroxy-alkyl etherified sophorolipids 112 and 113 
2.4.3. Modifications at the end of the lipid tail 
A first modification at the end of the lipid tail, i.e. the synthesis of sophorolipid alkyl esters 89, was 
already described in Scheme 11. More sophorolipid alkyl esters 89 were synthesized by Zhang et al. 
in order to evaluate the relationship between the length of the alkyl ester chain and the interfacial 
properties of the derivatives (Scheme 19).86 The surface tension was measured for all the derivatives. 
Critical micelle concentration (CMC) and the minimum surface tension decreased for increasing alkyl 
ester chain length. Adsorption at solid/liquid interfaces was studied as well, demonstrating 
adsorption on alumina but much less on silica. Hydrogen bonding was proposed to be the primary 
driving force for adsorption on alumina and the maximum adsorption density suggested bilayer 
formation at higher concentrations. 
 
Scheme 19. Alkaline alcoholysis towards sophorolipid esters 89 
The transesterification of an -linolenic acid based sophorolipid mixture into sophorolipid methyl 
ester 89f was described by Gupta & Prabhune (Scheme 19).87 Their minimum inhibitory 
concentrations against Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa were 
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determined and proved to be respectively 20, 10 and 10 µg/mL for the fermentation product and 
respectively >20, 20 and 20 µg/mL for sophorolipid methyl ester 89f.88 
Enzyme-catalyzed transesterifications at the lipid tail are described by Carr & Bisht (Scheme 20).89 
Sophorolipid methyl ester 89a was transformed into the corresponding peracylated sophorolipid 
methyl esters 114 through reaction with acetic and propionic anhydride in the presence of a catalytic 
amount of DMAP. Different enzymes were evaluated for the transesterification in presence of n-
butanol and i-butanol. Only Novozym 435 proved to be successful for the transesterification of both 
methyl ester 89a and peracylated methyl esters 114 respectively, into sophorolipid butyl ester 115 
and peracylated sophorolipid esters 116. Deacylation of the sugar head did not occur. It is suggested 
that the presence of the macrolactonic ring is necessary to fit the sugar head in the binding pocket of 
the lipase for deacylation to occur. A lipase catalyzed hydrolysis of the lipid tail was performed with 
AYS and Novozym 435 in a phosphate buffer, yielding peracylated sophorolipid acids 117. 
 
Scheme 20. Enzyme-catalyzed transesterifications at the lipid tail 
Transesterification at the lipid tail was extended by Nuñez et al. for the coupling of a sugar monomer 
to the diacetylated sophorolipid methyl ester 90a (Scheme 21).90 A first attempt with glucose was not 
successful due to its poor solubility in organic solvents. Functionalization of the hydroxyl groups 
proved necessary where ketalization is favored for its selectivity. Galactose was used instead of 
glucose since the primary alcohol still has to be available for the transesterification. The 
transesterification reaction was performed with immobilized Novozym 435 and sophorolipid sugar 
esters 118 were formed which varied in the degree of acetylation. Deacetylation occurred through 
the lipase-catalyzed transesterification of the acetylated primary alcohols and the functionalized 
galactose unit. Deacetylation at the 6”-position resulted in the formation of 1,6”-sophorolipid lactone 
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91 (9%) and its 6’-acetylated analogue (14%) (Scheme 11). Acid hydrolysis with HBF4 was performed 
for the deprotection of the acetyl and ketal groups towards sophorolipid galactopyranose ester 119. 
 
Scheme 21. Transesterification towards sophorolipid galactopyranose ester 119 
Coupling of sophorolipid acid 2 with different amino acids is described by Azim et al. (Scheme 22).91 
The crude fermentation product was transformed into sophorolipid acid 2 through alkaline hydrolysis 
with NaOH. Protected amino acid conjugated sophorolipids 120 and amino acid conjugated 
sophorolipid alkyl esters 121 were synthesized using DCC coupling. Deprotection of the different 
protecting groups yielded amino acid conjugated sophorolipids 122. Deprotection of benzyl ester 
groups in compounds 120a-d was performed by hydrogenation on Pd/C which simultaneously 
resulted in the reduction of the double bond. Deprotection of t-butyl groups in compound 120e was 
accomplished under acid conditions. 
The antimicrobial, anti-HIV and spermicidal activity were evaluated for amino acid conjugated 
sophorolipid alkyl esters 121 and amino acid conjugated sophorolipids 122. All tested derivatives 
possessed antimicrobial activity against Gram-positive and Gram-negative organisms. The best 
results were obtained for leucine conjugated sophorolipid 122c, with MIC values of 1 and 2 µg/mL 
against respectively Moraxella sp. and S. sanguinis. Also the leucine conjugated sophorolipid ethyl 
ester 121b featured high activity, especially against Moraxella sp. with a MIC value of 830 µg/mL. 
Monoacetylated ethyl ester sophorolipid (MAEE) was also included in the antimicrobial screening 
and showed higher activity against all the organisms except for leucine conjugated sophorolipid ethyl 
ester 121b against Moraxella sp. All tested derivatives displayed virus inactivation with an EC50 below 
200 µg/mL. The esterified derivatives 121 are more potent than the corresponding non-esterified 
compounds 122. Leucine conjugated sophorolipid 121c was the most potent and displayed even 
higher anti-HIV activity than the commercial spermicide nonoxynol-9 (EC50≈65 µg/ml). None of the 
tested derivatives displayed significant spermicidal activity. Nonoxynol-9 and MAEE were used as 
positive controls. 
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Scheme 22. Synthesis of amino acid conjugated sophorolipids 
Synthesis of sophorolipid amides 123 is described in a patent published by Schofield et al. (Scheme 
23).92 Non-biogenic sophorolipid amides 123a-123i and biogenic sophorolipid amides 123j-123p were 
synthesized from sophorolipid methyl ester 89a through amidation with the corresponding amines. 
Sophorolipid N’,N’-dimethylethylamide 123b was quaternized with methyl iodide to the sophorolipid 
quaternary ammonium salt 124. This compound was also hydrogenated to the saturated 
sophorolipid N’,N’-dimethylethylamide 125 and subsequently quaternized to the saturated 
sophorolipid quaternary ammonium salt 126. Antimicrobial activities were evaluated against a wide 
variety of micro-organisms. 
 
Scheme 23. Synthesis of non-biogenic and biogenic sophorolipid amides 
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Hydrogenation of diacetylated sophorolipid lactone 1 and sophorolipid acid 2 was also performed, 
yielding respectively the saturated diacetylated sophorolipid lactone 40 and the saturated 
sophorolipid acid 13 (Scheme 24).92 Antimicrobial activities were evaluated against a wide variety of 
micro-organisms. 
 
Scheme 24. Hydrogenation of diacetylated sophorolipid lactone 1 and sophorolipid acid 2 
2.4.4. Sophorolipid polymerization 
The sophorolipid lactone 92 was used by Bisht et al. for the synthesis of polymers with amphiphilic 
properties (Scheme 25).93 Homopolymerisation was performed with AIBN as initiator, yielding 
sophorolipid homopolymer 127. This polymer is soluble in DMF and DMSO but not in water. To 
increase the hydrophilic character of the polymer, copolymers 128 were produced with acrylic acid 
and acrylamide. The copolymer composition was controlled by the monomer feed ratio. Copolymers 
128a and 128b were synthesized with respectively 3, 5, 10 and 50 mol % and 0.5, 1, 2, 3, 5 and 
50 mol % sophorolipid lactone 92 in the feed. Copolymer 128b is soluble in water with less than 
3 mol % sophorolipid lactone 92 in the feed. 
 
Scheme 25. Homo- and copolymerization of sophorolipid lactone 92 
A ring-opening metathesis polymerization (ROMP) for the synthesis of a poly(sophorolipid) 129 from 
sophorolipid lactone 1 was first described by Gao et al. (Scheme 26).94 The presence of degradable 
links in the polymer structure makes these polymers promising bioresorbable materials. Three 
different ruthenium-based Grubbs catalysts were evaluated and the highest yields were obtained 
with catalyst 131. 
State of the art   
30 
 
 
Scheme 26. Ring-opening metathesis polymerization towards poly(sophorolipid) 129 
The solid-state properties of this poly(sophorolipid) were evaluated by Zini et al.95 Both Z and E 
double bonds are present in the poly(sophorolipid), respectively in 90% and 10%. Thermogravimetric 
analysis demonstrated the presence of two main degradation steps. The first step around 350 °C may 
be associated with the degradation of the hydrophilic sugar moieties, the second step around 450 °C 
can be attributed to the thermal degradation of the hydrophobic fatty acid chain. The combined 
results of differential scanning calorimetry (DSC), X-ray diffraction (XRD) and temperature modulated 
DSC (TMDSC) suggest that the poly(sophorolipid) possesses crystalline domains which melt at 123 °C 
and has a glass transition at 61 °C. A kinetic study on the polymerization mechanism was performed 
by Peng et al., categorizing it as an enthalpy driven ROMP.96 The effect of catalyst loading, monomer 
concentration and solvent choice were evaluated for polymerization with Grubbs catalysts 131 
and 132. 
The structural diversity of the poly(sophorolipid) was expanded by Peng et al. through the 
incorporation of modified sophorolipid lactone monomers in the polymer product (Scheme 27).75 The 
di-acetylated, mono-acetylated, non-acetylated and butyrated sophorolipid lactones 1, 11, 12 and 
93a were homopolymerized according the optimal conditions which were determined in the kinetic 
study. TGA analysis showed that all polymers are stable up to 200°C and DSC analysis was used to 
analyze their thermal behavior. No melting transitions were observed for the mono- and non-
acetylated sophorolipid polymers, probably due to the absence of a crystalline phase caused by a 
restricted chain mobility. These polymers show significant potential as substrates for bone tissue 
engineering due to their solid-state properties. Biological properties relevant for tissue engineering 
were determined for all polymers except for the non-acetylated sophorolipid polymer 133b due to 
stability problems. Cytotoxicity on human mesenchymal stem cells was evaluated via LDH and cell 
proliferation assays and a similar cytocompatibility was observed as the control tissue culture 
polystyrene (TCPS). All three polymers also displayed similar cell adhesion and spreading as the 
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control CTPS. The capacity of the three polymers to support the differentiation of the mesenchymal 
stem cells to an osteoblast cell phenotype was evaluated, giving the best results for butyrated 
sophorolipid polymer 133c compared to the control TCPS. Finally, degradation of the polymers in an 
osteogenesis medium was determined. All three polymers underwent an appreciable molecular 
weight loss in fourteen days and the degradation rate was dependent on the substitution at the 
sugar moiety. 
 
Scheme 27. Homopolymerization of sophorolipid lactone derivatives 
Copolymers of diacetylated sophorolipid lactone 1 and methacrylated or azidated sophorolipid 
compounds were prepared with control of the presence of the clickable functional groups (Scheme 
28).75 Functionalization of the methacrylate containing copolymer 134a via a thiol-ene reaction was 
performed with mercaptoethanol as a model compound. Similarly, functionalization of the azide 
containing copolymer 134b was performed with 3-butyn-1-ol via the azide-alkyne cycloaddition 
reaction. Copolymers containing both methacrylate and azide groups were also prepared. 
 
Scheme 28. Synthesis of copolymers with methacrylate and azide groups 
Ring-opening polymerization of sophorolipid lactones with lipases was explored by Hu & Ju (Scheme 
29).97 The starting material for the polymerization was a mixture of -1 C18:1 diacetylated 
sophorolipid 1, -1 C16:0 diacetylated sophorolipid 135 and  C16:0 diacetylated sophorolipid 136. 
Ethyl acetate, pyridine, isopropyl ether, toluene, cyclohexane and hexane were evaluated as solvents 
for polymerization with porcine pancreatic lipase (PPL), giving the highest conversion in isopropyl 
ether and toluene. An evaluation of the reaction mechanism revealed that the diacetylated 
sophorolipid lactones were selectively deacetylated at the 6’-position prior to the ring-opening 
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polymerization. This results in linkage of the monomers via both the 6’-position and the 4”-position 
at the sugar moiety. Four different lipases were used to evaluate the conversion efficiency in both 
acetonitrile and isopropyl ether, namely PPL, immobilized Mucor miehei lipase (MML), lyophilized 
Candida antarctica lipase (CAL-B) and lyophilized Pseudomonas sp. lipase (PSL). The highest 
conversion was obtained with MML in isopropyl ether, but CAL-B proved to be the least solvent 
sensitive. Substrate selectivity depended on the temperature, with an increasing conversion at 60 °C 
but decreasing conversion at 50 °C for larger ring sizes. The overall polymerization proceeded the 
fastest at 60 °C. 
 
Scheme 29. Enzymatic ring-opening polymerization of sophorolipid lactones 
2.4.5. Modifications towards short-chained sophorolipids 
The synthesis of short-chained sophorolipids was described by Develter and Fleurackers, and by Van 
Bogaert et al. (Scheme 30).26, 98 The esters dodecyl pentanoate, pentyl dodecanoate, decyl 
heptanoate, dodecyl malonate, myristyl malonate and dodecyl glutarate were used for the synthesis 
of sophorolipid esters 138 by Starmerella bombicola. These sophorolipid esters were subjected to 
alkaline hydrolysis, yielding short-chained sophorolipids 139. An alternative strategy for the 
production of short-chained derivatives implied the ozonolysis reaction of sophorolipid acid 2 in 
water towards C9 sophorolipid acid 140. The mixture of this short-chained sophorolipid acid and 
azelaic acid reduced the surface tension of water to 30 mN/m and dynamic surface tension 
measurements indicated that the reduction of the surface tension was faster compared to crude 
sophorolipids after fermentation. The mixture proved to be a better wetting agent than Simulsol 
AS48 and a comparable hydrotrope as Simulsol AS48 and crude sophorolipids. 
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Scheme 30. Synthesis of short-chained sophorolipids 
Ring-opening cross-metathesis of sophorolipid lactone 1 was performed by Peng et al. for the 
synthesis of short-chained sophorolipid derivatives (Scheme 31).99 The cross-metathesis reactions 
with n-acrylates, trans-3-hexene, 1-hexene and ethylene were catalyzed with a second generation 
Grubbs catalyst 141. Cross-metathesis with n-acrylates resulted in the synthesis of three gemini type 
sophorolipids 142. Subsequent ethanolysis reaction yielded the corresponding ethyl ester 143. Cross-
methathesis with trans-3-hexene, 1-hexene and ethylene followed by ethanolysis and optional 
hydrogenation yielded short-chain alkyl sophorolipids 145 and 146. Hydrogenation of unsaturated 
alkyl sophorolipid 145 was not performed since this terminal double bond is valuable for further 
functionalization. Critical micelle concentrations were determined via the Wilhelmy plate method 
and n-dodecyl--D-maltoside was used as a reference compound for comparison. Both the CMC and 
minimum surface tension (min) decrease with increasing hydrophobicity and are thus dependent on 
the chain length. The maximum surface adsorption density (m) and minimum surface coverage area 
per surfactant (Amin) were also calculated. Increasing the chain length results in a higher packing 
density and lower minimum surface area, especially from alkyl sophorolipid 145 to alkyl sophorolipid 
146a. Sophorolipid ethyl ester 143 displayed the highest packing density and lowest minimum 
surface area despite its hydrophilic character. It is thought that the ester moiety induces additional 
lateral attraction which reduces the distance between the molecules at the air-water interface. 
Comparison of the values for n-dodecyl--D-maltoside and alkyl sophorolipid 146a demonstrates 
that sophorose occupies a larger effective area than maltose at the air-water interface. The influence 
of the chain length of alkyl sophorolipids on the CMC proved to be smaller than that of alkyl 
glucoside and maltoside sugar-based surfactants. This is likely due to the higher effective area 
occupied by the sophorose group. 
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Scheme 31. Ring-opening cross metathesis towards short-chain sophorolipids 
2.4.6. Degradation of sophorolipids in smaller building blocks 
Deacetylated sophorolipid acid 2 was converted into the -1 hydroxy fatty acid 7 by Rau et al. via 
acid hydrolysis (Scheme 32).79 The -1 hydroxy fatty acid 7 is a rare fatty acid which is difficult to 
prepare via organic synthesis. This fatty acid could be used as a building block for the synthesis of 
pharmaceutically valuable products and for polyester- and macrocyclic lactones. 
 
Scheme 32. Degradation towards 17-hydroxy oleic acid 7 
Zerkowski and Solaiman described the synthesis of polyfunctional fatty amines starting from 
sophorolipids (Scheme 33).100 In a first step, sophorolipid lactone 1 is subjected to acid methanolysis 
to yield methyl 17-hydroxy oleate 147. An allylic substitution was used to introduce an amine 
function at the allylic position of the double bond. Methyl 17-hydroxy oleate 147 was reacted with 
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N-bromosuccinimide and sodium azide towards azide 148 and was subsequently subjected to a 
Staudinger reaction. Protection of the amine function towards Boc-protected amine 149 was 
performed without intermediate isolation. Amine 149 was further subjected to a Mitsunobu reaction 
with phthalimide to yield diamine 150. After conversion of the ester function of amine 149 into a 
carboxylic acid function, a Curtius rearrangement with diphenylphosphorylazide and a Mitsunobu 
reaction were performed to yield triamine 152. 
 
Scheme 33. Synthesis of polyfunctional fatty amines from sophorolipids (part 1) 
Further modifications of methyl 17-hydroxy oleate 147 comprised a Mitsunobu reaction towards 
subterminal amine 153 with phthalimide and the synthesis of azide 154 followed by a Staudinger 
reaction and protection of the amine function towards Boc-protected amine 155 (Scheme 34). 
Conversion of the ester function into a carboxylic acid function and a subsequent Curtius 
rearrangement yielded diamine 156. Finally, methyl 17-hydroxy oleate 147 was converted into 
17-hydroxy oleic acid 7 and was subsequently subjected to a Curtius rearrangement to yield amine 
157 and isocyanate 158. The latter was converted into urea derivative 159 with mono-Boc 
piperazine. Amine 157 was transformed into azide 160 and subsequently subjected to a Staudinger 
reaction with protection of the amine function towards Ns-protected amine 161. Amine 157 was also 
reacted with N-bromosuccinimide and sodium azide towards azide 162 and additionally subjected to 
a Staudinger reaction and protection of the amine function towards Fmoc-protected amine 163. 
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Scheme 34. Synthesis of polyfunctional fatty amines from sophorolipids (part 2) 
A similar strategy was adopted by Zerkowski and Solaiman for the synthesis of polyhydroxy fatty 
acids (Scheme 35).101 Methyl 17-hydroxy oleate 147 was converted into 17-hydroxy oleic acid 7 and 
subsequently reduced towards diol 164 via an intermediate activated ester. The primary alcohol was 
selectively protected with t-butyldiphenylsilyl chloride after which the secondary alcohol was 
oxidized with pyridinium dichromate towards keton 165. Allylic hydroxylation with selenium dioxide 
of methyl 17-hydroxy oleate 147 yielded two isomers 166 and 167. The former was protected with 
t-butyldiphenylsilyl chloride, converted to carboxylic acid 168 and reduced to the primary alcohol 
169. The latter was protected with acetic anhydride and subjected to the Sharpless’ asymmetric 
dihydroxylation towards methyl ester 170. 
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Scheme 35. Synthesis of polyhydroxy compounds from sophorolipids (part 1) 
Protection of methyl 17-hydroxy oleate 147 with t-butyldiphenylsilyl chloride followed by hydrolysis 
yielded carboxylic acid 171, which was subsequently reduced to alcohol 172 (Scheme 36). Sharpless’ 
asymmetric dihydroxylation and protection with 2,2-dimethoxypropane yielded alcohol 173. Olefin 
metathesis of methyl 17-hydroxy oleate 147 with a Grubbs’ first generation catalyst resulted in 
diol 174. Methyl 17-hydroxy oleate 147 was also directly subjected to Sharpless’ asymmetric 
dihydroxylation towards methyl ester 175 and subsequently protected with 2,2-dimethoxypropane 
towards methyl ester 176. Treatment with 1,2-dibromotetrachloroethane resulted in bromide 177. A 
new double bond was formed upon elimination with DBU towards methyl ester 178. Sharpless’ 
asymmetric dihydroxylation yielded methyl ester 179 whereas allylic hydroxylation with selenium 
dioxide resulted in three isomeric products 180. 
Sophorolipids were applied by Hoffmann et al. in the synthesis of the natural products 
Ebracteatoside C, Zizybeoside I and phenethyl glucoside (Scheme 37).102 The crude sophorolipid 
fermentation product was transformed into the sophorolipid methyl ester 89a. After protection of 
the carbohydrate hydroxyl groups and reduction of the double bond, sophorolipid methyl esters 61 
and 182 were transformed into anomeric sophorose bromides 37 and 183. The acetylated sophorose 
bromide 37 was then treated under Koenigs-Knorr conditions with benzyl alcohol or 
2-phenethylethanol to yield Zizybeoside 185 or phenethyl glycoside 186 after deprotection under 
Zemplén conditions. Sophorose bromides 37 and 183 were hydrolyzed and subsequently reacted 
with trichloroacetonitrile to form the trichloroacetimidates 188. Glycosylation of the acetate 
protected derivative 188a selectively led to -anomer 189a. Benzoate protected derivative 188b was 
glycosylated with Pd(CH3CN)4(BF4)2 to selectively form the enriched -anomer 189b and was 
subsequently hydrolyzed to furnish Ebracteatoside C 190. 
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Scheme 36. Synthesis of polyhydroxy compounds from sophorolipids (part 2) 
 
Scheme 37. Synthesis of natural products from sophorolipids 
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2.5. Sophorolipid based nanoparticles 
The application of sophorolipids for the formation of magnetic cobalt nanoparticles is described by 
Kasture et al. (Figure 3, Scheme 38).103 Sophorolipids have the advantage over oleic acid that they are 
better water soluble which resulted in the formation of more stable nanoparticles. The cobalt 
nanoparticles were synthesized by reduction of Co2+ with sodium borohydride using the sophorolipid 
acid 2 as capping agent. The nanoparticles were obtained from aqueous dispersions as a stable 
powder via simple centrifugation or magnetic separation and could easily be redispersed in water. 
Transmission electron microscopy (TEM) revealed that well separated, polydisperse particles were 
obtained with an average particle size of around 50 nm. The binding of the sophorolipids to the 
cobalt nanoparticle surface via the carboxylic acid function and the double bond was confirmed by 
Fourier transform infrared spectroscopy (FTIR). Room-temperature magnetization measurements 
were performed to demonstrate the good magnetic features of the sophorolipid-capped 
nanoparticles. 
 
Figure 3. Sophorolipids as nanoparticle capping agents 
 
Scheme 38. Sophorolipid-capped cobalt nanoparticles 
Kasture et al. also described the formation of sophorolipid based silver nanoparticles (Scheme 39).104 
The sophorolipid acids 2 and 191 were used as reducing and capping agents in the synthesis of the 
nanoparticles with silver nitrate under alkaline conditions at different temperatures. The differences 
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in size and dispersion for oleic acid sophorolipid-capped nanoparticles (OA) and linoleic acid 
sophorolipid-capped nanoparticles (LA) at different temperatures were evaluated. Particle size 
distribution was determined via both transmission electron microscopy (TEM) and dynamic light 
scattering measurements (DLS). It was observed that particle size decreased with increasing 
temperature and longer time is needed at low temperatures to obtain complete particle formation 
and growth.  
 
Scheme 39. Sophorolipid-capped silver nanoparticles 
The nanoparticles were isolated as a stable powder via centrifugation and air-drying which could 
easily be redispersed in water.105 Just like for the cobalt nanoparticles, binding of the sophorolipids to 
the silver nanoparticle surface occurs via the carboxylic acid function and the double bond. 
Continuous flow synthesis of sophorolipid-capped silver nanoparticles is described by Kumar et al.106 
Stearic acid based sophorolipid 13 was used as reducing and capping agent for the continuous flow 
experiments since the resulting nanoparticles were formed faster and featured a better size 
uniformity than those synthesized with oleic acid based sophorolipid 2. The influence of the flow rate 
on the average particle size and particle size distribution were evaluated. Higher flow rates led to 
better mixing but reduced residence time, which resulted in an incomplete reaction towards large 
polydisperse particles. At lower flow rates, the reaction was complete and small monodisperse 
spherical nanoparticles were obtained. The synthesis of sophorolipid-capped silver nanoparticles via 
segmented flow in a microreactor was performed by Kumar et al.107 Both liquid-liquid and gas-liquid 
segmented flows were applied with respectively kerosene and air as inert phase. The particle size 
was much smaller for gas-liquid flow than for liquid-liquid flow and the particle size distribution could 
be controlled by the choice of inert phase. Singh et al. investigated the antibacterial activities of 
these sophorolipid-capped silver nanoparticles.105 For sophorolipids as such, good inhibition was 
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obtained against the Gram-positive bacteria Bacillus subtilis and Staphylococcus aureus while there 
was only a faint inhibition against the Gram-negative bacterium Pseudomonas aeruginosa. In case of 
the sophorolipid-capped nanoparticles, Bacillus subtilis and Staphylococcus aureus were exposed to 
concentrations ranging from 20 to 100 µg/mL. The cell survival of Bacillus subtilis dropped to 0.4% 
after one hour, but no survival was observed for Pseudomonas aeruginosa. Sophorolipid-capped 
silver nanoparticles are thus more effective against Gram-negative bacteria. Silver proved to be the 
cause of the observed antibacterial effects via the induction of pore formation in the bacterial cell 
membrane through the formation of reactive oxygen species. 
The same methodology was applied by D’Britto et al. for the synthesis of silver nanoparticle studded 
polyethylene scaffolds (Scheme 40).108 The polymer scaffold was first treated with in situ generated 
ammonia plasma to introduce amine groups. Sophorolipid 2 was covalently attached to the polymer 
surface via an amidation reaction followed by formation of silver nanoparticles at the polymer 
surface with silver nitrate. The size of these silver nanoparticles was approximately 60 to 70 nm. The 
antimicrobial activity of the modified polyethylene scaffolds against the Gram-positive bacteria 
Bacillus subtilis and Staphylococcus aureus, and the Gram-negative bacteria Pseudomonas 
aeruginosa and Escherichia coli was evaluated. Within six hours of exposure, the silver nanoparticle 
studded polyethylene scaffolds displayed a broad activity against both the Gram-positive and Gram-
negative bacteria. The adhesion and proliferation of mammalian cells on the polymer scaffolds was 
also evaluated. This revealed that the growth of the mammalian cells was encouraged by the silver 
nanoparticle studded polyethylene scaffolds and that the cells exhibited good viability. These 
modified polymer scaffolds are good candidates for tissue-engineering and bio-implant applications. 
 
Scheme 40. Synthesis of silver nanoparticle studded polyethylene scaffolds 
Dhar et al. described the use of sophorolipids for the synthesis of biocompatible gold nanoparticles 
(Scheme 41).109 Gellan gum 192 was used as the primary reducing and capping agent in the 
formation of the gold nanoparticles with chloroauric acid, followed by conjugation of the 
nanoparticles with sophorolipid acid 2. The nanoparticles were further loaded with the anticancer 
drug doxorubicin hydrochloride 193. The average particle size was determined via transmission 
electron microscopy and amounted to 13 and 17 nm for respectively the gellan gum capped 
nanoparticles and the sophorolipid conjugated nanoparticles. After fluorescent labeling, the efficient 
cellular uptake of the nanoparticles by human glioma cell line LN-229 was demonstrated. The in vitro 
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cytotoxicity of both sophorolipid-conjugated nanoparticles and doxorubicin chloride loaded 
nanoparticles were evaluated and compared to free doxorubicin chloride 193 against human glioma 
cell line LN-229 and human glioma stem cell line HNHC-2. The doxorubicin loaded nanoparticles 
performed better then both the sophorolipid-conjugated nanoparticles and the free doxorubicin 
chloride 193 against both cell lines. This synergistic effect could be explained by the better cell 
penetration of the doxorubicin loaded nanoparticles compared to free doxorubicin chloride 193. 
 
Scheme 41. Sophorolipid-conjugated gellan gum capped gold nanoparticles 
The formation of sophorolipid-capped iron oxide nanoparticles was executed by Baccile et al. 
(Scheme 42).110 The magnetic iron nanoparticles were synthesized with iron (II) chloride and iron (III) 
chloride in the presence of ammonia at room temperature and 80°C. Both a two-step and one-step 
procedure were applied which resulted in nanoparticles with respectively a maghemite (-Fe2O3) or 
two-line ferrihydrite (Fe5HO8∙4H2O) structure. Particle size distribution was determined via both 
transmission electron microscopy (TEM) and dynamic light scattering measurements (DLS). A very 
broad particle size distribution was obtained for the one-way synthesis pathway at room 
temperature via TEM, while monodisperse nanoparticles were obtained in all other cases. A narrow 
size distribution was obtained for all samples via DLS measurement in water and all average sizes are 
systematically higher than those measured by TEM. When DLS measurements were performed in an 
ethanol/water mixture (8:2), particle sizes increased compared to those measured in water, 
indicating the aggregation of the nanoparticles into large aggregates. The much higher increase of 
the average particle size for the nanoparticles synthesized at room temperature indicated that 
sophorolipids were more loosely bonded to the nanoparticle surface. FTIR analysis revealed that the 
sophorolipids are mainly attached to the nanoparticle surface via the carboxylic acid function. 
Adsorption studies were performed for the sophorolipid-capped iron oxide nanoparticles with two 
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lectines, namely Concanavalin A and lectin from Bandeiraea simplicifolia. No specific interaction 
occurred with the lectin from Bandeiraea simplicifolia, but affinity for Concanavalin A was observed. 
Sophorolipid-capped iron oxide nanoparticles thus proved to be interesting as selective targets for 
sugar/protein interactions. 
 
Scheme 42. Sophorolipid-capped iron oxide nanoparticles 
Singh et al. described the synthesis of sophorolipid self-assembled vesicular mesostructures via laser 
irradiation and their subsequent loading with iron oxide nanoparticles (Scheme 43).111 Laser 
irradiated sophorolipids proved to be highly fluorescent and in the case of diacetylated sophorolipid 
acid 9, uniform spherical microstructures were obtained. Upon irradiation, sheet-like structures are 
formed initially which are converted into fully developed spherical mesostructures after one hour. By 
adjusting the irradiation conditions, nanoparticles of approximately 100 nm could be obtained. After 
drying, the sophorolipid mesostructures could easily be redispersed in water. When Fe3O4 
nanoparticles were added during the synthesis, sophorolipid mesostructures embedded with iron 
oxide nanoparticles were obtained. An MTT-assay on a HeLa derived cell line revealed that the 
sophorolipid mesostructures displayed no cytotoxicity against eukaryotic cells. It was also 
demonstrated that the sophorolipid mesostructures loaded with iron oxide nanoparticles could serve 
as effective hyperthermia agents. 
 
Scheme 43. Synthesis of sophorolipid mesostructures wether or not loaded with iron oxide nanoparticles 
Sophorolipid conjugated cadmium telluride quantum dots (CdTe QD) were synthesized by Singh et al. 
(Scheme 44).112 In a first step, 3-mercaptopropionic acid was used as the capping agent in the 
synthesis of the CdTe QDs. Terminal amine groups were introduced via an EDC-mediated amidation 
reaction with ethylenediamine prior to the coupling of diacetylated sophorolipid acid 9. The obtained 
nanoparticles were nearly monodispersed with an average particle size of 5 nm for both CdTe QDs 
194 and sophorolipid conjugated CdTe QDs 196 via TEM analysis. DLS measurements indicated 
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average particle sizes of 8 and 118 nm for respectively CdTe QDs 194 and sophorolipid conjugated 
CdTe QDs 196. Bioimaging studies revealed that sophorolipid conjugated CdTe QDs 196 were taken 
up in the cytosol of a cancer cell line. Cytotoxicity studies demonstrated a specific toxicity against the 
cancer cell line compared to a control cell line. 
 
Scheme 44. Synthesis of sophorolipid conjugated cadmium telluride quantum dots 
Basak et al. described the synthesis of sophorolipid functionalized zinc oxide nanoparticles (Scheme 
45).113 Diacetylated sophorolipid acid 9 was used for the nanoparticle synthesis in combination with 
zinc nitrate hexahydrate under alkaline conditions. The average particle size was calculated via the 
Debye-Scherrer formula and was found to be 6.55 and 6.02 nm for respectively naked and 
sophorolipid-capped zinc oxide nanoparticles. The antimicrobial activities of the zinc oxide 
nanoparticles were evaluated against the Gram-negative bacterium Salmonella enterica and the 
fungus Candida albicans. The sophorolipid-capped zinc oxide nanoparticles proved to exhibit a 
significant inhibitory effect on the growth of both strains at a concentration of 5000 µg/mL. Higher 
activities were observed for the sophorolipid-capped zinc oxide nanoparticles than for the naked zinc 
oxide nanoparticles, probably due to the better penetration of the former ones in the pathogenic 
cells. The mechanism of cell damage on S. enterica consisted of cell elongation followed by cell wall 
disruption. In the case of C. albicans, complete cell rupture occurred while cell elongation was not 
detected. A higher antimicrobial activity was observed against S. enterica compared to C. albicans. 
 
Scheme 45. Sophorolipid-capped zinc oxide nanoparticles 
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3. Results and discussion 
3.1. Synthesis of the intermediate sophorolipid aldehyde 
3.1.1. Development of a synthetic pathway towards the sophorolipid aldehyde 
In a first attempt to synthesize the desired sophorolipid aldehyde 198, diacetylated sophorolipid 
lactone 1 was directly subjected to an ozonolysis reaction (Scheme 46). Safety precautions should be 
taken during this reaction since the formation of unstable ozonides could result in explosions. 
Therefore, the reaction was performed in a taped washing flask at -78 °C on a small scale of 
maximum 30 g. The sophorolipid starting material was dissolved in dry dichloromethane and a pinch 
of Sudan III dye was added to indicate the end of the reaction. The mixture was purged with ozone 
until the red color dissipated and flushed with nitrogen to remove all traces of ozone. Dimethyl 
sulfide was added for the reductive work-up towards the intermediate dialdehyde 197. The 
formation of the sophorolipid dialdehyde 197 was demonstrated via LC-MS and NMR analysis. Small 
amounts of the corresponding mono- and dicarboxylic acid derivatives were also detected via LC-MS 
analysis. Purification of the sophorolipid dialdehyde 197 was not successful either via column 
chromatography with ethyl acetate or 5% methanol in dichloromethane as eluent or via 
recrystallization from ethanol. A successful purification was obtained via automated column 
chromatography by applying a gradient of 2 column volumes (CV) at 20:80 ethyl acetate/petroleum 
ether, 25 CV to 100% ethyl acetate and 5 CV at 100% ethyl acetate. However, a low yield of only 24% 
was obtained with this purification procedure. 
 
Scheme 46. Synthesis of sophorolipid aldehyde 198 via ozonolysis and alkaline methanolysis 
Therefore, the crude ozonolysis reaction mixture was directly subjected to an alkaline methanolysis 
with sodium methoxide in methanol to synthesize the desired sophorolipid aldehyde 198. After 
reaction, sophorolipid aldehyde 198 could not be detected via LC-MS analysis. Instead, the aldol 
condensation product 199, formed from the methyl 9-oxononoate by-product, was detected as the 
major product, together with small amounts of the C9-sophorolipid acid and the aldol condensation 
product 200 (Figure 4). The synthesis of the latter compound was confirmed via NMR-analysis. These 
results indicate that the alkaline conditions of the methanolysis reaction are not compatible with the 
aldehyde functions present in the structure. 
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Figure 4. Aldol condensation products after alkaline methanolysis of sophorolipid dialdehyde 197 
A reversed reaction sequence, i.e. alkaline methanolysis of diacetylated sophorolipid lactone 1 
followed by an ozonolyis reaction, was evaluated as alternative reaction pathway towards 
sophorolipid aldehyde 198 (Scheme 47). The alkaline methanolysis was performed with 3 equivalents 
of sodium methoxide in methanol based on a literature procedure to yield sophorolipid methyl ester 
89a.74 After reaction, the mixture was acidified with acetic acid and the sophorolipid ester was 
purified via precipitation in water. In subsequent reactions towards sophorolipid methyl ester 89a, a 
catalytic amount of sodium methoxide (0.15 equivalents) proved to be sufficient to perform the 
alkaline methanolysis. In a first attempt to synthesize sophorolipid aldehyde 198 from sophorolipid 
methyl ester 89a, the ozonolysis reaction was performed in dichloromethane as previously 
described. However, no reaction occurred, probably due to the insolubility of sophorolipid methyl 
ester 89a in dichloromethane. Tetrahydrofuran was evaluated as alternative solvent since it is also 
compatible with ozonolysis reactions, but although some reaction occurred, the formation of 
sophorolipid aldehyde 198 could not be observed. 
 
Scheme 47. Synthesis of sophorolipid aldehyde 198 via alkaline methanolysis and ozonolysis 
To prevent unwanted side-reactions during the ozonolysis, the sugar head of sophorolipid methyl 
ester 89a was protected with acetyl groups. Both acetyl chloride and acetic anhydride were 
evaluated for this protection step (Scheme 48). Acetylation with 7 equivalents of acetyl chloride in 
pyridine only resulted in mono-, di-, tri- and tetra-acetylation of sophorolipid methyl ester 89a. Even 
with 25 equivalents of acetyl chloride, no complete acetylation could be obtained. Acetylation with 
acetic anhydride was performed according to a literature procedure and resulted in the complete 
acetylation towards peracetylated sophorolipid methyl ester 114a.89 The amount of acetic anhydride 
could be reduced to 7.05 equivalents and the reaction time was reduced to 1 hour. Peracetylated 
sophorolipid methyl ester 114a was obtained in quantitative yield and high purity after reaction 
work-up. Further purification via column chromatography with a 7:3 mixture of petroleum 
   Results and discussion 
47 
 
ether/ethyl acetate as eluent was performed, resulting in a yield of 76%. However, this purification 
step had no significant effect on the ozonolysis reaction and was therefore not repeated. Ozonolysis 
of this protected sophorolipid ester in dichloromethane resulted in the synthesis of the desired 
sophorolipid aldehyde 201. 
 
Scheme 48. Acetylation of sophorolipid methyl ester 89a and subsequent ozonolysis towards sophorolipid aldehyde 201 
Different methods were evaluated for the purification of sophorolipid aldehyde 201. At first, the 
purification was attempted via the formation of the sodium bisulfite adduct 202 (Scheme 49). 
Different solvents, reaction conditions and bases were evaluated for the bisulfite addition and the 
reverse reaction (Table 1). The best results were obtained for entry 8, but these results were not 
reproducible. Although it was possible to isolate sophorolipid aldehyde 201 from the reaction 
mixture in the absence of methyl 9-oxononanoate, the yields were always very low. High amounts of 
the sodium bisulfite adduct 202 were still present in the organic phase after extraction or filtration, 
indicating that its solubility in the organic phase is too high. In view of the bad results obtained for 
the bisulfite addition reaction, this procedure was not suitable for the purification of sophorolipid 
aldehyde 201. 
 
Scheme 49. Sophorolipid aldehyde purification via the formation of the sodium bisulfite adduct 202 
Therefore, it was attempted to purify sophorolipid aldehyde 201 via column chromatography. 
Chromatography on normal phase silica with a 6:4 mixture of petroleum ether/ethyl acetate was 
performed, resulting in a yield up to 66%. However, large amounts of solvent were needed to elute 
sophorolipid aldehyde 201 from the column. Other attempts with 5% methanol in dichloromethane 
as eluent on normal phase silica and a 6:4 mixture of petroleum ether/ethyl acetate on alumina 
resulted in lower yields (38% and 49% respectively). Therefore, the use of automated column 
chromatography was evaluated. This alternative purification procedure could drastically reduce the 
amount of solvent and time necessary for the purification. When a gradient of 1 column volume (CV) 
at 89:11 petroleum ether/ethyl acetate, 10 CV to 10:90 petroleum ether/ethyl acetate and 1 CV at 
10:90 petroleum ether/ethyl acetate was applied, sophorolipid aldehyde 201 could be purified in a 
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yield up to 67%. The purity of the product could be increased by applying a gradient of 2 CV at 20:80 
diethyl ether/hexane, 15 CV to 100% diethyl ether and 8 CV at 100% diethyl ether. 
Table 1. Conditions for the bisulfite addition and reverse reaction in the purification of sophorolipid aldehyde 201 
 Bisulfite addition Reverse reaction 
Entry NaHSO3 Solvent Time Temp. Isolation Base Solvent Time Yield 
1 1.1 eq 
EtOAc / 
H2O (1:1) 
18h rt Extraction 
4.5 eq 
K2CO3 
EtOAc 2h 16% 
2 2.2 eq dry CH2Cl2 18h  Extraction 
5 eq 
K2CO3 
EtOAc 2h 3% 
3 2.2 eq 
EtOAc / 
hexane 
18h 30 °C Filtration 
2.5 eq 
K2CO3 
EtOAc 2h 8% 
4 4.4 eq 
MeOH / 
H2O (5:1) 
90’ rt Extraction 
5 eq 
K2CO3 
EtOAc 2h / 
5 4.4 eq 
ACN /  
H2O (5:1) 
90’ rt Extraction 
5 eq 
K2CO3 
EtOAc 2h 32% 
6 10 eq 
EtOAc / 
H2O (5:1) 
30’ 
30’ 
40 °C 
0 °C 
Filtration 
5 eq 
K2CO3 
EtOAc 10’ 6% 
7 10 eq 
ACN /  
H2O (5:1) 
15’ 
45’ 
40 °C 
0 °C 
Filtration 
5 eq 
K2CO3 
H2O /  
ACN (5:1) 
2h / 
8 5 eq 
ACN /  
H2O (5:1) 
15’ 
45’ 
40 °C 
0 °C 
Extraction 
5 eq 
NaHCO3 
EtOAc 30’ 38% 
9 10 eq 
EtOAc / 
H2O (5:1) 
15’ 
45’ 
40 °C 
rt 
Extraction 
5 eq 
NaHCO3 
EtOAc 30’ 46%* 
10 
10 eq 
(aq.)** 
EtOH 30’ 0 °C Filtration 
10 eq 
NaHCO3 
EtOAc 30’ / 
11 
10 eq 
(aq.)** 
Et2O 30’ 0 °C Filtration 
10 eq 
NaHCO3 
EtOAc 30’ / 
* Product was not completely pure after the purification step 
** aq. = aqueous solution 
3.1.2. Optimization of the synthetic pathway towards the sophorolipid aldehyde 
For the first reaction step, i.e. the alkaline methanolysis with sodium methoxide in methanol, the 
quality of the sophorolipid starting material proved to be a critical factor. The best results were 
obtained with sophorolipid lactones derived from fermentations using oleic acid and yeast extract. A 
Starmerella bombicola lactone esterase overexpression strain (oe sble) was used for the selective 
synthesis of diacetylated sophorolipid lactone 1.22 Pure sophorolipid methyl ester 89a could be 
obtained after precipitation in a yield ranging from 58 to 90%. With sophorolipid lactones from 
fermentations using canola oil and corn steep liquor (CSL), problems were encountered during the 
reaction work-up since precipitation of the product did not occur. This lack of precipitation after 
alkaline methanolysis of sophorolipid lactones from fermentations using canola oil and CSL could be 
solved by washing the starting product with an aqueous sodium bicarbonate solution after 
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dissolution in ethyl acetate. Although the lack of precipitation was hereby circumvented, an extra 
step was added to the synthetic pathway. To determine whether the lack of precipitation was due to 
the canola oil or CSL, synthesis of sophorolipid methyl ester 89a was also performed on sophorolipid 
lactones derived from a fermentation using canola oil and yeast extract. The reaction was performed 
in parallel with the alkaline methanolysis of sophorolipid lactones from a fermentation using oleic 
acid and yeast extract on the one hand, and canola oil and CSL on the other hand. For the alkaline 
methanolysis of the sophorolipid lactones from a fermentation using canola oil and yeast extract, 
precipitation was obtained after reaction work-up, but the obtained yield was lower compared to 
product derived from the fermentation using oleic acid (54% versus 70%). Moreover, a more 
heterogeneous product was obtained, which can be expected since canola oil still contains other 
fatty acids next to oleic acid. Diacetylated sophorolipid lactones obtained from fermentations using 
oleic acid and yeast extract are thus clearly more suitable for this synthetic pathway. On the one 
hand, the use of yeast extract is necessary to obtain precipitation of sophorolipid methyl ester 89a 
after reaction work-up. On the other hand, oleic acid is preferred to obtain a higher yield and a more 
homogeneous product. 
At first, the ozonolysis reaction was performed in dichloromethane and dimethyl sulfide was used for 
the reductive work-up towards sophorolipid aldehyde 201. Although the desired product could be 
isolated in high yield, the methyl 9-oxononanoate by-product could not be detected via LC-MS 
analysis. Instead, only the presence of the stable 1,2,4-trioxolane (ozonide) intermediate 203 was 
observed (Figure 5). The presence of high concentrations of residual ozonides after reaction work-up 
with dimethyl sulfide has already been described by the research group of Patrick Dussault.114 As the 
isolation of methyl 9-oxononanoate is most desirable for a green synthetic pathway, the formation of 
the ozonide intermediate 203 had to be prevented. This would have a positive effect on green 
chemistry metrics such as the environmental (E) factor and the atom economy. 
 
Figure 5. Methyl 9-oxononanoate derived ozonide intermediate 203 
Different procedures were evaluated to prevent the formation of the ozonide intermediate 203. All 
procedures are based on trapping the Criegee intermediate which is formed after decomposition of 
the primary ozonide. In a first attempt, 3 equivalents of N-methylmorpholine N-oxide were added to 
the ozonolysis reaction mixture (Scheme 50).114 The amine oxide can react with the Criegee 
intermediate to form a tetrahedral intermediate. Fragmentation of this intermediate will yield the 
desired aldehyde product. Work-up was performed by adding 1 equivalent of acetic acid and washing 
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the reaction mixture with water. However, both with dichloromethane and acetonitrile as solvent at 
0 °C, no complete reaction towards sophorolipid aldehyde 201 was obtained. 
 
Scheme 50. Ozonolysis reaction in the presence of N-methylmorpholine N-oxide 
Also water was evaluated as trapping agent. Therefore, the ozonolysis reaction was performed in a 
mixture of 5% water in acetonitrile at 0 °C (Scheme 51).115 After the reaction, 1 equivalent of sodium 
bisulfite was added to destroy the peroxide formed during the reaction. Although complete 
conversion was obtained with this procedure, the formation of the ozonide intermediate 203 still 
occurred. 
 
Scheme 51. Ozonolysis reaction in the presence of water 
A final attempt comprised the use of methanol as trapping agent. Methanol (1 equivalent) was added 
to the reaction mixture in order to trap the Criegee intermediate as a hydroperoxyacetal (Scheme 
52).116 Reduction of the hydroperoxyacetal with sodium triacetoxyborohydride furnished the desired 
aldehyde. This procedure proved to be successful to prevent the formation of the ozonide 
intermediate 203. Care should be taken to add exactly 1 equivalent of sodium triacetoxyborohydride 
for the reductive work-up. In case more reducing agent was added, reduction towards the 
sophorolipid alcohol derivative could be detected as well via LC-MS analysis. 
 
Scheme 52. Ozonolysis reaction in the presence of methanol 
To develop a greener synthetic pathway, it was attempted to use methanol as solvent for the 
ozonolysis reaction in order to replace dichloromethane which is classified as a hazardous solvent. 
Good results were obtained for the first trials performed with product from small scale fermentation 
batches (3 L) using oleic acid and canola oil. The reaction temperature was first raised to 0 °C and 
later on to room temperature to avoid solubility problems which occurred at lower temperatures. To 
ensure safe reaction conditions, the flask was taped during the reaction. However, when the 
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ozonolysis reactions were performed with product derived from a fermentation using canola oil and 
CSL, the formation of an unwanted sophorolipid methyl acetal 204 was observed as well (Scheme 
53). The amount of sophorolipid methyl acetal 204 in the reaction product was estimated to be 25-
40% based on NMR analysis. Automated flash chromatography of the ozonolysis product did not 
result in the separation of sophorolipid aldehyde 201 from sophorolipid methyl acetal 204. The 
transformation of sophorolipid methyl acetal 204 back into sophorolipid aldehyde 201 was 
attempted with trifluoroacetic acid in a mixture of ethyl acetate and water, but was not always 
reproducible. The addition of oxalic acid pretreated silica was also not successful.117 Only stirring the 
reaction mixture for 4 hours with a 2 N hydrochloric acid solution in ethyl acetate could convert 
sophorolipid acetal 204 back to the desired sophorolipid aldehyde 201. However, a lower yield (only 
48%) was obtained after purification. 
 
Scheme 53. Synthesis of sophorolipid methyl acetal 205 during the ozonolysis reaction 
As the problems arose with product from the fermentation using canola oil and CSL, it was 
anticipated that the fermentation substrate caused the formation of sophorolipid acetal 204. 
However, when the ozonolysis was performed again on peracetylated sophorolipid methyl ester 
114a derived from an oleic acid fermentation, the formation of sophorolipid acetal 204 also 
occurred. This demonstrated that the acetal formation is not related to variations in the 
fermentation substrate. Since a catalytic amount of acid is generally used to induce acetal formation, 
it was assumed that the only remaining explanation was that some traces of acid were responsible 
for the formation of the unwanted sophorolipid acetal 204. To prove this, addition of sodium 
bicarbonate to the ozonolysis reaction was attempted in order to neutralize any traces of acid. With 
this new reaction procedure, the presence of sophorolipid acetal 204 in the reaction mixture was 
indeed no longer observed. The origin of the trace of acid is still unknown. The presence of acetic 
acid seems the most plausible option, deriving from the previous acetylation reaction with acetic 
anhydride or exempted from the sodium triacetoxyborohydride reducing agent. However, in one 
particular case where 1 equivalent of acetic acid was deliberately added, acetal formation was not 
observed. Nevertheless, only traces of acid can catalyze the formation of the sophorolipid acetal 204. 
Ethanol and isopropanol were also evaluated as solvents for the ozonolysis reaction. The use of these 
solvents could not prevent the acetal formation in the absence of sodium bicarbonate. Moreover, 
the Sudan III dye was not easily soluble in both solvents, which raised problems to determine the end 
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of the reaction. Therefore, methanol is the most suitable solvent for the ozonolysis reaction. 
However, a slight increase of impurities present in the ozonolysis reaction product could be detected 
when methanol was used as solvent instead of dichloromethane, overoxidation to the corresponding 
sophorolipid acid occurred more easily and slightly lower yields were generally obtained via 
automated column chromatography. The less visible color change in methanol than in 
dichloromethane could be the cause for the overoxidation. The optimized synthetic pathway for the 
synthesis of sophorolipid aldehyde 201 is depicted in Scheme 54. 
 
Scheme 54. Optimized synthetic pathway towards sophorolipid aldehyde 201 
Different green chemistry metrics were evaluated for the optimized synthetic pathway towards 
sophorolipid aldehyde 201 (Table 2).118 Two scenarios are evaluated, namely the isolation of only 
sophorolipid aldehyde 201 as desired product (Scenario A) which is compared to the isolation of 
sophorolipid aldehyde 201 together with methyl 9-oxononanoate as a valuable by-product 
(Scenario B). A first metric is the carbon efficiency (CE) which estimates the percentage of carbon 
from the reagents that is contained in the final product. This metric does not take into account the 
amount of solvent used and waste generated during the process such as the amount of solvent. A 
second metric is the atom economy (AE) which estimates the total amount of reagents that are 
incorporated into the final product. Also here, only the reagents which are incorporated into the final 
product are taken into account. Solvent use and waste generation are not quantified. A third metric 
is the reaction mass efficiency (RME) which takes into account the reaction yield, the atom economy, 
the stoichiometry of the reaction and the amount of waste products. This metric takes into account 
all process conditions and therefore offers a good estimation of the greenness of the overall 
synthetic pathway. The RME is inversely related to environmental (E-) factor. This fourth metric 
estimates the amount of waste produced for the synthesis of a certain amount of product. The 
E-factor thus also offers a good estimation of the greenness of the overall synthetic pathway. The 
calculated E-factors lie in the range of those for fine chemicals (5-50 kg/kg).118 
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Table 2. Overview of the green chemistry metrics for the production of only sophorolipid aldehyde 201 (Scenario A) and 
its production in combination with the isolation of the methyl 9-oxononanoate by-product (Scenario B). CE = carbon 
efficiency, AE = atom economy, SF = stoichiometric factor, RME = reaction mass efficiency,  = reaction yield, c = mass 
reaction catalyst, s = mass reaction solvent, w = mass reaction waste, m = mass target product. 
Parameter Formula Scenario A Scenario B 
CE (%) 
(Amount of carbon in product) ∗ 100
Total amount of carbon in reagents
 54 69 
AE (%) 
(Molecular weigth of product) ∗ 100
∑ Molecular weigth of reagents
 50 62 
SF 1 +
(AE) ∗ ∑ mass of excess reagent
Expected product mass at 100% yield
 1.0033 1.0032 
RME (%) ε ∗ (AE) ∗
1
SF
∗ [
1
1 +
ε ∗ (AE) ∗ (c + s + w)
(SF) ∗ m
] 0.048 0.060 
E-factor 
(kg/kg) 
Mass waste
Mass product
 17.55 9.53 
3.1.3. Synthesis of a sophorolipid alcohol intermediate 
In the course of the optimization of the synthetic pathway towards the sophorolipid aldehyde, the 
synthesis of sophorolipid alcohol 204 was also attempted (Scheme 55). When the reduction of 
sophorolipid aldehyde with sodium borohydride was performed in methanol, only the deprotected 
sophorolipid alcohol could be detected by LC-MS analysis. Changing the solvent to tetrahydrofuran 
solved this problem and sophorolipid alcohol 205 could be isolated in a high yield of 91%. The direct 
synthesis of sophorolipid alcohol 205 from peracetylated sophorolipid methyl ester 114a could also 
be performed by using sodium borohydride instead of sodium triacetoxyborohydride for the 
reductive work-up after the ozonolysis reaction. When 2 equivalents of the reducing agent were 
used, the presence of sophorolipid aldehyde 201 was also detected. Therefore, 2.5 equivalents had 
to be used to obtain complete reduction. Sophorolipid alcohol 205 was purified via automated 
column chromatography by applying a step-wise gradient of 10 column volumes (CV) at 20:80 ethyl 
acetate/petroleum ether, 10 CV at 30:70 ethyl acetate/petroleum ether, 20 CV at 40:60 ethyl 
acetate/petroleum ether, 5 CV at 80:20 ethyl acetate/petroleum ether and 5 CV at 90:10 ethyl 
acetate/petroleum ether. The yield of the purified sophorolipid alcohol 205 was 58%. However, this 
purification was not further optimized. 
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Scheme 55. Synthesis of intermediate sophorolipid alcohol 204 
3.1.4. Incorporation of petroselinic acid in sophorolipid derivatives towards a C12 
sophorolipid aldehyde 
In the previous section, the development of a synthetic pathway towards the C9 sophorolipid 
aldehyde 201 is described. This procedure was extended to the production of a C12 sophorolipid 
aldehyde via the incorporation of petroselinic acid in the sophorolipid structure. 
Petroselinic acid is a rather uncommon fatty acid. With its double bond at the 6,7-position, it is a 
positional isomer of oleic acid. The position of this double bond influences the properties of the fatty 
acid. For example, the melting point of petroselinic acid is 30 °C, while the melting point of oleic acid 
is only 14 °C.119 Petroselinic acid is found in high amounts in the seed oils from plants belonging to 
the Apiaceae family, also known as Umbelliferae, and the Araliaceae family.120 The quantity of 
petroselinic acid varies from 31 to 75% in the vegetable oil of fruits from Coriandrum sativum, one of 
the most enriched sources of petroselinic acid. This vegetable oil can be extracted from the fruits via 
twin-screw extrusion.121 Petroselinic acid is already applied in cosmetic formulations as a 
moisturizing and anti-aging agent, and as a skin-irritation reducing agent in -hydroxy acid containing 
compositions.122-124 Besides, a considerable antimicrobial activity against several bacteria, yeast and 
mold species was observed.120 Several modifications of petroselinic acid are described, among others 
towards surfactants and the nylon 66 precursor adipic acid.119-120, 125 When incorporated in 
triglycerides, lipolysis by pancreatic lipase occurs at a much lower efficiency than for oleic acid 
triglycerides.119, 126 Therefore, petroselinic acid rich oils may offer a low-fat alternative for 
conventional vegetable oils. It was also suggested that petroselinic acid inhibits the synthesis of 
arachidonic acid, which could counteract the vasoconstrictive effects related to arachidonic acid 
overproduction.127-128 
Being a structural isomer of oleic acid, petroselinic acid could be applied for the synthesis of a new 
type of sophorolipids. As the properties for petroselinic acid differ considerably from those of oleic 
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acid, it can be anticipated that petroselinic acid derived sophorolipids will possess different biological 
activities and self-assembly properties than the oleic acid based sophorolipids. Moreover, when the 
previously described synthetic pathway is applied to the petroselinic acid based sophorolipids, the 
synthesis of a C12 sophorolipid aldehyde can be accomplished. 
As mentioned before, petroselinic acid is the major fatty acid in the vegetable oil of Coriandrum 
sativum fruits. This vegetable oil was isolated via twin-screw extrusion at the Laboratoire de Chimie 
Agro-industrielle (ENSIACET, Université de Toulouse) via a previously reported procedure.121 The 
identification of the different fatty acids and their distribution in the vegetable oil was determined 
via gas chromatography analysis of the fatty acid methyl esters at the same research group (Table 3). 
Petroselinic acid is clearly the major fatty acid, constituting 73.3% of all fatty acids. Linoleic acid and 
oleic acid are present in a lower amount, respectively 13.9% and 5% of all fatty acids. The 
triglycerides from the vegetable oil were hydrolyzed into glycerol and a fatty acid mixture via an 
alkaline hydrolysis with sodium hydroxide (Scheme 56). Petroselinic acid 207 was isolated from the 
reaction mixture via crystallization in absolute ethanol. A high yield of 80% was obtained, based on 
the amount of petroselinic acid present in the vegetable oil. 
 
Scheme 56. Alkaline hydrolysis towards petroselinic acid 
Table 3. Fatty acid composition (%) of the vegetable oil of 
Coriandrium sativum fruits. SFA = saturated fatty acid; 
MUFA = monounsaturated fatty acid; PUFA = 
polyunsaturated fatty acid; n.d. = not detected. 
Fatty acid Content (%) 
Caproic acid (C6:0) n.d. 
Myristic acid (C14:0) 0.2 
Palmitic acid (C16:0) 3.3 
Palmitoleic acid (C16:1) 0.2 
Margaric acid (C17:0) n.d. 
Stearic acid (C18:0) 0.7 
Petroselinic acid (C18:1n-12) 73.3 
Oleic acid (C18:1n-9) 5.0 
cis-Vaccenic acid (C18:1n-7) 1.3 
Linoleic acid (C18:2) 13.9 
Linolenic acid (C18:3) 0.1 
Arachidic acid (C20:0) 0.1 
Gadoleic acid (C20:1) n.d. 
SFA 4.2 
MUFA 79.9 
PUFA 14.0 
Identified fatty acids 98.1 
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Petroselinic acid 207 was then used as substrate for microbial sophorolipid production. The 
sophorolipid fermentation was performed in cooperation with the InBio research group (Ghent 
University). A Starmerella bombicola lactone esterase overexpression strain (oe sble) was used for 
the selective synthesis of diacetylated sophorolipid lactone 208.22 The S. bombicola oe sble strain was 
cultivated on Lang medium (132 g/L glucose monohydrate; 4g/L yeast extract; 5 g/L sodium citrate 
tribasic dihydrate; 1.5 g/L NH4Cl; 1 g/L KH2PO4; 0.16 g/L K2HPO4; 0.7 g/L MgSO4∙7H2O; 0.5 g/L NaCl; 
0.27 g/L CaCl2∙2H2O) in a Biostat
® B 3 L culture vessel (Sartorius-BBI Systems) with a working volume 
of 1.1 L. Temperature (30 °C), pH (3.5), stirring rate, and air flow rate (1.5 L/min) were controlled by 
the Biostat® B control unit.129 100 mL of 30 h old shake flask cultures was used for inoculation of the 
culture vessel. 20 g of petroselinic acid was added to the reactor just after inoculation. From then on, 
an extra portion of 5 g petroselinic acid was added every 24 h. The fermentation parameters are 
depicted in Figure 6. The initial pH of 5.8 was allowed to drop spontaneously till 3.5 and was 
maintained at this value afterwards by automated addition of a 5 N NaOH solution. After 147 h of 
inoculation, glucose was almost completely depleted upon which additional glucose was added to 
the medium to ensure optimal sophorolipid production. After 18 h, the stirring rate was raised to 700 
rpm since the dissolved oxygen (pO2) dropped to 3%. After 163 h, the stirring rate was raised once 
more to 800 rpm since the produced sophorolipid lactones formed a highly viscous broth. 
Maintaining the dissolved oxygen at an adequate level is crucial for the sophorolipid production, 
since the cytochrome P450 monooxygenase enzyme requires aerobic conditions. The growth of the 
culture was monitored by measuring the optical density (OD). However, the determination of the 
amount of colony forming units (CFU) would have been more informative since residual fatty acids 
and produced sophorolipids can interfere with the OD measurement. 
 
Figure 6. Sophorolipid fermentation parameters depicted in function of time 
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The fermentation broth was transferred to a 2 L flask and the culture vessel was rinsed with 500 mL 
water which was also collected (Figure 7). The fermentation broth was kept overnight at 50 °C to 
induce precipitation of the sophorolipid lactones. Afterwards, the upper water layer which contains 
the yeast cells was removed, filtered over a Whatman filter and once more kept overnight at 50 °C to 
induce precipitation of residual sophorolipid lactones. The sophorolipid fraction was suspended in 
water, transferred to a 2 L erlenmeyer and shaken overnight at 4 °C to induce crystallization of the 
sophorolipid lactones. However, crystallization did not occur as is the case for oleic acid based 
sophorolipid lactones. Therefore, the dense sophorolipid phase was separated from the water phase, 
dissolved in ethyl acetate and washed with an aqueous sodium bicarbonate solution. The ethyl 
acetate phase was dried over magnesium sulfate and concentrated under reduced pressure. The 
water phase was also extracted with ethyl acetate, washed with sodium bicarbonate, dried over 
magnesium sulfate and concentrated under reduced pressure. After the downstream processing, a 
total amount of 44 g was obtained as a white powder from the combined ethyl acetate fractions. This 
corresponds to a total production of 40 g/L. 
 
Figure 7. Downstream processing for sophorolipid purification 
Pure diacetylated sophorolipid lactone 208 was obtained after the downstream processing as a white 
powder. Incorporation of de novo synthesized fatty acids such as oleic acid was not observed via 
NMR-analysis. Comparison of oleic acid based sophorolipid lactone 1 and petroselinic acid based 
sophorolipid lactone 208 via 13C-NMR clearly demonstrates the difference between the two 
sophorolipid compounds (Figure 8). This difference can be seen most clearly by comparing the peaks 
for the double bond carbon atoms. The difference in ppm value for both carbon peaks is much bigger 
for petroselinic based sophorolipid lactone 208 than for oleic acid based sophorolipid 1. Moreover, 
the presence of a minor fraction of another double bond moiety can be detected for oleic acid based 
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sophorolipid 1 which is not the case for petroselinic based sophorolipid lactone 208, indicating a 
higher purity for the latter compound. 
 
Figure 8. Comparison of oleic acid based sophorolipid lactone (A) and petroselinic acid based sophorolipid lactone (B) by 
13
C NMR 
Diacetylated sophorolipid lactone 208 was subsequently subjected to alkaline hydrolysis with NaOH 
to yield petroselinic acid based sophorolipid acid 209 (Scheme 57). For both petroselinic acid based 
sophorolipid compounds, the critical micelle concentration (CMC) value and the corresponding 
surface tension were determined and compared to their oleic acid based counterparts (Table 4). The 
CMC of a surfactant is the lowest concentration for which micelles are formed. The surface tension 
measurements were determined in cooperation with the Particle and Interfacial Technology Group 
(Ghent University). Much lower CMC values are obtained for the petroselinic acid based 
sophorolipids compared to their oleic acid based counterparts. However, the minimal surface tension 
at these CMC values is almost the same. A different spatial orientation of the hydrophilic and 
hydrophobic parts of the petroselinic acid based sophorolipids, due to which they experience less 
steric hindrance and repulsion, could explain their lower CMC values compared to their oleic acid 
based counterparts. After all, when a certain compound experiences more repulsion and the 
molecules can approach less close to each other, the air-water interface will be completely saturated 
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at a lower concentration, resulting in the formation of micelles at a lower concentration. To evaluate 
this hypothesis, the 3D structures of the oleic and petroselinic acid based sophorolipid lactones were 
simulated with the software Chem3D Pro 14.0 (Figure 9). These simulations support the hypothesis, 
since the hydrophilic and hydrophobic regions of the petroselinic acid based sophorolipid lactone 
appear to occupy a bigger area than those of the oleic acid based sophorolipid lactone. One should 
take into account that these simulations are only a first indication of the 3D structure, since quantum 
chemical calculations are necessary to obtain a realistic simulation of the standard geometry for each 
structure. However, a further investigation of the geometry of these compounds falls without the 
scope of this project. The increasing hydrophobicity for petroselinic acid based sophorolipid lactone 
compared to petroselinic acid based sophorolipid acid resulted in a decreasing CMC value, as was the 
case for their oleic acid based counterparts. 
 
Scheme 57. Alkaline hydrolysis towards petroselinic acid based sophorolipid acid 209 
Table 4. Comparison of the critical micelle concentration and corresponding 
surface tension for petroselinic acid (PA) and oleic acid (OA) based 
sophorolipid compounds 
 CMC (mg/L) Surface tension (mN/m) 
PA SL lactone 4.2 ± 0.1 34.3 ± 0.0 
OA SL lactone 45.1 ± 0.1 33.9 ± 0.7 
PA SL acid 154 ± 5 42.0 ± 0.3 
OA SL acid 245 ± 9 40.9 ± 0.3 
 
Figure 9. Simulation of the 3D structure of oleic acid based sophorolipid lactone (A) and petroselinic acid based 
sophorolipid lactone (B) with the software Chem3D Pro 14.0 after minimization of the energy for each structure 
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The previously described synthetic pathway was applied to the petroselinic acid based diacetylated 
sophorolipid lactone 208 for the synthesis of the C12 sophorolipid aldehyde 212 (Scheme 58). 
Sophorolipid lactone 208 was transformed into sophorolipid methyl ester 210 via alkaline 
methanolysis with 0.15 equivalents of sodium methoxide in methanol. Protection of the sugar head 
group via acetylation with acetic anhydride yielded peracetylated sophorolipid methyl ester 211. 
Cleavage of the double bond was obtained via ozonolysis in methanol with 1 equivalent of sodium 
bicarbonate and reductive work-up with 1 equivalent of sodium triacetoxyborohydride. C12 
sophorolipid aldehyde 212 was purified via automated column chromatography using a gradient of 2 
CV at 20:80 diethyl ether/hexane, 15 CV to 100% diethyl ether and 9 CV at 100% diethyl ether. 
 
Scheme 58. Chemical modification towards sophorolipid aldehyde 212 
3.1.5. Conclusions 
A synthetic pathway towards the desired sophorolipid aldehyde intermediate was successfully 
developed. The influence of the fermentation conditions and the concomitant purity of the starting 
product on the chemical derivatization proved to be a first critical factor. Diacetylated sophorolipid 
lactones obtained from fermentations with a Starmerella bombicola oe sble strain using oleic acid 
and yeast extract as substrate were most suitable as starting product. On the one hand, the use of 
this modified yeast strain and oleic acid as substrate is preferred to obtain a higher yield and a more 
homogeneous product. On the other hand, the use of yeast extract is necessary to obtain 
precipitation of the sophorolipid methyl ester 89a after reaction work-up. 
The ozonolysis reaction proved to be a second critical factor and can be addressed as the bottleneck 
of the synthetic pathway. In the optimized reaction procedure, the isolation of methyl 
9-oxononanoate as a valuable by-product was enabled and methanol is used as solvent instead of 
dichloromethane to increase the green character of the synthetic pathway. However, a slight 
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increase of impurities present in the ozonolysis reaction product could be detected, i.e. 
overoxidation to the corresponding sophorolipid acid occurred more easily and slightly lower yields 
were generally obtained via automated column chromatography. Green chemistry metrics were 
calculated for two scenarios where wheter or not the islation of the methyl 9-oxononanoate 
by-product was taken into account. For both scenarios, an E-factor was obtained which lies in the 
range of E-factors for fine chemicals. Future work could focus on the use of continuous flow 
microreactor technology to ensure a higher control of the reaction parameters, resulting in a higher 
selectivity and an increase in process efficiency and safety. Moreover, it would enable the safe-scale 
up, eventually to an industrial scale, of this potential dangerous reaction. 
The synthetic pathway was extended to the production of a sophorolipid alcohol intermediate by 
adjusting the reductive work-up of the ozonolysis reaction and to the production of a C12 
sophorolipid aldehyde via the incorporation of petroselinic acid in the sophorolipid structure. 
Therefore, this synthetic pathway resulted in the successful synthesis of three sophorolipid 
intermediates, i.e. sophorolipid aldehyde 201, sophorolipid alcohol 204, and C12 sophorolipid 
aldehyde 212 (Figure 10). 
 
Figure 10. Intermediate sophorolipid derivatives  
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3.2. Modification of the intermediate sophorolipid aldehyde towards 
new sophorolipid derivatives 
3.2.1. Reductive amination towards sophorolipid amines 
The intermediate sophorolipid aldehyde 201 was used for the formation of a broad set of innovative 
sophorolipid derivatives. The first step in this modification pathway comprised the synthesis of 
sophorolipid amines via reductive amination. 
The reductive amination with a variety of secondary amines was evaluated ( Scheme 59). 
Sophorolipid aldehyde 201 was dissolved in methanol, 1 equivalent of secondary amine, 
2 equivalents of sodium cyanoborohydride and 5 equivalents of acetic acid were added and the 
mixture was stirred overnight at room temperature. After evaporation of the solvent, the reaction 
product was dissolved in ethyl acetate for a washing step with sodium bicarbonate. When the 
reductive amination was performed with highly pure sophorolipid aldehyde 201, sophorolipid amines 
213 were obtained in high purity and no extra purification step was needed. However, further 
purification proved to be necessary to obtain highly pure product for further modification reactions 
when less pure sophorolipid aldehyde 201 was used. 
At first, the purification was attempted via acid-base extraction. After evaporation of the solvent, the 
reaction product was dissolved in ethyl acetate and 5 equivalents of acetic acid were additionally 
added. The mixture was stirred for 30 minutes and subsequently extracted with water. The combined 
water fractions were stirred for 30 minutes with 10 equivalents of sodium bicarbonate and 
subsequently extracted with ethyl acetate to isolate sophorolipid amines 213. However, the isolated 
yields were very low (1-50%), probably due to the hydrophobic character of sophorolipid amines 213 
which is induced by the acetyl groups. Moreover, this purification step generally did not result in an 
increased purity of the product. Therefore, automated column chromatography was also evaluated 
for the purification of sophorolipid amines 213. When a gradient with ethyl acetate/petroleum ether 
as eluent was applied, tailing of the sophorolipid amines on the column was observed. This tailing 
could be avoided by adding triethylamine to the eluent, resulting in the complete purification of the 
different sophorolipid amine derivatives. 
 
 Scheme 59. Reductive amination of sophorolipid aldehyde 201 towards sophorolipid amines 213  
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Reductive amination with primary amines was also evaluated. When the same reaction conditions 
were applied as for the reductive amination with secondary amines, a mixture of secondary 
sophorolipid amines 214 and bolaamphiphilic sophorolipid amines 215 was obtained (Scheme 60). 
The selective formation of either secondary sophorolipid amines 214 or bolaamphiphilic sophorolipid 
amines 216 was evaluated with methylamine (Scheme 61). For the reductive amination towards 
N-methyl sophorolipid amine 214a, 5 equivalents of methylamine were used and the mixture of 
sophorolipid aldehyde 201 and methylamine was stirred for 1 hour at room temperature prior to the 
addition of sodium cyanoborohydride and acetic acid. N-methyl sophorolipid amine 214a was 
obtained in high purity after reaction work-up and did not require further purification. N-methyl 
bolaamphiphilic sophorolipid amine 215a was selectively formed by using only 0.5 equivalents of 
methylamine and applying the same reaction conditions as described for the reductive amination 
with the secondary amines. The synthesis of more bolaamphiphilic sophorolipid amines 215 and their 
purification will be described in chapter 3.2.4. (Synthesis of bolaamphiphilic sophorolipids). 
 
Scheme 60. Reductive amination with primary amines towards a mixture of secondary sophorolipid amines 214 and 
bolaamphiphilic sophorolipid amines 215 
 
Scheme 61. Selective formation of N-methyl sophorolipid amine 214a and N-methyl bolaamphiphilic sophorolipid 215a 
The reductive amination with isopropylamine was also evaluated (Scheme 62). In contrast to the 
reductive amination with methylamine, sodium borohydride and acetic acid could be added together 
with 2 equivalents of the amine. An increased steric hindrance of the isopropyl group probably 
prevents a second reductive amination. N-isopropyl sophorolipid amine 214b was obtained in high 
purity after reaction work-up and did not require further purification. 
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Scheme 62. Reductive amination towards N-isopropyl sophorolipid amine 214b 
In the course of the development of the synthetic pathway towards sophorolipid aldehyde 201, the 
reductive amination of sophorolipid dialdehyde 197 was also evaluated with primary amines 
(Scheme 63). When the reaction was performed with 2 equivalents of primary amine, no formation 
of the desired sophorolipid diamine 216 could be detected by LC-MS analysis. Instead, the formation 
of an amino-sophorolipid lactone 217 was observed, which is in accordance with the results obtained 
for the reductive amination of sophorolipid aldehyde 201 with primary amines. 
 
Scheme 63. Reductive amination of sophorolipid dialdehyde 197 with primary amines 
Natural sophorolipid lactones possess better antimicrobial and anticancer activities than the 
sophorolipid acid derivatives (vide supra).46, 58 Therefore, it was attempted to selectively synthesize a 
varied set of amino-sophorolipid lactones 217 which could subsequently be quaternized in order to 
enhance their antimicrobial activity. According to the reductive amination of sophorolipid aldehyde 
201 with primary amines, the selective synthesis of amino-sophorolipid lactones 217 was attempted 
with 1 equivalent of methylamine, butylamine, benzylamine or octadecylamine (Scheme 64). 
Although the formation of methyl, benzyl and octadecyl sophorolipid lactones 217a, 217c and 217d 
was confirmed by LC-MS and NMR analysis, the purification of these derivatives via automated flash 
chromatography was not successful. An extensive evaluation of the purification of these derivatives 
and successful synthesis of butyl amino-sophorolipid lactone 217b still has to be performed. 
 
Scheme 64. Reductive amination of sophorolipid dialdehyde 197 towards amino-sophorolipid lactones 217 
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3.2.2. Synthesis of quaternary ammonium sophorolipids 
The sophorolipid tertiary amines 213 were used for the synthesis of a varied set of quaternary 
ammonium sophorolipids. Quaternization of the derivatives can have a great influence on the 
solubility and biological activity of the derivatives. For example, quaternary ammonium salts are a 
class of cationic surfactants which often possess antimicrobial activities. Moreover, several cationic 
lipids have proven to be efficient gene delivery vectors (vide infra). 
At first, it was attempted to synthesize the methyl carbonate quaternary ammonium salts 218 via 
reaction with dimethyl carbonate (Scheme 65).130 The reaction was performed in dry ethanol in a 
pressure vial with 10 equivalents of dimethyl carbonate. After evaporation of the solvent and excess 
of dimethyl carbonate, only the starting product could be detected by NMR-analysis. 
 
Scheme 65. Synthesis of methyl carbonate quaternary ammonium salts 218 
The quaternization reaction was also evaluated with butyl bromide (Scheme 66). The reaction was 
performed in acetone with 1 equivalent of butyl bromide and 5 equivalents of potassium carbonate. 
Also with this procedure, only the starting product could be detected by NMR-analysis. 
 
Scheme 66. Synthesis of bromide quaternary ammonium salts 219 
Alternatively, alkyl iodides were applied for the quaternization reaction. The reaction was performed 
in acetonitrile at room temperature with addition of 2.6 equivalents of methyl or butyl iodide at 0 °C. 
Although quaternization did occur with this procedure, only partial conversion was obtained after 
6 days. When the reaction was performed in a pressure vial at 80 °C with 5 equivalents of alkyl 
iodide, complete conversion could be obtained after 18 or 48 hours for quaternization with methyl or 
butyl iodide, respectively (Scheme 67). The quaternary ammonium sophorolipids 220 could be 
further purified via sonication of the product in ether. However, this purification was mostly not 
necessary. A set of nine different peracetylated quaternary ammonium sophorolipids 220 was 
synthesized (Table 5, Figure 11). Quaternization of N,N-dibenzyl sophorolipid amine 213g with butyl 
iodide was also attempted, but this reaction was not successful. 
Results and discussion   
66 
 
 
Scheme 67. Synthesis of iodide quaternary ammonium salts 220 
Table 5. Reaction conditions for the synthesis of quaternary ammonium sophorolipids 220 
Amine R3I Time (h) Yield (%) 
213a methyl iodide 18 220a 91 
213c methyl iodide 18 220b 89 
213d methyl iodide 18 220c 96 
213d butyl iodide 48 220d 94 
213e methyl iodide 18 220e quant. 
213f methyl iodide 18 220f 89 
213g methyl iodide 18 220g quant. 
213h methyl iodide 18 220h 98 
213h butyl iodide 48 220i quant. 
 
Figure 11. Library of peracetylated quaternary ammonium sophorolipids 220 
This set of nine peracetylated quaternary ammonium sophorolipids was deprotected to obtain water 
soluble quaternary ammonium salt derivatives. This deprotection was performed via an alkaline 
methanolysis with 0.15 equivalents of sodium methoxide in methanol (Scheme 68). The quaternary 
ammonium sophorolipids 221 could be further purified via sonication in acetone. This also resulted in 
the synthesis of a set of nine different quaternary ammonium sophorolipids (Table 6, Figure 12). 
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Scheme 68. Deprotection via alkaline methanolysis towards quaternary ammonium sophorolipids 221 
Table 6. Yield for the synthesis of quaternary ammonium sophorolipids 221 
Quaternary ammonium sophorolipid  Yield (%) 
220a  221a quant. 
220b  221b 88 
220c  221c quant. 
220d  221d quant. 
220e  221e quant. 
220f  221f quant. 
220g  221g 99 
220h  221h 97 
220i  221i 66 
 
Figure 12. Library of deprotected quaternary ammonium sophorolipids 221 
Measurement of the CMC value and the corresponding surface tension was attempted for the 
quaternary ammonium sophorolipids. The CMC of a surfactant is the lowest concentration for which 
micelles are formed. The surface tension measurements were determined in cooperation with the 
Particle and Interfacial Technology Group (Ghent University) via the Wilhelmy plate method (see 
Experimental procedures). The peracetylated quaternary ammonium sophorolipids 220 are not easily 
soluble in water. Sonication at elevated temperatures was necessary to dissolve the compounds at a 
concentration of 1 g/L. The measurements were performed with an intermediate washing step of the 
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platinum plate in a saturated sodium dodecyl sulfate solution. Without this washing step, it seemed 
that the platinum plate got contaminated with the product since measurement of pure water did no 
longer result in a surface tension of 72 mN/m. At a concentration of 1 g/L, the CMC was not reached 
for compounds 220a and 220f (Figure 13). Evaluation at higher concentrations was not performed 
due to the poor solubility of the compounds. The measurement of CMC values only makes sense 
when the compounds form a clear solution in water. 
The deprotected sophorolipid quaternary ammonium salts 221 are readily soluble in water. However, 
the CMC was not reached at a concentration of 1 g/L for compounds 221a and 221c (Figure 14). For 
compound 221c, extra measurements were performed starting at a concentration of 15.5 g/L. Even 
at this high concentration, the CMC was not reached. Evaluation at higher concentrations did not 
seem sensible in the light of surfactant properties. Surface tension measurements for compounds 
221b and 221h resulted in decreasing surface tensions for decreasing concentrations which is not 
sensible at all. It was not possible to perform sensible measurements for these compounds. One 
hypothesis that could explain these unexpected results is that other types of nanostructures are 
formed, which are dependent on the concentration of the compound. 
  
Figure 13. Surface tension measurements at different concentrations (logC) for compounds 220a (A) and 220f (B) 
 
Figure 14. Surface tension measurements at different concentrations (logC) for compounds 221a (A) and 221c (B) 
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The self-assembly behavior of the quaternary ammonium sophorolipid 220 and 221 was evaluated 
via small-angle X-ray scattering (SAXS) analysis (see Experimental procedures). The evaluation of the 
self-assembly was performed by Dr. Niki Baccile with the help of Lisa Van Renterghem and Isabelle 
Van de Velde. All samples were analyzed in milliQ grade water at room temperature in a final 
concentration of 0.5 wt %. The samples were then analyzed within 1 to 3 hours after sample 
preparation. The peracetylated quaternary ammonium sophorolipids 220 required sonication and 
heating to dissolve them completely. These samples revealed to be sensitive to the X-ray beam and 
underwent beam damage. To overcome this problem, which was probably due to the presence of 
the acetyl groups, short acquisition times in combination with a flow-through analysis were used. 
 
Figure 15. Small-angle X-ray scattering (SAXS) pattern with the q-value in function of the scattering intensity I 
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For almost all compounds, the curves display an intense scattering signal at q < 0.7 nm-1 (Figure 15). 
This pronounced scattering signal at low q-values indicates that large aggregates are formed. 
However, the amount of aggregates is probably quite low. At higher q-values, the signal is very low 
and noisy. The deprotected quaternary ammonium sophorolipids 221h and 221i, having an octadecyl 
chain on the nitrogen atom, display a scattering response which is very different from all other 
compounds. In this case, the signal shows a plateau at low q-values with a clear oscillation centered 
at a q-value around 4 nm-1. This shape is typical for spherical micelles and the model-independent 
Guinier analysis indicates a radius of 3.3 ± 0.1 nm for both samples. This nice behavior may be 
attributed to the presence of the long aliphatic chain in the quaternary ammonium sophorolipids, 
which is much shorter for all other derivatives. It can be hypothesized that if the quaternary 
ammonium group is located close to the carbohydrate head, a long aliphatic chain will be needed to 
provide a sufficient hydrophobic tail for micelle formation. More experiments such as transmission 
electron microscopy (TEM) analysis are needed to further study the self-assembly behavior of the 
quaternary ammonium sophorolipids. 
The antimicrobial activity of the quaternary ammonium sophorolipids 220 and 221 was evaluated 
together with sophorolipid aldehyde 201, sophorolipid alcohol 204 and tertiary sophorolipid amines 
213a-e/g-h. The evaluation of the antimicrobial activities was performed by the Laboratory for 
Microbiology (Ghent University). The Gram-negative strains Escherichia coli LMG 8063 and Klebsiella 
pneumoniae LMG 2095, and the Gram-positive strains Staphylococcus aureus LMG 8064 and Bacillus 
subtilis LMG 13579 were chosen as test strains. The bioassay was carried out in 96-well microtiter 
plates at a concentration of approximately 0.5 mg/mL of the test compound and 104 CFU/mL test 
bacteria. None of the test compounds showed significant growth inhibition of Escherichia coli LMG 
8063 and Klebsiella pneumoniae LMG 2095. Compounds 220b, 220c, 220d, 220e, 220f, 220g, 220h, 
220i, 221b, 221h and 221i showed significant growth inhibition of Staphylococcus aureus LMG 8064 
and Bacillus subtilis LMG 13579. 
For the active compounds, the minimum inhibitory concentration (MIC) was determined against a 
test panel of four Gram-positive strains, namely Staphylococcus aureus LMG 8064, Enterococcus 
faecium LMG 11397, Bacillus subtilis LMG 13579 and Streptococcus pneumoniae LMG 16738. The 
MIC value is considered as the lowest concentration of the test compound for which a lack of visible 
bacterial growth is observed. The bioassay was carried out in 96-well microtiter plates at a 
concentration range between 100 and 2.5 µg/mL or 1000 and 5 µg/mL of the test compounds for 
respectively strong or weak inhibitors and 104 CFU/mL test bacteria. The MIC values for the active 
compounds are given in Table 7 together with the MIC values for the antibiotic gentamicin sulfate. 
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Microscopic analysis in addition to the determination of the MIC values revealed that lysis of the cells 
occurred at the active concentrations. 
The lowest MIC values of 5 µg/mL was obtained with compounds 221h and 221i against all four 
Gram-positive test strains. Low MIC values of 10 µg/mL were obtained with compounds 220h and 
220i, also against all four Gram-positive test strains. Interestingly, these activities lie in the same 
concentration range as that of the antibiotic gentamicin sulfate. All four compounds perform as good 
or better as gentamicin sulfate against E. faecium and S. pneumoniae. Compounds 221h and 221i 
even perform as good as gentamicin sulfate against S. aureus and B. subtilis. For better comparison, 
the MIC values were converted on the basis of their molecular weight (Table 8). On this basis, we can 
conclude that compounds 220h, 220i, 221h and 221i are more active against all four Gram-positive 
test strains than the antibiotic gentamicin sulfate. 
Gentamicin sulfate is used to treat several types of antibiotic infections caused by the Gram-negative 
strains Pseudomonas aeruginosa, Proteus species, Escherichia coli, Klebsiella pneumoniae, 
Enterobacter aerogenes, Serratia marcescens and the Gram-positive meticillin-susceptible 
Staphylococcus species.131 This antibiotic is included by the World Health Organization (WHO) in the 
List of Essential Medicines.132 Its mode of action is binding to the 30S subunit of bacterial ribosomes, 
hereby preventing the protein synthesis. Gentamicin sulfate also binds to the lipopolysaccharide 
layer of Gram-negative bacteria, hereby disrupting the permeability of the cell wall. Although the 
quaternary ammonium sophorolipids 220h and 220i are not active against Gram-negative strains, 
their activity against Gram-positive strains can be considered as reasonably good. However, the fact 
that gentamicin sulfate is mostly active against Gram-negative strains makes it difficult to give an 
appreciation of the activity of the quaternary ammonium sophorolipids 220h and 220i in comparison 
with this antibiotic. Moreover, it should be taken into account that these results are obtained with in 
vitro testing and that further in vivo testing is necessary to determine the actual antibiotic potential 
of these compounds. It would have been more informative to include -lactam antibiotics as 
reference compounds since these are mostly active against Gram-positive strains. Their mode of 
action is inhibiting the synthesis of the peptidoglycan layer in the bacterial cell wall, resulting in 
cytolysis and cell death. Quaternary ammonium compounds are known to exert antibiotic properties. 
Their activity is related to their cationic surfactant properties and their mode of action is interacting 
with the cell membrane, resulting in cell damage and leaking.133-134 Microscopic analysis revealed that 
cell lysis occurred at the active concentrations, which supports both hypotheses. However, since 
these sophorolipid derivatives are quaternary ammonium compounds, the second hypothesis seems 
most plausible. More experiments are needed, for example with isotopic labeled derivatives, to 
determine the mode of action. 
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To evaluate the influence of the carbohydrate head on the antimicrobial properties, the 
deglycosylated derivatives of quaternary ammonium sophorolipids 220h and 221i were also 
synthesized. In a first step, the synthesis of hydroxylated quaternary ammonium salts 223 was 
attempted starting from N-methyl,N-octadecyl sophorolipid amine 213h (Scheme 69A). The 
sophorolipid amine was subjected to acid methanolysis, followed by purification via automated 
column chromatography. (S)-9-(methyl(octadecyl)amino)nonan-2-ol 222 was subsequently 
quaternized with methyl and butyl iodide towards the hydroxylated quaternary ammonium salts 
223a and 223b. These compounds possess a subterminal hydroxyl function, resulting from the 
stereoselective hydroxylation of the fatty acid in the fermentation process. Since this hydroxyl 
function could also influence the amphiphilic properties of the quaternary ammonium salts, synthesis 
of the non-hydroxylated quaternary ammonium salts 225 was attempted as well (Scheme 69B). 
N-methyl,N-nonyloctadecan-1-amine 224 was synthesized via reductive amination of nonanal and 
N-methyl,N-octadecylamine, followed by quaternization with methyl and butyl iodide towards the 
non-hydroxylated quaternary ammonium salts 225a and 225b. 
 
Scheme 69. Synthesis of hydroxylated and non-hydroxylated quaternary ammonium salts 223 and 225 
The antimicrobial activity of the deglycosylated quaternary ammonium salts 223 and 225 was 
evaluated together with the quaternary ammonium sophorolipids 220h-i and 221h-i and the natural 
diacetylated sophorolipid lactone 1 and sophorolipid acid 2. The evaluation of the antimicrobial 
activities was performed by the Laboratory of Pharmaceutical Microbiology (Prof. T. Coenye, Ghent 
University). The Gram-negative bacteria Escherichia coli LMG 8063, Klebsiella pneumoniae LMG 2095 
and Pseudomonas aeuruginosa PAO1, and the Gram-positive bacteria Staphylococcus aureus ATCC 
6538 and Staphylococcus aureus Mu50 (a multi-resistent strain) were chosen as test organisms. The 
bioassay was carried out in 96-well plates in a concentration series ranging from 1000 to 0.48 µg/mL 
of test compound and approximately 5 x 104 bacteria in a final volume of 200 µL. Only one of the 
compounds showed weak activity against one of the Gram-negative strains, i.e. quaternary 
ammonium sophorolipid 221i displayed a MIC1/2 of 500 µg/mL against P. aeruginosa. MIC1/2 is the 
minimum inhibitory concentration at which the growth of the strain is reduced by 50%. 
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For all ten compounds, both MIC and minimum bactericidal concentration (MBC) values were 
determined against the two Gram-positive strains (Table 9). The MBC value is considered as the 
lowest concentration of the test compound at which no more viability of the test organism can be 
observed. Therefore, it is an indication of the microbial death whereas the MIC value is only an 
indication of the inhibition of microbial growth. The MIC values obtained for the quaternary 
ammonium sophorolipids 220h-i and 221h-i against S. aureus ATCC 6538 were consistent with the 
previously obtained results.  
Table 9. Minimum inhibitory and bactericidal concentrations (µg/mL) against S. aureus ATCC 6538 and S. aureus Mu50 
  1 2 220h 220i 221h 221i 223a 223b 225a 225b 
S. aureus 
ATCC 6538 
MIC 31.25 >1000 7.81 7.81 1.95 1.95 1.95 1.95 31.25 15.63 
MBC 62.5 >1000 7.81 250 7.81 1.95 31.25 31.25 31.25 15.63 
S. aureus 
Mu50 
MIC 62.5 >1000 31.25 62.5 3.9 3.9 62.5 62.5 125 62.5 
MBC 62.5 >1000 62.5 250 15.63 15.63 62.5 62.5 125 125 
The best results were obtained for the deprotected quaternary ammonium sophorolipid 221h and 
221i against both S. aureus strains, especially when compared on basis of their molecular weight 
(Table 10). This clearly indicates that the presence of the carbohydrate head has a positive effect on 
the antimicrobial activity. Moreover, the hydroxylated quaternary ammonium salts 223 perform 
generally better than the non-hydroxylated quaternary ammonium salts 225. In view of these results, 
it can be hypothesized that an increased hydrophilic character of the compounds results in an 
increased antimicrobial activity. However, no conclusions on the mode of action can be made based 
on these data. 
Table 10. Minimum inhibitory and bactericidal concentrations (µM) against S. aureus ATCC 6538 and S. aureus Mu50 
  1 2 220h 220i 221h 221i 223a 223b 225a 225b 
S. aureus 
ATCC 6538 
MIC 45.4 >1607 6.59 6.36 2.18 2.09 3.44 3.21 56.68 26.33 
MBC 90.79 >1607 6.59 204 8.76 2.09 55.08 51.28 56.68 26.33 
S. aureus 
Mu50 
MIC 90.79 >1607 26.36 50.91 4.37 4.18 110 103 227 105 
MBC 90.79 >1607 52.72 204 17.53 16.73 110 103 227 211 
The deprotected quaternary ammonium sophorolipids 221h and 221i were evaluated on their ability 
to affect an already established biofilm of S. aureus ATCC 6538 and S. aureus Mu50. This biofilm 
assay was performed in 96-well plates with previously formed biofilms after removal of the 
non-adhered cells. At a concentration of 20 µg/mL of test compound, no effect was observed for 
both compounds against both S. aureus strains. This concentration was higher than both the MIC and 
MBC value of both compounds. 
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S. aureus Mu50 is a meticillin-resistant Staphylococcus aureus (MRSA) strain with vancomycin 
resistance. Therefore, the activities obtained with the quaternary ammonium sophorolipids 221h and 
221i against both S. aureus strains can be considered as reasonably good. However, it should be 
taken into account that these results are obtained with in vitro testing and that further in vivo testing 
is necessary to determine to actual antibiotic potential of these compounds. 
In view of the good antimicrobial activities obtained for the C9 quaternary ammonium sophorolipids 
which possess an octadecyl chain, the synthesis of their C12 counterparts was attempted (Scheme 
70). The C12 N-methyl,N-octadecyl sophorolipid amine 226 was synthesized via reductive amination 
of C12 sophorolipid aldehyde 212 with N-methyl,N-octadecylamine. Sophorolipid amine 226 was 
purified via automated column chromatography with an ethyl acetate/triethylamine/hexane mixture 
as eluent. The subsequent quaternization was performed with methyl and butyl iodide for 18 and 48 
hours, respectively, furnishing the corresponding peracetylated quaternary ammonium sophorolipids 
227 in high purity. Deprotection was performed with 2 equivalents of triethylamine in a mixture of 
methanol and water under reflux conditions.135 Evaporation of the reagent, solvent and methyl 
acetate byproduct yielded pure C12 quaternary ammonium sophorolipids 228. 
 
Scheme 70. Synthesis of C12 quaternary ammonium sophorolipids starting from sophorolipid aldehyde 212 
The antimicrobial activity of the peracetylated C12 quaternary ammonium sophorolipids 227 and the 
deprotected C12 quaternary ammonium sophorolipids 228 was evaluated together with the 
petroselinic acid based sophorolipid lactone 208 and sophorolipid acid 209. The evaluation of the 
antimicrobial activities was performed by the Laboratory of Pharmaceutical Microbiology (Prof. 
T. Coenye, Ghent University). The Gram-negative bacteria Escherichia coli LMG 8063, Klebsiella 
pneumoniae LMG 2095 and Pseudomonas aeruginosa PAO1, and the Gram-positive bacteria 
Staphylococcus aureus ATCC 6538 and Staphylococcus aureus Mu50 (a multi-resistant strain) were 
chosen as test organisms. The bioassay was performed as described for the deglycosylated 
derivatives 223 and 225 (vide supra). 
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Table 11. Minimum inhibitory concentrations (µg/mL) against S. aureus ATCC 6538 and S. aureus Mu50 
 208 209 227a 227b 228a 228b 
S. aureus ATCC 6538 31.25 >1000 15.63 15.63 62.5 31.25 
S. aureus Mu50 250 >1000 1000 500 62.5 62.5 
Only one of the compounds, i.e. deprotected quaternary ammonium sophorolipid 228a, showed 
weak activity against the two Gram-negative strains K. pneumoniae and P. aeruginosa with a MIC 
value of 1000 µg/mL against both organisms. For the petroselinic acid based sophorolipid lactone 
208 and sophorolipid acid 209, similar activities were obtained as their oleic acid based counterparts 
(Table 11). Only the activity of petroselinic acid based sophorolipid lactone 208 against S. aureus 
Mu50 is considerably lower than the activity of oleic acid based sophorolipid lactone 1. The activity 
of all four C12 quaternary ammonium sophorolipids is lower than their corresponding C9 quaternary 
ammonium sophorolipids, even when compared on a molecular basis (Table 12). Whereas the MIC 
values of the peracetylated quaternary ammonium sophorolipids 227 against S. aureus ATCC 6538 
still lie in the same concentration range as those of the corresponding C9 compounds, their MIC 
values against S. aureus Mu50 are much higher. The MIC values of the deprotected quaternary 
ammonium sophorolipids 228 against both S. aureus strains are also considerably higher than those 
of the corresponding C9 compounds. 
Table 12. Minimum inhibitory concentrations (µM) against S. aureus ATCC 6538 and S. aureus Mu50 
 208 209 227a 227b 228a 228b 
S. aureus ATCC 6538 45.40 >1607 12.73 12.31 66.9 32.03 
S. aureus Mu50 363.2 >1607 815 394 66.9 64.1 
The quaternary ammonium sophorolipids 220 and 221 and the deglycosylated quaternary 
ammonium salts 223 and 225 were also evaluated on their suitability as gene delivery vectors. These 
transfection efficacies were determined by the CEMCA UMR 6521 and INSERM UMR 1078 research 
groups (Prof. P.-A. Jaffrès, Brest University). Cationic lipids constitute a class of amphiphilic 
compounds which can be used to compact, protect and carry pDNA or other nucleic acids such as 
mRNA, shRNA or siRNA for in vitro or in vivo applications.136-140 This class of vectors was initially used 
by Felgner et al.141 Since then, many types of cationic lipids were designed, leading to a better 
understanding of the mode of action and the identification of efficient vectors.142-144 For example, 
recent clinical trials demonstrated some benefits for the administration of CFTR genes to cystic 
fibrosis patients using a cationic lipid as carrier.145 Moreover, synthetic vectors such as cationic lipids 
can be administered multiple times without any side reaction, in contrast to viral vectors which are 
efficient carriers for transfection but can induce an immune response from the first 
administration.146-147 Many cationic lipids possess a structure inspired on natural amphiphilic 
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compounds such as phospholipids with the aim to produce non-toxic or low-toxic vectors.148 
Recently, research is focusing on the development of renewable based gene delivery vectors, since 
natural derived products are expected to have an enhanced biocompatibility.149-162 Glycerol-based 
cationic lipids were widely studied and cationic lipids with natural lipid chains such as oleyl, linoleyl 
or phytanyl chains were used to produce efficient vectors.149-152 MacDonald and co-workers alkylated 
natural diacylglycerophosphocholine to produce cationic lipids.153-155 Aminoglycosides, spermine-
based vectors and trimethylarsonium-based compounds (these latter being widely present in sea 
food) were also incorporated as cationic polar head to produce efficient vectors for gene delivery.139, 
156-164 Therefore, the assessment of new natural cationic amphiphilic compounds for nucleic acid 
delivery is of great interest. In view of the multiple beneficial biological activities and self-assembly 
properties described for the natural sophorolipids (vide supra), cationic sophorolipid derivatives can 
be considered as suitable vectors for gene delivery. 
From the set of eighteen quaternary ammonium sophorolipids, five compounds (220a, 220h, 221a, 
221h and 221i) were evaluated for their ability to form supramolecular aggregates in water solution 
by using the method of hydration of a lipid film. In order to determine the importance of the 
carbohydrate head, the deglycosylated quaternary ammonium salts 223 and 225 were also 
evaluated. For all liposomal solutions, the size of the particles and their surface charge were 
determined via DLS and zeta measurements, respectively. The formation of a homogenous 
formulation is a necessary prerequisite for the evaluation of the suitability of quaternary ammonium 
salts as vectors for gene delivery. From the five compounds which were evaluated, only compounds 
221h and 221i produced homogenous formulations. For the other quaternary ammonium 
sophorolipids, their weak amphiphilic character (limited hydrophobic domain) likely explained the 
absence of well characterized nanoparticles in water. These results are consistent with the results 
obtained via the SAXS analysis. Compounds 221h, 221i, 223a/b and 225a/b were formulated with or 
without 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE). Especially for the quaternary 
ammonium sophorolipids 221h and 221i, and to a lesser extent for hydroxylated quaternary 
ammonium salts 223a/b, formulation with DOPE proved to be necessary to obtain homogenous 
formulations (Table 13). Formulations with DOPE also resulted in the formation of much smaller 
particles in comparison to formulations without DOPE. All zeta potentials were clearly positive as 
expected for liposomes generated from cationic lipid derivatives. 
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Table 13. Size and zeta potential measurements of liposomal solutions prepared at 1.5 mM without (left) or with (right) 
DOPE 
 Size (nm) Polydisp. index Zeta (mV) Size (nm) Polydisp. index Zeta (mV) 
    + DOPE 
221h 186 ± 110 0.94 29.9 54 ± 0.5 0.22 49.2 
221i 275 ± 49 0.56 27.9 94 ± 0.1 0.20 40.8 
223a 288 ± 23 0.53 35.9 35 ± 0.7 0.36 49.1 
223b 289 ± 9 0.30 27.6 43 ± 0.8 0.28 49.4 
225a 169 ± 2 0.34 42.4 47 ± 0.9 0.40 51.0 
225b 212 ± 5 0.37 24.7 78 ± 1.2 0.27 52.9 
The capacity to compact plasmid DNA (pDNA) was evaluated for all liposomal formulations by pDNA 
retardation assays on agarose gel electrophoresis. This was performed at different charge ratios (CR) 
which is defined as the number of positive charges provided by the cationic lipid derivative divided 
by the number of negative charges carried by the pDNA. A commercial lipofection agent, 
lipofectamine (LFM), and the cationic lipophosphoramidate BSV36 were used as reference 
compounds. In the absence of any co-lipid, no pDNA compaction was observed for any of the six 
compounds (Figure 16). When formulated with DOPE, quaternary ammonium sophorolipid 221h and 
221i still remained almost inefficient to compact pDNA (Figure 17). For hydroxylated quaternary 
ammonium salts 223a/b, very weak compaction was observed. Only both non-hydroxylated 
quaternary ammonium salts 225a/b demonstrated some ability to compact pDNA, at a similar level 
as LFM. Altogether, these results suggest that a better compaction of pDNA is obtained for less 
hydrophilic compounds. 
 
Figure 16. Ability for pDNA complexation of compounds 221h, 221i, 223a/b and 225a/b, formulated without DOPE, at 
various charge ratios (CR). For each compound, the profile of retardation assay (panel A) and the corresponding relative 
fluorescence intensity (panel B) of the lower DNA band (i.e. the supercoiled pDNA) are shown. The legend for panel B is 
given for each compound in panel A. 
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Figure 17. Ability for pDNA complexation of compounds 221h, 221i, 223a/b and 225a/b, formulated with DOPE, at 
various charge ratios (CR). For each compound, the profile of retardation assay (panel A) and the corresponding relative 
fluorescence intensity (panel B) of the lower DNA band (i.e. the supercoiled pDNA) are shown. The legend for panel B is 
given for each compound in panel A. 
The cationic lipids where then evaluated in respect of their ability to deliver DNA into various cell 
lines. Three human-derived cell lines were included, namely melanoma cells (SKMEL28) and two 
airway epithelial cells, i.e. lung carcinoma (A549) and normal bronchial (16HBE) cells. A fourth cell 
line was a mouse myoblast cell line (C2C12) which was only used for the evaluation of the 
formulations incorporating DOPE. A reporter (luciferase-encoding) pDNA was used that allowed the 
determination of the transfection efficiency via highly sensitive luminescence measurements. Each 
formulation was evaluated at different CR, similar to those previously considered for the DNA 
complexation assay. 
Concerning the efficiency of liposomes prepared without DOPE, only the ones derived from non-
hydroxylated quaternary ammonium salts 225a/b were able to transfect one of the cell lines studied 
(16HBE) (Figure 18). All other liposomes without DOPE were completely inefficient to transfect any of 
the considered cell lines. On the contrary, when formulated with DOPE, all derivatives demonstrated 
some ability to transfect one or more cell lines. The quaternary ammonium sophorolipids 221h and 
221i efficiently transfected 16HBE and A549 cell lines, whereas lower efficiencies were obtained for 
the transfection of SKMEL28 cell line (Figure 19). This observation could be related to the low 
compaction properties of the formulations of compounds 221h and 221i with DOPE as shown in 
Figure 19. Two hypotheses can be formulated: 1) Compared to cell lines A549 and 16HBE, cell line 
SKMEL28 requires efficient pDNA compacting agents to observe transfection that likely occurs via an 
endocytosis pathway. This hypothesis is consistent with the compaction properties of 225a/b or LFM 
and their respective transfection efficacies. 2) The second hypothesis would implicate a different 
mechanism that could involve the temporary poration of the membrane which was recently 
observed by Ilies and coworkers for another kind of cationic lipids.165 The quaternary ammonium 
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salts 223a/b and 225a/b were also efficient to deliver the pDNA into all four cell lines with the best 
results obtained at CR2 or CR4 (Figure 20). It can be noticed that the chemical structure of 225a/b is 
close to that of didodecyldimethylammonium bromide (DDAB) or dodecyltrimethylammonium 
bromide which were reported previously as vectors for gene delivery.166-167 
Regarding the toxicity of the different compounds, it is noteworthy that they exhibited quite 
different effects towards the viability of the cells. However, these effects were similar whether or not 
DOPE was incorporated in the formulation (Figrue 21). Quaternary ammonium salts 223a/b and 
225a/b were highly detrimental for the cells from a CR as low as 2 (Figure 22, Figure 23). This high 
toxicity was clearly associated with a decrease of the transfection efficacy at CR higher than 2, except 
for the C2C12 cell line where a decrease of the transfection efficacy occurred at CR higher than 4. 
This may be explained by a detergent effect exerted by these cationic amphiphilic compounds. On 
the contrary, quaternary ammonium sophorolipids 221h and 221i were much better tolerated by the 
cells. No real toxicity against SKMEL28 and only a moderate CR-dependent toxicity against the three 
other cell lines were noticed. These results strongly suggest that the biocompatibility of 
sophorolipids is – at least in part – due to the sugar group they specifically incorporate. Hence, 
despite that quaternary ammonium sophorolipids 221h and 221i poorly interacted with pDNA, they 
were clearly more efficient transfection vectors than their deglycosylated analogues 223a/b and 
225a/b since they exert a much lower toxicity to the different cell lines. Many recent reports 
highlight that there is no strict relationship between the ability of a given vector to retard DNA on 
agarose gel and its ability to transfect cells in vitro. Actually, a balance should be found between 
stability of complexes (in order to form aggregates dense enough to contact and enter cells) and 
lability (to release DNA once inside the cells).151, 168-169 However, no general conclusion can be drawn 
since such an equilibrium might depend on many parameters including the cationic lipid considered, 
the experimental conditions employed (e.g. the medium used to prepare the lipoplexes), the cells to 
treat, etc. Such a balance may also determine the toxicity experienced by the cells. 
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Different green chemistry metrics were also evaluated for the quaternary ammonium sophorolipids 
221h and 221i, which proved to be the most promising derivatives of this chapter (Table 14). For 
both compounds, the valorization of the methyl 9-oxononanoate by-product is taken into account. 
The three extra reaction steps for the synthesis of the quaternary ammonium sophorolipids from 
sophorolipid aldehyde 201 result in a fourfold increase of the E-factor. However, these values lie 
between the range of E-factors for fine chemicals (5-50) and pharmaceuticals (25-100). 
Table 14. Overview of the green chemistry metrics for the production of quaternary ammonium sophorolipids 221h and 
221i. CE = carbon efficiency, AE = atom economy, SF = stoichiometric factor, RME = reaction mass efficiency,  = reaction 
yield, c = mass reaction catalyst, s = mass reaction solvent, w = mass reaction waste, m = mass target product. 
Parameter Formula 221h 221i 
CE (%) 
(Amount of carbon in product) ∗ 100
Total amount of carbon in reagents
 60 61 
AE (%) 
(Molecular weigth of product) ∗ 100
∑ Molecular weigth of reagents
 55 56 
SF 1 +
(AE) ∗ ∑ mass of excess reagent
Expected product mass at 100% yield
 1.35 1.44 
RME (%) ε ∗ (AE) ∗
1
SF
∗ [
1
1 +
ε ∗ (AE) ∗ (c + s + w)
(SF) ∗ m
] 0.021 0.016 
E-factor 
(kg/kg) 
Mass waste
Mass product
 36.27 45.43 
3.2.3. Synthesis of sophorolipid amine oxides 
The sophorolipid tertiary amines 213 were also used for the synthesis of a varied set of sophorolipid 
amine oxides. Amine oxides possess non-ionic or cationic surfactant properties depending on the pH 
of the solution. Also here, oxidation of the derivatives can have a great influence on the solubility and 
biological activity of the derivatives. For example, the introduction of the polar N-oxide group 
increases the solubility of the compounds in water. Moreover, they are known to possess good 
foaming properties and to increase the skin compatibility of detergent products.170 
At first, the oxidation reaction was attempted with hydrogen peroxide which was considered as a 
green oxidizing agent since only water would be formed as byproduct. The reaction was performed in 
methanol at room temperature with 2 equivalents of hydrogen peroxide (Scheme 71).117 The excess 
of hydrogen peroxide was destroyed upon addition of 5 mg of platinum black. However, although 
   Results and discussion 
85 
 
some oxidation occurred, no complete conversion towards sophorolipid amine oxides 229 was 
obtained after 48 hours. When sodium bisulfite was used for the destruction of excess hydrogen 
peroxide, only starting product could be detected. Probably, sodium bisulfite reduces the formed 
sophorolipid amine oxide back to the sophorolipid amine. 
 
Scheme 71. Synthesis of sophorolipid amine oxides 229 by oxidation with hydrogen peroxide 
When the reaction was performed in methanol with 5 equivalents of hydrogen peroxide and 
2 equivalents of sodium hydroxide at 50 °C, complete conversion towards the deprotected 
sophorolipid amine oxides was obtained.171 However, the deprotected sophorolipid amine oxides 
could not be purified easily, neither for reaction with sodium hydroxide or sodium methoxide. 
Several attempts were performed to oxidize sophorolipid amines 213 with hydrogen peroxide 
without deprotection of the carbohydrate head. Performing the reaction in methanol with 
5 equivalents of hydrogen peroxide and 5 wt % dimethyl carbonate at 50 °C was not successful after 
3 hours. Different reaction conditions were evaluated for the oxidation of sophorolipid amines 213 in 
a pressure vial at elevated temperatures (Table 15). All reactions were performed with 5 equivalents 
of hydrogen peroxide. In all cases, synthesis of the desired sophorolipid amine oxides was detected, 
but partial or complete deprotection of the carbohydrate head took place during the reaction. 
Table 15. Reaction conditions for sophorolipid amine oxidation with 5 equivalents of hydrogen peroxide in a pressure vial 
Entry Solvent Temperature (°C) Time (h) Work-up Deprotection 
1 MeOH 90 3 Fe2O3 Partial 
2 MeOH 90 2 Fe2O3 Partial 
3 MeOH 50 1 Fe2O3 Partial 
4 ACN 50 1 Fe2O3 Partial 
5 MeOH 60 1 Pt black Partial 
6 MeOH (+ 0.15 eq NaOMe) 60 1 Fe2O3 Complete 
Oxidation of sophorolipid amines 213 was also evaluated via an ozonolysis reaction. In the work of 
the research group of Patrick Dussault, it is described that the ozonolysis of tertiary amines results in 
the formation of amine oxides, a procedure which was exploited by the researchers to prevent the 
formation of stable ozonide intermediates (vide supra).114 The reaction was performed in methanol 
which was sparged with ozone for 2 minutes (Scheme 72). Although the synthesis of peracetylated 
sophorolipid amine oxides 229 was detected, complicated reaction mixtures were mostly obtained. 
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Scheme 72. Synthesis of sophorolipid amine oxides 229 by oxidation with ozone 
Finally, 3-chloroperoxybenzoic acid (mCPBA) was evaluated for the synthesis of sophorolipid amine 
oxides 229. The reaction was performed in dry THF with 1.4 equivalents of mCPBA, first 30 minutes 
at 0 °C and then 90 minutes at room temperature.172 With mCPBA as oxidizing agent, complete 
conversion to the desired peracetylated sophorolipid amine oxides 229 was easily accomplished 
(Scheme 73). However, different conditions had to be evaluated to remove the benzoic acid 
byproduct from the reaction mixture. At first, the purification of sophorolipid amine oxides 229 was 
attempted via filtration over a basic alumina column when dissolved in ethyl acetate.172 Elution with 
methanol should furnish the purified amine oxides. However, benzoic acid was still present after the 
purification step. Secondly, purification was attempted via addition of potassium carbonate to the 
reaction and filtration of the solids. Also here, benzoic acid was still present after the purification 
step. Finally, the sophorolipid amine oxides 229 could be purified via a washing step with sodium 
bicarbonate when dissolved in ethyl acetate. Sophorolipid amine oxides 229 were obtained in high 
purity and did not require further purification. A set of seven different peracetylated sophorolipid 
amine oxides 229 was synthesized (Table 16, Figure 24). 
 
Scheme 73. Synthesis of sophorolipid amine oxides 229 by oxidation with mCPBA 
Table 16. Yield for the synthesis of sophorolipid amine oxides 229 
Sophorolipid amine Yield (%) 
213a 229a 79 
213c 229b 87 
213d 229c 93 
213e 229d 95 
213f 229e 94 
213g 229f 63 
213h 229g 92 
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Figure 24. Library of peracetylated sophorolipid amine oxides 229 
This set of seven peracetylated sophorolipid amine oxides was deprotected to obtain water soluble 
amine oxide derivatives. This deprotection was performed with 2 equivalents of triethylamine in a 
mixture of methanol and water under reflux conditions (Scheme 74).135 Evaporation of the reagent, 
solvent and methyl acetate byproduct yielded pure sophorolipid amine oxides 230. This also resulted 
in the synthesis of a set of seven different sophorolipid amine oxides (Table 17, Figure 25). 
 
Scheme 74. Deprotection towards sophorolipid amine oxides 230 
Table 17. Yield for the synthesis of sophorolipid amine oxides 230 
Sophorolipid amine oxide Yield (%) 
229a 230a quant. 
229b 230b 95 
229c 230c 84 
229d 230d quant. 
229e 230e 91 
229f 230f quant. 
229g 230g 81 
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Figure 25. Library of deprotected sophorolipid amine oxides 230 
The antimicrobial activity of both peracetylated and deprotected sophorolipid amine oxides 229 and 
230 was evaluated. The evaluation of the antimicrobial activities was performed by the Laboratory of 
Pharmaceutical Microbiology (Ghent University). The Gram-negative bacteria Escherichia coli LMG 
8063, Klebsiella pneumoniae LMG 2095 and Pseudomonas aeuruginosa PAO1, and the Gram-positive 
bacteria Staphylococcus aureus ATCC 6538 and Staphylococcus aureus Mu50 were chosen as test 
organisms. The bioassay was carried out in 96-well plates in a concentration series ranging from 1000 
to 0.48 µg/mL of test compound and approximately 5 x 104 bacteria in a final volume of 200 µL. Only 
sophorolipid amine oxide 230f showed weak activity against Pseudomonas aeruginosa PAO1 with a 
MIC1/2 value of 1000 µg/mL. These results demonstrate that the quaternary ammonium group of the 
quaternary ammonium sophorolipids 220 and 221 was the key factor to induce the antimicrobial 
activities, since no antimicrobial activity was demonstrated for these very similar sophorolipid amine 
oxides. 
3.2.4. Synthesis of bolaamphiphilic sophorolipids 
Bolaamphiphilic derivatives are amphiphilic compounds which contain two hydrophilic parts linked 
by a hydrophobic linker. Currently, there is a lot of interest in synthetic bolaamphiphiles because of 
the unusual architectures created by such molecules.173 They form monolayer membranes which can 
organize into micelles, vesicles, nanotubuli, etc. These configurations often arise spontaneously, they 
are self-organizing structures. The best known natural examples of bolaamphiphiles are the 
tetraether lipid membranes of the archaeabacteria which are able to grow under very extreme 
temperatures and at very high salt concentrations. These features are supposed to be linked to the 
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stability of the membranes due to the presence of the bolaamphiphiles. As a result, they can for 
example be used in drug delivery applications to form or stabilize vesicles. Most liposomes currently 
used for this purpose face stability problems.174 Moreover, bolaamphiphiles can be used as 
membrane-spanning linkers in biosensors to detect proteins, antibodies, viruses, etc.175 They can also 
serve as channels for ion transport.173 Fluorescent bolaamphiphiles can be used as transmembrane 
probes for lipid imaging to visualize for example ether lipids in the brain.176 
A first set of bolaamphiphilic sophorolipid derivatives was synthesized via reductive amination of 
sophorolipid aldehyde 201 with several diamines. A set of secondary diamines 231 with an ethylene-, 
hexamethylene- or o-phenylenelinker and methyl, butyl or octadecyl groups was selected for the 
synthesis of the desired bolaamphiphilic sophorolipids (Figure 26). Since only 
N,N’-dimethylethylenediamine 231a and N,N’-dimethylhexamethylenediamine 231b are 
commercially available, other secondary diamines had to be synthesized. 
 
Figure 26. N,N'-dialkyldiamines 231 as substrates for the reductive amination towards bolaamphiphilic sophorolipids 
The intermediate diamides 234 were synthesized via a Schotten-Bauman reaction with acid chlorides 
232 and diamines 233 (Scheme 75). Subsequently, these intermediate diamides were reduced with a 
borane tetrahydrofuran complex towards the desired N,N’-dialkyldiamines 231. With this procedure, 
a total set of eight different N,N’-dialkyldiamines 231 was available, including the commercially 
available N,N’-dimethylethylenediamine 231a and N,N’-dimethylhexamethylenediamine 231b. 
 
Scheme 75. Synthesis of N,N'-dialkyldiamines 231 
The synthesis of the desired bolaamphiphilic sophorolipids 235 was performed with 0.5 equivalents 
of N,N’-dialkyldiamines 231 according to the reaction conditions described for the synthesis of the 
tertiary sophorolipid amines 213 (Scheme 76). The reductive amination of sophorolipid aldehyde 201 
with N,N’-dialkyldiamines 231a-d resulted in the synthesis of the desired bolaamphiphilic 
sophorolipids 235a-d (Table 18). The compounds were purified via automated column 
chromatography with a hexane/ethyl acetate/triethylamine mixture as eluent. However, reductive 
amination with N,N’-dialkyldiamines 231e-h was not successful. In the case of 
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N,N’-dioctadecyldiamines 231e, 231f and 231h, a poor solubility of the diamines in the reaction 
solvent prevented the synthesis of the desired bolaamphiphilic sophorolipids. When tetrahydrofuran 
was evaluated as solvent instead of methanol, no reductive amination occurred either. In the case of 
N,N’-dibutyl-o-phenylenediamine 231g, the reductive amination did occur but no complete 
conversion could be obtained due to the steric hindrance caused by the close proximity of the two 
butyl groups. 
 
Scheme 76. Synthesis of bolaamphiphilic sophorolipids 235 via reductive amination with N,N’dialkyldiamines 231 
Table 18. Yield for the synthesis of N,N-dialkyl bolaamphiphilic sophorolipids 235 
Bolaamphiphilic sophorolipid R-group Linker Yield (%) 
235a Me ethylene 31 
235b Me hexamethylene 31 
235c Bu ethylene 41 
235d Bu hexamethylene 27 
235e C18H37 ethylene / 
235f C18H37 hexamethylene / 
235g Bu o-phenylene / 
235h C18H37 o-phenylene / 
Alternative procedures were evaluated for the synthesis of bolaamphiphilic sophorolipids with 
octadecyl groups on the nitrogen atom. At first, the introduction of the octadecyl group was 
attempted via quaternization of the N,N’-dimethyl bolaamphiphilic sophorolipids 235a and 235b with 
octadecyl iodide. However, no quaternization occurred with 2 equivalents of octadecyl iodide in 
acetonitrile or toluene as solvent after 72 hours (Scheme 77). 
 
Scheme 77. Quaternization of N,N'-dimethyl bolaamphiphilic sophorolipids 235a and 235b with octadecyl iodide 
Therefore, an alternative procedure was designed which comprised the formation of secondary 
bolaamphiphilic sophorolipid amines as intermediates. The synthesis of a set of secondary 
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bolaamphiphilic sophorolipid amines was attempted via reductive amination with primary diamines. 
At first, the synthesis was evaluated with 0.5 equivalents of primary diamines according to the 
reaction conditions described for the synthesis of the tertiary sophorolipid amines 213. With this 
procedure, a broad reaction mixture was obtained. In view of the results obtained for the synthesis 
of the secondary sophorolipid amines 214, similar overalkylations will cause the formation of this 
broad reaction mixture. Therefore, the mixture of sophorolipid aldehyde 201 and diamine was also 
stirred for 1 hour at room temperature prior to the addition of sodium cyanoborohydride and acetic 
acid (Scheme 78). This procedure proved to be successful with ethylenediamine but not with 
o-phenylenediamine. 
 
Scheme 78. Synthesis of bolaamphiphilic sophorolipids 237 via reductive amination with primary diamines 
Subsequently, an attempt was made to alkylate the ethylenediamine bolaamphiphilic sophorolipid 
237 with octadecyl iodide. No purification was performed prior to the alkylation. Therefore, no yield 
was determined for this intermediate. The reaction was performed with 2 equivalents of octadecyl 
iodide in toluene for 24 hours at room temperature (Scheme 79). However, also this procedure was 
not successful for the synthesis of N,N’-dioctadecyl bolaamphiphilic sophorolipid 235e. Only starting 
compound could be detected via NMR analysis. 
 
Scheme 79. Alkylation of ethylenediamine bolaamphiphilic sophorolipid 237 with octadecyl iodide 
Finally, two reductive aminations in sequence were evaluated for the synthesis of N,N’-dialkyl 
bolaamphiphilic sophorolipids 235 (Scheme 80). First, the mixture of sophorolipid aldehyde 201 and 
diamine was stirred for 1 hour at room temperature as previously described. Subsequently, 
1 equivalent of a second aldehyde is added, together with 4 equivalents of sodium cyanoborohydride 
and 5 equivalents of acetic acid. The reaction mixture was stirred overnight at room temperature and 
the reaction work-up was performed similarly as for the other reductive aminations. This dual 
reductive amination procedure was successful for the synthesis of N,N’-dibutyl bolaamphiphilic 
sophorolipid 235c, although the reaction product was less pure than the one obtained after reductive 
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amination with N,N’-dibutyl ethylene diamine 234c. However, when this dual reductive amination 
was applied for the synthesis of N,N’-dioctadecyl bolaamphiphilic sophorolipids 235e and 235f, the 
formation of the desired compounds could not be observed by NMR. Therefore, a set of only four 
different N,N’-dialkyl bolaamphiphilic sophorolipids 235 could successfully be synthesized (Figure 27). 
 
Scheme 80. Dual reductive amination towards N,N'dialkyl bolaamphiphilic sophorolipids 235 
 
Figure 27. Library of N,N’-dialkyl bolaamphiphilic sophorolipids 235 
This set of four N,N’-dialkyl bolaamphiphilic sophorolipids 235 was transformed into the deprotected 
N,N’-dialkyl bolaamphiphilic sophorolipids 238, peracetylated dicationic bolaamphiphilic 
sophorolipids 239 and deprotected dicationic bolaamphiphilic sophorolipids 240 (Scheme 81). The 
deprotection was performed with 2 equivalents of triethylamine in a mixture of methanol and water 
under reflux conditions as was already described for the amine oxides. Evaporation of the reagent, 
solvent and the methyl acetate byproduct yielded pure deprotected N,N’-dialkyl bolaamphiphilic 
sophorolipids 238, resulting in the synthesis of a set of four different derivatives (Table 19, 
Figure 28). 
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Scheme 81. Modification of N,N'-dialkyl bolaamphiphilic sophorolipids 235 via quaternization and deprotection 
Table 19. Yield deprotected N,N'-dialkyl bolaamphiphilic sophorolipids 238 
Bolaamphiphilic sophorolipid Yield (%) 
235a 238a 94 
235b 238b 95 
235c 238c 91 
235d 238d 89 
 
Figure 28. Library of deprotected N,N’-dialkyl bolaamphiphilic sophorolipids 238 
The quaternization was performed in a pressure vial with 10 equivalents of methyl iodide. After 
48 hours, complete conversion towards the dicationic bolaamphiphilic sophorolipids 239 was 
obtained and no further purification of the derivatives was required. This resulted in the synthesis of 
a set of four different peracetylated dicationic bolaamphiphilic sophorolipids (Table 20, Figure 29). In 
a previous research project at our research group, the double quaternization of a 
bis(7-azabicyclo[2.2.1.]heptane) derivative with an ethylene linker to a dicationic compound proved 
to be unsuccessful, even upon reaction with 20 equivalents of methyl iodide at room temperature.177 
Therefore, it could be anticipated that the large charge repulsion on the small ethylene linker could 
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also inhibit the formation of the dicationic bolaamphiphilic sophorolipids 239a and 239c. However, 
NMR-analysis clearly confirmed the successful synthesis of both compounds. 
Table 20. Yield peracetylated dicationic bolaamphiphilic sophorolipids 239 
Bolaamphiphilic sophorolipid Yield (%) 
235a 239a quant. 
235b 239b quant. 
235c 239c 93 
235d 239d 94 
 
Figure 29. Library of peracetylated dicationic bolaamphiphilic sophorolipids 239 
The deprotection of the quaternary ammonium bolaamphiphilic sophorolipids 239 was performed 
with 2 equivalents of triethylamine in a mixture of methanol and water under reflux conditions as 
was already described before. Evaporation of the reagent, solvent and methyl acetate byproduct 
yielded pure deprotected dicationic bolaamphiphilic sophorolipids 240. This resulted in the synthesis 
of a set of four different deprotected dicationic bolaamphiphilic sophorolipids (Table 21, Figure 30). 
Table 21. Yield deprotected dicationic bolaamphiphilic sophorolipids 240 
Quaternary ammonium 
bolaamphiphilic sophorolipid Yield (%) 
239a 240a 96 
239b 240b 96 
239c 240c 79 
239d 240d 94 
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Figure 30. Library of deprotected dicationic bolaamphiphilic sophorolipids 240 
Another class of bolaamphiphilic sophorolipids was synthesized via the reductive amination of 
sophorolipid aldehyde 201 with primary amines (vide supra). The selective formation of N-alkyl 
bolaamphiphilic sophorolipid amines 215 was accomplished by using only 0.5 equivalents of primary 
amine and applying the same reaction conditions as described for the reductive amination with the 
secondary amines (Scheme 82). A set of four different peracetylated N-alkyl bolaamphiphilic 
sophorolipid amines 215 was synthesized. Purification was first attempted via automated column 
chromatography with different gradients of a hexane/ethyl acetate/triethylamine mixture as eluent. 
However, this purification was only successful for N-methyl bolaamphiphilic sophorolipid 215a. For 
the other three derivatives, the purification was performed via preparative TLC with ethyl acetate as 
eluent, resulting in pure peracetylated N-alkyl bolaamphiphilic sophorolipid amines 215b-d (Table 22, 
Figure 31). 
 
Scheme 82. Synthesis of bolaamphiphilic sophorolipids 215 via reductive amination with primary amines 
Table 22. Yield for the synthesis of bolaamphiphilic sophorolipids 215 
Bolaamphiphilic sophorolipid R-group Yield (%) 
215a Me 55 
215b Bu 15 
215c Bn 39 
215d C18H37 18 
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Figure 31. Library of N-alkyl bolaamphiphilic sophorolipids 215 
This set of four peracetylated N-alkyl bolaamphiphilic sophorolipids 215 was transformed into the 
deprotected N-alkyl bolaamphiphilic sophorolipids 241, peracetylated monocationic bolaamphiphilic 
sophorolipids 242 and deprotected monocationic bolaamphiphilic sophorolipids 243 (Scheme 83). 
The deprotection was performed with 2 equivalents of triethylamine in a mixture of methanol and 
water under reflux conditions. Evaporation of the reagent, solvent and the methyl acetate byproduct 
yielded pure deprotected N-alkyl bolaamphiphilic sophorolipids 241, resulting in the synthesis of a 
set of four different deprotected N-alkyl bolaamphiphilic derivatives (Table 23, Figure 32). 
 
Scheme 83. Modification of N-alkyl bolaamphiphilic sophorolipids 215 via quaternization and deprotection 
Table 23. Yield deprotected N-alkyl bolaamphiphilic sophorolipids 241 
Bolaamphiphilic sophorolipid Yield (%) 
215a 241a quant. 
215b 241b 92 
215c 241c 80 
215d 214d 99 
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Figure 32. Library of deprotected N-alkyl bolaamphiphilic sophorolipids 241 
The quaternization was performed in a pressure vial with 5 equivalents of methyl iodide. After 
18 hours, complete conversion towards the quaternary ammonium bolaamphiphilic sophorolipids 
242 was obtained and no further purification of the derivatives was required. This resulted in the 
synthesis of a set of four different peracetylated monocationic bolaamphiphilic sophorolipids 
(Table 24, Figure 33). 
Table 24. Yield peracetylated monocationic bolaamphiphilic sophorolipids 242 
Bolaamphiphilic sophorolipid Yield (%) 
215a 242a 94 
215b 242b 95 
215c 242c 96 
215d 242d 97 
 
Figure 33. Library of peracetylated quaternary ammonium bolaamphiphilic sophorolipids 242 
The deprotection of the peracetylated monocationic bolaamphiphilic sophorolipids 242 was 
performed with 2 equivalents of triethylamine in a mixture of methanol and water under reflux 
conditions as was already described before. Evaporation of the reagent, solvent and the methyl 
acetate byproduct yielded pure deprotected monocationic bolaamphiphilic sophorolipids 243, 
resulting in a set of four different deprotected monocationic bolaamphiphilic sophorolipids (Table 25, 
Figure 34). 
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Table 25. Yield deprotected monocationic bolaamphiphilic sophorolipids 243 
Bolaamphiphilic sophorolipid Yield (%) 
242a 243a 80 
242b 243b 96 
242c 243c 96 
242d 243d 95 
 
Figure 34. Library of deprotected monocationic bolaamphiphilic sophorolipids 243 
The antimicrobial activity of the peracetylated and deprotected N,N’-dialkyl bolaamphiphilic 
sophorolipids 235 and 238, peracetylated and deprotected dicationic bolaamphiphilic sophorolipids 
239 and 240, peracetylated and deprotected N-alkyl bolaamphiphilic sophorolipids 215 and 241, and 
peracetylated and deprotected monocationic bolaamphiphilic sophorolipids 242 and 243 was 
evaluated. The evaluation of the antimicrobial activities was performed by the Laboratory of 
Pharmaceutical Microbiology (Prof. T. Coenye, Ghent University). The Gram-negative bacteria 
Escherichia coli LMG 8063, Klebsiella pneumoniae LMG 2095 and Pseudomonas aeruginosa PAO1, 
and the Gram-positive bacteria Staphylococcus aureus ATCC 6538 and Staphylococcus aureus Mu50 
were chosen as test organisms. The bioassay was carried out in 96-well plates in a concentration 
series ranging from 2500 to 1.22 µg/ml of test compound and approximately 5 x 104 bacteria in a 
final volume of 200 µL. None of the evaluated compounds showed activity against the three Gram-
negative strains. A set of eleven bolaamphiphilic sophorolipids showed activity against one or both of 
the Gram-positive strains (Table 26). 
Table 26. Minimum inhibitory concentrations (µg/ml) against S. aureus ATCC 6538 and S. aureus Mu50 
 235b 239a 239b 239c 239d 241b 242a 242b 242c 243c 243d 
S. aureus ATCC 6538 625 312 156 39 78 625 156 78 78 156 156 
S. aureus Mu50 2500 1250 625 312 78 >2500 312 78 78 >2500 312 
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For a better comparison of the evaluated derivatives with each other and with the previous set of 
quaternary ammonium sophorolipids, the MIC values were converted based on their molecular 
weight (Table 27). Within this set of bolaamphiphilic sophorolipid derivatives, the peracetylated 
dicationic and monocationic congeners 239 and 242 proved to be the most active. The highest 
activity was obtained for peracetylated N,N’-dibutyl,N,N’-dimethyl ethylene bolaamphiphilic 
sophorolipid diaminium diodide 239c. However, this MIC value is still a tenfold higher than the one 
obtained for the deprotected quaternary ammonium sophorolipids 221h and 221i. 
Table 27. Minimum inhibitory concentrations (µM) against S. aureus ATCC 6538 and S. aureus Mu50 
 235b 239a 239b 239c 239d 241b 242a 242b 242c 243c 243d 
S. aureus ATCC 6538 375 165 80 20 38 392 92 45 44 132 116 
S. aureus Mu50 1501 660 321 158 38 >1569 184 45 44 >2114 232 
3.2.5. Conclusions 
Four different classes of sophorolipid derivatives were successfully synthesized: intermediate 
sophorolipid amines, quaternary ammonium sophorolipids, sophorolipid amine oxides and 
bolaamphiphilic sophorolipids. 
The purity of the sophorolipid amines after reductive amination proved to be highly dependent on 
the quality of the sophorolipid aldehyde. No extra purification step was needed after reductive 
amination with highly pure sophorolipid aldehyde which was derived from ozonolysis reactions with 
dichloromethane as solvent. However, further purification proved to be necessary in case methanol 
was used as solvent for the ozonolysis reaction due to the slightly decreased purity of this ozonolysis 
product. Therefore, a balance should be found between the green character of the ozonolysis solvent 
and its influence on the purity and concomitant purification steps of the sophorolipid amine 
derivatives after reductive amination. As stated before, the use of continuous flow microreactor 
technology could offer a solution to increase the purity of the sophorolipid aldehyde synthesized via 
ozonolysis in methanol. 
All derivatives have been evaluated for their antimicrobial activity against a set of Gram-positive and 
Gram-negative strains. None of the derivatives displayed significant activity against any of the 
Gram-negative strains. The quaternary ammonium sophorolipids, monocationic bolaamphiphilic 
sophorolipids and dicationic sophorolipids proved to be the most active derivatives. The best results 
were obtained for the deprotected quaternary ammonium sophorolipids which possess an octadecyl 
chain on the nitrogen atom (Figure 35). These derivatives were even more active than the antibiotic 
gentamicin sulfate against the four Gram-positive strains S. aureus, E. faecium, B. subtilis and S. 
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pneumoniae in in vitro evaluations. Moreover, evaluation of the deglycosylated derivatives of these 
two quaternary ammonium sophorolipids demonstrated that the presence of the carbohydrate head 
has a positive effect on the antimicrobial activity. 
 
Figure 35. Quaternary ammonium sophorolipids 221h and 221i 
Evaluation of the quaternary ammonium sophorolipids on their suitability as gene delivery vectors 
indicated that these same two quaternary ammonium sophorolipids with an octadecyl chain were 
the most efficient derivatives. Moreover, evaluation of their deglycosylated derivatives 
demonstrated that the presence of the carbohydrate head highly increased the cell viability of the 
evaluated cell lines and concomitant biocompatibility of these quaternary ammonium sophorolipids. 
In view of their biological activities, quaternary ammonium sophorolipids 221h and 221i can be 
regarded as the best candidates for pharmaceutical applications and for further property evaluation. 
The presence of the carbohydrate head proved to be necessary for a high antimicrobial activity 
against Gram-positive strains and an efficient transfection with high cell viability. Although 
sophorolipid amine oxide 230g displays a very similar structure, no antimicrobial activity was 
observed for this compound. This indicates that the quaternary ammonium group is also a key factor 
to induce the antimicrobial activity. The evaluation of some green chemistry metrics for the synthesis 
of quaternary ammonium sophorolipids 221h and 221i indicated that the E-factors for their synthetic 
pathways lie between the range of E-factors for fine chemicals (5-50) and pharmaceuticals (25-100). 
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3.3. Perspectives 
In view of their antimicrobial properties and transfection efficiencies, the deprotected quaternary 
ammonium sophorolipids with an octadecyl chain on the nitrogen atom proved to be the best 
candidates for further optimization and industrial applications. As stated in the introduction, the 
focus has to be on high added-value applications for the pharmaceutical sector to render the new 
derivatives economically competitive. Before the production process can be applied on a commercial 
scale, changes have to be made to some of the reaction steps (Scheme 84). 
 
Scheme 84. Flow chart for the commercial production of deprotected quaternary ammonium sophorolipid 221h 
First of all, the ozonolysis reaction proved to be the bottleneck of this synthetic pathway. The choice 
of the reaction solvent proved to have a big influence on the purity of the sophorolipid aldehyde 
intermediate and on the necessity of a subsequent purification step of the sophorolipid amines. The 
use of continuous flow microreactor technology ensures a higher control of the reaction parameters, 
resulting in a higher selectivity and an increase in the process efficiency and safety. Moreover, it 
would enable the safe scale-up, eventually to a commercial scale, of this potential dangerous 
reaction. Reductive work-up of the ozonolysis reaction via hydrogenation should be evaluated as 
alternative for sodium triacetoxyborohydride. Automated chromatography purification after this 
reaction step should be avoided to reduce operating costs and enable the scale-up of the process. 
Therefore, distillation of the methyl 9-oxononanoate by-product 244, which has a boiling point of 
125-145 °C at 12 mbar, should be examined. This by-product can be valorized as a precursor for 
biopolymer products.178 
Secondly, the reductive amination should be performed in two subsequent steps. In the synthesis 
pathway towards deprotected quaternary ammonium sophorolipid 221h, a first step comprises the 
imination of the sophorolipid aldehyde with octadecylamine, followed by hydrogenation towards the 
intermediate secondary sophorolipid amine. In the second step, imination with formaldehyde and 
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subsequent hydrogenation results in the synthesis of the desired tertiary sophorolipid amine. With 
this reaction sequence, the use of the more expensive N-methyloctadecylamine and the more 
hazardous sodium cyanoborohydride reducing agent is avoided. Finally, triethylamine can be used 
instead of DMAP for the acetylation reaction to reduce product costs and facilitate product 
purification. 
Based on the optimized reaction pathway, an attempt was made to estimate the production price for 
the deprotected quaternary ammonium sophorolipid 221h on a 10 kg scale (Table 28). A first 
scenario is based on the actual reaction yields, a second scenario is based on a yield of 90% for each 
reaction step and a third scenario is based on an average production yield of 71%. 
Table 28. Estimated product price for the production of 10 kg deprotected quaternary ammonium sophorolipid 221h. For 
three different scenarios, the raw material and solvent demand is calculated in function of the reaction yield. 
 Scenario 1 Scenario 2 Scenario 3 
Methanolysis    
Yield (%) 90 90 90 
SL lactone (kg) 33 15 11 
NaOMe (kg) 0.39 0.17 0.13 
Dry MeOH (L) 66 30 22 
Acetylation    
Yield (%) 99 90 99 
Ac2O (kg) 30.83 13.58 10.20 
Et3N (kg) 0.65 0.29 0.22 
THF (L) 137 60 45 
Ozonolysis    
Yield (%) 67 90 90 
MeOH (L) 850 350 280 
By-product (kg) 5.33 2.86 2.37 
Reductive amination    
Yield (%) 40 90 90 
Octadecylamine (kg) 7.71 4.15 3.43 
Formaldehyde (kg) 0.86 0.46 0.38 
Dry MeOH (kg) 44 24 20 
Quaternization    
Yield (%) 99 90 99 
MeI (kg) 1.62 1.97 1.62 
ACN (L) 60 72 60 
Deprotection    
Yield (%) 99 90 99 
Et3N (kg) 2.29 2.52 2.29 
MeOH (L) 35 37 35 
Overall yield (%) 23 53 71 
Estimated raw material cost (€) 347 219 174 
Estimated solvent cost (€) 1362 846 679 
Estimated total cost (€) 2138-5700 1331-3550 1068-2847 
Estimated product price (€/kg) 214-570 133-355 107-285 
   Results and discussion 
103 
 
The raw material and solvent costs for the different scenarios are based on current commercial 
prices for products on kg scale and are estimated to amount to 30-80% of the total production 
cost.179 Even in the most optimal scenario, the production price of deprotected quaternary 
ammonium sophorolipid will still be higher than 100 €/kg. This clearly indicates that the new 
sophorolipid derivatives will only be economically competitive in high added-value applications, for 
example for the pharmaceutical sector, if they offer advantages over the currently available 
products. However, a reduction in the total production cost could still be accomplished if the 
recycling of solvents and reagents such as triethylamine would be feasible and if the reactions would 
be performed on a larger scale. 
For each scenario, the green chemistry metrics were also calculated (Table 29). Carbon efficiency and 
atom economy are not dependent on the process conditions and are therefore the same as in 
Table 14. The assumption was made that stoichiometric amounts of acetic anhydride and methyl 
iodide can be used, giving a stoichiometric factor (SF) of 1. For each scenario, a distinction was made 
whether the solvents are considered as waste (A) or can be reused (B). The recycling of solvents 
offers the possibility to reduce the E-factor more than tenfold. 
Table 29. Overview of the green chemistry metrics for the production of quaternary ammonium sophorolipid 221h for 
the three different scenarios. A distinction is made for each scenario whether the solvents are considered as waste (A) or 
can be reused (B). RME = reaction mass efficiency, AE = atom economy, SF = stoichiometric factor,  = reaction yield, c = 
mass reaction catalyst, s = mass reaction solvent, w = mass reaction waste, m = mass target product. 
Parameter Formula Scenario 1 Scenario 2 Scenario 3 
  A B A B A B 
RME (%) ε ∗ (AE) ∗
1
SF
∗ [
1
1 +
ε ∗ (AE) ∗ (c + s + w)
(SF) ∗ m
] 0.013 0.081 0.024 0.179 0.029 0.235 
E-factor 
(kg/kg) 
Mass waste
Mass product
 66.79 4.93 37.17 2.18 31.52 1.69 
Apart from the commercialization of the currently synthesized sophorolipid derivatives, further 
research can also focus on the synthesis of new types of sophorolipid derivatives. As stated before, 
the sophorolipid microbial production pathway limits the fatty acid incorporation to C16 or C18 
hydrophobic substrates. In this work, the synthesis of C9 and C12 sophorolipid intermediates was 
accomplished after incorporation of oleic acid and petroselinic acid, respectively, in the sophorolipid 
structure. In addition, polyunsaturated fatty acids such as linoleic and linolenic acid can be 
incorporated in the sophorolipid structure for the synthesis of C6 and C3 sophorolipid intermediates. 
This will enable a thorough evaluation of the influence of the sophorolipid chain length on their 
biological and physico-chemical properties. 
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The set of sophorolipid derivatives can be further extended with the synthesis of other sophorolipid 
compounds. Sophorolipid betaines 245, another class of zwitterionic surfactants, can be synthesized 
from the tertiary sophorolipid amines 213 (Scheme 85). These derivatives will also possess cationic 
surfactant properties depending on the pH of the solution, which can have a great influence on their 
solubility and biological activity. 
 
Scheme 85. Proposed synthesis of sophorolipid betaines 245 
Sophorolipid ether derivatives 246 and sophorolipid urea derivatives 247, two types of nonionic 
surfactants, can be synthesized from sophorolipid alcohol 204 and secondary sophorolipid amines 
214, respectively (Scheme 86). These glyco-ether derivatives and urea derivatives offer perspectives 
for anti-cancer properties. Sophorolipid alcohol 204 and secondary sophorolipid amines 214 can also 
be modified with different diisocyanates towards a new class of bolaamphiphilic sophorolipids 248 
(Scheme 87). These bolaamphiphilic sophorolipids possess carbamate or urea moieties, which could 
have an enhanced self-assembly through stabilization of nanostructures via hydrogen-bond 
formation. 
 
Scheme 86. Proposed synthesis of sophorolipid ether derivatives 246 and sophorolipide urea derivatives 247 
 
Scheme 87. Proposed synthesis of a new class of bolaamphiphilic sophorolipids 248 
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4. Experimental procedures 
4.1. Materials and general methods 
4.1.1. Materials 
The sophorolipid starting compound was obtained from Ecover (Malle, Belgium) and from the InBio 
research group (Department of Biochemical and Microbial Technology, Ghent University, Belgium). 
This starting product consists of 93.4% C18:1 diacetylated subterminal hydroxylated sophorolipid 
lactone 1, 4.1% diacetylated sophorolipid acids and 2.5% diacetylated terminal hydroxylated 
sophorolipid lactone. Small amounts of C18:0 and C18:2 lactone can be present in this fermentation 
product, together with the acidic forms due to hydrolysis. The vegetable oil of Coriandrum sativum 
fruits was isolated via twin-screw extrusion at LCA via a previously reported procedure.121 
Trimethylsulfonium hydroxide (TMSH), t-butyl methyl ether (TBME), hydrochloric acid (HCl), hexane, 
sodium citrate tribasic dihydrate, ammonium chloride (NH4Cl), potassium phosphate monobasic 
(KH2PO4), potassium phosphate dibasic (K2HPO4), magnesium sulfate heptahydrate (MgSO4∙7H2O), 
calcium chloride dihydrate (CaCl2∙2H2O), sodium, 4-dimethylaminopyridine (DMAP), Sudan III, diethyl 
ether, borane tetrahydrofuran complex (BH3-THF), dibutylamine, N-butylmethylamine, N-
butylbenzylamine, N-benzylmethylamine, N-methyloctadecylamine, N,N’-dimethylethylenediamine, 
N,N’-dimethylhexamethylenediamine, methylamine, isopropylamine, platinum black, acetic acid, 
acetyl chloride, potassium carbonate (K2CO3), acetonitrile, N-methylmorpholine N-oxide (NMMO), 
sodium borohydride (NaBH4), oxalic acid, dimethyl carbonate, butyl iodide, sulfuric acid (H2SO4), 
iron(III) oxide (Fe2O3), 3-chloroperoxybenzoic acid (mCPBA), oleoyl chloride and 
hexamethylenediamine were purchased from Sigma-Aldrich (Belgium). Yeast extract was purchased 
from Difco (Belgium). Sodium hydroxide (NaOH), dry methanol, acetic anhydride, sodium 
triacetoxyborohydride (NaBH(OAc)3), dimethylamine, diethylamine, dibenzylamine, butylamine, 
benzylamine, octadecylamine, sodium cyanoborohydride (NaBH3CN), hydrogen peroxide, nonanal, 
triethylamine, dimethyl sulfide (Me2S), pyridine, sodium bisulfite, sodium dodecyl sulfate, butyryl 
chloride, ethylenediamine and o-phenylenediamine were purchased from Acros Organics (Belgium). 
Magnesium sulfate (MgSO4), sodium bicarbonate (NaHCO3) and methyl iodide were purchased from 
Fisher Scientific (Belgium). Octadecyl iodide, stearoyl chloride and octadecanal were purchased from 
TCI Europe (Belgium). Butyl bromide was purchased from De Bruyne Instruments (Belgium). Ethyl 
acetate, tetrahydrofuran (THF), ethanol and acetone were purchased from Chem-Lab (Belgium). 
Methanol and petroleum ether were purchased from VWR (Belgium). Glucose monohydrate was 
purchased from Cargill (Belgium). Sodium chloride (NaCl) was purchased from Colruyt (Belgium). 
Commercially available products were used without further purification. Dry tetrahydrofuran (THF) 
was distilled from sodium; dry dichloromethane was distilled from calcium hydride; dry acetonitrile 
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(ACN) was distilled over molecular sieves; dry ethanol (EtOH) was distilled from magnesium and 
iodine according to the method of Lund and Bjerrum. 
4.1.2. Ozonolysis reaction 
The ozonolysis reaction was performed with an Ozonia Triogen Model LAB2B laboratory ozone 
generator, connected to a Bronkhorst Flow-Bus E-7000 type mass flow meter to control the dry air 
inflow and an Anseros Ozomat Model GM Non-Dispersive UV-analyzer to measure the ozone 
concentration. 
4.1.3. Chromatography purification of reaction mixtures 
Analysis of reaction mixtures was performed via thin-layer chromatography (TLC) using silica plates 
(Merck Kieselgel 60 with F254 indicator, precoated, 0.25 mm) and different solvent mixtures. 
Visualization of the analyzed mixtures was performed by means of UV fluorescence (254 or 366 nm) 
or coloring with a potassium permanganate solution. Column chromatography was performed on 
silica gel (Acros, particle size 0.035-0.070 mm, pore diameter ca. 6 nm) or on alumina gel (Merck, 
pore size 60 Å, HF254, type E, basic) in a glass column with different solvent mixtures. A suitable 
solvent system is determined via TLC analysis. Automated column chromatography is performed with 
a Grace Reveleris flash chromatography system with reusable silica columns (Reveleris, particle size 
40-63 µm) as solid phase. The flow rate and gradient of the solvent system can be adjusted manually 
to the column size and the nature of the reaction mixture. Detection of the eluting compounds can 
be performed via UV analysis at two different wavelengths which can be chosen manually and via 
evaporative light-scattering detection (ELSD). Preparative TLC is performed with silica plates (Sigma-
Aldrich, 2000 microns) as solid phase and different solvent mixtures. A suitable solvent system is 
determined via TLC analysis. Visualization of the compounds was performed by means of UV 
fluorescence (254 or 366 nm) or coloring with a potassium permanganate solution. 
4.1.4. LC-MS chromatography 
LC-MS analyses were performed on an Agilent apparatus, using a Supelco Ascentis Express C18 
column (L 3 cm x ID 4.6 mm) with 2.7 µm fused-core particles (90 Å pore size). This apparatus is 
equipped with a UV detector (operating at 220.8 nm, 254.8 nm and 280.8 nm) and connected to an 
Agilent 1100 series LC/MSD type SL mass spectrometer with Electron Spray Ionization geometry (ESI 
70 eV) and using a Mass Selective Detector (single quadrupole). 
4.1.5. NMR spectroscopy 
1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance III Nanobay 
400 MHz NMR spectrometer. The compounds were dissolved in deuterated solvents as indicated 
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with the spectral data of each compound. Tetramethylsilane (TMS) was used as an internal standard. 
The assignment of the different peaks was performed using DEPT, 2D-HSQC and 2D-COSY spectra. 
Peak multiplicities are described by the following abbreviations: s = singlet, d = doublet, t= triplet, 
q = quadruplet, sept = septet, m = multiplet, br = broad with their accompanying coupling constants. 
4.1.6. Infrared spectroscopy 
Infrared spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer. All compounds 
were analyzed in neat form with an Attenuated Total Reflectance (ATR) accessory while applied on a 
ZnSe crystal. Only selected absorbances max are reported. 
4.1.7. Mass analysis 
Low resolution mass spectra of pure compounds were recorded via direct injection on an Agilent 
1100 Series LC/MSD type SL mass spectrometer with Electron Spray Ionization geometry (ESI 70 eV) 
and using a Mass Selective Detector (quadrupole) with simultaneous positive and negative ion 
detection. High resolution mass spectrometry (HRMS) analyses were performed using an Agilent 
1100 Series HPLC coupled to an Agilent 6220 TOF-Mass Spectrometer equipped with ESI/APCI-
multimode source. 
4.1.8. Melting points 
Melting points of solid compounds were measured on a Wagner and Munz Kofler-Heizbank (Type 
WME) with a temperature range of 46-266 °C. Calibration of the apparatus was performed with 
reference materials. 
4.1.9. Optical rotation 
Optical rotation measurements are performed with a Jasco P-2000 Series polarimeter. A sample of 
the compound is dissolved in an optical cell (3.5 mm ID x 100 mm) at a well-known concentration c 
(mg/mL). The optical rotation is determined at a wavelength of 589 nm. 
4.1.10. Determination of the fatty acid composition 
Determination of the fatty acid composition of the coriander oil was performed by gas 
chromatography (GC). An oil sample was dissolved in TBME at a concentration of 20 mg/mL. A 100 µL 
aliquot of this solution was converted to methyl esters by the addition of 50 µL of a 0.2 M TMSH 
solution in methanol. The resulting fatty acid methyl esters were subjected to GC analysis using a 
Varian 3800 (USA) gas chromatograph equipped with a flame ionization detector. Separation of the 
methyl esters was achieved in a CP select CB (Varian, USA) fused silica capillary column (50 m, 
0.25 mm i.d., 0.25 µm film thickness). The initial oven temperature was held at 185 °C for 40 minutes, 
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after which it was increased to 250 °C for 10 minutes. The temperature of the injector and the 
detector was kept at 250 °C. Helium was used as the carrier gas with a flow rate of 1.2 mL/min. The 
determination was carried out in triplicate. 
4.1.11. Monitoring sophorolipid fermentation 
Growth of the culture was frequently monitored by measuring optical density at 600 nm (Jasco, 
V-630 Bio Spectrophotometer). Cell dry weight was obtained by centrifugation (5 min, 14 000 rpm, 
Sigma 4-15 centrifuge) of 1 mL reactor broth in pre-dried and weighed falcons. The pellets were 
subsequently washed once with 1 mL physiological solution (9 g/L NaCl) and dried at 60 °C to a 
constant weight. Glucose concentrations were measured with a 2700 Select Biochemistry Analyzer 
(YSI). 
4.1.12. Surface tension measurements 
The determination of the surface tension was performed at room temperature via the Wilhelmy 
plate method. A platinum plate is brought into contact with an air-water surface and the force 
exerted on the plate is measured with a mass balance (Figure 36A). This force is directly related to 
the surface tension (Figure 36B). The surface tension is plotted in function of the concentration (log 
scale) and the CMC is determined as the lowest concentration for which the minimal surface tension 
is measured (Figure 36C). At increasing concentrations below the CMC, surfactant compounds 
assemble at the air-water interface until the interface is completely saturated with surfactant. 
Increasing the concentration above the CMC results in the formation of micelles. 
 
Figure 36. (A) Setup for surface tension measurements via the Wilhelmy plate method. (B) Formula to calculate the 
surface tension from the measured mass. (C) Surface tension in function of the concentration (log scale) to determine the 
critical micelle concentration. 
All glassware and the platinum plate were rinsed with sulfochromic acid prior to the experiment to 
avoid interference of traces of residual compounds. A dilution series in distilled water ranging from 
2.0 g/L to 0.01 mg/L was prepared and the surface tension was determined for each sample. The 
CMC values were determined as the concentration at which the minimal surface tension was reached 
when plotting the natural logarithm of the sophorolipid concentration against the surface tension. 
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For sophorolipid lactone 208, the concentration of solubilized sophorolipid was determined with the 
TOC-5000 (Shimadzu) since this compound is not well soluble in water. With the bruto formula 
(C34H56O14), the actual sophorolipid concentration could be calculated. 
4.1.13. Antimicrobial activity assay 
A first antimicrobial activity assay was performed at the Laboratory for Microbiology (Ghent 
University, Belgium). The six test strains Escherichia coli LMG 8063, Klebsiella pneumoniae LMG 2095, 
Staphyllococcus aureus LMG 8064, Bacillus subtilis LMG 13579, Enterococcus faecium LMG 11397 and 
Streptococcus pneumoniae LMG 16738 were grown in Mueller Hinton II (MH) broth medium. LMG 
13579 was incubated at 28 °C for 24 h, all other strains were incubated at 37 °C. Inocula with a 
density of 105 CFU/mL were prepared in MH broth. The bioassay was carried out in sterile 96-well 
microtiter plates. The test compounds were delivered as a solution in DMSO at a concentration of 
approximately 50 mg/mL. For the antimicrobial screening, working solutions of test compounds were 
prepared by mixing 200 µL of the supplied DMSO solutions of the compounds and 800 µL MH culture 
broth. The antimicrobial activity of each compound was tested in duplicate against a single test strain 
in a test volume of 200 µL at a final concentration of approximately 0.5 mg/mL test compound and 
104 CFU/mL test bacteria. Positive and negative control consisted of a 0.5 mg/mL gentamicin 
sulphate solution and sterile saline, respectively. For the determination of the MIC values, a stock 
solution of 2 mg/mL was used to prepare the dilution series. The MIC of the selected compounds was 
tested in duplicate against a single test strain in a test volume of 200 µL at a final concentration 
ranging from 100 to 2.5 µg/mL test compound and 104 CFU/mL test bacteria. For comparative 
purposes, a dilution series of the antibiotic gentamicin sulfate was included in a concentration 
ranging from 100 to 2.5 µg/mL. Depending on the test strains, plates were incubated at 28 or 37 °C 
for 24 h under aerobic conditions. Bacterial growth was scored visually. Turbidity levels comparable 
to those in the positive or negative control wells were regarded as positive or negative, respectively, 
for antimicrobial activity of the compound in question.  
A second antimicrobial activity assay was performed at the Laboratory for Microbiology (Ghent 
University). Antimicrobial activity against Escherichia coli LMG 8063, Klebsiella pneumoniae LMG 
2095, Pseudomonas aeruginosa PAO1, Staphylococcus aureus ATCC 6538 and Staphylococcus aureus 
Mu50 was assessed by a broth dilution method (CLSI, 2012). Strains with LMG designation were 
obtained from the BCCM/LMG Bacteria Collection (Ghent, Belgium) while strain ATCC 6538 was 
obtained from the American Type Culture Collection (Manassas, VA). S. aureus Mu50 was a kind gift 
of P. Vandamme (Ghent, Belgium). All strains were grown aerobically at 37 °C on Mueller Hinton agar 
(LabM, Heywood, UK). The minimal inhibitory concentration that inhibited growth by at least 50% 
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compared to the untreated control (MIC1/2), the minimal inhibitory concentration that inhibited 
growth completely (MIC) and the minimal bactericidal concentration at which no more cell viability 
of the test organism can be observed (MBC) were used as a measure of activity. MIC1/2, MIC and MBC 
values were determined using flat-bottomed 96-well microtiter plates (TPP, Trasadingen, 
Switzerland). Concentrations of compounds tested ranged from 0.48 to 2500 µg/mL in Mueller 
Hinton broth (LabM). The inoculum was standardized at approximately 5 x 105 colony forming 
units/mL. The plates were incubated at 37 °C for 24 h and the optical density was determined at 
590 nm using a multilabel microtiter plate reader (Envision Xcite, Perkin Elmer LAS, Waltham, MA). 
Clinical and Laboratory Standards Institute (CLSI) (2012) Performance Standards for Antimicrobial 
Susceptibility Testing. Twentieth second Informational Supplement M100-S22. Wayne, PA, USA. 
The biofilm assay was performed at the Laboratory for Microbiology (Ghent University). 
Staphylococcus aureus ATCC 6538 and Staphylococcus aureus Mu50 were cultured on Trypton Soy 
agar plates (TSA, LabM, Lancashire, UK). From these pure cultures, overnight suspensions were made 
by inoculating 10 mL Trypton Soy broth (TSB, LabM, Lancashire, UK) with a loopful of 
microorganisms. Both strains were grown aerobically at 37 °C. Biofilms were formed as previously 
described.180 Overnight suspensions were adjusted with TSB of 0.05. These optical densities 
correspond approximately 2.5 x 107 Colony Forming Units (CFU)/mL. A 100 µL of the diluted cell 
suspension were transferred to the wells of a polystyrene round-bottomed 96-well microtiter plate 
(MTP, SPL, Lifescience, Korea) and incubated at 37 °C. Blanco control wells were filled with sterile 
medium. Medium was removed after 4 h and biofilms were rinsed with Physiological Saline (PS) to 
remove non-adhered cells. Fresh medium was subsequently added to the wells and plates were 
further incubated for 20 h. These biofilms were rinsed with PS and treated with 100 µL of test 
compound at a concentration of 20 µg/mL for 24 h at 37 °C. The treatments were removed and the 
biofilms were rinsed with PS. To determine the CFU, 100 µL PS was added to the wells containing the 
treated biofilms and the MTP was sonicated and vortexed twice. The detached cells were quantified 
by conventional plating. 
4.1.14. SAXS analysis 
In small-angle X-ray scattering (SAXS) experiments, the scattering of a monochromatic X-ray beam 
over a certain range of scattering angles upon contact with a sample is analyzed (Figure 37A). For 
small scattering angles, q-values are calculated in function of the scattering angle and the 
wavelength of the X-ray beam (Figure 37B). An isotropic scattering pattern is detected on the X-ray 
detector, displaying a variety in scattering intensity in function of the scattering angles (Figure 37C). 
A plot is made displaying the integrated scattering intensity over all scattering angles in function of 
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the q-value (Figure 37D). This plot contains information on the size and shape of the particles present 
in the analyzed sample. To determine the particle size, a Guinier plot is made in which q2 is plotted in 
function of log[I(q)]. From the slope of the obtained graph in the low q-region, the radius of gyration 
is derived which has a direct relationship to the radius of the particles. 
 
Figure 37. (A) Scattering of a monochromatic X-ray beam over a certain range of scattering angles. (B) Formula to 
calculate the q-value. (C) Isotropic scattering pattern detected with the X-ray detector. (D) Small-angle X-ray scattering 
(SAXS) plot displaying the scattering intensity I(q) in function of the q-value. 
SAXS experiments have been performed using a flow-through polycarbonate 2 mm capillary. Data 
have been acquired on the high brilliance ID02 beamline at the ESRF synchrotron (Grenoble, France) 
using a 1 m sample-to-detector distance and an energy of 12.46 keV. The acquisition time was 100 
ms and three experiments were averaged out. A CCD camera was used to collect the scattered 
photons and integrated azimuthally to obtain a typical I(q) spectrum. Contribution of the solvent 
(water) and capillary have been measured prior to the experiment and were duly subtracted during 
the data treatment. All data have been corrected for the transmission of the direct beam and were 
scaled to be in absolute scale. 
4.1.15. Transfection assay 
The liposomal solutions were prepared by hydration of a lipid film. A 1.5 mM solution (1 mL) of each 
compound was prepared in chloroform, formulated with or without DOPE (1:1 compound/DOPE) and 
evaporated under reduced pressure to produce a thin lipid film. Water (1 mL) was added to 
rehydrate this lipid film in a time period of 7 days at room temperature. The solution was vortexed 
(10 s) and sonicated (30 min at 50 °C) at 45 kHz using a VWR ultrasonic bath. The size and zeta 
potential were determined for each liposomal formulation. 
Lipoplexes were prepared by mixing pDNA (pEGFP-Luc, Clontech) with each liposomal solution in 
OptiMEM (Gibco). Addition of pDNA to the liposomal solutions was performed at concentrations 
corresponding to CR ranging from 1 to 8. The obtained mixtures were incubated at room 
temperature for 1 hour before being subjected to electrophoresis in a 0.8% agarose gel at 100 V, 
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90 mA. The gel was previously stained with SYBRgold nucleic acid gel staining (Life Technologies) and 
visualized using a UV transilluminator (Fischer Bioblock). 
The in vitro reporter gene assay via luciferase measurement was carried out as reported 
previously.150, 181 In short, the four cell lines were grown in either EMEM (16HBE) or DMEM (A549, 
SKMEL28 and C2C12) both supplemented with 10% bovine fetal serum, 1% antibiotic and 1% 
L-glutamine. All incubations were performed at 37 °C in a humidified atmosphere containing 5% CO2. 
The day before transfection, the cells were seeded into a 96-well plate at a density of 25,000 cells per 
well. Lipoplexes were prepared as detailed above and then added dropwise to each well; the 
commercial formulation Lipofectamine Reagent (Invitrogen) was used as a positive transfection 
control whereas naked DNA was used as negative control. DOPE was not added to the positive and 
negative control. After 48 h at 37 °C, the culture medium was removed and the cells were lysed with 
Passive Lysis Buffer (Promega) prior to examination via a chemiluminescent assay (Luciferase Assay 
System, Promega) to determine the luciferase expression. The total protein content of each cell 
lysate was determined using the BC assay kit (Uptima). Finally, data were expressed as relative light 
units (RLU) per milligram of total proteins (mean ± SD with n=3). 
The cell viability was considered as a marker of the toxicity resulting from the exposition of the cells 
to the lipoplexes. For this purpose, the Vialight kit (Lonza) was used to determine the ATP content 
which reflects the number of living cells in culture. This assay was used as recommended by the 
manufacturer. Results were expressed as percentages relative to the viability of non-transfected cells 
used as reference (100% cell viability). 
  
  Experimental procedures 
113 
 
4.2. Synthetic procedures and characterization 
4.2.1. Synthesis of the intermediate sophorolipid aldehyde 
General procedure for the synthesis of (S)-8-([4”-(9-oxononanoyl)oxy,6’,6”-diacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-nonanal (197): In a 250 mL flame dried washing flask, 
8.04 g sophorolipid lactone 1 (11.67 mmol, 1 eq) was dissolved in 100 mL dry CH2Cl2 and a pinch of 
Sudan III was added. The reaction mixture was cooled down to -78 °C and sparged with ozone until 
the red color of the reaction mixture dissipated. Upon the addition of 4.35 g Me2S (70.03 mmol, 6eq), 
the mixture was stirred for 1 h at room temperature. The mixture was washed 3 times with 10 mL 
brine and the organic phase was dried over MgSO4, filtered and concentrated under reduced 
pressure. Sophorolipid dialdehyde 197 was purified by automated column chromatography as an 
off-white solid with a petroleum ether/ethyl acetate mixture as eluent (2.00 g, 24%). Gradient: 2 CV 
20% EtOAc, 25 CV 20-100% EtOAc, 13 CV 100% EtOAc. 
 1H-NMR (400 MHz, CDCl3): H 1.23 (3H, d, J=6.2 Hz, CH3CH), 1.26-
1.46 (13H, m, CHaHbCHCH3, 6xCH2(CH2)2), 1.56-1.66 (7H, m, 
CHaHbCHCH3, CH2CH2(C=O)O, 2xCH2CH2(C=O)H), 2.07 (3H, s, 
CH3C=O), 2.09 (3H, s, CH3C=O), 3.32-2.37 (2H, m, CH2CH2(C=O)O), 
2.43 (2H, txd, J=7.2 Hz, J=1.6 Hz, CH2(C=O)H), 2.45 (2H, txd, J=7.2 Hz, 
J=1.6 Hz, CH2(C=O)H), 3.39-3.57 (4H, m, 4xCHOC), 3.62-3.70 (3H, m, 
3x CHOC), 3.73-3.80 (1H, m, CH3CHO), 4.08-4.12 (1H, m, CHCHaHbOAc), 4.19 (1H, dxd, J=12.2 Hz, J=4.9 
Hz, CHCHaHbOAc), 4.31-4.35 (2H, m, CHCH2OAc), 4.45 (1H, d, J=7.6 Hz, CH(O)2), 4.54 (1H, d, J=7.8 Hz, 
CH(O)2), 4.91 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.06 (4H, br s, 4xOH), 9.75 (1H, t, J=1.7 Hz, 
CH2(C=O)H), 9.76 (1H, t, J=1.6 Hz, CH2(C=O)H). 
13C-NMR (100 MHz, CDCl3): C 20.8 (CH3C=O), 20.9 
(CH3C=O), 21.3 (CH3CH), 21.9 (CH2CH2(C=O)H), 21.9 (CH2CH2(C=O)H), 24.6 (CH2CH2(C=O)O), 24.9 
(CH2(CH2)2), 28.7 (CH2(CH2)2), 28.8 (CH2(CH2)2), 28.9 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.4 (CH2(CH2)2), 
34.1 (CH2CH2(C=O)O), 36.4 (CH2CHCH3), 43.8 (CH2(C=O)H), 43.8 (CH2(C=O)H), 62.4 (CH2OAc), 63.5 
(CH2OAc), 69.8 (CHOC), 70.4 (CHOC), 72.6 (CHOC), 73.3 (CHOC), 74.0 (CHOC), 74.1 (CHOC), 76.0 
(CHOC), 77.4 (CH3CHO), 81.5 (CHOC), 100.9 (CH(O)2), 103.6 (CH(O)2), 170.7 (CH2(C=O)O), 171.5 
(CH2(C=O)O), 173.2 (CH2(C=O)O), 203.0 (CH2(C=O)H), 203.1 (CH2(C=O)H). 
General procedure for the synthesis of methyl (S)-17-([2’-O--D-glucopyranosyl--D-
glucopyranosyl]-oxy)-cis-9-octadecenoate (89a): In a 100 mL flame dried round-bottomed flask, 
29.80 g sophorolipid lactone 1 (43.27 mmol, 1 eq) was dissolved in 50 mL dry methanol and 1.62 mL 
sodium methoxide (6.49 mmol, 0.15 eq) was added. The flask was equipped with a reflux condenser 
and a CaCl2 guard-tube to protect the reaction mixture from atmospheric moisture. The reaction 
Experimental procedures   
114 
 
mixture was stirred for 3h at reflux temperature, cooled down to room temperature and acidified to 
neutral pH with acetic acid. The mixture was concentrated under reduced pressure, dissolved in 
deionized water and cooled down to 0 °C in an ice bath. The sophorolipid methyl ester 89a 
precipitated as a white powder. The precipitate was filtered, washed with water and dried under 
reduced pressure (22.26 g, yield 81%). 
General procedure for the synthesis of methyl (S,Z)-17-([2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-9-octadecenoate (114a): In a 100 mL flame dried round-
bottomed flask, 21.56 g sophorolipid methyl ester 89a (33.86 mmol, 1 eq) was dissolved in 100 mL 
dry THF. The flask was equipped with a CaCl2 guard-tube to protect the reaction mixture from 
atmospheric moisture and 25.4 mL acetic anhydride (270.84 mmol, 8 eq) and 1.654 g DMAP (13.54 
mmol, 0.4 eq) were added. The reaction mixture was stirred for 1 h at room temperature, 
concentrated under reduced pressure and dissolved in ethyl acetate. The mixture was washed 3 
times with a 10 mL saturated NaHCO3-solution and the organic phase was dried over MgSO4, filtered 
and concentrated under reduced pressure. Peracetylated sophorolipid methyl ester 114a was 
isolated as a viscous colorless oil (32.49 g, quantitative yield). 
General procedure for the synthesis of (S)-8-([2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-nonanal (201): In a 250 mL flame dried washing flask, 
12.49 g peracetylated sophorolipid methyl ester 114a (13.41 mmol, 1 eq) was dissolved in 100 mL 
methanol. A pinch of Sudan III indicator and 1 equivalent of NaHCO3 were added. The reaction 
mixture was sparged with ozone at room temperature until the red color of the reaction mixture 
dissipated. The mixture was stirred for 1 h at room temperature with 2.84 g NaBH(OAc)3 
(13.41 mmol, 1 eq), concentrated under reduced pressure and dissolved in ethyl acetate. The 
mixture was washed 3 times with 10 mL brine and the organic phase was dried over MgSO4, filtered 
and concentrated under reduced pressure. Peracetylated sophorolipid aldehyde 201 was purified by 
automated column chromatography as a viscous colorless oil with a petroleum ether/diethyl ether 
mixture as eluent (7.03 g, 67%). Gradient: 2CV 20% Et2O, 15 CV 20-100% Et2O, 8 CV 100% Et2O. 
For characterization purposes, a small amount of sophorolipid aldehyde 201 was purified through a 
sodium bisulfite addition reaction. In a 50 mL round-bottomed flask, 0.42 g sophorolipid aldehyde is 
dissolved in 25 mL ethyl acetate and NaHSO3 (2.67 mmol, 5 eq) was added. The mixture was stirred 
for 30 min at room temperature, extraxted 3 times with 10 mL water and 2.34 mL saturated NaHCO3-
solution (2.67 mmol, 5 eq) were added to the water phase. The water phase was extracted 3 times 
with 10 mL ethyl acetate and the organic phase was dried over MgSO4, filtered and concentrated 
under reduced pressure. 
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IR (cm-1) max: 1036 (CHOCH), 1064 (CHOCH), 1224 (COAc), 1367, 
1748 (C=O). 1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, 
CH3CH), 1.28-1.45 (7H, m, 3xCH2(CH2)2, CHaHbCHCH3), 1.54-1.62 (1H, 
m, CHaHbCHCH3), 1.68 (2H, txt, J=7.4 Hz, J=7.3 Hz, CH2CH2(C=O)H), 
1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 
2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 2.47 (2H, txd, 
J=7.4 Hz, J=1.8 Hz, CH2(C=O)H), 3.63-3.76 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.11 (2H, m, 
2xCHCHaHbOAc), 4.23-4.31 (2H, m, 2xCHCHaHbOAc), 4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 
Hz, CH(O)2), 4.90 (1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.05 
(1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 ((1H, dxd, J=9.5 Hz, 
J=9.5 Hz, CHOC), 9.78 (1H, t, J=1.8 Hz, HC=O). 13C-NMR (100 MHz, CDCl3): C 20.3 (CH3C=O), 
20.4 (2xCH3C=O), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 21.3 (CH3CH), 
22.1 (CH2CH2(C=O)H), 24.6 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 36.4 (CH2CHCH3), 
43.7 (CH2(C=O)H), 61.9 (CH2OAc), 62.1 (CH2OAc), 68.2 (CHOC), 68.7 (CHOC), 71.2 (CHOC), 
71.5 (CHOC), 71.6 (CHOC), 72.9 (CHOC), 74.6 (CHOC), 77.3 (CHOC), 77.9 (CHOC), 100.3 (CH(O)2), 101.2 
(CH(O)2), 169.3 (CH3C=O), 169.4 (CH3C=O), 169.6 (CH3C=O), 169.9 (CH3C=O), 170.1 (CH3C=O), 170.4 
(CH3C=O), 170.5 (CH3C=O), 202.9 (HC=O). MS (ESI): m/z Exact mass calculated for C35H56NO19 
[M+NH4
+]: 794.3441. Found: 794.3438. 
General procedure for the synthesis of (S)-8-([2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-nonanol (204): In a 250 mL flame dried washing flask, 
2.12 g peracetylated sophorolipid methyl ester 114a (2.28 mmol, 1 eq) was dissolved in 100 mL dry 
CH2Cl2. A pinch of Sudan III indicator and 0.07 g methanol (2.28 mmol, 1 eq) were added. The 
reaction mixture was sparged with ozone at room temperature until the red color of the reaction 
mixture dissipated. The mixture was stirred for 1 h at room temperature with 0.22 g NaBH4 
(5.70 mmol, 2.5 eq). The mixture was washed 3 times with 10 mL brine and the organic phase was 
dried over MgSO4, filtered and concentrated under reduced pressure. Peracetylated sophorolipid 
alcohol 204 was purified by automated column chromatography as a viscous colorless oil with a 
petroleum ether/ethyl acetate mixture as eluent (1.02 g, 58%). Gradient: 10 CV 20% EtOAc, 10 CV 
30% EtOAc, 20 CV 40% EtOAc, 5 CV 80% EtOAc, 5 CV 90% EtOAc. 
 IR (cm-1) max: 1034(CHOCH), 1063 (CHOCH), 1215 (COAc), 1366, 
1744 (C=O), 3540 (OH). 1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, 
J=6.2 Hz, CH3CH), 1.26-1.46 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 
1.54-1.65 (3H, m, CHaHbCHCH3, CH2CH2OH), 1.99 (3H, s, CH3C=O), 
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2.00 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.09 (6H, s, 
2xCH3C=O), 3.62-3.75 (6H, m, 2xCHCH2OAc, CH3CHO, CHOC, CH2OH), 4.07-4.11 (2H, m, 
2xCHCHaHbOAc), 4.22-4.32 (2H, m, 2xCHCHaHbOAc), 4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 
Hz, CH(O)2), 4.91 (1H, dxd, J=9.5 Hz, J=6.4 Hz, CHOC), 4.93 (1H, dxd, J=8.8 Hz, J=8.8 Hz, CHOC), 5.06 
(1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.13 (1H, dxd, J=9.3 Hz, J=9.3 Hz, CHOC), 5.17 ((1H, dxd, J=9.5 Hz, 
J=9.5 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 20.4 (CH3C=O), 20.5 (CH3C=O), 20.6 (2xCH3C=O), 20.7 
(CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 24.9 (CH2(CH2)2), 25.7 (CH2(CH2)2), 29.7 
(CH2(CH2)2), 29.7 (CH2(CH2)2), 32.8 (CH2CH2OH), 36.7 (CH2CHCH3), 62.0 (CH2OAc), 62.3 (CH2OAc), 62.7 
(CH2OH), 68.3 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 71.6 (CHOC), 71.7 (CHOC), 73.0 (CHOC), 74.8 
(CHOC), 77.5 (CHOC), 78.2 (CHOC), 100.4 (CHOC), 101.4 (CHOC), 169.5 (CH3C=O), 169.6 (CH3C=O), 
169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 (CH3C=O), 170.6 (2xCH3C=O). MS (ESI): m/z Exact mass 
calculated for C35H58NO19Na [M+NH4
+]: 796.3598. Found: 796.3588. 
General procedure for the isolation of petroselinic acid (207): In a 2 L flask, 446.10 g of coriander oil 
is weighed and 800 ml of a 3N sodium hydroxide solution is added. The reaction mixture is refluxed 
for 2.5 hours, cooled down and acidified to pH 1 with a 3 N hydrochloric acid solution. The mixture is 
extracted with hexane and washed with water. The organic phase is dried over magnesium sulfate, 
filtered and concentrated under reduced pressure. Pure petroselinic acid is obtained through 
crystallization in absolute ethanol at -20 °C as a white solid at room temperature (251.07 g, 80%). 
1H-NMR (400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 Hz, CH3), 
1.26-1.36 (18H, m, 9xCH2), 1.37-1.44 (2H, m, 
CH2(CH2)2COOH), 1.62-1.69 (2H, m, CH2CH2COOH), 2.01 (2H, dxt, J=7.0 Hz, J=6.9 Hz, CH2CH=CH), 2.05 
(2H, dxt, J=7.1 Hz, J=7.1 Hz, CH2CH=CH), 2.36 (2H, t, J=7.5 Hz, CH2COOH), 5.29-5.41 (2H, m, CH=CH), 
11.60 (1H, br s, COOH). 13C-NMR (100 MHz, CDCl3): C 14.1 (CH3), 22.7 (CH2), 24.3 (CH2CH2COOH), 
26.8 (CH2CH=CH), 27.2 (CH2CH=CH), 29.1 (CH2(CH2)2COOH), 29.3, 29.4, 29.6, 29.7, 29.7, 29.7, 31.9 
(8xCH2), 34.0 (CH2COOH), 128.9 (CH=CH), 130.6 (CH=CH), 180.1 (COOH). Tm: 30-31°C. 
Characterization of petroselinic acid based diacetylated sophorolipid lactone (208): 1H-NMR 
(400 MHz, MeOD): H 1.23 (3H, d, J=6.2 Hz, CHCH3), 1.31-1.50 (16H, m, 
7xCH2(CH2)2, CHaHbCHCH3, CHaHbCH2CHCH3), 1.53-1.59 (2H, m, CHaHbCHCH3, 
CHaHbCH2CHCH3), 1.61-1.74 (2H, m, CH2CH2C=O), 2.03-2.11 (4H, m, 2xCH2CH=CH), 
2.06 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.33-2.47 (2H, m, CH2C=O), 3.29-3.36 
(2H, m, 2xCHOC), 3.45 (1H, dxd, J=9.1 Hz, J=7.7 Hz, CHOC), 3.46-3.50 (1H, m, 
CHOC), 3.58 (1H, dxd, J=9.1 Hz, J=9.1 Hz, CHOC), 3.60 (1H, dxd, J=9.4 Hz, J=9.4 Hz, 
CHOC), 3.66 (1H, dxdxd, J=10.0 Hz, J=3.8 Hz, J=3.8 Hz, CHOC), 3.71-3.79 (1H, m, CH3CHO), 4.09-4.14 
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(2H, m, CH2OAc), 4.21 (1H, dxd, J=11.8 Hz, J=6.4 Hz, CHaHbOAc), 4.38 (1H, dxd, J=11.8 Hz, J=2.1 Hz, 
CHaHbOAc),4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.67 (1H, dxd, J=7.7 Hz, CH(O)2), 4.84-4.89 (1H, m, CHOC), 
5.33-5.43 (2H, m, CH=CH). 13C-NMR (100 MHz, MeOD): C 19.3 (CH3C=O), 19.5 (CH3C=O), 20.5 
(CH3CH), 23.9 (CH2CH2C=O), 25.1 (CH2CH2CHCH3), 26.1 (CH2CH=CH), 26.6 (CH2CH=CH), 28.5 
(CH2(CH2)2), 29.0 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.7 (CH2(CH2)2), 29.7 (CH2(CH2)2), 29.8 (CH2(CH2)2), 
30.0 (CH2(CH2)2), 33.2 (CH2C=O), 37.2 (CH2CHCH3), 62.7 (CH2OAc), 63.4 (CH2OAc), 70.2 (CHOC), 70.5 
(CHOC), 72.0 (CHOC), 73.4 (CHOC), 73.6 (CHOC), 75.2 (CHOC), 76.5 (CHOC), 78.7 (CHOC), 81.9 (CHOC), 
102.2 (CH(O)2), 103.8 (CH(O)2), 128.6 (CH=CH), 130.5 (CH=CH), 170.8 (C=O), 171.3 (C=O), 172.9 (C=O). 
General procedure for the synthesis of (S,Z)-17-([2’-O--D-glucopyranosyl--D-glucopyranosyl]-
oxy)-6-octadecenoic acid (209): In a 100 mL round-bottomed flask, 1.01 g lactonic SL 208 (1.47 
mmol, 1 eq) was dissolved in aqueous 3 N NaOH and refluxed for 20 minutes. The reaction mixture 
was cooled down and acidified with concentrated HCl to pH 5 to induce precipitation of sophorolipid 
acid 209 as a white powder. The precipitate was filtered, washed with water and dried under 
reduced pressure (0.87 g, yield 95%). 
1H-NMR (400 MHz, MeOD): H 1.27 (3H, d, J=6.2 Hz, 
CH3CH), 1.30-1.48 (17H, m, 8xCH2(CH2)2, CHaHbCHCH3), 
1.60-1.67 (3H, m, CHaHbCHCH3, CH2CH2COOH), 2.04-
2.11 (4H, m, 2xCH2CH=CH), 2.31 (2H, t, J=7.4 Hz, 
CH2COOH), 3.24-3.36 (5H, m, CHOC), 3.40 (1H, dxd, 
J=8.7 Hz, J=8.7 Hz, CHOC), 3.47 (1H, dxd, J=8.4 Hz, J=8.4 Hz, CHOC), 3.58 (1H, dxd, J=8.7 Hz, J=8.7 Hz, 
CHOC), 3.66-3.71 (2H, m, 2xCHaHbOH), 3.82-3.89 (3H, m, 2xCHaHbOH, CHOC), 4.47 (1H, d, J=7.7 Hz, 
CH(O)2), 4.66 (1H, d, J=7.8 Hz, CH(O)2), 5.33-5.43 (2H, m, CH=CH). 
13C-NMR (100 MHz, MeOD): C 20.5 
(CH3CH), 24.3 (CH2CH2COOH), 24.9 (CH2(CH2)2), 26.4 (CH2CH=CH), 26.8 (CH2CH=CH), 28.9 (CH2(CH2)2), 
29.0 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.5 (3xCH2(CH2)2), 29.6 (CH2(CH2)2), 33.5 (CH2COOH), 36.4 
(CH2CHCH3), 61.3 (CH2OH), 61.6 (CH2OH), 70.1 (CHOC), 70.4 (CHOC), 74.4 (CHOC), 76.3 (2xCHOC), 
76.8 (CHOC), 76.9 (CHOC), 77.5 (CHOC), 80.5 (CHOC), 101.3 (CH(O)2), 103.2 (CH(O)2), 128.9 (CH=CH), 
129.9 (CH=CH), 176.2 (COOH). 
General procedure for synthesis of methyl (S,Z)-17-([2’-O--D-glucopyranosyl--D-glucopyranosyl]-
oxy)-6-octadecenoate (210): In a 100 mL flame dried round-bottomed flask, sodium methoxide was 
formed in situ by addition of 0.05 g sodium (2.05 mmol, 0.15 eq) to 20 mL dry methanol and 9.39 g 
lactonic SL 208 (13.64 mmol, 1 eq) was subsequently added. The flask was equipped with a reflux 
condenser and a CaCl2 guard-tube to protect the reaction mixture from atmospheric moisture. The 
reaction mixture was stirred for 3 h at reflux temperature, cooled down to room temperature and 
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acidified to neutral pH with acetic acid. The mixture was concentrated under reduced pressure, 
dissolved in deionized water and cooled down to 0 °C in an ice bath. The sophorolipid methyl ester 
210 precipitated as a white powder. The precipitate was filtered, washed with water and dried under 
reduced pressure (7.81 g, yield 90%). 
1H-NMR (400 MHz, MeOD): H 1.27 (3H, d, J=6.2 Hz, 
CH3CH), 1.31-1.50 (17H, m, CHaHbCHCH3, 
8xCH2(CH2)2), 1.60-1.67 (3H, m, CHaHbCHCH3, 
CH2CH2COOMe), 2.03-2.10 (4H, m, 2xCH2CH=CH), 
2.34 (2H, t, J=7.4 Hz, CH2COOMe), 3.23-3.36 (5H, m, 
5xCHOC), 3.40 (1H, dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.45-3.49 (1H, m, CHOC), 3.58 (1H, dxd, J=8.7 Hz, 
J=8.7 Hz, CHOC), 3.65-3.70 (2H, m, 2xCHaHbOH), 3.67 (3H, s, OCH3), 3.81-3.89 (3H, m, 2xCHaHbOH, 
CHOC), 4.47 (1H, d, J=7.7 Hz, CH(O)2), 4.66 (1H, d, J=7.8 Hz, CH(O)2), 5.32-5.43 (2H, m, CH=CH). 
13C-
NMR (100 MHz, MeOD): C 20.5 (CH3CH), 24.2 (CH2CH2COOMe), 24.9 (CH2(CH2)2), 26.4 (CH2CH=CH), 
26.8 (CH2CH=CH), 28.9 (CH2(CH2)2), 29.0 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.5 (3xCH2(CH2)2), 29.6 
(CH2(CH2)2), 33.3 (CH2COOMe), 36.5 (CH2CHCH3), 50.7 (OCH3), 61.4 (CH2OH), 61.7 (CH2OH), 70.1 
(CHOC), 70.4 (CHOC), 74.5 (CHOC), 76.4 (2xCHOC), 76.8 (CHOC), 76.9 (CHOC), 77.5 (CHOC), 80.5 
(CHOC), 101.3 (CH(O)2), 103.3 (CH(O)2), 128.9 (CH=CH), 130.0 (CH=CH), 174.5 (COOMe). 
General procedure for synthesis of methyl (S,Z)-17-([2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-6-octadecenoate (211): In a 100 mL flame dried round-
bottomed flask, 5.59 g sophorolipid methyl ester 210 (8.78 mmol, 1 eq) was dissolved in 50 mL dry 
THF. The flask was equipped with a CaCl2 guard-tube to protect the reaction mixture from 
atmospheric moisture and 5.93 mL acetic anhydride (61.87 mmol, 7.05 eq) and 0.43 g DMAP (3.51 
mmol, 0.4 eq) were added. The reaction mixture was stirred for 1 h at room temperature, 
concentrated under reduced pressure and dissolved in ethyl acetate. The mixture was washed 3 
times with a 10 mL saturated NaHCO3-solution and the organic phase was dried over MgSO4, filtered 
and concentrated under reduced pressure. Peracetylated sophorolipid methyl ester 211 was isolated 
as a viscous colorless oil (8.17 g, quantitative yield). 
1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, 
CH3CH), 1.26-1.41 (17H, m, CHaHbCHCH3, 8xCH2(CH2)2), 
1.56-1.68 (3H, m, CHaHbCHCH3, CH2CH2COOMe), 1.98-
2.08 (4H, m, 2xCH2CH=CH), 1.98 (3H, s, CH3C=O), 2.00 
(3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 (3H, s, 
CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.31 (2H, t, J=7.5 Hz, CH2COOMe), 3.63-3.75 
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(4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 3.67 (3H, s, OCH3), 4.06-4.10 (2H, m, 2xCHaHbOAc), 4.22-4.31 
(2H, m, 2xCHaHbOAc), 4.48 (1H, d, J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 Hz, CH(O)2), 4.91 (1H, dxd, 
J=8.9 Hz, J=7.8 Hz, CHOC), 4.93 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.06 (1H, dxd, J=9.5 Hz, J=9.5 Hz, 
CHOC), 5.13 (1H, dxd, J=9.3 Hz, J=9.3 Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.29-5.40 
(2H, m, CH=CH). 13C-NMR (100 MHz, CDCl3): C 20.5 (CH3C=O), 20.5 (2xCH3C=O), 20.6 (CH3C=O), 20.7 
(2xCH3C=O), 20.8 (CH3C=O), 21.2 (CH3CH), 24.6 (CH2CH2COOMe), 25.1 (CH2(CH2)2), 26.8 (CH2CH=CH), 
27.2 (CH2CH=CH), 29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.6 (CH2(CH2)2), 29.7 (CH2(CH2)2), 29.7 
(2xCH2(CH2)2), 29.8 (CH2(CH2)2), 34.0 (CH2COOMe), 36.5 (CH2CHCH3), 51.4 (OCH3), 62.0 (CH2OAc), 62.2 
(CH2OAc), 68.2 (CHOC), 68.9 (CHOC), 71.3 (CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.1 (CHOC), 74.6 
(CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 129.0 (CH=CH), 130.5 (CH=CH), 
169.3 (CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 (CH3C=O), 170.6 (CH3C=O), 
170.6 (CH3C=O), 174.1 (COOMe). 
General procedure for the synthesis of (S)-11-([2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl]-oxy)-dodecananal (212): In a 250 mL washing flask, 1.00 g 
peracetylated sophorolipid methyl ester (1.07 mmol, 1 eq) 211 was dissolved in 50 mL MeOH. 0.09 g 
NaHCO3 (1.07 mmol, 1 eq) and a pinch of Sudan III indicator were added. The reaction mixture was 
sparged with ozone at room temperature until the red color of the reaction mixture dissipated. After 
addition of 0.23 g NaBH(OAc)3 (1.07 mmol, 1 eq), the mixture was stirred for 1 h at room 
temperature, concentrated under reduced pressure and dissolved in ethyl acetate. The mixture was 
washed 3 times with 10 mL brine and the organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure. Peracetylated sophorolipid aldehyde 212 was purified by 
automated column chromatography as a viscous colorless oil with a hexane/diethyl ether mixture as 
eluent (3.46 g, 60%). Gradient: 2 CV 20% Et2O, 10 CV 20-100% Et2O, 9 CV 100% Et2O. 
1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, CH3CH), 
1.26-1.43 (13H, m, 6xCH2(CH2)2, CHaHbCHCH3), 1.55-1.69 (3H, 
CHaHbCHCH3, CH2CH2(C=O)H), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, 
CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, 
s, CH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.42 (2H, txd, J=7.4 Hz, 
J=1.9 Hz, CH2(C=O)H), 3.63-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 
2xCHaHbOAc), 4.22-4.31 (2H, m, 2xCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.72 (1H, d, J=8.0 Hz, 
CH(O)2), 4.91 (1H, dxd, J=9.3 Hz, J=8.4 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.06 (1H, 
dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 
Hz, CHOC), 9.76 (1H, t, J=1.9 Hz, HC=O). 13C-NMR (100 MHz, CDCl3): C 20.5 (CH3C=O), 20.5 
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(2xCH3C=O), 20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.8 (CH3C=O), 21.3 (CH3CH), 22.1 (CH2CH2(C=O)H), 
25.0 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.7 (CH2(CH2)2), 29.7 
(CH2(CH2)2), 36.5 (CH2CHCH3), 43.9 (CH2(C=O)H), 62.0 (CH2OAc), 62.3 (CH2OAc), 68.3 (CHOC), 68.9 
(CHOC), 71.3 (CHOC), 71.6 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.7 (CHOC), 77.6 (CHOC), 78.0 (CHOC), 
100.4 (CH(O)2), 101.2 (CH(O)2), 169.3 (CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 
170.3 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O), 203.0 (HC=O). 
4.2.2. Synthesis of sophorolipid amines 
General procedure for the synthesis of secondary peracetylated sophororlipid amines (213): In a 50 
mL flask, 1.57 g peractylated sophoroplipid aldehyde 201 (2.02 mmol, 1 eq) was dissolved in 25 mL 
methanol and the secondary amine (2.02 mmol, 1 eq), 0.25 g NaBH3CN (4.04 mmol, 2 eq) and 
0.58 mL acetic acid (10.09 mmol, 5 eq) were added sequentially. The reaction mixture was stirred 
overnight at room temperature, concentrated under reduced pressure and dissolved in ethyl acetate. 
The mixture was washed 3 times with a saturated NaHCO3-solution and the organic phase was dried 
over MgSO4, filtered and concentrated under reduced pressure. The peracetylated sophorolipid 
amines were purified by automated column chromatography as a viscous colourless oil with a 
hexane/ethyl acetate/triethylamine mixture as eluent (mixture A = 16% triethylamine in ethyl 
acetate). 
N,N-dimethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213a): Purification gradient: 2 CV 20% mixture A, 35 CV 
20-60% mixture A, 2 CV 60% mixture A. (1.53 g, 38%). IR (cm-1) 
max: 1034 and 1063 (CHOCH), 1215 (COAc), 1367, 1744 (C=O). 
1H-
NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, CH3CH), 1.25-1.45 
(9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.52-1.58 (1H, m, CHaHbCHCH3), 
1.68-1.76 (2H, m, CH2CH2N), 1.99 (3H, s, CH3C=O), 1.99 (3H, s, 
CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (3H, s, 2xCH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 
2.09 (3H, s, CH3C=O), 2.70 (6H, s, 2xCH3N), 2.85-2.89 (2H, m, CH2N), 3.55-3.75 (4H, m, 2xCHCH2OAc, 
CH3CHO, CHOC), 4.06-4.11 (2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, 
J=7.7 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.87 (1H, dxd, J=9.6 Hz, J=8.1 Hz, CHOC), 4.93 (1H, 
dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.02 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.12 (1H, dxd, J=9.5 Hz, J=9.5 
Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 20.6 (CH3C=O), 
20.6 (2xCH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 24.7 
(CH2(CH2)2), 24.8 (CH2CH2N), 26.6 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 36.5 (CH2CHCH3), 
43.4 (2xCH3N), 58.4 (CH2N), 62.2 (CH2OAc), 62.2 (CH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 
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71.5 (CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.7 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 
(CH(O)2), 169.6 (2xCH3C=O), 169.8 (CH3C=O), 170.0 (CH3C=O), 170.1 (CH3C=O), 170.6 (CH3C=O), 170.6 
(CH3C=O). MS (ESI): m/z Exact mass calculated for C37H60NO18 [M+H
+]: 806.3805. Found: 806.3802. 
N,N-diethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])nonan-1-amine (213b): Purification was performed via an acid/base extraction procedure. 
(0.26 g, 50%). IR (cm-1) max: 1034 and 1064 (CHOCH), 1218 
(COAc), 1366, 1743 (C=O). 1H-NMR (400 MHz, CDCl3): H 1.21 (3H, 
d, J=6.2 Hz, CH3CH), 1.27-1.44 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 
1.34 (6H, t, J=7.3 Hz, 2xCH3CH2), 1.51-1.58 (1H, m, CHaHbCHCH3), 
1.68-1.76 (2H, m, CH2CH2N), 1.98 (3H, s, CH3C=O), 1.99 (3H, s, 
CH3C=O), 2.02 (6H, s, 2xCH3C=O), 2.05 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 
2.94-2.98 (2H, m, CH2CH2N), 3.09 (4H, q, J=7.3 Hz, 2xCH3CH2N), 3.63-3.74 (4H, m, 2xCHCH2OAc, 
CH3CHO, CHOC), 4.04-4.10 (2H, m, 2xCHCHaHbOAc), 4.22-4.27 (2H, m, 2xCHCHaHbOAc), 4.46 (1H, d, 
J=7.6 Hz, CH(O)2), 4.69 (1H, d, J=8.0 Hz, CH(O)2), 4.86 (1H, dxd, J=9.5 Hz, J=8.2 Hz, CHOC), 4.92 (1H, 
dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.00 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.11 (1H, dxd, J=9.3 Hz, J=9.3 
Hz, CHOC), 5.16 (1H, dxd, J=9.3 Hz, J=9.3 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 8.8 (2xCH3CH2), 
20.4 (CH3C=O), 20.6 (3xCH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 23.3 
(CH2CH2N), 24.7 (CH2(CH2)2), 26.8 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.4 (CH2(CH2)2), 36.5 (CH2CHCH3), 
46.9 (2xCH3CH2N), 51.4 (CH2CH2N), 62.2 (2xCH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.5 
(CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 
(CH(O)2), 169.6 (2xCH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.1 (CH3C=O), 170.6 (CH3C=O), 170.6 
(CH3C=O). MS (ESI): m/z Exact mass calculated for C39H64NO18 [M+H
+]: 834.4118. Found: 834.4111. 
N-butyl,N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213c): Purification gradient: 2 CV 15% mixture A, 35 CV 
15-55% mixture A, 2 CV 55% mixture A. (1.12 g, 52%). 
IR (cm-1) max: 1033 and 1063 (CHOCH), 1216 (COAc), 1366, 
1745 (C=O). 1H-NMR (400 MHz, CDCl3): H 0.95 (3H, t, J=7.3 
Hz, CH3CH2), 1.22 (3H, d, J=6.2 Hz, CH3CH), 1.26-1.42 (11H, m, 
5xCH2(CH2)2, CHaHbCHCH3), 1.54-1.66 (5H, m, 2xCH2CH2N, 
CHaHbCHCH3), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 
2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.48 (3H, s, CH3N), 2.63-2.68 (4H, m, 
2xCH2N), 3.64-3.76 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.11 (2H, m, 2xCHCHaHbOAc), 4.22-
4.29 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.72 (1H, d, J=8.0 Hz, CH(O)2), 4.89 (1H, 
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dxd, J=9.5 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.03 (1H, dxd, J=9.6 Hz, J=9.6 
Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-
NMR (100 MHz, CDCl3): C 13.8 (CH3CH2), 20.4 (CH3CH2), 20.5 (CH3C=O), 20.6 (3xCH3C=O), 20.7 
(CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.4 (CH3CH), 24.8 (CH2CH2N), 25.4 (CH2(CH2)2), 27.2 
(CH2(CH2)2), 27.6 (CH2CH2N), 29.5 (CH2(CH2)2), 29.5 (CH2(CH2)2), 36.5 (CH2CHCH3), 41.0 (CH3N), 56.6 
(CH2N), 56.9 (CH2N), 62.1 (CH2OAc), 62.2 (CH2OAc), 68.3 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 71.6 
(CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.7 (CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.2 
(CH(O)2), 169.4 (CH3C=O), 169.5 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.6 
(CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C40H66NO18 [M+H
+]: 848.4274. 
Found: 848.4305. 
N,N-dibutyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])nonan-1-amine (213d): Purification gradient: 2 CV 5% mixture A, 35 CV 5-50% mixture A, 2 CV 
50% mixture A. (0.71 g, 53%). IR (cm-1) max: 1034 and 1064 
(CHOCH), 1217 (COAc), 1366, 1745 (C=O). 1H-NMR (400 MHz, 
CDCl3): H 0.97 (6H, t, J=7.3 Hz, 2xCH3CH2), 1.22 (3H, d, J=6.2 
Hz, CH3CH), 1.26-1.43 (13H, m, CHaHbCHCH3, 2xCH2CH3, 
4xCH2(CH2)2), 1.54-1.60 (1H, m, CHaHbCHCH3), 1.61-1.72 (6H, 
m, 3xCH2CH2N), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 2.03 (3H, s, 
CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 2.83-2.88 (6H, m, 3xCH2N), 
3.64-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 
2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.88 (1H, dxd, J=9.4 Hz, 
J=8.0 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.03 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 
5.13 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100 MHz, 
CDCl3): C 13.6 (2xCH3CH2), 20.2 (2xCH3CH2), 20.4 (CH3C=O), 20.5 (3xCH3C=O), 20.7 (CH3C=O), 20.7 
(CH3C=O), 20.8 (CH3C=O), 21.4 (CH3CH), 24.0 (CH2CH2N), 24.8 (CH2(CH2)2), 26.2 (2xCH2CH2N), 27.0 
(CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 36.5 (CH2CHCH3), 52.7 (2xCH2N), 52.9 (CH2N), 62.1 
(CH2OAc), 62.2 (CH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.5 (CHOC), 71.7 (CHOC), 72.9 
(CHOC), 74.7 (CHOC), 77.6 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.2 (CH(O)2), 169.4 (CH3C=O), 
169.5 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.1 (CH3C=O), 170.5 (CH3C=O), 170.6 (CH3C=O). 
MS (ESI): m/z Exact mass calculated for C43H72NO18 [M+H
+]: 890.4744. Found: 890.4761. 
  
  Experimental procedures 
123 
 
N-methyl,N-benzyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213e): Purification gradient: 2 CV 5% mixture A, 35 CV 5-50% 
mixture A, 2 CV 50% mixture A. (1.19 g, 40%). IR (cm-1) max: 
733, 1033 and 1063 (CHOCH), 1214 (COAc), 1366, 1746 
(C=O). 1H-NMR (400 MHz, CDCl3): H 1.22 (3H, t, J=6.1 Hz, 
CH3CH), 1.25-1.42 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.51-
1.63 (3H, m, CH2CH2N, CHaHbCHCH3), 1.98 (3H, s, CH3C=O), 
2.00 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.07 (3H, s, 
CH3C=O), 2.08 (3H, s, CH3C=O), 2.18 (3H, s, CH3N), 2.38 (2H, t, J=7.5 Hz, CH2N), 3.48 (2H, s, CaromCH2N), 
3.63-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 4.22-4.31 (2H, m, 
2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 Hz, CH(O)2), 4.91 (1H, dxd, J=9.2 Hz, 
J=7.8 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.06 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 
5.13 (1H, dxd, J=9.3 Hz, J=9.3 Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 7.21-7.31 (5H, m, 
5xCHarom). 
13C-NMR (100 MHz, CDCl3): C 20.5 (CH3C=O), 20.6 (2xCH3C=O), 20.6 (CH3C=O), 20.7 
(2xCH3C=O), 20.8 (CH3C=O), 21.2 (CH3CH), 25.0 (CH2(CH2)2), 27.4 (CH2CH2N), 27.5 (CH2(CH2)2), 29.7 
(CH2(CH2)2), 29.8 (CH2(CH2)2), 36.4 (CH2CHCH3), 42.2 (CH3N), 57.6 (CH2CH2N), 62.0 (CaromCH2N, 
CH2OAc), 62.3 (CH2OAc), 68.3 (CHOC), 68.9 (CHOC), 71.3 (CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.1 
(CHOC), 74.6 (CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 126.8 (CHarom), 128.1 
(2xCHarom), 129.0 (2xCHarom), 139.3 (Carom), 169.3 (CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 
(CH3C=O), 170.3 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for 
C43H64NO18 [M+H
+]: 882.4118. Found: 882.4160. 
N-butyl,N-benzyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213f): Purification gradient: 2 CV  5% mixture A, 35 CV 5-50% 
mixture A, 2 CV 50% mixture A. (1.92 g, 49%). IR (cm-1) max: 
1034 and 1064 (CHOCH), 1213 (COAc), 1365, 1747 (C=O). 1H-
NMR (400 MHz, CDCl3): H 0.87 (3H, t, J=7.3 Hz, CH3CH2), 1.21 
(3H, d, J=6.2 Hz, CH3CH), 1.24-1.39 (11H, m, CH2CH3, 4xCH2(CH2)2, 
CHaHbCHCH3), 1.40-1.50 (4H, m, 2xCH2CH2N), 1.56-1.62 (1H, m, 
CHaHbCHCH3), 1.97 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 
2.06 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.38-2.42 (4H, m, 2xCH2CH2N), 3.54 
(2H, s, CaromCH2N), 3.62-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 
2xCHCHaHbOAc), 4.22-4.31 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 
Hz, CH(O)2), 4.87-4.95 (2H, m, 2xCHOC), 5.06 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.13 (1H, dxd, J=9.3 
Hz, J=9.3 Hz, CHOC), 5.16 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 7.19-7.23 (1H, m, CHarom), 7.27-7.34 
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(4H, m, CHarom). 
13C-NMR (100 MHz, CDCl3): C 14.1 (CH3CH2), 20.5 (CH3C=O), 20.5 (2xCH3C=O), 20.6 
(CH3C=O), 20.6 (CH3CH2), 20.7 (2xCH3C=O), 20.8 (CH3C=O), 21.2 (CH3CH), 25.1 (CH2(CH2)2), 27.0 
(CH2CH2N), 27.5 (CH2(CH2)2), 29.2 (CH2CH2N), 29.7 (2xCH2(CH2)2), 36.4 (CH2CHCH3), 53.5 (CH2CH2N), 
53.8 (CH2CH2N), 58.6 (CaromCH2N), 62.0 (CH2OAc), 62.3 (CH2OAc), 68.2 (CHOC), 68.9 (CHOC), 71.3 
(CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.6 (CHOC), 77.7 (CHOC), 78.0 (CHOC), 100.4 
(CH(O)2), 101.1 (CH(O)2), 126.5 (CHarom), 128.0 (2xCHarom), 128.8 (2xCHarom), 140.3 (Carom), 169.3 
(CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 (CH3C=O), 170.6 (CH3C=O), 170.6 
(CH3C=O). MS (ESI): m/z Exact mass calculated for C46H70NO18 [M+H
+]: 924.4587. Found: 924.4625. 
N,N-dibenzyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213g): Purification gradient: 2 CV 1% mixture A, 35 CV 1-50% 
mixture A, 2 CV 50% mixture A. (1.33 g, 48%). IR (cm-1) max: 
733, 1033 and 1064 (CHOCH), 1214 (COAc), 1366, 1746 
(C=O). 1H-NMR (400 MHz, CDCl3): H 1.21 (3H, d, J=6.2 Hz, 
CH3CH), 1.22-1.39 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.50-
1.61 (3H, m, CH2CH2N, CHaHbCHCH3), 1.96 (3H, s, CH3C=O), 
2.00 (6H, s, 2xCH3C=O), 2.02 (3H, s, CH3C=O), 2.05 (3H, s, CH3C=O), 2.05 (3H, s, CH3C=O), 2.07 (3H, s, 
CH3C=O), 2.41 (2H, t, J=7.2 Hz, CH2CH2N), 3.55 (4H, s, 2xCaromCH2N), 3.62-3.74 (4H, m, 2xCHCH2OAc, 
CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 4.22-4.30 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, 
J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 Hz, CH(O)2), 4.91 (1H, dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 4.93 (1H, 
dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.06 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.13 (1H, dxd, J=9.3 Hz, J=9.3 
Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 7.19-7.37 (10H, m, 10xCHarom). 
13C-NMR (100 
MHz, CDCl3): C 20.5 (CH3C=O), 20.5 (2xCH3C=O), 20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.8 (CH3C=O), 
21.2 (CH3CH), 25.0 (CH2(CH2)2), 26.9 (CH2CH2N), 27.3 (CH2(CH2)2), 29.7 (CH2(CH2)2), 29.7 (CH2(CH2)2), 
36.4 (CH2CHCH3), 53.4 (CH2CH2N), 58.2 (2xCaromCH2N), 62.0 (CH2OAc), 62.3 (CH2OAc), 68.2 (CHOC), 
68.9 (CHOC), 71.3 (CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.1 (CHOC), 74.6 (CHOC), 77.7 (CHOC), 77.9 
(CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 126.7 (2xCHarom), 128.1 (4xCHarom), 128.8 (4xCHarom), 140.0 
(2xCarom), 169.3 (CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 (CH3C=O), 170.6 
(CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C49H68NO18 [M+H
+]: 958.4431. 
Found: 958.4421. 
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N-methyl,N-octadecyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine (213h): Purification gradient: 2 CV 10% mixture A, 35 CV 
10-50% mixture A, 2 CV 50% mixture A. (2.11 g, 39%). 
IR (cm-1) max: 1034 and 1063 (CHOCH), 1216 (COAc), 1366, 
1747 (C=O). 1H-NMR (400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 
Hz, CH3CH2), 1.21 (3H, d, J=6.2 Hz, CH3CH), 1.25-1.40 (39H, m, 
CH2CH3, 18xCH2(CH2)2, CHaHbCHCH3), 1.41-1.51 (4H, m, 
2xCH2CH2N), 1.56-1.62 (1H, m, CHaHbCHCH3), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.01 (3H, s, 
CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.20 (3H, s, CH3N), 2.28-
2.33 (4H, m, 2xCH2CH2N), 3.63-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 
2xCHCHaHbOAc), 4.22-4.31 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 
Hz, CH(O)2), 4.89-4.95 (2H, m, 2xCHOC), 5.06 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.13 (1H, dxd, J=9.3 
Hz, J=9.3 Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 14.1 
(CH3CH2), 20.5 (CH3C=O), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.8 
(CH3C=O), 21.2 (CH3CH), 22.7 (CH3CH2), 25.0 (CH2(CH2)2), 27.3 (CH2CH2N), 27.4 (CH2CH2N), 27.7 
(CH2(CH2)2), 27.7 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.6-29.7 (12xCH2(CH2)2), 29.8 (CH2(CH2)2), 31.9 
(CH2(CH2)2), 36.5 (CH2CHCH3), 42.3 (CH3N), 58.0 (CH2CH2N), 58.0 (CH2CH2N), 62.0 (CH2OAc), 62.3 
(CH2OAc), 68.2 (CHOC), 68.9 (CHOC), 71.3 (CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.1 (CHOC), 74.6 
(CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 169.3 (CH3C=O), 169.4 (CH3C=O), 
169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z 
Exact mass calculated for C54H94NO18 [M+H
+]: 1044.6465. Found: 1044.6499. 
N-methyl,N-octadecyl-((S)-11-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])dodecan-1-amine (226): Purification gradient: 2 CV 15% mixture A, 25 CV 
15-60% mixture A, 2 CV 60% mixture A. (1.22 g, 46%). 
1H-NMR (400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 Hz, 
CH3CH2), 1.22 (3H, d, J=6.2 Hz, CH3CH), 1.24-1.40 (45H, 
m, CH2CH3, 21xCH2(CH2)2, CHaHbCHCH3), 1.41-1.50 (4H, 
m, 2xCH2CH2N), 1.56-1.66 (1H, m, CHaHbCHCH3), 1.99 
(3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, 
CH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.20 (3H, s, CH3N), 2.28-2.32 (4H, m, 2xCH2CH2N), 3.63-3.75 (4H, m, 
2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 4.23-4.32 (2H, m, 2xCHCHaHbOAc), 
4.48 (1H, d, J=7.6 Hz, CH(O)2), 4.74 (1H, d, J=8.0 Hz, CH(O)2), 4.89-4.96 (2H, m, 2xCHOC), 5.07 (1H, 
dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.13 (1H, dxd, J=9.3 Hz, J=9.3 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 
Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 14.1 (CH3CH2), 20.5 (CH3C=O), 20.6 (2xCH3C=O), 20.6 
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(CH3C=O), 20.7 (2xCH3C=O), 20.8 (CH3C=O), 21.2 (CH3CH), 22.7 (CH3CH2), 25.1 (CH2(CH2)2), 27.3 
(CH2CH2N), 27.4 (CH2CH2N), 27.6 (CH2(CH2)2), 27.7 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.6-29.7 
(14xCH2(CH2)2), 29.7 (CH2(CH2)2), 29.8 (CH2(CH2)2), 31.9 (CH2(CH2)2), 36.5 (CH2CHCH3), 42.3 (CH3N), 
58.0 (CH2CH2N), 58.0 (CH2CH2N), 61.9 (CH2OAc), 62.2 (CH2OAc), 68.2 (CHOC), 68.8 (CHOC), 71.3 
(CHOC), 71.7 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.6 (CHOC), 77.6 (CHOC), 78.0 (CHOC), 100.4 
(CH(O)2), 101.1 (CH(O)2), 169.3 (CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.3 
(CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). 
General procedure for the synthesis of N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--
D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine (214a): In a 50 mL flask, 0.51 g 
peractylated sophoroplipid aldehyde 201 (3.25 mmol, 5 eq) was dissolved in 25 mL methanol and 
after addition of 1.63 ml of methyl amine (0.65 mmol, 1 eq), the mixture was stirred at room 
temperature. After 1 hour, 0.08 g NaBH3CN (1.30 mmol, 2 eq) and 0.19 mL acetic acid (3.25 mmol, 
5 eq) were added sequentially. The reaction mixture was stirred overnight at room temperature, 
concentrated under reduced pressure and dissolved in ethyl acetate. The mixture was washed 3 
times with a saturated NaHCO3-solution and the organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure. Methyl sophorolipid amine 214a was obtained in high purity 
without further purification (0.31 g, 60%). 
1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, CH3CH), 1.26-
1.43 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.54-1.66 (3H, m, 
CHaHbCHCH3, CH2CH2N), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 
2.03 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 
2.08 (6H, s, 2xCH3C=O), 2.55 (3H, s, CH3N), 2.76 (2H, t, J=7.5 Hz, 
CH2N), 3.64-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 3.96 (1H, br s, NH), 4.07-4.10 (2H, m, 
2xCHCHaHbOAc), 4.22-4.30 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.72 (1H, d, J=8.0 
Hz, CH(O)2), 4.89 (1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.04 
(1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, 
J=9.5 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 (CH3C=O), 20.6 (3xCH3C=O), 20.7 (CH3C=O), 20.7 
(CH3C=O), 20.8 (CH3C=O), 21.4 (CH3CH), 24.8 (CH2(CH2)2), 26.9 (CH2(CH2)2), 28.0 (CH2CH2N), 29.5 
(CH2(CH2)2), 29.5 (CH2(CH2)2), 34.9 (CH3N), 36.5 (CH2CHCH3), 50.9 (CH2N), 62.1 (CH2OAc), 62.3 
(CH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 71.6 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.7 
(CHOC), 77.6 (CHOC), 78.0 (CHOC), 100.4 (CH(O)2), 101.2 (CH(O)2), 169.6 (CH3C=O), 169.7 (CH3C=O), 
169.8 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.6 (CH3C=O), 170.7 (CH3C=O). 
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General procedure for the synthesis of N-isopropyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O-
-D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine (214b): In a 50 mL flask, 0.16 g 
peractylated sophoroplipid aldehyde 201 (0.21 mmol, 1 eq) was dissolved in 25 mL methanol and 
0.72 ml isopropyl amine (0.42 mmol, 2 eq), 0.03 g NaBH3CN (0.42 mmol, 2 eq) and 0.06 mL acetic 
acid (1.06 mmol, 5 eq) were added sequentially. The reaction mixture was stirred overnight at room 
temperature, concentrated under reduced pressure and dissolved in ethyl acetate. The mixture was 
washed 3 times with a saturated NaHCO3-solution and the organic phase was dried over MgSO4, 
filtered and concentrated under reduced pressure. Methyl sophorolipid amine 214b was obtained in 
high purity without further purification (0.13 g, 73%). 
1H-NMR (400 MHz, CDCl3): H 1.22 (3H, d, J=6.2 Hz, CH3CHCH2), 
1.24-1.47 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.42 (6H, d, J=6.5 
Hz, 2x CH3CHN), 1.54-1.63 (1H, m, CHaHbCHCH3), 1.76-1.84 (2H, 
m, CH2CH2N), 2.00 (6H, s, 2xCH3C=O), 2.04 (6H, s, 2xCH3C=O), 2.06 
(3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 2.98 
(2H, t, J=7.9 Hz, CH2N), 3.37 (1H, sept, J=6.5 Hz, CHN), 3.65-3.76 (4H, m, 2xCHCH2OAc, CH3CHO, 
CHOC), 4.07-4.11 (2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 2xCHCHaHbOAc), 4.50 (1H, d, J=7.6 Hz, 
CH(O)2), 4.73 (1H, d, J=8.0 Hz, CH(O)2), 4.86-4.90 (1H, m, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, 
CHOC), 5.03 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.18 (1H, 
dxd, J=9.4 Hz, J=9.4 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 18.8 (2x CH3CHN), 20.5 (CH3C=O), 20.6 
(2xCH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.8 (2xCH3C=O), 21.4 (CH3CHCH2), 24.7 (CH2(CH2)2), 25.9 
(CH2(CH2)2), 26.5 (CH2CH2N), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 36.5 (CH2CHCH3), 45.2 (CH2N), 51.0 
(CHN), 62.2 (2xCH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.6 (CHOC), 71.7 (CHOC), 72.9 
(CHOC), 74.6 (CHOC), 77.6 (CHOC), 77.9 (CHOC), 100.3 (CH(O)2), 101.2 (CH(O)2), 169.7 (2xCH3C=O), 
169.8 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.7 (CH3C=O), 170.8 (CH3C=O). 
4.2.3. Synthesis of quaternary ammonium sophorolipids 
General procedure for synthesis of peracetylated sophorolipid quaternary ammonium salts: In a 
10 mL flame dried pressure resistant vial, peracetylated sophorolipid amine was dissolved in dry 
acetonitrile. The solution was cooled down to 0 °C and the alkyl iodide (5 eq) was added. The vial was 
closed and heated to 80 °C for the specified reaction time. The reaction mixture was concentrated 
under reduced pressure and recrystallized from diethyl ether if necessary to yield the peracetylated 
sophorolipid quaternary ammonium salt. 
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N,N,N-trimethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220a): (0.82 g, 91%), orange-yellow powder, 
mp 85 °C. IR (cm-1) max: 729, 917, 1033 (CHOCH), 1216 (COAc), 
1366, 1741 (C=O). 1H-NMR (400MHz, CDCl3):  1.22 (3H, d, J=6.2 
Hz, CHCH3), 1.25-1.47 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.51-
1.58 (1H, m, CHaHbCHCH3), 1.80-1.88 (2H, m, CH2CH2N), 1.99 (3H, 
s, CH3C=O), 1.99 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 2.03 (3H, s, 
CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 3.47 (9H, s, 3xCH3N), 3.54-
3.58 (2H, m, CH2CH2N), 3.65-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 
2xCHCHaHbOAc), 4.22-4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.70 (1H, d, J=8.0 
Hz, CH(O)2), 4.86 (1H, dxd, J=9.6 Hz, J=8.1 Hz, CHOC), 4.92 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 4.99 
(1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.11 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, 
J=9.5 Hz, CHOC). 13C-NMR (100MHz, CDCl3):  20.5 (CH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.7 
(2xCH3C=O), 20.8 (2xCH3C=O), 21.6 (CH3CH), 23.0 (CH2CH2N), 24.6 (CH2(CH2)2), 26.1 (CH2(CH2)2), 29.3 
(CH2(CH2)2), 29.4 (CH2(CH2)2), 36.6 (CH2CHCH3), 53.6 (3xCH3N), 62.2 (CH2OAc), 62.4 (CH2OAc), 67.4 
(CH2CH2N), 68.5 (CHOC), 68.9 (CHOC), 71.2 (CHOC), 71.4 (CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.8 
(CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 (CH(O)2), 169.7 (2xCH3C=O), 169.7 (CH3C=O), 
170.0 (CH3C=O), 170.0 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass 
calculated for C38H62NO18 [M-I
-]: 820.3961. Found: 820.3963. 
N-butyl,N,N-dimethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220b): (0.44 g, 89%), orange-yellow powder, mp 
73 °C. IR (cm-1) max: 728, 918, 1034 (CHOCH), 1218 (COAc), 
1366, 1745 (C=O). 1H-NMR (400MHz, CDCl3):  1.02 (3H, t, 
J=7.3 Hz, CH2CH3), 1.22 (3H, d, J=6.1 Hz, CHCH3), 1.26-1.50 
(11H, m, CH2CH3, 4xCH2(CH2)2, CHaHbCHCH3), 1.52-1.58 (1H, 
m, CHaHbCHCH3), 1.71-1.84 (4H, m, 2xCH2CH2N), 1.99 (3H, s, 
CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 
2.09 (3H, s, CH3C=O), 3.39 (6H, s, 2xCH3N), 3.45-3.50 (2H, m, CH2CH2N), 3.59-3.63 (2H, m, CH2CH2N), 
3.66-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 4.22-4.27 (2H, m, 
2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.70 (1H, d, J=8.0 Hz, CH(O)2), 4.84-4.89 (1H, m, 
CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 4.99 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.11 (1H, 
dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100MHz, CDCl3):  
13.8 (CH2CH3), 19.6 (CH2CH3), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.7 (CH3C=O), 20.8 
(CH3C=O), 20.8 (CH3C=O), 21.6 (CH3CH), 22.7 (CH2CH2N), 24.7 (CH2CH2N, CH2(CH2)2), 26.3 (CH2(CH2)2), 
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29.4 (CH2(CH2)2), 29.4 (CH2(CH2)2), 36.6 (CH2CHCH3), 51.5 (2xCH3N), 62.2 (CH2OAc), 62.4 (CH2OAc), 
64.1 (CH2CH2N), 64.3 (CH2CH2N), 68.6 (CHOC), 68.9 (CHOC), 71.3 (CHOC), 71.4 (CHOC), 71.7 (CHOC), 
72.9 (CHOC), 74.8 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 (CH(O)2), 169.7 
(2xCH3C=O), 169.8 (CH3C=O), 170.0 (2xCH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact 
mass calculated for C41H68NO18 [M-I
-]: 862.4431. Found: 862.4443. 
N,N-dibutyl,N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220c): (0.80 g, 96%), yellow powder, mp 70 °C. IR 
(cm-1) max: 728, 917, 1032 and 1062 (CHOCH), 1216 (COAc), 
1366, 1742 (C=O). 1H-NMR (400 MHz, CDCl3): H 1.02 (6H, t, 
J=7.3 Hz, 2xCH2CH3), 1.22 (3H, d, J=6.2 Hz, CHCH3), 1.26-1.52 
(13H, m, 2xCH2CH3, 4xCH2(CH2)2, CHaHbCHCH3), 1.54-1.58 
(1H, m, CHaHbCHCH3), 1.70-1.79 (6H, m, 3xCH2CH2N), 1.99 
(3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, 
CH3C=O), 2.09 (3H, s, CH3C=O), 3.31 (3H, s, CH3N), 3.38-3.43 (2H, m, CH2CH2N), 3.45-3.57 (4H, m, 
2xCH2CH2N), 3.65-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 
4.22-4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.87 
(1H, dxd, J=9.6 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.00 (1H, dxd, J=9.7 Hz, 
J=9.7 Hz, CHOC), 5.12 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 
13C-NMR (100 MHz, CDCl3): C 13.7 (2xCH2CH3), 19.7 (2xCH2CH3), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 
(2xCH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 22.4 (CH2CH2N), 24.4 
(2xCH2CH2N), 24.7 (CH2(CH2)2), 26.4 (CH2(CH2)2), 29.4 (2xCH2(CH2)2), 36.5 (CH2CHCH3), 49.1 (CH3N), 
61.6 (CH2CH2N), 61.7 (2xCH2CH2N), 62.2 (CH2OAc), 62.3 (CH2OAc), 68.5 (CHOC), 68.8 (CHOC), 71.2 
(CHOC), 71.4 (CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.7 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 
(CH(O)2), 101.2 (CH(O)2), 169.6 (2xCH3C=O), 169.7 (CH3C=O), 170.0 (2xCH3C=O), 170.6 (CH3C=O), 
170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C44H74NO18 [M-I
-]: 904.4900. Found: 
904.4921. 
N,N,N-tributyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220d): (0.56 g, 94%), brown-yellow powder, 
mp 67 °C. IR (cm-1) max: 730, 919, 1034 and 1064 (CHOCH), 
1217 (COAc), 1366, 1743 (C=O). 1H-NMR (400MHz, CDCl3):  
1.02 (9H, t, J=7.3 Hz, 3xCH2CH3), 1.22 (3H, d, J=6.2 Hz, 
CHCH3), 1.27-1.51 (15H, m, 3xCH2CH3, 4xCH2(CH2)2, 
CHaHbCHCH3), 1.53-1.58 (1H, m, CHaHbCHCH3), 1.68-1.77 (8H, 
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m, 4xCH2CH2N), 1.98 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (3H, s, 
CH3C=O), 2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 3.31-3.35 (2H, m, CH2CH2N), 3.37-3.42 (6H, m, 
3xCH2CH2N), 3.65-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 
4.21-4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.87 
(1H, dxd, J=9.5 Hz, J=8.2 Hz, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.00 (1H, dxd, J=9.7 Hz, 
J=9.7 Hz, CHOC), 5.12 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 
13C-NMR (100MHz, CDCl3):  13.7 (3xCH2CH3), 19.8 (3xCH2CH3), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 
(CH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 22.3 
(CH2CH2N), 24.3 (3xCH2CH2N), 24.7 (CH2(CH2)2), 26.5 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 
36.6 (CH2CHCH3), 59.2 (3xCH2CH2N), 59.3 (CH2CH2N), 62.2 (CH2OAc), 62.4 (CH2OAc), 68.6 (CHOC), 68.9 
(CHOC), 71.3 (CHOC), 71.5 (CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 
100.5 (CH(O)2), 101.3 (CH(O)2), 169.6 (CH3C=O), 169.6 (CH3C=O), 169.8 (CH3C=O), 170.0 (2xCH3C=O), 
170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C47H80NO18 [M-I
-]: 946.5370. 
Found: 946.5374. 
N-benzyl,N,N-dimethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220e): (0.45 g, quant.), off-white powder, 
mp 79 °C. IR (cm-1) max: 726, 914, 1033 and 1063 (CHOCH), 
1217 (COAc), 1366, 1743 (C=O). 1H-NMR (400MHz, CDCl3):  
1.22 (3H, d, J=6.1 Hz, CHCH3), 1.26-1.44 (9H, m, 4xCH2(CH2)2, 
CHaHbCHCH3), 1.51-1.59 (1H, m, CHaHbCHCH3), 1.85-1.92 (2H, 
m, CH2CH2N), 1.95 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 
2.01 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.09 (3H, s, 
CH3C=O), 3.32 (6H, s, 2xCH3N), 3.50-3.54 (2H, m, CH2CH2N), 3.65-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, 
CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 4.22-4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, 
CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.84-4.89 (1H, m, CHOC), 4.92 (1H, dxd, J=9.7 Hz, J=9.7 Hz, 
CHOC), 5.00 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.05 (2H, s, CaromCH2N), 5.11 (1H, dxd, J=9.5 Hz, J=9.5 
Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 7.43-7.51 (3H, m, 3xCHarom), 7.69-7.70 (2H, m, 
2xCHarom). 
13C-NMR (100MHz, CDCl3): 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 (2xCH3C=O), 20.7 
(CH3C=O), 20.8 (2xCH3C=O), 21.5 (CH3CH), 22.7 (CH2CH2N), 24.6 (CH2(CH2)2), 26.2 (CH2(CH2)2), 29.3 
(CH2(CH2)2), 29.4 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.8 (2xCH3N), 62.2 (CH2OAc), 62.3 (CH2OAc), 63.8 
(CH2CH2N), 67.0 (CaromCH2N), 68.5 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.4 (CHOC), 71.8 (CHOC), 72.9 
(CHOC), 74.8 (CHOC), 77.8 (CHOC), 77.9 (CHOC), 100.5 (CH(O)2), 101.2 (CH(O)2), 127.2 (Carom), 129.2 
(2xCHarom), 130.8 (CHarom), 133.2 (2xCHarom), 169.6 (2xCH3C=O), 169.7 (CH3C=O), 170.0 (2xCH3C=O), 
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170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C44H66NO18 [M-I
-]: 896.4274. 
Found: 896.4270. 
N-benzyl,N-butyl,N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-hepta-acetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220f): (0.12 g, 89%), light yellow powder, 
mp 76 °C. IR (cm-1) max: 727, 916, 1033 and 1062 (CHOCH), 
1216 (COAc), 1366, 1742 (C=O). 1H-NMR (400 MHz, CDCl3): 
H 1.01 (3H, t, J=7.3 Hz, CH3CH2), 1.22 (3H, d, J=6.2 Hz, 
CH3CH), 1.26-1.49 (11H, m, CH2CH3, 4xCH2(CH2)2, 
CHaHbCHCH3), 1.52-1.59 (1H, m, CHaHbCHCH3), 1.78-1.89 (4H, 
m, 2xCH2CH2N), 1.94 (3H, s, CH3C=O), 2.00-2.02 (9H, m, 3xCH3C=O), 2.06-2.09 (9H, m, 3xCH3C=O), 
3.22 (3H, s, CH3N), 3.32-3.41 (2H, m, CH2CH2N), 3.43-3.59 (2H, m, CH2CH2N), 3.65-3.76 (4H, m, 
2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 4.21-4.27 (2H, m, 2xCHCHaHbOAc), 
4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.85-5.02 (5H, m, 3xCHOC, CaromCH2N), 
5.11 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 7.44-7.51 (3H, m, 
3xCHarom), 7.66-7.69 (2H, m, 2xCHarom). 
13C-NMR (100 MHz, CDCl3): C 13.7 (CH3CH2), 19.7 (CH3CH2), 
20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 (CH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 
(CH3C=O), 21.5 (CH3CH), 22.6 (CH2CH2N), 24.6 (CH2CH2N), 24.7 (CH2(CH2)2), 26.4 (CH2(CH2)2), 29.4 
(CH2(CH2)2), 29.4 (CH2(CH2)2), 36.5 (CH2CHCH3), 47.8 (CH3N), 60.3 (CH2CH2N), 60.4 (CH2CH2N), 62.2 
(CH2OAc), 62.4 (CH2OAc), 65.0 (CaromCH2N), 68.5 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.4 (CHOC), 71.7 
(CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.7 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.2 (CH(O)2), 127.0 
(Carom), 129.3 (2xCHarom), 130.8 (CHarom), 133.2 (2xCHarom), 169.6 (2xCH3C=O), 169.8 (CH3C=O), 170.0 
(2xCH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C47H72NO18 [M-
I-]: 938.4744. Found: 938.4755. 
N,N-dibenzyl,N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220g): (0.84 g, quant.), brown-yellow powder, 
mp 82 °C. IR (cm-1) max: 1037 (CHOCH), 1229 (COAc), 1367, 
1749 (C=O). 1H-NMR (400 MHz, CDCl3): H 1.23 (3H, d, J=6.2 
Hz, CH3CH), 1.26-1.47 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 
1.52-1.58 (1H, m, CHaHbCHCH3), 1.91 (3H, s, CH3C=O), 1.95-
2.09 (2H, m, CH2CH2N), 1.99 (3H, s, CH3C=O), 2.01 (3H, s, 
CH3C=O), 2.01 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 3.15 
(3H, s, CH3N), 3.21-3.25 (2H, m, CH2CH2N), 3.66-3.76 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.11 
(2H, m, 2xCHCHaHbOAc), 4.22-4.28 (2H, m, 2xCHCHaHbOAc), 4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.70 (1H, 
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d, J=8.0 Hz, CH(O)2), 4.86-5.20 (9H, m, 5xCHOC, 2xCaromCH2N), 7.45-7.69 (10H, m, 10xCHarom). 
13C-NMR 
(100 MHz, CDCl3): C 20.4 (CH3C=O), 20.6 (2xCH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 
20.8 (CH3C=O), 21.4 (CH3CH), 22.8 (CH2CH2N), 24.6 (CH2(CH2)2), 26.4 (CH2(CH2)2), 29.3 (CH2(CH2)2), 
29.4 (CH2(CH2)2), 36.4 (CH2CHCH3), 46.5 (CH3N), 59.3 (CH2CH2N), 62.2 (CH2OAc), 62.3 (CH2OAc), 64.5 
(2xCaromCH2N), 68.5 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.4 (CHOC), 71.6 (CHOC), 72.9 (CHOC), 74.7 
(CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 127.1 (2xCarom), 129.3 (4xCHarom), 
130.7 (2xCHarom), 133.2 (4xCHarom), 169.6 (CH3C=O), 169.6 (CH3C=O), 169.7 (CH3C=O), 
170.0 (2xCH3C=O), 170.5 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for 
C50H70NO18 [M-I
-]: 972.4587. Found: 972.4574. 
N,N-dimethyl,N-octadecyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-ammonium iodide (220h): (0.51 g, 98%), orange-yellow powder, 
mp 50 °C. IR (cm-1) max: 729, 918, 1034 and 1063 (CHOCH), 
1217 (COAc), 1366, 1746 (C=O). 1H-NMR (400 MHz, CDCl3): H 
0.88 (3H, t, J=6.7 Hz, CH3CH2), 1.22 (3H, d, J=6.2 Hz, CH3CH), 
1.26-1.46 (39H, m, CH2CH3, 18xCH2(CH2)2, CHaHbCHCH3), 1.51-
1.58 (1H, m, CHaHbCHCH3), 1.71-1.82 (4H, m, 2xCH2CH2N), 
1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, 
CH3C=O), 2.09 (3H, s, CH3C=O), 3.39 (6H, s, 2xCH3N), 3.46-3.50 (2H, m, CH2CH2N), 3.55-3.59 (2H, m, 
CH2CH2N), 3.65-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 4.22-
4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.84-4.89 
(1H, m, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.00 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 
5.12 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100 MHz, 
CDCl3): C 14.1 (CH3CH2), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.7 (CH3C=O), 20.8 
(2xCH3C=O), 21.5 (CH3CH), 22.6 (CH2CH2N), 22.7 (CH2CH2N), 22.9 (CH3CH2), 24.6 (CH2(CH2)2), 26.2 
(CH2(CH2)2), 26.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 
29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 29.6-29.7 (8xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.5 (CH2CHCH3), 51.4 
(2xCH3N), 62.2 (CH2OAc), 62.3 (CH2OAc), 64.2 (2xCH2CH2N), 68.5 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 
71.4 (CHOC), 71.7 (CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 
(CH(O)2), 169.6 (2xCH3C=O), 169.7 (CH3C=O), 170.0 (2xCH3C=O), 170.5 (CH3C=O), 170.6 (CH3C=O). MS 
(ESI): m/z Exact mass calculated for C55H96NO18 [M-I
-]: 1058.6622. Found: 1058.6611. 
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N-butyl,N-methyl,N-octadecyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--
D-glucopyranosyl)-oxy])nonan-1-ammonium iodide (220i): (0.59 g, quant.), viscous yellow oil. 
IR (cm-1) max: 727, 909, 1035 and 1064 (CHOCH), 1222 
(COAc), 1366, 1747 (C=O). 1H-NMR (400 MHz, CDCl3): H 0.88 
(3H, t, J=6.8 Hz, CH3CH2), 1.02 (3H, t, J=7.3 Hz, CH3CH2), 1.22 
(3H, d, J=6.2 Hz, CH3CH), 1.26-1.52 (41H, m, 2xCH2CH3, 
18xCH2(CH2)2, CHaHbCHCH3), 1.54-1.62 (1H, m, CHaHbCHCH3), 
1.68-1.79 (6H, m, 3xCH2CH2N), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (6H, s, 2xCH3C=O), 
2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 3.31 (3H, s, CH3N), 3.38-3.53 (6H, m, 
3xCH2CH2N), 3.65-3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.11 (2H, m, 2xCHCHaHbOAc), 
4.22-4.27 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.7 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.87 
(1H, dxd, J=9.6 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.00 (1H, dxd, J=9.7 Hz, 
J=9.7 Hz, CHOC), 5.12 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 
13C-NMR (100 MHz, CDCl3): C 13.7 (CH3CH2), 14.1 (CH3CH2), 19.7 (CH3CH2), 20.5 (CH3C=O), 20.6 
(CH3C=O), 20.6 (2xCH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.5 (CH3CH), 22.4 
(CH2CH2N), 22.5 (CH2CH2N), 22.6 (CH3CH2), 24.4 (CH2CH2N), 24.7 (CH2(CH2)2), 26.3 (CH2(CH2)2), 26.4 
(CH2(CH2)2), 29.2-29.7 (14xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.1 (CH3N), 61.6 
(2xCH2CH2N), 61.9 (CH2CH2N), 62.2 (CH2OAc), 62.4 (CH2OAc), 68.5 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 
71.4 (CHOC), 71.8 (CHOC), 72.9 (CHOC), 74.8 (CHOC), 77.8 (CHOC), 78.0 (CHOC), 100.5 (CH(O)2), 101.3 
(CH(O)2), 169.6 (2xCH3C=O), 169.8 (CH3C=O), 170.0 (2xCH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS 
(ESI): m/z Exact mass calculated for C58H102NO18 [M-I
-]: 1100.7091. Found: 1100.7077. 
N,N-dimethyl,N-octadecyl-((S)-11-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])dodecan-1-ammonium iodide (227a): (0.57 g, 99%), orange-yellow powder. 
1H-NMR (400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 Hz, 
CH3CH2), 1.22 (3H, d, J=6.2 Hz, CH3CH), 1.24-1.44 (45H, 
m, CH2CH3, 21xCH2(CH2)2, CHaHbCHCH3), 1.53-1.63 (1H, 
m, CHaHbCHCH3), 1.69-1.78 (4H, m, 2xCH2CH2N), 1.99 
(3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.03 (3H, s, 
CH3C=O), 2.04 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (6H, s, 2xCH3C=O), 3.40 (6H, s, 2xCH3N), 
3.48-3.57 (4H, m, 2xCH2CH2N), 3.64-3.76 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.10 (2H, m, 
2xCHCHaHbOAc), 4.23-4.30 (2H, m, 2xCHCHaHbOAc), 4.48 (1H, d, J=7.7 Hz, CH(O)2), 4.74 (1H, d, J=8.0 
Hz, CH(O)2), 4.90 (1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.05 
(1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, 
J=9.5 Hz, CHOC). 13C-NMR (100 MHz, CDCl3): C 14.1 (CH3CH2), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.6 
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(2xCH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.2 (CH3CH), 22.6 (CH3CH2), 22.7 
(CH2CH2N), 22.8 (CH2CH2N), 24.9 (CH2(CH2)2), 26.1 (CH2(CH2)2), 26.1 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 
(CH2(CH2)2), 29.3 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.4 (CH2(CH2)2), 
29.6 (10xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.4 (CH2CHCH3), 51.5 (2xCH3N), 62.0 (CH2OAc), 62.2 (CH2OAc), 
64.1 (2xCH2CH2N), 68.2 (CHOC), 68.8 (CHOC), 71.2 (CHOC), 71.6 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 
74.6 (CHOC), 77.6 (CHOC), 77.9 (CHOC), 100.3 (CH(O)2), 101.1 (CH(O)2), 169.4 (CH3C=O), 169.5 
(CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). 
N-butyl,N-methyl,N-octadecyl-((S)-11-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl-
-D-glucopyranosyl)-oxy])dodecan-1-ammonium iodide (227b): (0.57 g, 97%), viscous orange-yellow 
oil. 1H-NMR (400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 Hz, 
CH3CH2), 1.02 (3H, t, J=7.3 Hz, CH3CH2), 1.22 (3H, d, 
J=6.2 Hz, CH3CH), 1.24-1.52 (47H, m, 2xCH2CH3, 
21xCH2(CH2)2, CHaHbCHCH3), 1.55-1.63 (1H, m, 
CHaHbCHCH3), 1.67-1.75 (6H, m, 3xCH2CH2N), 1.99 (3H, 
s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 
2.04 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (6H, s, 2xCH3C=O), 3.33 (3H, s, CH3N), 3.40-3.52 (6H, 
m, 3xCH2CH2N), 3.64-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.05-4.10 (2H, m, 2xCHCHaHbOAc), 
4.23-4.30 (2H, m, 2xCHCHaHbOAc), 4.48 (1H, d, J=7.6 Hz, CH(O)2), 4.73 (1H, d, J=8.0 Hz, CH(O)2), 4.90 
(1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.05 (1H, dxd, J=9.6 Hz, 
J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 
13C-NMR (100 MHz, CDCl3): C 13.8 (CH3CH2), 14.1 (CH3CH2), 19.7 (CH3CH2), 20.5 (CH3C=O), 20.6 
(CH3C=O), 20.6 (2xCH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 20.8 (CH3C=O), 21.3 (CH3CH), 22.5 
(CH2CH2N), 22.5 (CH2CH2N), 22.7 (CH3CH2), 24.4 (CH2CH2N), 25.0 (CH2(CH2)2), 26.3 (2xCH2(CH2)2), 29.1 
(CH2(CH2)2), 29.2 (CH2(CH2)2), 29.3 (2xCH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (2xCH2(CH2)2), 29.6 
(CH2(CH2)2), 29.6-29.7 (9xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.2 (CH3N), 61.6 (CH2CH2N), 
61.7 (CH2CH2N), 61.8 (CH2CH2N), 62.1 (CH2OAc), 62.2 (CH2OAc), 68.3 (CHOC), 68.8 (CHOC), 71.2 
(CHOC), 71.6 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.6 (CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.4 
(CH(O)2), 101.1 (CH(O)2), 169.4 (CH3C=O), 169.5 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 
(CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). 
General procedure for the synthesis of deprotected sophorolipid quaternary ammonium salts: In a 
25 mL flame dried round-bottomed flask, the peracetylated sophorolipid quaternary ammonium salt 
was dissolved in dry methanol and sodium methoxide (0.15 eq) was added. The reaction mixture was 
stirred overnight at room temperature, concentrated under reduced pressure and recrystallized from 
acetone to yield the pure deprotected sophorolipid quaternary ammonium salt. 
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N,N,N-trimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-ammonium 
iodide (221a): (0.30 g, quant.), off-white powder, mp 119 °C. IR (cm-1) max: 726, 914, 1022 and 1068 
(CHOCH), 3358 (OH). 1H-NMR (400MHz, MeOD):  1.16 (3H, d, 
J=6.3 Hz, CHCH3), 1.19-1.42 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 
1.46-1.54 (1H, m, CHaHbCHCH3), 1.67-1.75 (2H, m, 3xCH2CH2N), 
3.04 (9H, s, 3xCH3N), 3.09-3.31 (8H, m, CH2CH2N, 6xCHOC), 3.39 
(1H, dxd, J=9.0 Hz, J=7.8 Hz, CHOC), 3.46 (1H, dxd, J=8.7 Hz, J=8.7 
Hz, CHOC), 3.53-3.58 (2H, m, 2xCHCHaHbOH), 3.70-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.35 (1H, d, 
J=7.6 Hz, CH(O)2), 4.59 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD):  20.7 (CHCH3), 22.6 
(CH2CH2N), 24.6 (CH2(CH2)2), 25.9 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 
52.2 (3xCH3N), 61.4 (CH2OH), 61.6 (CH2OH), 66.5 (CH2CH2N), 70.2 (CHOC), 70.4 (CHOC), 74.7 (CHOC), 
76.4 (2xCHOC), 76.8 (CHOC), 77.0 (CHOC), 77.7 (CHOC), 79.8 (CHOC), 101.6 (CH(O)2), 103.0 (CH(O)2). 
MS (ESI): m/z Exact mass calculated for C24H48NO11 [M-I
-]: 526.3222. Found: 526.3218. 
N-butyl,N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221b): (0.34 g, 88%), white powder, mp 70 °C. IR (cm-1) max: 726, 908, 1030 and 
1069 (CHOCH), 3348 (OH). 1H-NMR (400 MHz, MeOD): H 0.93 
(3H, t, J=7.4 Hz, CH2CH3), 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.19-
1.44 (11H, m, CH2CH3, 4xCH2(CH2)2, CHaHbCHCH3), 1.46-1.54 
(1H, m, CHaHbCHCH3), 1.61-1.72 (4H, m, 2xCH2CH2N), 2.98 (6H, 
s, 2xCH3N), 3.10-3.24 (9H, m, 2xCH2CH2N, 5xCHOC), 3.29 (1H, 
dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.38 (1H, dxd, J=9.1 Hz, J=7.8 Hz, CHOC), 3.46 (1H, dxd, J=8.7 Hz, J=8.7 
Hz, CHOC), 3.53-3.58 (2H, m, 2xCHCHaHbOH), 3.70-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.35 (1H, d, 
J=7.6 Hz, CH(O)2), 4.58 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.6 (CH2CH3), 19.3 
(CH2CH3), 20.7 (CHCH3), 22.2 (CH2CH2N), 24.1 (CH2CH2N), 24.7 (CH2(CH2)2), 26.0 (CH2(CH2)2), 29.0 
(CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.8 (2xCH3N), 61.4 (CH2OH), 61.6 (CH2OH), 63.9 
(CH2CH2N), 64.1 (CH2CH2N), 70.2 (CHOC), 70.5 (CHOC), 74.7 (CHOC), 76.4 (2xCHOC), 76.8 (CHOC), 
77.0 (CHOC), 77.6 (CHOC), 80.0 (CHOC), 101.6 (CH(O)2), 103.0 (CH(O)2). MS (ESI): m/z Exact mass 
calculated for C27H54NO11 [M-I
-]: 568.3691. Found: 568.3689. 
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N,N-dibutyl,N-methyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (2218c): (0.43 g, quant.), white powder, mp 94 °C. IR (cm-1) max: 725, 916, 1024 
and 1069 (CHOCH), 3344 (OH). 1H-NMR (400 MHz, MeOD): 
H 0.92 (6H, t, J=7.4 Hz, 2xCH2CH3), 1.14 (3H, d, J=6.2 Hz, 
CHCH3), 1.20-1.42 (13H, m, 2xCH2CH3, 4xCH2(CH2)2, 
CHaHbCHCH3), 1.45-1.53 (1H, m, CHaHbCHCH3), 1.57-1.67 (6H, 
m, 3xCH2CH2N), 2.93 (3H, s, CH3N), 3.09-3.24 (11H, m, 
3xCH2CH2N, 5xCHOC), 3.28 (1H, dxd, J=8.8 Hz, J=8.8 Hz, CHOC), 3.35 (1H, dxd, J=9.0 Hz, J=7.9 Hz, 
CHOC), 3.46 (1H, dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 3.52-3.57 (2H, m, 2xCHCHaHbOH), 3.69-3.76 (3H, m, 
2xCHCHaHbOH, CHOC), 4.34 (1H, d, J=7.7 Hz, CH(O)2), 4.55 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100 
MHz, MeOD): C 12.6 (2xCH2CH3), 19.4 (2xCH2CH3), 20.6 (CHCH3), 21.9 (CH2CH2N), 23.8 (2xCH2CH2N), 
24.7 (CH2(CH2)2), 26.1 (CH2(CH2)2), 28.9 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 47.5 (CH3N), 
61.2 (2xCH2CH2N), 61.4, 61.5, 61.7 (2xCH2OH, CH2CH2N), 70.3 (CHOC), 70.5 (CHOC), 74.7 (CHOC), 76.4 
(CHOC), 76.5 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.6 (CHOC), 80.3 (CHOC), 101.5 (CH(O)2), 103.3 
(CH(O)2). MS (ESI): m/z Exact mass calculated for C30H60NO11 [M-I
-]: 610.4161. Found: 610.4162. 
N,N,N-tributyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-ammonium 
iodide (221d): (0.22 g, quant.), off-white powder, mp 100 °C. IR (cm-1) max: 724, 906, 1027 and 1072 
(CHOCH), 3370 (OH). 1H-NMR (400MHz, MeOD):  0.93 (9H, 
t, J=7.4 Hz, 3xCH2CH3), 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.19-
1.44 (15H, m, 3xCH2CH3, 4xCH2(CH2)2, CHaHbCHCH3), 1.46-
1.52 (1H, m, CHaHbCHCH3), 1.53-1.63 (8H, m, 3xCH2CH2N), 
3.10-3.23 (13H, m, 4xCH2CH2N, 5xCHOC), 3.29 (1H, dxd, J=8.8 
Hz, J=8.8 Hz, CHOC), 3.37 (1H, dxd, J=9.1 Hz, J=7.7 Hz, CHOC), 3.46 (1H, dxd, J=8.7 Hz, J=8.7 Hz, 
CHOC), 3.53-3.58 (2H, m, 2xCHCHaHbOH), 3.70-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.35 (1H, d, J=7.7 
Hz, CH(O)2), 4.56 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD):  12.6 (3xCH2CH3), 19.3 
(3xCH2CH3), 20.6 (CHCH3), 21.5 (CH2CH2N), 23.5 (3xCH2CH2N), 24.7 (CH2(CH2)2), 26.1 (CH2(CH2)2), 28.9 
(CH2(CH2)2), 29.3 (CH2(CH2)2), 36.4 (CH2CHCH3), 58.1 (3xCH2CH2N), 58.4 (CH2CH2N), 61.4 (CH2OH), 61.6 
(CH2OH), 70.2 (CHOC), 70.5 (CHOC), 74.7 (CHOC), 76.4 (2xCHOC), 76.9 (CHOC), 76.9 (CHOC), 77.5 
(CHOC), 80.2 (CHOC), 101.5 (CH(O)2), 103.2 (CH(O)2). MS (ESI): m/z Exact mass calculated for 
C33H66NO11 [M-I
-]: 652.4630. Found: 652.4618. 
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N-benzyl,N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221e): (0.35 g, quant.), white powder, mp 76 °C. IR (cm-1) max: 726, 916, 1028 
and 1065 (CHOCH), 3360 (OH). 1H-NMR (400 MHz, MeOD): 
H 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.22-1.42 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.47-1.55 (1H, m, CHaHbCHCH3), 
1.78-1.86 (2H, m, CH2CH2N), 2.94 (6H, s, 2xCH3N), 3.10-3.31 
(8H, m, CH2CH2N, 6xCHOC), 3.39 (1H, dxd, J=9.1 Hz, J=7.7 Hz, 
CHOC), 3.46 (1H, dxd, J=8.8 Hz, J=8.8 Hz, CHOC), 3.54-3.58 (2H, m, 2xCHCHaHbOH), 3.70-3.78 (3H, m, 
2xCHCHaHbOH, CHOC), 4.35 (1H, d, J=7.6 Hz, CH(O)2), 4.45 (2H, s, CaromCH2N), 4.59 (1H, d, J=7.8 Hz, 
CH(O)2), 7.42-7.50 (5H, m, 5xCHarom). 
13C-NMR (100 MHz, MeOD): C 20.7 (CHCH3), 22.3 (CH2CH2N), 
24.6 7 (CH2(CH2)2), 26.0 7 (CH2(CH2)2), 29.0 7 (CH2(CH2)2), 29.3 7 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.0 
(2xCH3N), 61.4 (CH2OH), 61.7 (CH2OH), 64.6 (CH2CH2N), 67.4 (CaromCH2N), 70.2 (CHOC), 70.5 (CHOC), 
74.7 (CHOC), 76.4 (CHOC), 76.5 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.7 (CHOC), 80.0 (CHOC), 101.6 
(CH(O)2), 103.1 (CH(O)2), 127.6 (Carom), 129.0 (2xCHarom), 130.5 0 (CHarom), 132.7 0 (2xCHarom). MS (ESI): 
m/z Exact mass calculated for C30H52NO11 [M-I
-]: 602.3535. Found: 602.3527. 
N-benzyl,N-butyl,N-methyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221f): (0.31 g, quant.), white powder, mp 112 °C. IR (cm-1) max: 725, 908, 1025 
and 1071 (CHOCH), 3356 (OH). 1H-NMR (400MHz, MeOD): 
0.94 (3H, t, J=7.4 Hz, CH2CH3), 1.16 (3H, d, J=6.2 Hz, CHCH3), 
1.20-1.44 (11H, m, CH2CH3, 4xCH2(CH2)2, CHaHbCHCH3), 1.47-
1.55 (1H, m, CHaHbCHCH3), 1.67-1.82 (4H, m, 2xCH2CH2N), 
2.88 (3H, s, CH3N), 3.10-3.23 (9H, m, 2xCH2CH2N, 5xCHOC), 
3.29 (1H, dxd, J=8.8 Hz, J=8.8 Hz, CHOC), 3.38 (1H, dxd, J=9.1 Hz, J=7.8 Hz, CHOC), 3.46 (1H, dxd, J=8.6 
Hz, J=8.6 Hz, CHOC), 3.53-3.58 (2H, m, 2xCHCHaHbOH), 3.71-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.35 
(1H, d, J=7.6 Hz, CH(O)2), 4.45 (2H, s, CaromCH2N), 4.58 (1H, d, J=7.8 Hz, CH(O)2), 7.44-7.47 (5H, m, 
5xCHarom). 
13C-NMR (100MHz, MeOD):  12.6 (CH2CH3), 19.3 (CH2CH3), 20.6 (CHCH3), 22.0 (CH2CH2N), 
23.9 (CH2CH2N), 24.7 (CH2(CH2)2), 26.1 (CH2(CH2)2), 29.0 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.4 
(CH2CHCH3), 46.9 (CH3N), 60.6 (CH2CH2N), 61.0 (CH2CH2N), 61.4 (CH2OH), 61.6 (CH2OH), 65.3 
(CaromCH2N), 70.2 (CHOC), 70.5 (CHOC), 74.7 (CHOC), 76.4 (2xCHOC), 76.9 (CHOC), 77.0 (CHOC), 77.6 
(CHOC), 80.0 (CHOC), 101.6 (CH(O)2), 103.1 (CH(O)2), 127.5 (Carom), 129.0 (2xCHarom), 130.5 (CHarom), 
132.7 (2xCHarom). MS (ESI): m/z Exact mass calculated for C33H58NO11 [M-I
-]: 644.4004. Found: 
644.3998. 
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N,N-dibenzyl,N-methyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221g): (0.24 g, 99%), light brown powder, mp 158 °C. IR (cm-1) max: 702, 722, 
918, 1025 (CHOCH), 3350 (OH). 1H-NMR (400 MHz, MeOD): 
H 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.23-1.44 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.47-1.55 (1H, m, CHaHbCHCH3), 
1.87-1.95 (2H, m, CH2CH2N), 2.84 (3H, s, CH3N), 3.07-3.22 
(7H, m, CH2CH2N, 5xCHOC), 3.29 (1H, dxd, J=8.8 Hz, J=8.8 Hz, 
CHOC), 3.36-3.40 (1H, m, CHOC), 3.46 (1H, dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.53-3.58 (2H, m, 
2xCHCHaHbOH), 3.71-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.35 (1H, d, J=7.7 Hz, CH(O)2), 4.44 (2H, d, 
J=12.9 Hz, 2xCaromCHaHbN), 4.57 (2H, d, J=12.9 Hz, 2xCaromCHaHbN), 4.58 (1H, d, J=8.1 Hz, CH(O)2), 
70.43-70.50 (10H, m, 10xCHarom). 
13C-NMR (100 MHz, MeOD): C 20.6 (CHCH3), 22.2 (CH2CH2N), 24.6 
(CH2(CH2)2), 26.0 (CH2(CH2)2), 28.9 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.4 (CH2CHCH3), 46.2 (CH3N), 60.7 
(CH2CH2N), 61.4 (CH2OH), 61.7 (CH2OH), 65.5 (2xCaromCH2N), 70.2 (CHOC), 70.5 (CHOC), 74.7 (CHOC), 
76.4 (CHOC), 76.5 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.6 (CHOC), 80.1 (CHOC), 101.6 (CH(O)2), 103.2 
(CH(O)2), 127.4 (2xCarom), 129.1 (4xCHarom), 130.5 (2xCHarom), 132.9 (4xCHarom). MS (ESI): m/z Exact 
mass calculated for C36H56NO11 [M-I
-]: 678.3848. Found: 678.3843. 
N,N-dimethyl,N-octadecyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221h): (0.22 g, 97%), white powder, mp 114 °C. IR (cm-1) max: 728, 906, 1073 
(CHOCH), 3360 (OH). 1H-NMR (400 MHz, MeOD): H 0.79 (3H, 
t, J=6.8 Hz, CH2CH3), 1.14 (3H, d, J=6.2 Hz, CHCH3), 1.18-1.43 
(39H, m, CH2CH3, 18xCH2(CH2)2, CHaHbCHCH3), 1.44-1.53 (1H, 
m, CHaHbCHCH3), 1.61-1.70 (4H, m, 2xCH2CH2N), 2.97 (6H, s, 
2xCH3N), 3.08-3.24 (9H, m, 2xCH2CH2N, 5xCHOC), 3.28 (1H, 
dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.36 (1H, dxd, J=9.1 Hz, J=7.8 Hz, CHOC), 3.45 (1H, dxd, J=8.8 Hz, J=8.8 
Hz, CHOC), 3.52-3.57 (2H, m, 2xCHCHaHbOH), 3.68-3.76 (3H, m, 2xCHCHaHbOH, CHOC), 4.33 (1H, d, 
J=7.7 Hz, CH(O)2), 4.57 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100 MHz, MeOD): C 13.1 (CH2CH3), 20.7 
(CHCH3), 22.2 (CH2CH2N), 22.2 (CH2CH2N), 22.3 (CH2CH3), 24.7 (CH2(CH2)2), 26.0 (2xCH2(CH2)2), 28.8 
(CH2(CH2)2), 29.0 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 
29.3-29.4 (8xCH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 (CH2CHCH3), 49.8 (2xCH3N), 61.4 (CH2OH), 61.7 
(CH2OH), 64.1 (2xCH2CH2N), 70.3 (CHOC), 70.6 (CHOC), 74.8 (CHOC), 76.4 (CHOC), 76.6 (CHOC), 76.8 
(CHOC), 77.0 (CHOC), 77.7 (CHOC), 80.1 (CHOC), 101.6 (CH(O)2), 103.2 (CH(O)2). MS (ESI): m/z Exact 
mass calculated for C41H82NO11 [M-I
-]: 764.5882. Found: 764.5871. 
  Experimental procedures 
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N-butyl,N-methyl,N-octadecyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-
ammonium iodide (221i): (0.19 g, 66%), yellow powder, mp 109 °C. IR (cm-1) max: 728, 907, 1028 
and 1070 (CHOCH), 3355 (OH). 1H-NMR (400 MHz, MeOD): 
H 0.80 (3H, t, J=6.8 Hz, CH2CH3), 0.93 (3H, t, J=7.3 Hz, 
CH2CH3), 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.19-1.44 (41H, m, 
2xCH2CH3, 18xCH2(CH2)2, CHaHbCHCH3), 1.47-1.55 (1H, m, 
CHaHbCHCH3), 1.57-1.67 (6H, m, 3xCH2CH2N), 2.93 (3H, s, 
CH3N), 3.10-3.22 (11H, m, 3xCH2CH2N, 5xCHOC), 3.29 (1H, dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 3.35-3.39 
(1H, m, CHOC), 3.46 (1H, dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.54-3.58 (2H, m, 2xCHCHaHbOH), 3.70-3.78 
(3H, m, 2xCHCHaHbOH, CHOC), 4.35 (1H, d, J=7.6 Hz, CH(O)2), 4.57 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR 
(100 MHz, MeOD): C 12.6 (CH2CH3), 13.0 (CH2CH3), 19.3 (CH2CH3), 20.6 (CHCH3), 21.8 (CH2CH2N), 21.9 
(CH2CH2N), 22.3 (CH2CH3), 23.8 (CH2CH2N), 24.7 (CH2(CH2)2), 26.0 (CH2(CH2)2), 26.1 (CH2(CH2)2), 28.8 
(CH2(CH2)2), 29.0 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.4 (9xCH2(CH2)2), 
31.7 (CH2(CH2)2), 36.5 (CH2CHCH3), 47.4 (CH3N), 61.1, 61.4, 61.5, 61.7 (2xCH2OH, 3xCH2CH2N), 70.2 
(CHOC), 70.5 (CHOC), 74.7 (CHOC), 76.4 (CHOC), 76.5 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.6 (CHOC), 
80.2 (CHOC), 101.6 (CH(O)2), 103.2 (CH(O)2). MS (ESI): m/z Exact mass calculated for C44H88NO11 
[M-I-]: 806.6352. Found: 806.6346. 
N,N-dimethyl,N-octadecyl-((S)-11-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])dodecan-1-
ammonium iodide (228a): (0.17 g, 70%), white powder.1H-NMR (400 MHz, MeOD): H 0.94 (3H, t, 
J=6.6 Hz, CH2CH3), 1.29 (3H, d, J=6.2 Hz, CHCH3), 1.31-
1.57 (45H, m, CH2CH3, 21xCH2(CH2)2, CHaHbCHCH3), 1.60-
1.68 (1H, m, CHaHbCHCH3), 1.76-1.85 (4H, m, 
2xCH2CH2N), 3.13 (6H, s, 2xCH3N), 3.25-3.38 (9H, m, 
2xCH2CH2N, 5xCHOC), 3.42 (1H, dxd, J=8.7 Hz, J=8.7 Hz, 
CHOC), 3.49 (1H, dxd, J=8.5 Hz, J=8.5 Hz, CHOC), 3.60 (1H, dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.67-3.72 
(2H, m, 2xCHCHaHbOH), 3.83-3.91 (3H, m, 2xCHCHaHbOH, CHOC), 4.50 (1H, d, J=7.6 Hz, CH(O)2), 4.69 
(1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100 MHz, MeOD): C 13.1 (CH2CH3), 20.6 (CHCH3), 22.2 
(2xCH2CH2N), 22.3 (CH2CH3), 24.8 (CH2(CH2)2), 26.0 (2xCH2(CH2)2), 28.8 (2xCH2(CH2)2), 29.1 (CH2(CH2)2), 
29.2 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.4 (11xCH2(CH2)2), 29.5 (CH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 
(CH2CHCH3), 49.9 (2xCH3N), 61.4 (CH2OH), 61.7 (CH2OH), 64.0 (2xCH2CH2N), 70.1 (CHOC), 70.5 
(CHOC), 74.5 (CHOC), 76.4 (2xCHOC), 76.9 (2xCHOC), 77.6 (CHOC), 80.4 (CHOC), 101.5 (CH(O)2), 103.3 
(CH(O)2). 
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N-butyl,N-methyl,N-octadecyl-((S)-11-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])dodecan-1-ammonium iodide (228b): (0.05 g, 19%), white powder. 1H-NMR (400 MHz, MeOD): 
H 0.95 (3H, t, J=6.8 Hz, CH2CH3), 1.07 (3H, t, J=7.3 Hz, 
CH2CH3), 1.30 (3H, d, J=6.2 Hz, CHCH3), 1.32-1.56 (47H, 
m, 2xCH2CH3, 21xCH2(CH2)2, CHaHbCHCH3), 1.60-1.69 (1H, 
m, CHaHbCHCH3), 1.71-1.83 (6H, m, 3xCH2CH2N), 3.09 
(3H, s, CH3N), 3.26-3.39 (11H, m, 3xCH2CH2N, 5xCHOC), 
3.43 (1H, dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.50 (1H, dxd, 
J=8.4 Hz, J=8.4 Hz, CHOC), 3.60 (1H, dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.67-3.73 (2H, m, 2xCHCHaHbOH), 
3.83-3.92 (3H, m, 2xCHCHaHbOH, CHOC), 4.50 (1H, d, J=7.6 Hz, CH(O)2), 4.69 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.7 (CH2CH3), 13.1 (CH2CH3), 19.4 (CH2CH3), 20.6 (CHCH3), 21.9 
(2xCH2CH2N), 22.4 (CH2CH3), 23.9 (CH2CH2N), 24.9 (CH2(CH2)2), 26.0 (2xCH2(CH2)2), 28.8 (2xCH2(CH2)2), 
29.1-29.6 (15xCH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 (CH2CHCH3), 47.5 (CH3N), 61.2-61.7 (2xCH2OH, 
3xCH2CH2N), 70.1 (CHOC), 70.5 (CHOC), 74.5 (CHOC), 76.4 (3xCHOC), 76.9 (CHOC), 77.6 (CHOC), 80.5 
(CHOC), 101.4 (CH(O)2), 103.3 (CH(O)2). 
General procedure for the synthesis of (S)-9-(methyl(octadecyl)amino)nonan-2-ol (222): 
N-methyl,N-octadecyl sophorolipid amine 213h (0.76 g, 0.73 mmol) was dissolved in 20 mL 
methanol, a few drops of concentrated sulfuric acid were added, and the mixture was refluxed 
overnight. Subsequently, an aqueous 2 N sodium hydroxide solution was added until an alkaline pH 
was obtained. The organic solvent was evaporated under reduced pressure and the resulting water 
layer was extracted with diethyl ether. The organic phase was dried over magnesium sulfate, filtered 
and concentrated under reduced pressure. Compound 222 was purified via automated flash 
chromatography with a hexane/ethyl acetate/thriethylamine mixture as eluent. Purification gradient: 
2 CV 5% mixture A, 30 CV 5-60% mixture A, 2 CV 60% mixture A (mixture A = 16% triethylamine in 
ethyl acetate). Compound 222 was isolated as a viscous colorless oil (0.13 g, 43%). 
1H-NMR (400MHz, CDCl3): H 0.88 (3H, t, 
J=6.9 Hz, CH3CH2), 1.18 (3H, d, J=6.2 Hz, 
CH3CH), 1.25-1.35 (38H, m, CH3CH2, 18xCH2(CH2)2), 1.38-1.49 (6H, m, 2xCH2CH2N, CH2CHCH3), 1.94 
(1H, br s, OH), 2.20 (3H, s, CH3N), 2.28-2.32 (4H, m, 2xCH2CH2N), 3.74-3.82 (1H, m, CHOH). 
13C-NMR 
(100MHz, CDCl3): C 14.1 (CH3CH2), 22.7 (CH3CH2), 23.5 (CH3CH), 25.7 (CH2(CH2)2), 27.2 (2xCH2CH2N), 
27.6 (CH2(CH2)2), 27.7 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.6-29.7 (13xCH2(CH2)2), 31.9 (CH2(CH2)2), 39.4 
(CH2CHCH3), 41.3 (CH3N), 57.9 (CH2N), 57.9 (CH2N), 68.1 (CHOH). MS (ESI): m/z Exact mass calculated 
for C28H60NO [M+H
+]: 426.4669. Found: 426.4655. 
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General procedure for synthesis of N-((S)-8-hydroxynonyl)-N,N-dimethyloctadecan-1-ammonium 
iodide (223a). In a 10 mL pressure resistant vial, 0.071 g of compound 222 (0.17 mmol) was dissolved 
in a 1:1 mixture of acetone and acetonitrile. The solution was cooled down to 0 °C and 0.05 mL of 
methyl iodide (0.83 mmol, 5 eq) was added. The vial was closed and heated to 80 °C for 72 hours. 
The reaction mixture was concentrated under reduced pressure to yield compound 223a as a yellow 
waxy solid (0.097 g, 98%). 
1H-NMR (400MHz, CDCl3): H 0.88 (3H, t, 
J=6.8 Hz, CH3CH2), 1.19 (3H, d, J=6.2 Hz, 
CH3CH), 1.26-1.46 (40H, m, CH2CHCH3, 
CH3CH2, 18xCH2(CH2)2), 1.68-1.77 (4H, m, 2xCH2CH2N), 3.38 (6H, s, 2xCH3N), 3.46-3.52 (2H, m, CH2N), 
3.53-3.58 (2H, m, CH2N), 3.67 (1H, s, CHOH), 3.77-3.84 (1H, m, CHOH). 
13C-NMR (100MHz, CDCl3): C 
14.1 (CH3CH2), 22.7 (2xCH2CH2N), 22.8 (CH3CH2), 23.6 (CH3CH), 25.4 (CH2(CH2)2), 25.9 (CH2(CH2)2), 26.2 
(CH2(CH2)2), 28.9 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.4 (CH2(CH2)2), 
29.5 (CH2(CH2)2), 29.6 (CH2(CH2)2), 29.7 (7xCH2(CH2)2), 31.9 (CH2(CH2)2), 39.0 (CH2CHCH3), 51.5 
(2xCH3N), 64.4 (2xCH2N), 67.9 (CHOH). MS (ESI): m/z Exact mass calculated for C29H62NO [M-I
-]: 
440.4826. Found: 440.4843. Optical rotation: []D
25 19.0 ± 3.5 (c 0.100, EtOH). 
General procedure for synthesis of N-butyl,N-((S)-8-hydroxynonyl)-N-methyloctadecan-1-
ammonium iodide (223b): In a 10 mL pressure resistant vial, 0.063 g of compound 222 (0.15 mmol) 
was dissolved in a 1:1 mixture of acetone and acetonitrile. The solution was cooled down to 0 °C and 
0.08 mL of butyl iodide (0.74 mmol, 5 eq) was added. The vial was closed and heated to 80 °C for 72 
hours. The reaction mixture was concentrated under reduced pressure to yield compound 223b as a 
yellow waxy solid (0.099 g, 87%). 
1H-NMR (400MHz, CDCl3): H 0.88 (3H, t, 
J=6.8 Hz, CH3CH2), 1.02 (3H, t, J=7.3 Hz, 
CH3CH2), 1.19 (3H, d, J=6.2 Hz, CH3CH), 
1.26-1.50 (42H, m, CH2CHCH3, 2xCH3CH2, 18xCH2(CH2)2), 1.65-1.74 (6H, m, 3xCH2CH2N), 3.31 (3H, s, 
CH3N), 3.40-3.49 (6H, m, 3xCH2N), 3.67 (1H, s, CHOH), 3.77-3.84 (1H, m, CHOH). 
13C-NMR (100MHz, 
CDCl3): C 13.8 (CH3CH2), 14.1 (CH3CH2), 19.7 (CH3CH2), 22.5 (CH2CH2N), 22.5 (CH2CH2N), 22.7 
(CH3CH2), 23.6 (CH3CH), 24.4 (CH2CH2N), 25.4 (CH2(CH2)2), 26.1 (CH2(CH2)2), 26.3 (CH2(CH2)2), 29.0 
(CH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 
29.6 (CH2(CH2)2), 29.7 (7xCH2(CH2)2), 31.9 (CH2(CH2)2), 39.0 (CH2CHCH3), 49.2 (CH3N), 61.6 (CH2N), 61.7 
(CH2N), 61.9 (CH2N), 67.9 (CHOH). MS (ESI): m/z Exact mass calculated for C32H68INO [M-I
-]: 482.5295. 
Found: 482.5309. Optical rotation: []D
25 9.5 ± 0.5 (c 0.105, EtOH). 
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General procedure for synthesis of N-methyl,N-nonyloctadecan-1-amine (224): Nonanal (0.21 g, 
1.44 mmol) and N-methyl,N-octadecylamine (0.41 g, 1.44 mmol) were dissolved in 10 mL methanol, 
0.18 g NaBH3CN (2.88 mmol, 2 eq) and 0.41 mL acetic acid (7.21 mmol, 5 eq) were added 
sequentially. The reaction mixture was stirred overnight at room temperature, concentrated under 
reduced pressure and dissolved in ethyl acetate. The mixture was washed 3 times with a saturated 
NaHCO3-solution and the organic phase was dried over MgSO4, filtered and concentrated under 
reduced pressure. Compound 224 was isolated as viscous colorless oil without further purification 
(0.57 g, 97%). 
1H-NMR (400MHz, CDCl3): H 0.88 (6H, t, 
J=6.8 Hz, 2xCH3CH2), 1.25-1.32 (42H, m, 
2xCH3CH2, 19xCH2(CH2)2), 1.44-1.50 (4H, 
m, 2xCH2CH2N), 2.23 (3H, s, CH3N), 2.32-2.36 (4H, m, 2xCH2N). 
13C-NMR (100MHz, CDCl3): C 14.1 
(2xCH3CH2), 22.7 (CH2CH2N), 22.7 (CH2CH2N), 27.1 (2xCH2CH2N), 27.6 (2xCH2(CH2)2), 29.3 (CH2(CH2)2), 
29.4 (CH2(CH2)2), 29.6-29.7 (13xCH2(CH2)2), 31.9 (CH2(CH2)2), 31.9 (CH2(CH2)2), 42.2 (CH3N), 57.8 
(2xCH2N). MS (ESI): m/z Exact mass calculated for C28H60N [M+H
+]: 410.4720. Found: 410.4710. 
General procedure for synthesis of N,N-dimethyl,N-nonyloctadecan-1-ammonium iodide (225a): In 
a 10 mL pressure resistant vial, 0.29 g of compound 224 (0.70 mmol) was dissolved in a 1:1 mixture 
of acetone and acetonitrile. The solution was cooled down to 0 °C and 0.22 mL of methyl iodide (3.49 
mmol, 5 eq) was added. The vial was closed and heated to 80 °C for 72 hours. The reaction mixture 
was concentrated under reduced pressure to yield compound 225a as an orange waxy solid (0.39 g, 
quant.). 
1H-NMR (400MHz, CDCl3): H 0.81 (6H, t, 
J=6.7 Hz, 2xCH3CH2), 1.19-1.36 (42H, m, 
2xCH3CH2, 19xCH2(CH2)2), 1.62-1.70 (4H, 
m, 2xCH2CH2N), 3.32 (6H, s, 2xCH3N), 3.44-3.48 (4H, m, 2xCH2N). 
13C-NMR (100MHz, CDCl3): C 14.1 
(CH3CH2), 14.1 (CH3CH2), 22.6 (CH3CH2), 22.7 (CH3CH2), 22.8 (2xCH2CH2N), 26.2 (2xCH2(CH2)2), 29.1 
(CH2(CH2)2), 29.2 (CH2(CH2)2), 29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 
29.5 (CH2(CH2)2), 29.6 (CH2(CH2)2), 29.6-29.7 (7xCH2(CH2)2), 31.8 (CH2(CH2)2), 31.9 (CH2(CH2)2), 51.6 
(2xCH3N), 64.2 (2xCH2N). MS (ESI): m/z Exact mass calculated for C29H62N [M-I
-]: 424.4877. Found: 
424.4881. 
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General procedure for synthesis of N-butyl,N-methyl,N-nonyloctadecan-1-ammonium iodide 
(225b): In a 10 mL pressure resistant vial, 0.28 g of compound 221 (0.70 mmol) was dissolved in a 1:1 
mixture of acetone and acetonitrile. The solution was cooled down to 0 °C and 0.39 mL of butyl 
iodide (3.47 mmol, 5 eq) was added. The vial was closed and heated to 80 °C for 72 hours. The 
reaction mixture was concentrated under reduced pressure to yield compound 222b as a yellow 
waxy solid (0.40 g, 97%). 
1H-NMR (400MHz, CDCl3): H 0.88 (6H, t, 
J=6.5 Hz, 2xCH3CH2), 1.02 (3H, t, J=7.3 Hz, 
CH3CH2), 1.26-1.50 (44H, m, 3xCH3CH2, 
19xCH2(CH2)2), 1.67-1.76 (6H, m, 3xCH2CH2N), 3.29 (3H, s, CH3N), 3.42-3.50 (6H, m, 3xCH2N). 
13C-NMR 
(100MHz, CDCl3): C 13.8 (CH3CH2), 14.1 (CH3CH2), 14.1 (CH3CH2), 19.7 (CH3CH2), 22.5 (2xCH2CH2N), 
22.6 (CH3CH2), 22.7 (CH3CH2), 24.5 (CH2CH2N), 26.3 (2xCH2(CH2)2), 29.1 (CH2(CH2)2), 29.2 (CH2(CH2)2), 
29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 29.6 
(CH2(CH2)2), 29.6-29.7 (7xCH2(CH2)2), 31.8 (CH2(CH2)2), 31.9 (CH2(CH2)2), 49.3 (CH3N), 61.7 (CH2N), 61.8 
(2xCH2N). MS (ESI): m/z Exact mass calculated for C32H68N [M-I
-]: 466.5346. Found: 466.5356. 
4.2.4. Synthesis of sophorolipid amine oxides 
General procedure for synthesis of peracetylated sophorolipid amine oxides (229): In a 50 mL flask, 
sophorolipid amine 213 (0.41 mmol, 1 eq) was dissolved in dry THF, cooled to 0 °C and 0.1 g mCPBA 
(0.58 mmol, 1.4 eq) was added. The mixture was stirred for 30 minutes at 0 °C and subsequently for 
1.5 h at room temperature. The mixture was concentrated under reduced pressure and the residue 
was dissolved in ethyl acetate. The solution was washed three times with a saturated NaHCO3 
solution, dried over MgSO4 and concentrated under reduced pressure to yield pure amine oxide 229 
as a viscous colorless oil. 
N,N-dimethyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229a): (0.36 g, 79%), IR (cm-1) max: 1036 and 1064 
(CHOCH), 1221 (COAc), 1367, 1746 (C=O). 1H-NMR (400MHz, 
CDCl3): H 1.22 (3H, d, J=6.2 Hz, CHCH3), 1.26-1.44 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.53-1.61 (1H, m, CHaHbCHCH3), 1.89-
1.96 (2H, m, CH2CH2N), 1.99 (3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 
2.02 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 
2.08 (3H, s, CH3C=O), 2.09 (3H, s, CH3C=O), 3.21 (6H, s, 2xCH3N), 3.27-3.31 (2H, m, CH2CH2N), 3.63-
3.74 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.11 (2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 
2xCHCHaHbOAc), 4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.70 (1H, d, J=8.0 Hz, CH(O)2), 4.89 (1H, dxd, J=9.5 Hz, 
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J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.03 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 
5.12 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100MHz, 
CDCl3): C 20.4 (CH3C=O), 20.6 (3xCH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.4 
(CHCH3), 23.9 (CH2CH2N), 24.8 (CH2(CH2)2), 26.7 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 36.5 
(CH2CHCH3), 58.2 (2xCH3N), 62.2 (CH2OAc), 62.2 (CH2OAc), 68.4 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 
71.5 (CHOC), 71.6 (CH2CH2N), 71.7 (CHOC), 73.0 (CHOC), 74.8 (CHOC), 77.7 (CHOC), 77.9 (CHOC), 
100.5 (CH(O)2), 101.2 (CH(O)2), 169.5 (CH3C=O), 169.5 (CH3C=O), 169.8 (CH3C=O), 170.0 (CH3C=O), 
170.2 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C37H60NO19 
[M+H+]: 822.3754. Found: 822.3759. 
N-butyl,N-methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229b): (0.29 g, 87%), IR (cm-1) max: 1036 and 1064 
(CHOCH), 1225 (COAc), 1367, 1746 (C=O). 1H-NMR (400MHz, 
CDCl3): H 0.91 (3H, t, J=7.3 Hz, CH2CH3), 1.15 (3H, d, J=6.2 Hz, 
CHCH3), 1.19-1.36 (11H, m, 5xCH2(CH2)2, CHaHbCHCH3), 1.46-
1.54 (1H, m, CHaHbCHCH3), 1.72-1.83 (4H, m, 2xCH2CH2N), 
1.92 (3H, s, CH3C=O), 1.93 (3H, s, CH3C=O), 1.95 (3H, s, 
CH3C=O), 1.96 (3H, s, CH3C=O), 1.99 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 3.01 
(3H, s, CH3N), 3.10-3.17 (4H, m, 2xCH2CH2N), 3.56-3.69 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 3.99-
4.04 (2H, m, 2xCHCHaHbOAc), 4.16-4.22 (2H, m, 2xCHCHaHbOAc), 4.39 (1H, d, J=7.6 Hz, CH(O)2), 4.64 
(1H, d, J=8.0 Hz, CH(O)2), 4.82 (1H, dxd, J=9.4 Hz, J=8.2 Hz, CHOC), 4.86 (1H, dxd, J=9.7 Hz, J=9.7 Hz, 
CHOC), 4.97 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.06 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.10 (1H, 
dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100MHz, CDCl3): C 13.8 (CH2CH3), 20.1 (CH2CH3), 20.4 
(CH3C=O), 20.5 (2xCH3C=O), 20.5 (CH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.3 
(CHCH3), 23.6 (CH2CH2N), 24.8 (CH2(CH2)2), 25.4 (CH2CH2N), 26.8 (CH2(CH2)2), 29.5 (CH2(CH2)2), 29.5 
(CH2(CH2)2), 36.4 (CH2CHCH3), 55.7 (CH3N), 62.1 (CH2OAc), 62.2 (CH2OAc), 68.3 (CHOC), 68.7 
(CH2CH2N), 68.8 (CHOC), 69.1 (CH2CH2N), 71.2 (CHOC), 71.5 (CHOC), 71.7 (CHOC), 73.0 (CHOC), 74.7 
(CHOC), 77.6 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.2 (CH(O)2), 169.4 (CH3C=O), 169.4 (CH3C=O), 
169.7 (CH3C=O), 170.0 (CH3C=O), 170.1 (CH3C=O), 170.5 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z 
Exact mass calculated for C40H66NO19 [M+H
+]: 864.4224. Found: 864.4260. 
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N,N-dibutyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])nonan-1-amine oxide (229c): (0.60 g, 93%), IR (cm-1) max: 1034 and 1063 (CHOCH), 1217 
(COAc), 1367, 1745 (C=O). 1H-NMR (400MHz, CDCl3): H 0.97 
(6H, t, J=7.3 Hz, 2xCH2CH3), 1.21 (3H, d, J=6.2 Hz, CHCH3), 
1.29-1.42 (13H, m, 6xCH2(CH2)2, CHaHbCHCH3), 1.53-1.61 (1H, 
m, CHaHbCHCH3), 1.73-1.84 (6H, m, 3xCH2CH2N), 1.99 (3H, s, 
CH3C=O), 2.00 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 
(3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 3.09-3.13 (6H, m, 
3xCH2CH2N), 3.63-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 
4.23-4.29 (2H, m, 2xCHCHaHbOAc), 4.47 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.89 
(1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.04 (1H, dxd, J=9.6 Hz, 
J=9.6 Hz, CHOC), 5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.16 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 
13C-NMR (100MHz, CDCl3): C 13.9 (2xCH2CH3), 20.2 (2xCH2CH3), 20.4 (CH3C=O), 20.6 (2xCH3C=O), 
20.6 (CH3C=O), 20.7 (2xCH3C=O), 20.8 (CH3C=O), 21.3 (CHCH3), 23.2 (CH2CH2N), 24.9 (CH2(CH2)2), 25.1 
(2xCH2CH2N), 27.0 (CH2(CH2)2), 29.5 (2xCH2(CH2)2), 36.4 (CH2CHCH3), 62.1 (CH2OAc), 62.2 (CH2OAc), 
65.9 (2xCH2CH2N), 66.3 (CH2CH2N), 68.3 (CHOC), 68.8 (CHOC), 71.3 (CHOC), 71.6 (CHOC), 71.8 
(CHOC), 73.0 (CHOC), 74.7 (CHOC), 77.6 (CHOC), 77.9 (CHOC), 100.4 (CH(O)2), 101.1 (CH(O)2), 169.3 
(CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.5 (CH3C=O), 170.6 
(CH3C=O). MS (ESI): m/z Exact mass calculated for C43H72NO19 [M+H
+]: 906.4693. Found: 906.4711. 
N-benzyl,N,methyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229d): (0.27 g, 95%), IR (cm-1) max: 1033 and 1062 
(CHOCH), 1215 (COAc), 1366, 1743 (C=O). 1H-NMR (400MHz, 
CDCl3): H 1.22 (3H, d, J=6.2 Hz, CHCH3), 1.26-1.43 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.53-1.61 (1H, m, CHaHbCHCH3), 
1.88-1.94 (1H, m, CHaHbCH2N), 1.97 (3H, s, CH3C=O), 2.00 
(3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.02 (3H, s, CH3C=O), 
2.04-2.09 (1H, m, CHaHbCH2N), 2.06 (3H, s, CH3C=O), 2.07 (3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 3.02 
(3H, s, CH3N), 3.14-3.18 (2H, m, CH2CH2N), 3.63-3.75 (4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.11 
(2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 2xCHCHaHbOAc), 4.38 (1H, d, J=12.9 Hz, CaromCHaHbN), 4.44 
(1H, d, J=12.9 Hz, CaromCHaHbN), 4.46-4.48 (1H, m, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.87-4.91 
(1H, m, CHOC), 4.93 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 5.04 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 
5.13 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.14-5.20 (1H, dxd, J=9.4 Hz, J=8.1 Hz, CHOC), 7.40-7.44 (3H, 
m, 3xCHarom), 7.53-7.55 (2H, m, 2xCHarom). 
13C-NMR (100MHz, CDCl3): C 20.4 (CH3C=O), 20.6 
(2xCH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.3 (CHCH3), 23.2 
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(CH2CH2N), 24.8 (CH2(CH2)2), 26.8 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.6 (CH2(CH2)2), 36.4 (CH2CHCH3), 
55.0 (CH3N), 62.1 (CH2OAc), 62.2 (CH2OAc), 68.3 (CHOC), 68.4 (CH2CH2N), 68.8 (CHOC), 71.3 (CHOC), 
71.5 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.1 (CaromCH2N), 74.7 (CHOC), 77.6 (CHOC), 77.8 (CHOC), 
100.4 (CH(O)2), 101.2 (CH(O)2), 128.7 (2xCHarom), 129.5 (CHarom), 130.7 (Carom), 132.2 (2xCHarom), 169.4 
(CH3C=O), 169.4 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.5 (CH3C=O), 170.6 
(CH3C=O). MS (ESI): m/z Exact mass calculated for C43H64NO19 [M+H
+]: 898.4067. Found: 898.4073. 
N-benzyl,N-butyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229e): (0.32 g, 94%), IR (cm-1) max: 1037 and 1065 
(CHOCH), 1227 (COAc), 1367, 1749 (C=O). 1H-NMR (400MHz, 
CDCl3): H 0.89 (3H, t, J=7.4 Hz, CH2CH3), 1.15 (3H, d, J=6.2 
Hz, CHCH3), 1.19-1.34 (11H, m, 5xCH2(CH2)2, CHaHbCHCH3), 
1.46-1.54 (1H, m, CHaHbCHCH3), 1.70-1.80 (2H, m, 
2xCHaHbCH2N), 1.83-1.91 (2H, m, 2xCHaHbCH2N), 1.90 (3H, s, 
CH3C=O), 1.93 (3H, s, CH3C=O), 1.94 (3H, s, CH3C=O), 1.96 (3H, s, CH3C=O), 1.99 (3H, s, CH3C=O), 2.01 
(3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.99-3.05 (4H, m, 2xCH2CH2N), 3.56-3.68 (4H, m, 2xCHCH2OAc, 
CH3CHO, CHOC), 3.99-4.04 (2H, m, 2xCHCHaHbOAc), 4.16-4.22 (2H, m, 2xCHCHaHbOAc), 4.29 (2H, s, 
CaromCH2N), 4.40 (1H, d, J=7.6 Hz, CH(O)2), 4.64 (1H, d, J=8.0 Hz, CH(O)2), 4.81-4.85 (1H, m, CHOC), 
4.86 (1H, dxd, J=9.8 Hz, J=9.8 Hz, CHOC), 4.98 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 5.06 (1H, dxd, J=9.4 
Hz, J=9.4 Hz, CHOC), 5.07-5.13 (1H, m, CHOC), 7.31-7.35 (3H, m, 3xCHarom), 7.49-7.51 (2H, m, 
2xCHarom). 
13C-NMR (100MHz, CDCl3): C 13.7 (CH2CH3), 20.1 (CH2CH3), 20.3 (CH3C=O), 20.4 
(2xCH3C=O), 20.4 (CH3C=O), 20.5 (CH3C=O), 20.6 (CH3C=O), 20.7 (CH3C=O), 21.2 (CHCH3), 23.3 
(CH2CH2N), 24.8 (CH2(CH2)2), 25.2 (CH2CH2N), 26.9 (CH2(CH2)2), 29.5 (CH2(CH2)2), 29.5 (CH2(CH2)2), 36.5 
(CH2CHCH3), 62.2 (CH2CH2N), 62.4 (CH2CH2N), 65.1 (CH2CH2N), 65.5 (CH2CH2N), 68.7 (CHOC), 69.1 
(CHOC), 70.6 (CaromCH2N), 71.4 (CHOC), 71.7 (CHOC), 71.9 (CHOC), 73.1 (CHOC), 74.8 (CHOC), 77.7 
(CHOC), 77.8 (CHOC), 100.5 (CH(O)2), 101.1 (CH(O)2), 128.4 (2xCHarom), 129.2 (CHarom), 130.7 (Carom), 
132.1 (2xCHarom), 169.2 (CH3C=O), 169.3 (CH3C=O), 169.6 (CH3C=O), 169.8 (CH3C=O), 170.0 (CH3C=O), 
170.3 (CH3C=O), 170.3 (CH3C=O). MS (ESI): m/z Exact mass calculated for C46H70NO19 [M+H
+]: 
940.4537. Found: 940.4575. 
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N,N-dibenzyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229f): (0.27 g, 63%), IR (cm-1) max: 1035 and 1064 
(CHOCH), 1223 (COAc), 1367, 1747 (C=O). 1H-NMR (400MHz, 
CDCl3): H 1.09-1.33 (9H, m, 4xCH2(CH2)2, CHaHbCHCH3), 1.14 
(3H, d, J=6.2 Hz, CHCH3), 1.46-1.52 (1H, m, CHaHbCHCH3), 
1.85-1.94 (2H, m, CH2CH2N), 1.89 (3H, s, CH3C=O), 1.93 (3H, 
s, CH3C=O), 1.94 (3H, s, CH3C=O), 1.96 (3H, s, CH3C=O), 1.99 
(3H, s, CH3C=O), 2.00 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.78-2.82 (2H, m, CH2CH2N), 3.56-3.65 
(4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.00-4.03 (2H, m, 2xCHCHaHbOAc), 4.16-4.22 (2H, m, 
2xCHCHaHbOAc), 4.25 (2H, d, J=12.5 Hz, 2xCaromCHaHbN), 4.34 (2H, dxd, J=12.5 Hz, J=3.7 Hz, 
2xCaromCHaHbN), 4.39 (1H, d, J=7.6 Hz, CH(O)2), 4.64 (1H, d, J=8.0 Hz, CH(O)2), 4.84 (1H, dxd, J=9.3 Hz, 
J=9.3 Hz, CHOC), 4.86 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 4.98 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 
5.06 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.10 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC), 7.31-7.35 (6H, m, 
6xCHarom), 7.52-7.57 (4H, m, 4xCHarom). 
13C-NMR (100MHz, CDCl3): C 20.5 (CH3C=O), 20.6 (2xCH3C=O), 
20.6 (CH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 (CH3C=O), 21.3 (CHCH3), 23.7 (CH2CH2N), 24.8 
(CH2(CH2)2), 26.7 (CH2(CH2)2), 29.4 (CH2(CH2)2), 29.5 (CH2(CH2)2), 36.4 (CH2CHCH3), 62.1 (CH2CH2N), 
62.3 (CH2CH2N),63.7 (CH2CH2N), 68.4 (CHOC), 68.9 (CHOC), 70.9 (2xCaromCH2N), 71.3 (CHOC), 71.6 
(CHOC), 17.8 (CHOC), 73.0 (CHOC), 74.7 (CHOC), 77.7 (CHOC), 77.8 (CHOC), 100.5 (CH(O)2), 101.1 
(CH(O)2), 128.5 (4xCHarom), 129.3 (2xCHarom), 130.8 (2xCarom), 132.3 (4xCHarom), 169.4 (CH3C=O), 169.5 
(CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 (CH3C=O), 170.6 (CH3C=O), 170.6 (CH3C=O). MS 
(ESI): m/z Exact mass calculated for C49H68NO19 [M+H
+]: 974.4380. Found: 974.4412. 
N-methyl,N-octadecyl-((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonan-1-amine oxide (229g): (0.52 g, 
92%), IR (cm-1) max: 1036 and 1064 (CHOCH), 1223 (COAc), 
1366, 1747 (C=O). 1H-NMR (400MHz, CDCl3): H 0.88 (3H, t, 
J=6.8 Hz, CH2CH3), 1.22 (3H, d, J=6.2 Hz, CHCH3), 1.24-1.42 
(39H, m, 19xCH2(CH2)2, CHaHbCHCH3), 1.54-1.60 (1H, m, 
CHaHbCHCH3), 1.81-1.89 (4H, m, 4xCH2CH2N), 1.99 (3H, s, 
CH3C=O), 2.00 (3H, s, CH3C=O), 2.01 (3H, s, CH3C=O), 2.03 (3H, s, CH3C=O), 2.06 (3H, s, CH3C=O), 2.08 
(3H, s, CH3C=O), 2.08 (3H, s, CH3C=O), 3.08 (3H, s, CH3N), 3.15-3.22 (4H, m, 2xCH2CH2N), 3.63-3.74 
(4H, m, 2xCHCH2OAc, CH3CHO, CHOC), 4.06-4.10 (2H, m, 2xCHCHaHbOAc), 4.23-4.29 (2H, m, 
2xCHCHaHbOAc), 4.46 (1H, d, J=7.6 Hz, CH(O)2), 4.71 (1H, d, J=8.0 Hz, CH(O)2), 4.89 (1H, dxd, J=9.4 Hz, 
J=8.1 Hz, CHOC), 4.93 (1H, dxd, J=9.7 Hz, J=9.7 Hz, CHOC), 5.04 (1H, dxd, J=9.6 Hz, J=9.6 Hz, CHOC), 
5.12 (1H, dxd, J=9.4 Hz, J=9.4 Hz, CHOC), 5.17 (1H, dxd, J=9.5 Hz, J=9.5 Hz, CHOC). 13C-NMR (100MHz, 
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CDCl3): C 14.1 (CH2CH3), 20.4 (CH3C=O), 20.6 (3xCH3C=O), 20.7 (CH3C=O), 20.7 (CH3C=O), 20.8 
(CH3C=O), 21.3 (CHCH3), 22.7 (CH2CH3), 23.5 (CH2CH2N), 23.7 (CH2CH2N), 24.8 (CH2(CH2)2), 26.8 
(CH2(CH2)2), 26.9 (CH2(CH2)2), 29.3-29.7 (13xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.4 (CH2CHCH3), 55.9 
(CH3N), 62.1 (CH2CH2N), 62.2 (CH2CH2N), 68.4 (CHOC), 68.8 (CHOC), 69.2 (CH2CH2N), 69.3 (CH2CH2N), 
71.3 (CHOC), 71.5 (CHOC), 71.8 (CHOC), 73.0 (CHOC), 74.7 (CHOC), 77.7 (CHOC), 77.9 (CHOC), 100.5 
(CH(O)2), 101.2 (CH(O)2), 169.4 (CH3C=O), 169.5 (CH3C=O), 169.7 (CH3C=O), 170.0 (CH3C=O), 170.2 
(CH3C=O), 170.5 (CH3C=O), 170.6 (CH3C=O). MS (ESI): m/z Exact mass calculated for C54H94NO19 
[M+H+]: 1060.6415. Found: 1060.6417. 
General procedure for synthesis of sophorolipid amine oxides (230): In a 50 mL flask, sophorolipid 
amine oxide 229 (0.45 mmol, 1 eq) was dissolved in a methanol/water mixture (1:1) and 13 mL Et3N 
(0.90 mmol, 2 eq) was added. The mixture was stirred for 2 h at reflux temperature and concentrated 
under reduced pressure to yield pure sophorolipid amine oxide 230 as an off-white sticky powder. 
N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230a): (0.23 g, quant.), IR (cm-1) max: 1025 and 1071 (CHOCH), 3348 (OH). 
1H-NMR (400MHz, 
MeOD): H 1.16 (3H, d, J=6.2 Hz, CHCH3), 1.19-1.44 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.44-1.54 (1H, m, CHaHbCHCH3), 1.72-
1.80 (2H, m, 2xCH2CH2N), 3.09 (6H, s, 2xCH3N), 3.12-3.24 (7H, m, 
5xCHOC, CH2CH2N), 3.27 (1H, dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.37 
(1H, dxd, J=9.0 Hz, J=7.8 Hz, CHOC), 3.46 (1H, dxd, J=8.7 Hz, J=8.7 
Hz, CHOC), 3.52-3.58 (2H, m, 2xCHCHaHbOH), 3.69-3.77 (3H, m, 2xCHCHaHbOH, CHOC), 4.34 (1H, d, 
J=7.7 Hz, CH(O)2), 4.57 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD): C 20.6 (CHCH3), 23.0 
(CH2CH2N), 24.7 (CH2(CH2)2), 26.2 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 
56.7 (2xCH3N), 61.4 (CH2OH), 61.7 (CH2OH), 70.1 (CHOC), 70.3 (CH2CH2N), 70.5 (CHOC), 74.6 (CHOC), 
76.4 (CHOC), 76.4 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.7 (CHOC), 80.0 (CHOC), 101.6 (CH(O)2), 103.0 
(CH(O)2).MS (ESI): m/z Exact mass calculated for C23H46NO12 [M+H
+]: 528.3015. Found: 528.3012. 
N-butyl,N-methyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230b): (0.11 g, 95%), IR (cm-1) max: 1032 and 1072 (CHOCH), 3352 (OH). 
1H-NMR (400MHz, MeOD): 
H 0.91 (3H, t, J=7.4 Hz, CH2CH3), 1.15 (3H, d, J=6.2 Hz, CHCH3), 
1.18-1.44 (11H, m, 5xCH2(CH2)2, CHaHbCHCH3), 1.44-1.55 (1H, 
m, CHaHbCHCH3), 1.65-1.77 (4H, m, 2xCH2CH2N), 3.02 (3H, s, 
CH3N), 3.08-3.23 (9H, m, 5xCHOC, 2xCH2CH2N), 3.27 (1H, dxd, 
J=8.9 Hz, J=8.9 Hz, CHOC), 3.35-3.39 (1H, m, CHOC), 3.45 (1H, 
dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 3.52-3.58 (2H, m, 2xCHCHaHbOH), 3.69-3.77 (3H, m, 2xCHCHaHbOH, 
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CHOC), 4.34 (1H, d, J=7.7 Hz, CH(O)2), 4.57 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD): C 
12.7 (CH2CH3), 19.5 (CH2CH3), 20.6 (CHCH3), 22.7 (CH2CH2N), 24.7 (CH2CH2N, CH2(CH2)2), 26.2 
(CH2(CH2)2), 29.1 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 53.5 (CH3N), 61.4 (CH2OH), 61.7 
(CH2OH), 68.0 (CH2CH2N), 68.2 (CH2CH2N), 70.1 (CHOC), 70.4 (CHOC), 74.6 (CHOC), 76.4 (2xCHOC), 
76.9 (CHOC), 77.0 (CHOC), 77.6 (CHOC), 80.1 (CHOC), 101.6 (CH(O)2), 103.1 (CH(O)2). MS (ESI): m/z 
Exact mass calculated for C26H52NO12 [M+H
+]: 570.3484. Found: 570.3499. 
N,N-dibutyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230c): (0.26 g, 84%), IR (cm-1) max: 1027 and 1073 (CHOCH), 
3334 (OH). 1H-NMR (400MHz, MeOD): H 1.02 (6H, t, J=7.4 
Hz, 2xCH2CH3), 1.27 (3H, d, J=6.2 Hz, CHCH3), 1.31-1.55 (13H, 
m, 6xCH2(CH2)2, CHaHbCHCH3), 1.58-1.66 (1H, m, 
CHaHbCHCH3), 1.71-1.82 (6H, m, 3xCH2CH2N), 3.20-3.35 (11H, 
m, 3xCH2CH2N, 5xCHOC), 3.39 (1H, dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.46-3.50 (1H, m, CHOC), 3.57 (1H, 
dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 3.64-3.70 (2H, m, 2xCHCHaHbOH), 3.81-3.89 (3H, m, 2xCHCHaHbOH, 
CHOC), 4.46 (1H, d, J=7.7 Hz, CH(O)2), 4.68 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD): C 
12.7 (2xCH2CH3), 19.6 (2xCH2CH3), 20.6 (CHCH3), 22.4 (CH2CH2N), 24.5 (2xCH2CH2N), 24.7 (CH2(CH2)2), 
26.3 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.4 (CH2(CH2)2), 36.5 (CH2CHCH3), 61.4 (CH2OH), 61.7 (CH2OH), 
64.8 (2xCH2CH2N), 65.1 (CH2CH2N), 70.1 (CHOC), 70.4 (CHOC), 74.6 (CHOC), 76.4 (2xCHOC), 76.9 
(CHOC), 76.9 (CHOC), 77.6 (CHOC), 80.2 (CHOC), 101.5 (CH(O)2), 103.1 (CH(O)2). MS (ESI): m/z Exact 
mass calculated for C29H58NO12 [M+H
+]: 612.3954. Found: 612.3965. 
N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230d): (0.38 g, quant.), IR (cm-1) max: 1023 and 1072 (CHOCH), 3332 (OH). 
1H-NMR (400MHz, 
MeOD): H 1.28 (3H, d, J=6.2 Hz, CHCH3), 1.31-1.56 (9H, m, 
4xCH2(CH2)2, CHaHbCHCH3), 1.58-1.69 (1H, m, CHaHbCHCH3), 
1.86-1.95 (1H, m, CHaHbCHCH3), 1.98-2.06 (1H, m, 
CHaHbCHCH3), 3.02 (3H, s, CH3N), 3.21-3.37 (7H, m, CH2CH2N, 
5xCHOC), 3.40 (1H, dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.47-3.51 
(1H, m, CHOC), 3.58 (1H, dxd, J=8.7 Hz, J=8.7 Hz, CHOC), 3.64-3.70 (2H, m, 2xCHCHaHbOH), 3.81-3.89 
(3H, m, 2xCHCHaHbOH, CHOC), 4.43 (1H, d, J=12.7 Hz, CaromCHaHbN), 4.46 (1H, d, J=7.7 Hz, CH(O)2), 
4.48 (1H, d, J=12.7 Hz, CaromCHaHbN), 4.69 (1H, d, J=7.8 Hz, CH(O)2), 7.44-7.49 (3H, m, 3xCHarom), 7.59-
7.62 (2H, m, 2xCHarom). 
13C-NMR (100MHz, MeOD): C 20.6 (CHCH3), 22.6 (CH2CH2N), 24.7 (CH2(CH2)2), 
26.3 (CH2(CH2)2), 29.1 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.5 (CH2CHCH3), 52.9 (CH3N), 61.4 (CH2OH), 61.7 
(CH2OH), 68.3 (CH2CH2N), 70.1 (CHOC), 70.4 (CHOC), 72.3 (CaromCH2N), 74.6 (CHOC), 76.4 (CHOC), 76.4 
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(CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.7 (CHOC), 80.1 (CHOC), 101.6 (CH(O)2), 103.1 (CH(O)2), 128.2 
(2xCHarom), 129.5 (CHarom), 129.8 (Carom), 132.5 (2xCHarom). MS (ESI): m/z Exact mass calculated for 
C29H50NO12 [M+H
+]: 604.3328. Found: 604.3353. 
N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230e): (0.28 g, 91%), IR (cm-1) max: 725, 906, 1030 and 1073 (CHOCH), 3359 (OH). 
1H-NMR 
(400MHz, MeOD): H 0.89 (3H, t, J=7.4 Hz, CH2CH3), 1.16 
(3H, d, J=6.2 Hz, CHCH3), 1.19-1.43 (11H, m, 5xCH2(CH2)2, 
CHaHbCHCH3), 1.46-1.55 (1H, m, CHaHbCHCH3), 1.67-1.82 
(4H, m, 2xCH2CH2N), 2.95-3.23 (9H, m, 2xCH2CH2N, 
5xCHOC), 3.27 (1H, dxd, J=8.9 Hz, J=8.9 Hz, CHOC), 3.37 (1H, 
dxd, J=9.0 Hz, J=7.8 Hz, CHOC), 3.46 (1H, dxd, J=8.5 Hz, J=8.5 Hz, CHOC), 3.52-3.58 (2H, m, 
2xCHCHaHbOH), 3.70-3.78 (3H, m, 2xCHCHaHbOH, CHOC), 4.31 (2H, s, CaromCH2N), 4.34 (1H, d, J=7.7 
Hz, CH(O)2), 4.56 (1H, d, J=7.8 Hz, CH(O)2), 7.31-7.38 (3H, m, 3xCHarom), 7.48-7.51 (2H, m, 2xCHarom). 
13C-NMR (100MHz, MeOD): C 12.7 (CH2CH3), 19.5 (CH2CH3), 20.6 (CHCH3), 22.6 (CH2CH2N), 24.7 
(CH2CH2N, CH2(CH2)2), 26.3 (CH2(CH2)2), 29.0 (CH2(CH2)2), 29.3 (CH2(CH2)2), 36.4 (CH2CHCH3), 61.4 
(CH2OH), 61.7 (CH2OH), 64.2 (CH2CH2N), 64.6 (CH2CH2N), 69.2 (CaromCH2N), 70.1 (CHOC), 70.4 (CHOC), 
74.6 (CHOC), 76.4 (CHOC), 76.4 (CHOC), 76.9 (CHOC), 77.0 (CHOC), 77.6 (CHOC), 80.2 (CHOC), 101.5 
(CH(O)2), 103.1 (CH(O)2), 128.2 (2xCHarom), 129.4 (CHarom), 129.7 (Carom), 132.3 (2xCHarom). MS (ESI): 
m/z Exact mass calculated for C32H56NO12 [M+H
+]: 646.3797. Found: 646.3813. 
N,N-dibenzyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230f): (0.036 g, quant.), 1H-NMR (400MHz, MeOD): H 1.14-1.21 (2H, m, CH2CH2CH2N), 1.24 (3H, d, 
J=6.2 Hz, CHCH3), 1.29-1.48 (7H, m, 3xCH2(CH2)2, 
CHaHbCHCH3), 1.55-1.62 (1H, m, CHaHbCHCH3), 1.89-1.97 (2H, 
m, CH2CH2N), 2.85-2.90 (2H, m, CH2CH2N), 3.21-3.33 (5H, m, 
5xCHOC), 3.38 (1H, dxd, J=8.9 Hz, J=8.9Hz, CHOC), 3.46 (1H, 
dxd, J=9.1 Hz, J=7.8 Hz, 3.56 (1H, dxd, J=8.8 Hz, J=8.8 Hz, 
CHOC), 3.62-3.68 (2H, m, 2xCHCHaHbOH), 3.78-3.87 (3H, m, 2xCHCHaHbOH, CHOC), 4.38 (2H, d, J=12.7 
Hz, 2xCaromCHaHbN), 4.44 (1H, d, J=7.7 Hz, CH(O)2), 4.48 (2H, d, J=12.7 Hz, 2xCaromCHaHbN), 4.65 (1H, d, 
J=7.8 Hz, CH(O)2), 7.41-7.45 (6H, m, 6xCHarom), 7.62-7.64 (4H, m, 4xCHarom). 
13C-NMR (100MHz, 
MeOD): C 20.6 (CHCH3), 23.1 (CH2CH2N), 24.7 (CH2(CH2)2), 26.2 (CH2(CH2)2), 28.9 (CH2(CH2)2), 29.2 
(CH2(CH2)2), 36.4 (CH2CHCH3), 61.4 (CH2OH), 61.7 (CH2OH), 63.7 (CH2CH2N), 69.7 (2xCaromCH2N), 70.1 
(CHOC), 70.5 (CHOC), 74.6 (CHOC), 76.4 (CHOC), 76.4 (CHOC), 76.9 (CHOC), 76.9 (CHOC), 77.5 (CHOC), 
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80.3 (CHOC), 101.5 (CH(O)2), 103.2 (CH(O)2), 128.2 (4xCHarom), 129.3 (2xCHarom), 130.1 (2xCarom), 132.4 
(4xCHarom). MS (ESI): m/z Exact mass calculated for C35H54NO12 [M+H
+]: 680.3641. Found: 680.3654. 
N,N-dimethyl-((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonan-1-amine oxide 
(230g): (0.34 g, 81%), IR (cm-1) max: 1030 and 1073 (CHOCH), 3346 (OH). 
1H-NMR (400MHz, MeOD): 
H 0.80 (3H, t, J=6.8 Hz, CH2CH3), 1.15 (3H, d, J=6.2 Hz, CHCH3), 
1.19-1.43 (39H, m, 19xCH2(CH2)2, CHaHbCHCH3), 1.46-1.54 (1H, 
m, CHaHbCHCH3), 1.66-1.76 (4H, m, 2xCH2CH2N), 3.01 (3H, s, 
CH3N), 3.10-3.23 (7H, m, CH2CH2N, 5xCHOC), 3.28 (1H, dxd, 
J=8.8 Hz, J=8.8 Hz, CHOC), 3.34-3.39 (1H, m, CHOC), 3.46 (1H, 
dxd, J=8.6 Hz, J=8.6 Hz, CHOC), 3.52-3.58 (2H, m, 2xCHCHaHbOH), 3.69-3.77 (3H, m, 2xCHCHaHbOH, 
CHOC), 4.34 (1H, d, J=7.7 Hz, CH(O)2), 4.57 (1H, d, J=7.8 Hz, CH(O)2). 
13C-NMR (100MHz, MeOD): C 
13.1 (CH2CH3), 20.6 (CHCH3), 22.3 (CH2CH3), 22.7 (2xCH2CH2N), 24.7 (CH2(CH2)2), 26.3 (2xCH2(CH2)2), 
29.0-29.4 (14xCH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 (CH2CHCH3), 53.6 (CH3N),61.4 (CH2OH), 61.7 (CH2OH), 
68.3 (2xCH2CH2N), 70.1 (CHOC), 70.4 (CHOC), 74.6 (CHOC), 76.4 (2xCHOC), 76.9 (CHOC), 77.0 (CHOC), 
77.6 (CHOC), 80.1 (CHOC), 101.6 (CH(O)2), 103.1 (CH(O)2). MS (ESI): m/z Exact mass calculated for 
C40H80NO12 [M+H
+]: 766.5675. Found: 766.5705. 
4.2.5. Synthesis of bolaamphiphilic sophorolipids 
General procedure for the synthesis of peracetylated N,N’-dialkyl bolaamphiphilic sophorolipid 
amines (235): In a 50 mL flask, 1.57 g peracetylated sophoroplipid aldehyde 201 (2.02 mmol, 1 eq) 
was dissolved in 25 mL methanol and the secondary diamine (1.01 mmol, 1 eq), 0.25 g NaBH3CN 
(4.04 mmol, 2 eq) and 0.58 mL acetic acid (10.09 mmol, 5 eq) were added sequentially. The reaction 
mixture was stirred overnight at room temperature, concentrated under reduced pressure and 
dissolved in ethyl acetate. The mixture was washed 3 times with a saturated NaHCO3-solution and 
the organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The 
peracetylated sophorolipid amines were purified by automated column chromatography as a viscous 
colorless oil with a hexane/ethyl acetate/triethylamine mixture as eluent (mixture A = 16% 
triethylamine in ethyl acetate). 
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N,N’-dimethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl-ethylene diamine (235a): Purification gradient: 2 CV 15% mixture A, 
20 CV 15-60% mixture A, 2 CV 60% mixture A. (0.26 g, 
31%), colorless viscous oil. 1H-NMR (400 MHz, CDCl3): 
H 1.22 (6H, d, J=6.1 Hz, 2xCH3CH), 1.26-1.41 (18H, m, 
2xCHaHbCHCH3, 8xCH2(CH2)2), 1.45-1.52 (4H, m, 
2xCH2CH2N), 1.56-1.63 (2H, m, 2xCHaHbCHCH3), 1.99 
(6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 
2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.24 (6H, s, 2xCH3N), 2.34-2.37 (4H, m, 2xCH2N), 2.48 (4H, s, 
2xCH2N), 3.63-3.75 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.10 (4H, m, 4xCHCHaHbOAc), 
4.22-4.31 (4H, m, 4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, J=8.0 Hz, 2xCH(O)2), 
4.88-4.93 (2H, m, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz 2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 
Hz, 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.4 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.5 H, J=9.5 Hz, 2xCHOC). 
13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 20.6 (6xCH3C=O), 20.7 (4xCH3C=O), 20.8 (2xCH3C=O), 
21.2 (2xCH3CH), 25.1 (2xCH2(CH2)2), 27.3 (2xCH2CH2N), 27.7 (2xCH2(CH2)2), 29.7 (2xCH2(CH2)2), 29.8 
(2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 42.6 (2xCH3N), 55.6 (2xCH2N), 58.5 (2xCH2N), 62.0 (2xCH2OAc), 
62.3 (2xCH2OAc), 68.3 (2xCHOC), 68.9 (2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.1 
(2xCHOC), 74.6 (2xCHOC), 77.7 (2xCHOC), 77.9 (2xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.3 
(2xCH3C=O), 169.4 (2xCH3C=O), 169.8 (2xCH3C=O), 170.0 (2xCH3C=O), 170.3 (2xCH3C=O), 170.6 
(2xCH3C=O), 170.6 (2xCH3C=O). MS (ESI): m/z Exact mass calculated for C74H117N2O36 [M+H
+]: 
1609.7381. Found: 1609.7412. 
N,N’-dimethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl-hexamethylene diamine (235b): Purification gradient: 2 CV 15% 
mixture A, 20 CV 15-60% mixture A, 2 CV 60% 
mixture A. (0.28 g, 31%), colorless viscous oil. 
1H-NMR (400 MHz, CDCl3): H 1.22 (6H, d, J=6.2 Hz, 
2xCH3CH), 1.26-1.40 (20H, m, 2xCHaHbCHCH3, 
9xCH2(CH2)2), 1.43-1.51 (8H, m, 4xCH2CH2N), 1.56-
1.63 (2H, m, 2xCHaHbCHCH3), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 
2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.20 (6H, s, 2xCH3N), 2.29-
2.34 (8H, m, 4xCH2N), 3.63-3.76 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.07-4.10 (4H, m, 
4xCHCHaHbOAc), 4.22-4.31 (4H, m, 4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, 
J=8.0 Hz, 2xCH(O)2), 4.91 (2H, dxd, J=9.1 Hz, J=9.1 Hz 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz 
2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 Hz 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.4 Hz 2xCHOC), 5.16 
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(2H, dxd, J=9.5 Hz, J=9.5 Hz 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 20.6 
(6xCH3C=O), 20.7 (4xCH3C=O), 20.8 (2xCH3C=O), 21.2 (2xCH3CH), 25.1 (2xCH2(CH2)2), 27.3 
(2xCH2CH2N), 27.3 (2xCH2CH2N), 27.7 (2xCH2(CH2)2), 27.7 (2xCH2(CH2)2), 29.7 (2xCH2(CH2)2), 29.8 
(2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 42.2 (2xCH3N), 57.9 (2xCH2N), 58.0 (2xCH2N), 68.2 (2xCHOC), 68.9 
(2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.0 (2xCHOC), 74.6 (2xCHOC), 77.7 
(2xCHOC), 77.9 (2xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.3 (2xCH3C=O), 169.4 (2xCH3C=O), 
169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.3 (2xCH3C=O), 170.6 (2xCH3C=O), 170.6 (2xCH3C=O). MS 
(ESI): m/z Exact mass calculated for C78H125N2O36 [M+H
+]: 1665.8007. Found: 1668.8089. 
N,N’-dibutyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl-ethylene diamine (235c): Purification gradient: 2 CV 7% mixture A, 
30 CV 7-60% mixture A, 2 CV 60% mixture A, 2 CV 
100% mixture A. (0.43 g, 41%), colorless viscous oil. 
1H-NMR (400 MHz, CDCl3): H 0.91 (6H, t, J=7.3 Hz, 
2xCH3CH2), 1.22 (6H, d, J=6.2 Hz, 2xCH3CH), 1.24-
1.48 (30H, m, 2xCHaHbCHCH3, 2xCH2CH3, 
8xCH2(CH2)2, 4xCH2CH2N), 1.57-1.63 (2H, m, 2xCHaHbCHCH3), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 
2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.40-2.44 (8H, m, 4xCH2N), 2.52 (4H, s, 2xCH2N), 3.63-3.75 (8H, 
m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.07-4.10 (4H, m, 4xCHCHaHbOAc), 4.22-4.31 (4H, m, 
4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.91 (2H, dxd, 
J=9.2 Hz, J=9.2 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 
Hz, 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.34 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC). 
13C-NMR (100 MHz, CDCl3): C 14.1 (2xCH3CH2), 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.6 (2xCH3C=O), 
20.6 (2xCH3C=O), 20.7 (4xCH3C=O), 20.8 (2xCH3CH2), 20.8 (2xCH3C=O), 21.2 (2xCH3CH), 25.1 
(2xCH2(CH2)2), 27.2 (2xCH2CH2N), 27.7 (2x CH2(CH2)2), 29.3 (2xCH2CH2N), 29.8 (2xCH2(CH2)2), 29.8 
(2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 52.3 (2xCH2N), 54.3 (2xCH2N), 54.9 (2xCH2N), 62.0 (2xCH2OAc), 
62.3 (2xCH2OAc), 68.2 (2xCHOC), 68.9 (2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.1 
(2xCHOC), 74.6 (2xCHOC), 77.7 (2xCHOC), 77.9 (2xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.3 
(2xCH3C=O), 169.4 (2xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.3 (2xCH3C=O), 170.6 
(2xCH3C=O), 170.6 (2xCH3C=O). MS (ESI): m/z Exact mass calculated for C74H117N2O36 [M+H
+]: 
1693.8320. Found: 1693.8377. 
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N,N’-dibutyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl-hexamethylene diamine (235d): Purification gradient: 2 CV 7% mixture 
A, 30 CV 7-60% mixture A, 2 CV 60% mixture A, 2 CV 
100% mixture A. (0.29 g, 27%), colorless viscous oil. 
1H-NMR (400 MHz, CDCl3): H 0.91 (6H, t, J=7.3 Hz, 
2xCH3CH2), 1.22 (6H, d, J=6.2 Hz, 2xCH3CH), 1.26-1.47 
(38H, m, 2xCHaHbCHCH3, 2xCH2CH3, 10xCH2(CH2)2, 
6xCH2CH2N), 1.57-1.63 (2H, m, 2xCHaHbCHCH3), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.01 
(6H, s, 2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.37-2.41 
(12H, m, 6xCH2N), 3.63-3.75 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.10 (4H, m, 
4xCHCHaHbOAc), 4.22-4.31 (4H, m, 4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, 
J=8.0 Hz, 2xCH(O)2), 4.91 (2H, dxd, J=9.3 Hz, J=8.3 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 
2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC), 5.13 (2H, dxd, J=9.3 Hz, J=9.3 Hz, 2xCHOC), 5.16 
(2H, dxd, J=9.4 Hz, J=9.4 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 14.1 (2xCH3CH2), 20.5 
(2xCH3C=O), 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (4xCH3C=O), 20.8 (2xCH3C=O), 
20.8 (2xCH3CH2), 21.2 (2xCH3CH), 25.1 (2xCH2(CH2)2), 27.0 (2xCH2CH2N), 27.1 (2xCH2CH2N), 27.7 
(2xCH2(CH2)2), 27.8 (2xCH2(CH2)2), 29.2 (2xCH2CH2N), 29.8 (2xCH2(CH2)2), 29.8 (2xCH2(CH2)2), 36.4 
(2xCH2CHCH3), 53.8 (2xCH2N), 54.2 (2xCH2N), 54.3 (2xCH2N), 62.0 (2xCH2OAc), 62.3 (2xCH2OAc), 68.2 
(2xCHOC), 68.9 (2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.0 (2xCHOC), 74.6 
(2xCHOC), 77.7 (2xCHOC), 77.9 (2xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.3 (2xCH3C=O), 
169.4 (2xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.3 (2xCH3C=O), 170.6 (2xCH3C=O), 170.6 
(2xCH3C=O). MS (ESI): m/z Exact mass calculated for C74H117N2O36 [M+H
+]: 1749.8946. Found: 
1749.8995. 
General procedure for the synthesis of deprotected N,N’-dialkyl bolaamphiphilic sophorolipid 
amines (238): In a 50 mL flask, N,N’-dialkyl bolaamphiphilic sophorolipid 235 (0.45 mmol, 1 eq) was 
dissolved in a methanol/water mixture (1:1) and 13 mL Et3N (0.90 mmol, 2 eq) was added. The 
mixture was stirred for 2 h at reflux temperature and concentrated under reduced pressure to yield 
pure deprotected N,N’-dialkyl bolaamphiphilic sophorolipid 238. 
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N,N’-dimethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-ethylene 
diamine (238a): (0.12 g, 94%), colorless sticky solid. 1H-NMR (400 MHz, MeOD): H 1.27 (6H, d, J=6.2 
Hz, 2xCHCH3), 1.31-1.56 (18H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3), 1.58-1.67 (6H, m, 2xCH2CH2N, 
2xCHaHbCHCH3), 2.52 (6H, s, 2xCH3N), 2.68-2.74 (4H, 
m, 2xCH2CH2N), 2.89 (4H, s, 2x CH2N), 3.22-3.52 (10H, 
m, 10xCHOC), 3.40 (2H, dxd, J=8.8 Hz, J=8.8 Hz, 
2xCHOC), 3.49 (2H, dxd, J=9.0 Hz, J=7.8 Hz, 2xCHOC), 3.58 (2H, dxd, J=8.8 Hz, J=8.8 Hz, 2xCHOC), 3.65-
3.70 (4H, m, 4xCHCHaHbOH), 3.81-3.89 (6H, m, 4xCHCHaHbOH, 2xCHOC), 4.46 (2H, d, J=7.6 Hz, 
2xCH(O)2), 4.69 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 20.6 (2xCHCH3), 24.8 
(2xCH2(CH2)2), 25.4 (2xCH2CH2N), 26.8 (2xCH2(CH2)2), 29.2 (2xCH2(CH2)2), 29.5 (2xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 40.4 (2xCH3N), 52.5 (2xCH2N), 57.2 (2xCH2CH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 
70.1 (2xCHOC), 70.5 (2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.9 (2xCHOC), 77.0 (2xCHOC), 77.6 
(2xCHOC), 80.2 (2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2). MS (ESI): m/z Exact mass calculated 
for C46H89N2O22 [M+H
+]: 1021.5902. Found: 1021.5899. 
N,N’-dimethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-
hexamethylene diamine (238b): (0.14 g, 95%), 
colorless sticky solid. 1H-NMR (400 MHz, MeOD): H 
1.26 (6H, d, J=6.2 Hz, 2xCHCH3), 1.29-1.54 (22H, m, 
10xCH2(CH2)2, 2xCHaHbCHCH3), 1.57-1.73 (10H, m, 
4xCH2CH2N, 2xCHaHbCHCH3), 2.67 (6H, s, 2xCH3N), 
2.88-2.93 (8H, m, 4xCH2CH2N), 3.20-3.33 (10H, m, 
10xCHOC), 3.39 (2H, dxd, J=8.9 Hz, J=8.9 Hz, 2xCHOC), 3.48 (2H, dxd, J=9.0 Hz, J=7.7 Hz, 2xCHOC), 
3.56 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.64-3.68 (4H, m, 4xCHCHaHbOH), 3.80-3.88 (6H, m, 
4xCHCHaHbOH, 2xCHOC), 4.45 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.68 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR 
(100 MHz, MeOD): C 20.6 (2xCHCH3), 24.3 (2xCH2CH2N), 24.5 (2xCH2(CH2)2), 24.7 (2xCH2CH2N), 26.1 
(2xCH2(CH2)2), 26.5 (2xCH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 39.5 
(2xCH3N), 56.1 (2xCH2CH2N), 56.3 (2xCH2CH2N), 61.4 (2xCH2OH), 61.6 (2xCH2OH), 70.2 (2xCHOC), 70.4 
(2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.9 (2xCHOC), 77.0 (2xCHOC), 77.6 (2xCHOC), 80.1 
(2xCHOC), 101.6 (2xCH(O)2), 103.1 (2xCH(O)2). MS (ESI): m/z Exact mass calculated for C50H97N2O22 
[M+H+]: 1077.6528. Found: 1077.6520. 
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N,N’-dibutyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-ethylene 
diamine (238c): (0.12 g, 91%), white sticky solid. 1H-NMR (400 MHz, MeOD): H 1.00 (6H, t, J=7.3 Hz, 
2xCH2CH3), 1.27 (6H, d, J=6.2 Hz, 2xCHCH3), 1.31-1.51 
(22H, m, 2xCH2CH3, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.53-
1.66 (10H, m, 4xCH2CH2N, 2xCHaHbCHCH3), 2.75-2.79 
(8H, m, 4xCH2CH2N), 2.92 (4H, s, 2xCH2N), 3.22-3.37 
(10H, m, 10xCHOC), 3.40 (2H, dxd, J=8.8 Hz, J=8.8 Hz, 
2xCHOC), 3.48 (2H, dxd, J=9.0 Hz, J=7.8 Hz, 2xCHOC), 3.58 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.65-
3.70 (4H, m, 4xCHCHaHbOH), 3.82-3.90 (6H, m, 4xCHCHaHbOH, 2xCHOC), 4.46 (2H, d, J=7.7 Hz, 
2xCH(O)2), 4.68 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.9 (2xCH2CH3), 20.1 
(2xCH2CH3), 20.6 (2xCHCH3), 24.8 (2xCH2(CH2)2), 25.2 (2xCH2CH2N), 27.0 (2xCH2(CH2)2), 27.3 
(2xCH2CH2N), 29.3 (2xCH2(CH2)2), 29.5 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 49.6 (2xCH2N), 53.3 
(2xCH2CH2N), 53.6 (2xCH2CH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 70.1 (2xCHOC), 70.4 (2xCHOC), 
74.6 (2xCHOC), 76.4 (4xCHOC), 76.9 (4xCHOC), 77.6 (2xCHOC), 80.3 (2xCHOC), 101.5 (2xCH(O)2), 
103.2 (2xCH(O)2). MS (ESI): m/z Exact mass calculated for C52H101N2O22 [M+H
+]: 1105.6841. Found: 
1105.6834. 
N,N’-dibutyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-
hexamethylene diamine (238d): (0.12 g, 89%), white sticky solid. 1H-NMR (400 MHz, MeOD): H 1.01 
(6H, t, J=7.3 Hz, 2xCH2CH3), 1.26 (6H, d, J=6.2 Hz, 
2xCHCH3), 1.20-1.55 (26H, m, 2xCH2CH3, 10xCH2(CH2)2, 
2xCHaHbCHCH3), 1.58-1.72 (14H, m, 6xCH2CH2N, 
2xCHaHbCHCH3), 2.96-3.00 (12H, m, 6xCH2CH2N), 3.21-
3.34 (10H, m, 10xCHOC), 3.40 (2H, dxd, J=8.8 Hz, J=8.8 
Hz, 2xCHOC), 3.48 (2H, dxd, J=9.0 Hz, J=7.8 Hz, 2xCHOC), 3.56 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 
3.64-3.69 (4H, m, 4xCHCHaHbOH), 3.81-3.88 (6H, m, 4xCHCHaHbOH, 2xCHOC), 4.45 (2H, d, J=7.6 Hz, 
2xCH(O)2), 4.68 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.6 (2xCH2CH3), 19.7 
(2xCH2CH3), 20.6 (2xCHCH3), 23.7 (2xCH2CH2N), 23.8 (2xCH2CH2N) 24.7 (2xCH2(CH2)2), 25.7 
(2xCH2CH2N), 26.0 (2xCH2(CH2)2), 26.5 (2xCH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.4 (2xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 52.4 (2xCH2N), 52.5 (2xCH2N), 52.8 (2xCH2N), 61.4 (2xCH2OH), 61.6 (2xCH2OH), 70.1 
(2xCHOC), 70.5 (2xCHOC), 74.7 (2xCHOC), 76.4 (4xCHOC), 76.9 (2xCHOC), 77.0 (2xCHOC), 77.6 
(2xCHOC), 80.2 (2xCHOC), 101.6 (2xCH(O)2), 103.1 (2xCH(O)2). MS (ESI): m/z Exact mass calculated 
for C56H109N2O22 [M+H
+]: 1161.7467. Found: 1161.7458. 
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General procedure for the synthesis of peracetylated dicationic bolaamphiphilic sophorolipids 
(239): In a 10 mL flame dried pressure resistant vial, peracetylated N,N’dialkyl bolaamphiphilic 
sophorolipid 235 was dissolved in dry acetonitrile. The solution was cooled down to 0 °C and the alkyl 
iodide (10 eq) was added. The vial was closed and heated to 80 °C for 48 hours. The reaction mixture 
was concentrated under reduced pressure to yield the peracetylated quaternary ammonium 
bolaamphiphilic sophorolipid 239. 
N,N,N’,N’-tetramethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--
D-glucopyranosyl)-oxy])nonyl-ethylene diaminium diodide (239a): (0.45 g, quant.), light yellow 
powder. 1H-NMR (400 MHz, CDCl3): H 1.22 (6H, d, 
J=6.1 Hz, 2xCHCH3), 1.26-1.51 (18H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3), 1.52-1.57 (2H, m, 2xCHaHbCHCH3), 
1.85-1.95 (4H, m, 2xCH2CH2N), 2.00 (12H, s, 
4xCH3C=O), 2.04 (6H, s, 2xCH3C=O), 2.05 (6H, s, 
2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.09 (6H, s, 2xCH3C=O), 2.10 (6H, s, 2xCH3C=O), 3.54-3.55 (12H, 
m, 4xCH3N), 3.66-3.81 (10H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC, 2xCH2N), 4.06-4.11 (4H, m, 
4xCHCHaHbOAc), 4.21-4.27 (4H, m, 4xCHCHaHbOAc), 4.51 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.71-4.73 (4H, 
m, 2xCH2N), 4.72 (2H, d, J=7.9 Hz, 2xCH(O)2), 4.86 (2H, dxd, J=9.5 Hz, J=8.1 Hz, 2xCHOC), 4.93 (2H, 
dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 4.99 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.12 (2H, dxd, J=9.6 Hz, 
J=9.6 Hz, 2xCHOC), 5.18 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 
(2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (2xCH3C=O), 20.8 (2xCH3C=O), 20.8 (4xCH3C=O), 21.0 (2xCH3C=O), 
21.5 (2xCHCH3), 22.8 (2xCH2CH2N), 24.6 (2xCH2(CH2)2), 26.0 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 29.3 
(2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 51.4 (4xCH3N), 56.8 (CH2N), 62.2 (2xCH2OAc), 62.5 (2xCH2OAc), 
66.2 (CH2N), 68.6 (2xCHOC), 68.8 (2xCHOC), 71.2 (2xCHOC), 71.5 (2xCHOC), 71.7 (2xCHOC), 72.9 
(2xCHOC), 74.8 (2xCHOC), 77.9 (2xCHOC), 77.9 (2xCHOC), 100.5 (2xCH(O)2), 101.2 (2xCH(O)2), 169.7 
(2xCH3C=O), 169.8 (2xCH3C=O), 169.9 (2xCH3C=O), 170.0 (4xCH3C=O), 170.6 (2xCH3C=O), 170.8 
(2xCH3C=O). 
N,N,N’,N’-tetramethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--
D-glucopyranosyl)-oxy])nonyl-hexamethylene diaminium diodide (239b): (0.40 g, quant.), yellow 
powder. 1H-NMR (400 MHz, CDCl3): H 1.22 (6H, d, 
J=6.2 Hz, 2xCHCH3), 1.25-1.47 (18H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3), 1.51-1.58 (2H, m, 2xCHaHbCHCH3), 
1.59-1.66 (4H, m, 2xCH2(CH2)2), 1.77-1.85 (4H, m, 
2xCH2CH2N), 1.98-2.09 (4H, m, 2xCH2CH2N), 1.99 (6H, 
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s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.03 (12H, s, 4xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 
2xCH3C=O), 2.09 (6H, s, 2xCH3C=O), 3.36-3.37 (12H, m, 4xCH3N), 3.45-3.49 (4H, m, 2xCH2N), 3.45-3.74 
(10H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC, 2xCH2N), 4.06-4.11 (4H, m, 4xCHCHaHbOAc), 4.22-4.27 
(4H, m, 4xCHCHaHbOAc), 4.47 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.70 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.86 (2H, 
dxd, J=9.5 Hz, J=8.1 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.00 (2H, dxd, J=9.7 Hz, 
J=9.7 Hz, 2xCHOC), 5.11 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC), 5.17 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 
2xCHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (2xCH3C=O), 20.7 
(2xCH3C=O), 20.7 (2xCH3C=O), 20.8 (4xCH3C=O), 21.5 (2xCHCH3), 21.9 (2xCH2CH2N), 22.7 
(2xCH2CH2N), 24.2 (2xCH2(CH2)2), 24.7 (2xCH2(CH2)2), 26.3 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 29.4 
(2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 51.2 (4xCH3N), 62.2 (2xCH2OAc), 62.3 (2xCH2OAc), 64.4 (2xCH2N), 
65.2 (2xCH2N), 68.5 (2xCHOC), 68.8 (2xCHOC), 71.2 (2xCHOC), 71.4 (2xCHOC), 71.7 (2xCHOC), 72.9 
(2xCHOC), 74.8 (2xCHOC), 77.8 (2xCHOC), 78.0 (2xCHOC), 100.5 (2xCH(O)2), 101.3 (2xCH(O)2), 169.6 
(4xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.0 (2xCH3C=O), 170.6 (2xCH3C=O), 170.6 
(2xCH3C=O). 
N,N’-dibutyl,N,N’-dimethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-ethylene diaminium diodide (239c): (0.38 g, 93%), 
light yellow powder. 1H-NMR (400 MHz, CDCl3): H 
0.98 (6H, t, J=7.3 Hz, 2xCH2CH3), 1.15 (6H, d, J=6.1 Hz, 
2xCHCH3), 1.19-1.56 (24H, m, 8xCH2(CH2)2, 
2xCH2CHCH3, 2xCH2CH3), 1.71-1.82 (8H, m, 
4xCH2CH2N), 1.93 (12H, s, 4CH3C=O), 1.97 (12H, s, 
4xCH3C=O), 1.99 (6H, s, 2xCH3C=O), 2.02 (6H, s, 2xCH3C=O), 2.02 (6H, s, 2xCH3C=O), 3.41-3.43 (6H, m, 
2xCH3N), 3.60-3.71 (16H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC, 4xCH2N), 3.99-4.04 (4H, m, 
4xCHCHaHbOAc), 4.14-4.21 (4H, m, 4xCHCHaHbOAc), 4.42-4.45 (2H, m, 2xCH(O)2), 4.52 (4H, s, 
2xCH2N), 4.66 (2H, d, J=7.8 Hz, 2xCH(O)2), 4.78-4.82 (2H, m, 2xCHOC), 4.86 (2H, dxd, J=9.7 Hz, J=9.7 
Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.05 (2H, dxd, J=9.6 Hz, J=9.6 Hz, 2xCHOC), 
5.10 (2H, dxd, J=9.6 Hz, J=9.6 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 13.8 (2xCH2CH3), 19.6 
(2xCH2CH3), 20.6 (4xCH3C=O), 20.7 (4xCH3C=O), 20.8 (4xCH3C=O), 20.9 (2xCH3C=O), 21.5 (2xCHCH3), 
22.7 (2xCH2CH2N), 24.7 (2xCH2(CH2)2, 2xCH2CH2N), 26.2 (2xCH2(CH2)2), 29.3 (4xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 49.0 (2xCH3N), 54.9 (2xCH2N), 62.2 (4xCH2OAc), 62.4 (4xCH2N), 68.6 (2xCHOC), 68.8 
(2xCHOC), 71.2 (2xCHOC), 71.5 (2xCHOC), 71.7 (2xCHOC), 72.9 (2xCHOC), 74.9 (2xCHOC), 77.9 
(4xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.7 (6xCH3C=O), 170.0 (4xCH3C=O), 170.6 
(2xCH3C=O). 
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N,N’-dibutyl,N,N’-dimethyl,N,N’-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-
glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-hexamethylene diaminium diodide (239d): (0.41 g, 
94%), yellow powder. 1H-NMR (400 MHz, CDCl3): H 
1.02 (6H, t, J=7.3 Hz, 2xCH2CH3), 1.22 (6H, d, J=6.2 Hz, 
2xCHCH3), 1.26-1.52 (22H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3, 2xCH2CH3), 1.54-1.59 (2H, m, 
2xCHaHbCHCH3), 1.62-1.67 (4H, m, 2xCH2(CH2)2), 1.68-
1.78 (8H, m, 4xCH2CH2N), 1.99-2.09 (4H, m, 2xCH2CH2N), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.03 (12H, s, 4xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.09 (6H, s, 
2xCH3C=O), 3.32 (6H, m, 2xCH3N), 3.35-3.53 (8H, 4xCH2N), 3.61-3.74 (14H, m, 4xCHCH2OAc, 
2xCH3CHO, 2xCHOC, 2xCH2N), 4.05-4.11 (4H, m, 4xCHCHaHbOAc), 4.22-4.27 (4H, m, 4xCHCHaHbOAc), 
4.46-4.48 (2H, m, 2xCH(O)2), 4.70 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.87 (2H, dxd, J=9.5 Hz, J=8.2 Hz, 
2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 4.98-5.03 (2H, m, 2xCHOC), 5.12 (2H, dxd, J=9.6 
Hz, J=9.6 Hz, 2xCHOC), 5.17 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 13.8 
(2xCH2CH3), 19.7 (2xCH2CH3), 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (2xCH3C=O), 20.7 (2xCH3C=O), 
20.7 (2xCH3C=O), 20.8 (4xCH3C=O), 21.5 (2xCHCH3), 21.7 (2xCH2CH2N), 22.4 (2xCH2CH2N), 24.3 
(2xCH2(CH2)2), 24.4 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.4 (2xCH2(CH2)2), 29.4 (2xCH2(CH2)2), 29.4 
(2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 49.0 (2xCH3N), 61.4 (2xCH2N), 61.7 (2xCH2N), 62.2 (2xCH2OAc), 
62.3 (2xCH2OAc), 62.7 (2xCH2N), 68.5 (2xCHOC), 68.8 (2xCHOC), 71.2 (2xCHOC), 71.4 (2xCHOC), 71.7 
(2xCHOC), 72.9 (2xCHOC), 74.8 (2xCHOC), 77.7 (2xCHOC), 78.0 (2xCHOC), 100.5 (2xCH(O)2), 101.3 
(2xCH(O)2), 169.6 (4xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.1 (2xCH3C=O), 170.6 
(2xCH3C=O), 170.6 (2xCH3C=O). 
General procedure for the synthesis of deprotected dicationic bolaamphiphilic sophorolipids (240): 
In a 50 mL flask, peracetylated dicationic bolaamphiphilic sophorolipid 239 (0.45 mmol, 1 eq) was 
dissolved in a methanol/water mixture (1:1) and 13 mL Et3N (0.90 mmol, 2 eq) was added. The 
mixture was stirred for 2 h at reflux temperature and concentrated under reduced pressure to yield 
pure dicationic bolaamphiphilic sophorolipid 240. 
N,N,N’,N’-tetramethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-
ethylene diaminium diodide (240a): (0.16 g, 96%), light yellow powder. 1H-NMR (400 MHz, MeOD): 
H 1.29 (6H, t, J=6.2 Hz, 2xCHCH3), 1.23-1.66 (20H, m, 
8xCH2(CH2)2, 2xCH2CHCH3), 1.88-1.96 (4H, m, 
CH2CH2N), 3.23-3.40 (10H, m, 10xCHOC), 3.35 (12H, s, 
4xCH3N), 3.45 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 
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3.51-3.64 (8H, m, 4xCHOC, 2xCH2N), 3.67-3.72 (4H, m, 4xCHCHaHbOH), 3.83-3.91 (6H, m, 
4xCHCHaHbOH, 2xCHOC), 4.13 (4H, s, 2xCH2N), 4.50 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.75 (2H, d, J=7.7 Hz, 
2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 20.8 (2xCHCH3), 22.5 (2xCH2CH2N), 24.6 (2xCH2(CH2)2), 25.9 
(2xCH2(CH2)2), 29.1 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.6 (2xCH2CHCH3), 50.7 (4xCH3N), 56.1 
(4xCH2N), 61.4 (2xCH2OH), 61.6 (2xCH2OH), 65.7 (2xCH2N), 70.2 (2xCHOC), 70.5 (2xCHOC), 74.7 
(2xCHOC), 76.4 (4xCHOC), 76.8 (2xCHOC), 77.1 (2xCHOC), 77.8 (2xCHOC), 79.5 (2xCHOC), 101.7 
(2xCH(O)2), 102.8 (2xCH(O)2). 
N,N,N’,N’-tetramethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl-
hexamethylene diaminium diodide (240b): (0.15 g, 96%), yellow powder. 1H-NMR (400 MHz, 
MeOD): H 1.29 (6H, t, J=6.2 Hz, 2xCHCH3), 1.33-1.58 
(22H, m, 10xCH2(CH2)2, 2xCHaHbCHCH3), 1.60-1.67 (2H, 
m, 2xCHaHbCHCH3), 1.79-1.92 (8H, m, 4xCH2CH2N), 
3.16 (12H, s, 4xCH3N), 3.21-3.35 (10H, m, 10xCHOC), 
3.37-3.45 (10H, m, 4xCH2N, 2xCHOC), 3.49-3.54 (2H, 
m, 2xCHOC), 3.60 (2H, dxd, J=8.5 Hz, J=8.5 Hz, 2xCHOC), 3.67-3.71 (4H, m, 4xCHCHaHbOH), 3.84-3.91 
(6H, m, 4xCHCHaHbOH, 2xCHOC), 4.49 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.72 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 20.7 (2xCHCH3), 22.1 (2xCH2CH2N), 22.3 (2xCH2CH2N), 24.6 
(2xCH2(CH2)2), 25.4 (2xCH2(CH2)2), 26.0 (2xCH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 50.0 (4xCH3N), 61.4 (2xCH2OH), 61.6 (2xCH2OH), 63.9 (2xCH2N), 64.3 (2xCH2N), 70.2 
(2xCHOC), 70.4 (2xCHOC), 74.7 (2xCHOC), 76.4 (4xCHOC), 76.8 (2xCHOC), 77.0 (2xCHOC), 77.6 
(2xCHOC), 80.0 (2xCHOC), 101.6 (2xCH(O)2), 103.0 (2xCH(O)2). 
N,N’-dibutyl,N,N’-dimethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])nonyl-ethylene diaminium diodide (240c): (0.13 g, 79%), light yellow powder. 1H-NMR (400 
MHz, MeOD): H 1.08 (6H, t, J=7.3 Hz, 2xCH2CH3), 1.28 
(6H, t, J=6.2 Hz, 2xCHCH3), 1.32-1.56 (22H, m, 
8xCH2(CH2)2, 2xCHaHbCHCH3, 2xCH2CH3), 1.58-1.67 (2H, 
m, 2xCHaHbCHCH3), 1.79-1.89 (8H, m, 4xCH2CH2N), 
3.22-3.37 (16H, m, 10xCHOC, 2xCH3N), 3.39-3.62 (14H, 
m, 6xCHOC, 4xCH2N), 3.66-3.70 (4H, m, 4xCHCHaHbOH), 3.82-3.89 (6H, m, 4xCHCHaHbOH, 2xCHOC), 
4.03 (4H, s, 2xCH2N), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.71-4.73 (2H, m, 2xCH(O)2). 
13C-NMR (100 
MHz, MeOD): C 12.8 (2xCH2CH3), 19.3 (2xCH2CH3), 20.8 (2xCHCH3), 22.4 (2xCH2CH2N), 24.2 
(2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.0 (2xCH2(CH2)2), 29.1 (2xCH2(CH2)2), 29.4 (2xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 48.4 (2xCH3N), 54.0 (2xCH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 62.3 (2xCH2N), 62.6 
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(2xCH2N), 70.2 (2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.3 (4xCHOC), 76.8 (2xCHOC), 76.9 
(2xCHOC), 77.7 (2xCHOC), 79.9 (2xCHOC), 101.5 (2xCH(O)2), 102.9 (2xCH(O)2). 
N,N’-dibutyl,N,N’-dimethyl,N,N’-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-
oxy])nonyl-hexamethylene diaminium diodide (240d): (0.18 g, 94%), yellow powder. 1H-NMR (400 
MHz, MeOD): H 1.07 (6H, t, J=7.3 Hz, 2xCH2CH3), 1.29 
(6H, t, J=6.2 Hz, 2xCHCH3), 1.32-1.58 (26H, m, 
10xCH2(CH2)2, 2xCHaHbCHCH3, 2xCH2CH3), 1.59-1.69 
(2H, m, 2xCHaHbCHCH3), 1.72-1.89 (12H, m, 
6xCH2CH2N), 3.11 (6H, s, 2xCH3N), 3.26 (2H, dxd, J=9.2 
Hz, J=7.9 Hz, 2xCHOC), 3.29-3.47 (22H, m, 4xCH2N, 2xCHOC, 6xCH2N), 3.51 (2H, dxd, J=9.1 Hz, J=7.7 
Hz, 2xCHOC), 3.60 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.67-3.71 (4H, m, 4xCHCHaHbOH), 3.84-3.91 
(6H, m, 4xCHCHaHbOH, 2xCHOC), 4.49 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.71 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.7 (2xCH2CH3), 19.4 (2xCH2CH3), 20.7 (2xCHCH3), 21.9 (2xCH2CH2N), 
22.0 (2xCH2CH2N), 23.9 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 25.5 (2xCH2(CH2)2), 26.1 (2xCH2(CH2)2), 29.0 
(2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 47.6 (2xCH3N), 61.4 (2xCH2OH, 4xCH2N), 61.6 
(2xCH2OH, 2xCH2N), 70.2 (2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.7 (2xCHOC), 
77.0 (2xCHOC), 77.6 (2xCHOC), 80.1 (2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2). 
General procedure for the synthesis of peracetylated N-alkyl bolaamphiphilic sophorolipids (215): 
In a 50 mL flask, 1.57 g peractylated sophoroplipid aldehyde 201 (2.02 mmol, 1 eq) was dissolved in 
25 mL methanol and the primary amine (1.01 mmol, 0.5 eq), 0.25 g NaBH3CN (4.04 mmol, 2 eq) and 
0.58 mL acetic acid (10.09 mmol, 5 eq) were added sequentially. The reaction mixture was stirred 
overnight at room temperature, concentrated under reduced pressure and dissolved in ethyl acetate. 
The mixture was washed 3 times with a saturated NaHCO3-solution and the organic phase was dried 
over MgSO4, filtered and concentrated under reduced pressure. The peracetylated N-methyl 
bolaamphiphilic sophorolipid 215a was purified by automated column chromatography with a 
hexane/ethyl acetate/trimethylamine mixture as eluent (mixture A = 16% triethylamine in ethyl 
acetate). The other three derivatives 215b-d were purified by preparative TLC with ethyl acetate as 
eluent. 
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N-methyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl amine (215a): Purification gradient: 2 CV 10% mixture A, 30 CV 10-60% 
mixture A, 5 CV 60% mixture A, 10 CV 100% mixture A. 
(0.52 g, 55%), white sticky solid. 1H-NMR (400 MHz, 
CDCl3): H 1.22 (6H, t, J=6.2 Hz, 2xCHCH3), 1.26-1.42 
(18H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.45-1.53 (4H, m, 
2xCH2CH2N), 1.56-1.63 (2H, m, 2xCHaHbCHCH3), 1.99 
(6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 
2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.23 (3H, s, CH3N), 2.33-2.37 (4H, m, 2xCH2N), 3.63-3.75 (8H, m, 
4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.11 (4H, m, 4xCHCHaHbOAc), 4.22-4.31 (4H, m, 
4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.91 (2H, dxd, 
J=9.4 Hz, J=9.4 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 
Hz, 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.4 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.5 H, J=9.5 Hz, 2xCHOC). 
13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 20.6 (4xCH3C=O), 20.6 (2xCH3C=O), 20.7 (4xCH3C=O), 
20.8 (2xCH3C=O), 21.2 (2xCHCH3), 25.0 (2xCH2(CH2)2), 27.1 (2xCH2CH2N), 27.7 (2xCH2(CH2)2), 29.7 
(2xCH2(CH2)2), 29.8 (2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 42.0 (CH3N), 57.8 (2xCH2N), 62.0 (2xCH2OAc), 
62.2 (2xCH2OAc), 68.2 (2xCHOC), 68.8 (2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.0 
(2xCHOC), 74.6 (2xCHOC), 77.7 (2xCHOC), 77.8 (2xCHOC), 100.4 (2xCH(O)2), 101.1 (2xCH(O)2), 169.3 
(2xCH3C=O), 169.4 (2xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.3 (2xCH3C=O), 170.6 
(2xCH3C=O), 170.6 (2xCH3C=O). 
N-butyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl amine (215b): (0.15 g, 15%), white sticky solid. 1H-NMR (400 MHz, 
CDCl3): H 0.91 (3H, t, J=7.3 Hz, CH2CH3), 1.22 (6H, d, 
J=6.2 Hz, 2xCHCH3), 1.24-1.48 (26H, m, 2xCH2(CH2)2, 
2xCHaHbCHCH3, CH2CH3, 3xCH2CH2N), 1.56-1.63 (2H, m, 
2xCHaHbCHCH3), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.03 (6H, s, 
2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.38-2.42 (6H, m, 3xCH2N), 3.64-3.75 
(8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.10(4H, m, 4xCHCHaHbOAc), 4.23-4.31 (4H, m, 
4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.74 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.88-4.93 (2H, m, 
2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC), 5.13 
(2H, dxd, J=9.4 Hz, J=9.4 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.4 H, J=9.4 Hz, 2xCHOC). 13C-NMR (100 MHz, 
CDCl3): C 14.1 (CH2CH3), 20.4 (2xCH3C=O), 20.5 (6xCH3C=O), 20.5 (2xCH3C=O), 20.6 (4xCH3C=O), 20.6 
(CH2CH3), 21.2 (2xCHCH3), 25.0 (2xCH2(CH2)2), 27.0 (2xCH2CH2N), 27.7 (2xCH2(CH2)2), 29.1 (CH2CH2N), 
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29.7 (2xCH2(CH2)2), 29.8 (2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 53.7 (CH2N), 54.2 (2xCH2N), 61.9 
(2xCH2OAc), 62.2 (2xCH2OAc), 68.2 (2xCHOC), 68.8 (2xCHOC), 71.2 (2xCHOC), 71.6 (2xCHOC), 71.8 
(2xCHOC), 73.0 (2xCHOC), 74.6 (2xCHOC), 77.6 (2xCHOC), 77.8 (2xCHOC), 100.3 (2xCH(O)2), 101.0 
(2xCH(O)2), 169.2 (2xCH3C=O), 169.3 (2xCH3C=O), 169.7 (2xCH3C=O), 169.9 (2xCH3C=O), 170.2 
(2xCH3C=O), 170.5 (2xCH3C=O), 170.5 (2xCH3C=O). 
N-benzyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl amine (215c): (0.38 g, 39%), white sticky solid. 1H-NMR (400 MHz, 
CDCl3): H 1.21 (6H, d, J=6.2 Hz, 2xCHCH3), 1.25-1.42 
(18H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.44-1.51 (4H, m, 
2xCH2CH2N), 1.54-1.63 (2H, m, 2xCHaHbCHCH3), 1.97 
(6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 
2xCH3C=O), 2.07 (6H, s, 2xCH3C=O), 2.07 (6H, s, 2xCH3C=O), 2.39-2.42 (4H, m, 2xCH2N), 3.55 (2H, s, 
CaromCH2N), 3.63-3.74 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.10 (4H, m, 4xCHCHaHbOAc), 
4.23-4.30 (4H, m, 4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, d, J=8.0 Hz, 2xCH(O)2), 
4.91 (2H, dxd, J=9.1 Hz, J=9.1 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.6 Hz, J=9.6 Hz, 2xCHOC), 5.06 (2H, dxd, 
J=9.5 Hz, J=9.5 Hz, 2xCHOC), 5.13 (2H, dxd, J=9.3 Hz, J=9.3 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.4 H, J=9.4 
Hz, 2xCHOC), 7.19-7.23 (1H, m, CHarom), 7.27-7.33 (4H, m, 4xCHarom). 
13C-NMR (100 MHz, CDCl3): C 
20.5 (2xCH3C=O), 20.6 (4xCH3C=O), 20.6 (2xCH3C=O), 20.7 (4xCH3C=O), 20.8 (2xCH3C=O), 21.2 
(2xCHCH3), 25.1 (2xCH2(CH2)2), 27.0 (2xCH2CH2N), 27.6 (2xCH2(CH2)2), 29.8 (4xCH2(CH2)2), 36.4 
(2xCH2CHCH3), 53.9 (2xCH2N), 58.4 (CaromCH2N), 62.0 (2xCH2OAc), 62.2 (2xCH2OAc), 68.2 (2xCHOC), 
68.9 (2xCHOC), 71.3 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.0 (2xCHOC), 74.6 (2xCHOC), 77.7 
(2xCHOC), 77.8 (2xCHOC), 100.4 (2xCH(O)2), 101.0 (2xCH(O)2), 126.5 (CHarom), 128.0 (2xCHarom), 128.8 
(2xCHarom), 140.4 (Carom), 169.3 (2xCH3C=O), 169.4 (2xCH3C=O), 169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 
170.3 (2xCH3C=O), 170.6 (2xCH3C=O), 170.6 (2xCH3C=O). 
N-octadecyl,N,N-bis((S)-8-L-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl amine (215d): (0.19 g, 18%), white sticky solid. 1H-NMR (400 MHz, 
CDCl3): H 0.88 (3H, t, J=6.8 Hz, CH2CH3), 1.22 (6H, d, 
J=6.2 Hz, 2xCHCH3), 1.24-1.48 (54H, m, 22xCH2(CH2)2, 
CH2CH3, 2xCHaHbCHCH3, 3xCH2CH2N), 1.55-1.64 (2H, m, 
2xCHaHbCHCH3), 1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.03 (6H, s, 
2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (12H, s, 4xCH3C=O), 2.37-2.43 (6H, m, 3xCH2N), 3.63-3.75 
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(8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.10 (4H, m, 4xCHCHaHbOAc), 4.23-4.31 (4H, m, 
4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.74 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.91 (2H, dxd, 
J=9.0 Hz, J=9.0 Hz, 2xCHOC), 4.93 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.06 (2H, dxd, J=9.5 Hz, J=9.5 
Hz, 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.4 Hz, 2xCHOC), 5.16 (2H, dxd, J=9.4 H, J=9.4 Hz, 2xCHOC). 
13C-NMR (100 MHz, CDCl3): C 14.1 (CH2CH3), 20.4 (2xCH3C=O), 20.5 (2xCH3C=O), 20.5 (2xCH3C=O), 
20.5 (2xCH3C=O), 20.7 (4xCH3C=O), 20.7 (2xCH3C=O), 21.2 (2xCHCH3), 22.6 (CH2CH3), 25.0 
(2xCH2(CH2)2), 27.0 (3xCH2CH2N), 27.7 (CH2(CH2)2), 27.8 (2xCH2(CH2)2), 29.3 (CH2(CH2)2), 29.6 
(CH2(CH2)2), 29.6 (10xCH2(CH2)2), 29.8 (2xCH2(CH2)2), 29.8 (2xCH2(CH2)2), 31.9 (CH2(CH2)2), 36.4 
(2xCH2CHCH3), 54.1 (CH2N), 54.2 (2xCH2N), 61.9 (2xCH2OAc), 62.2 (2xCH2OAc), 68.2 (2xCHOC), 68.8 
(2xCHOC), 71.2 (2xCHOC), 71.7 (2xCHOC), 71.8 (2xCHOC), 73.0 (2xCHOC), 74.6 (2xCHOC), 77.6 
(2xCHOC), 77.8 (2xCHOC), 100.4 (2xCH(O)2), 101.0 (2xCH(O)2), 169.2 (2xCH3C=O), 169.4 (2xCH3C=O), 
169.7 (2xCH3C=O), 170.0 (2xCH3C=O), 170.2 (2xCH3C=O), 170.5 (2xCH3C=O), 170.5 (2xCH3C=O). 
General procedure for the synthesis of deprotected N-alkyl bolaamphiphilic sophorolipids (241): In 
a 50 mL flask, N,N’-dialkyl bolaamphiphilic sophorolipid 215 (0.45 mmol, 1 eq) was dissolved in a 
methanol/water mixture (1:1) and 13 mL Et3N (0.90 mmol, 2 eq) was added. The mixture was stirred 
for 2 h at reflux temperature and concentrated under reduced pressure to yield pure N,N’-dialkyl 
bolaamphiphilic sophorolipid 241. 
N-methyl,N,N-bis((S)-8-L-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl amine (241a): 
(0.078 g, quant.), white powder. 1H-NMR (400 MHz, 
MeOD): H 1.16 (6H, d, J=6.1 Hz, 2xCHCH3), 1.18-1.45 
(18H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.47-1.54 (2H, m, 
2xCHaHbCHCH3), 1.56-1.63 (4H, m, 2xCH2CH2N), 2.61 (3H, 
s, CH3N), 2.84-2.88 (4H, m, 2xCH2N), 3.11-3.25 (10H, m, 
10xCHOC), 3.30 (2H, dxd, J=8.6 Hz, J=8.6 Hz, 2xCHOC), 3.36-3.40 (2H, m, 2xCHOC), 3.47 (2H, dxd, 
J=8.6 Hz, J=8.6 Hz, 2xCHOC), 3.54-3.59 (4H, m, 4xCHCHaHbOH), 3.70-3.78 (6H, m, 4xCHCHaHbOH, 
2xCHOC), 4.35 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.58 (2H, d, J=7.7 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, 
MeOD): C 20.7 (2xCHCH3), 24.3 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.5 (2xCH2(CH2)2), 29.0 
(2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 39.3 (CH3N), 56.2 (2xCH2N), 61.4 (2xCH2OH), 
61.7 (2xCH2OH), 70.1 (2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.4 (4CHOC), 76.8 (2xCHOC), 76.9 
(2xCHOC), 77.6 (2xCHOC), 80.1 (2xCHOC), 101.6 (2xCH(O)2), 103.1 (2xCH(O)2). 
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N-butyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl amine (241b): 
(0.060 g, 92%), white powder. 1H-NMR (400 MHz, 
MeOD): H 0.99 (3H, t, J=7.3 Hz, CH2CH3), 1.25 (6H, d, 
J=6.2 Hz, 2xCHCH3), 1.29-1.53 (20H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3, CH2CH3), 1.56-1.67 (8H, m, 
2xCHaHbCHCH3, 6xCH2CH2N), 2.88-2.92 (6H, m, 3xCH2N), 
3.21-3.35 (10H, m, 10xCHOC), 3.39 (2H, dxd, J=8.9 Hz, J=8.9 Hz, 2xCHOC), 3.47 (2H, dxd, J=9.1 Hz, 
J=7.8 Hz, 2xCHOC), 3.56 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.63-3.68 (4H, m, 4xCHCHaHbOH), 
3.80-3.87 (6H, m, 4xCHCHaHbOH, 2xCHOC), 4.45 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.67 (2H, d, J=7.8 Hz, 
2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 12.8 (CH2CH3), 19.9 (CH2CH3), 20.6 (2xCHCH3), 24.3 
(2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.2 (CH2CH2N), 26.7 (2xCH2(CH2)2), 29.1 (2xCH2(CH2)2), 29.4 
(2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 52.6 (CH2N), 53.0 (2xCH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 70.1 
(2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.9 (2xCHOC), 76.9 (2xCHOC), 77.6 
(2xCHOC), 80.2 (2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2). 
N-benzyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl amine (241c): 
(0.10 g, 80%), white powder. 1H-NMR (400 MHz, MeOD): 
H 1.27 (6H, d, J=6.1 Hz, 2xCHCH3), 1.29-1.50 (18H, m, 
8xCH2(CH2)2, 2xCHaHbCHCH3), 1.53-1.65 (6H, m, 
2xCHaHbCHCH3, 4xCH2CH2N), 2.57-2.61 (4H, m, 2xCH2N), 
3.24-3.37 (10H, m, 10xCHOC), 3.41 (2H, dxd, J=8.7 Hz, 
J=8.7 Hz, 2xCHOC), 3.49 (2H, dxd, J=8.4 Hz, J=8.4 Hz, 2xCHOC), 3.59 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 
2xCHOC), 3.65-3.71 (4H, m, 4xCHCHaHbOH), 3.77 (2H, s, CaromCH2N), 3.81-3.89 (6H, m, 4xCHCHaHbOH, 
2xCHOC), 4.47 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.67 (2H, d, J=7.7 Hz, 2xCH(O)2), 7.30-7.39 (5H, m, 
5xCHarom). 
13C-NMR (100 MHz, MeOD): C 20.6 (2xCHCH3), 24.8 (2xCH2(CH2)2), 25.5 (2xCH2CH2N), 27.1 
(2xCH2(CH2)2), 29.2 (2xCH2(CH2)2), 29.5 (2xCH2(CH2)2), 36.4 (2xCH2CHCH3), 53.2 (2xCH2N), 57.8 
(CaromCH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 70.1 (2xCHOC), 70.4 (2xCHOC), 74.5 (2xCHOC), 76.3 
(2xCHOC), 76.4 (2xCHOC), 76.9 (2xCHOC), 76.9 (2xCHOC), 77.5 (2xCHOC), 80.4 (2xCHOC), 101.4 
(2xCH(O)2), 103.2 (2xCH(O)2), 127.4 (CHarom), 128.1 (2xCHarom), 129.5 (2xCHarom), 136.7 (Carom). 
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N-octadecyl,N,N-bis((S)-8-L-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl amine 
(241d): (0.088 g, 99%), white powder. 1H-NMR (400 
MHz, MeOD): H 0.90 (3H, t, J=6.8 Hz, CH2CH3), 1.26 (6H, 
d, J=6.2 Hz, 2xCHCH3), 1.28-1.54 (48H, m, 22xCH2(CH2)2, 
2xCHaHbCHCH3, CH2CH3), 1.56-1.68 (8H, m, 
3xCHaHbCHCH3, 4xCH2CH2N), 2.90-2.96 (6H, m, 3xCH2N), 
3.21-3.34 (10H, m, 10xCHOC), 3.40 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.45-3.50 (2H, m, 2xCHOC), 
3.57 (2H, dxd, J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.64-3.69 (4H, m, 4xCHCHaHbOH), 3.80-3.87 (6H, m, 
4xCHCHaHbOH, 2xCHOC), 4.45 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.67 (2H, d, J=7.7 Hz, 2xCH(O)2). 
13C-NMR 
(100 MHz, MeOD): C 13.1 (CH2CH3), 20.7 (2xCHCH3), 22.4 (CH2CH3), 24.0 (CH2CH2N), 24.1 
(2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.6 (CH2(CH2)2), 26.7 (2xCH2(CH2)2), 29.0 (CH2(CH2)2), 29.1 
(2xCH2(CH2)2), 29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 (11xCH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 
(2xCH2CHCH3), 52.8 (CH2N), 52.9 (2xCH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 70.1 (2xCHOC), 70.4 
(2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.8 (2xCHOC), 76.9 (2xCHOC), 77.6 (2xCHOC), 80.2 
(2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2). 
General procedure for the synthesis of peracetylated monocationic bolaamphiphilic sophorolipids 
(242): In a 10 mL flame dried pressure resistant vial, peracetylated N,N’dialkyl bolaamphiphilic 
sophorolipid 215 was dissolved in dry acetonitrile. The solution was cooled down to 0 °C and the alkyl 
iodide (5 eq) was added. The vial was closed and heated to 80 °C for 18 hours. The reaction mixture 
was concentrated under reduced pressure to yield the peracetylated quaternary ammonium 
bolaamphiphilic sophorolipid 242. 
N,N-dimethyl,N,N-bis((S)-8-L-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl ammonium iodide (242a): (0.16 g, 94%), yellow powder. 1H-NMR (400 
MHz, CDCl3): H 1.22 (6H, d, J=6.2 Hz, 2xCHCH3), 1.26-
1.49 (18H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.50-1.64 
(2H, m, 2xCHaHbCHCH3), 1.75-1.85 (4H, m, 2xCH2CH2N), 
1.99 (6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.03 
(6H, s, 2xCH3C=O), 2.03 (6H, s, 2xCH3C=O), 2.06 (6H, s, 
2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.09 (6H, s, 2xCH3C=O), 3.34 (6H, s, 2xCH3N), 3.48-3.52 (4H, m, 
2xCH2N), 3.66-3.77 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.05-4.10 (4H, m, 4xCHCHaHbOAc), 
4.23-4.27 (4H, m, 4xCHCHaHbOAc), 4.49 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.72 (2H, d, J=8.0 Hz, 2xCH(O)2), 
4.86 (2H, dxd, J=9.5 Hz, J=8.2 Hz, 2xCHOC), 4.92 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.00 (2H, dxd, 
J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.12 (2H, dxd, J=9.9 Hz, J=9.9 Hz, 2xCHOC), 5.17 (2H, dxd, J=9.6 H, J=9.6 
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Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.8 (6xCH3C=O), 
20.9 (4xCH3C=O), 21.6 (2xCHCH3), 22.8 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.3 (2xCH2(CH2)2), 29.4 
(4xCH2(CH2)2), 36.6 (2xCH2CHCH3), 51.6 (2xCH3N), 62.3 (2xCH2OAc), 62.4 (2xCH2OAc), 64.8 (2xCH2N), 
68.6 (2xCHOC), 68.9 (2xCHOC), 71.3 (2xCHOC), 71.5 (2xCHOC), 71.7 (2xCHOC), 73.0 (2xCHOC), 74.8 
(2xCHOC), 77.8 (2xCHOC), 78.0 (2xCHOC), 100.5 (2xCH(O)2), 101.3 (2xCH(O)2), 169.7 (2xCH3C=O), 
169.7 (2xCH3C=O), 169.8 (2xCH3C=O), 170.0 (4xCH3C=O), 170.6 (4xCH3C=O). 
N-butyl,N-methyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl ammonium iodide (242b): (0.16 g, 95%), light yellow powder. 1H-NMR 
(400 MHz, CDCl3): H 1.02 (3H, t, J=7.3 Hz, CH2CH3), 1.22 
(6H, d, J=6.2 Hz, 2xCHCH3), 1.26-1.50 (20H, m, 
8xCH2(CH2)2, 2xCHaHbCHCH3, CH2CH3), 1.52-1.63 (2H, m, 
2xCHaHbCHCH3), 1.71-1.81 (6H, m, 3xCH2CH2N), 1.99 
(6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.03 (6H, s, 
2xCH3C=O), 2.04 (6H, s, 2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.09 (6H, s, 
2xCH3C=O), 3.27 (3H, s, CH3N), 3.40-3.51 (6H, m 3xCH2N), 3.66-3.77 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 
2xCHOC), 4.05-4.10 (4H, m, 4xCHCHaHbOAc), 4.23-4.27 (4H, m, 4xCHCHaHbOAc), 4.49 (2H, d, J=7.7 Hz, 
2xCH(O)2), 4.73 (2H, d, J=8.0 Hz, 2xCH(O)2), 4.86 (2H, dxd, J=9.4 Hz, J=8.2 Hz, 2xCHOC), 4.92 (2H, dxd, 
J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.00 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.13 (2H, dxd, J=9.4 Hz, J=9.4 
Hz, 2xCHOC), 5.17 (2H, dxd, J=9.4 H, J=9.4 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 13.8 (CH2CH3), 
19.7 (CH2CH3), 20.5 (2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (4xCH3C=O), 20.7 (2xCH3C=O), 20.8 
(4xCH3C=O), 21.5 (2xCHCH3), 22.5 (2xCH2CH2N), 24.4 (CH2CH2N), 24.7 (2xCH2(CH2)2), 26.5 
(2xCH2(CH2)2), 29.4 (4xCH2(CH2)2), 36.5 (2xCH2CHCH3), 49.4 (CH3N), 61.7 (CH2N), 61.9 (2xCH2N), 62.2 
(2xCH2OAc), 62.4 (2xCH2OAc), 68.5 (2xCHOC), 68.9 (2xCHOC), 71.3 (2xCHOC), 71.5 (2xCHOC), 71.7 
(2xCHOC), 73.0 (2xCHOC), 74.8 (2xCHOC), 77.8 (2xCHOC), 77.9 (2xCHOC), 100.5 (2xCH(O)2), 101.2 
(2xCH(O)2), 169.6 (4xCH3C=O), 169.8 (2xCH3C=O), 170.0 (2xCH3C=O), 170.1 (2xCH3C=O), 170.6 
(2xCH3C=O), 170.6 (2xCH3C=O). 
N-benzyl,N-methyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--D-
glucopyranosyl)-oxy])nonyl ammonium iodide (242c): (0.26 g, 96%), light yellow powder. 1H-NMR 
(400 MHz, CDCl3): H 1.22 (6H, d, J=6.2 Hz, 2xCHCH3), 
1.25-1.47 (18H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3), 1.51-
1.61 (2H, m, 2xCHaHbCHCH3), 1.81-1.93 (4H, m, 
2xCH2CH2N), 1.95 (6H, s, 2xCH3C=O), 2.00 (6H, s, 
2xCH3C=O), 2.01 (6H, s, 2xCH3C=O), 2.02 (6H, s, 
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2xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.09 (6H, s, 2xCH3C=O), 3.23 (3H, s, 
CH3N), 3.36-3.47 (4H, m, 2xCH2N), 3.65-3.76 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.06-4.11 
(4H, m, 4xCHCHaHbOAc), 4.22-4.27 (4H, m, 4xCHCHaHbOAc), 4.48 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.72 (2H, 
d, J=8.0 Hz, 2xCH(O)2), 4.85-4.90 (2H, m, 2xCHOC), 4.90 (2H, s, CaromCH2N), 4.93 (2H, dxd, J=9.9 Hz, 
J=9.9 Hz, 2xCHOC), 5.01 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 2xCHOC), 5.12 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 
2xCHOC), 5.17 (2H, dxd, J=9.5 H, J=9.5 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 20.5 (2xCH3C=O), 
20.6 (2xCH3C=O), 20.6 (2xCH3C=O), 20.6 (2xCH3C=O), 20.7 (2xCH3C=O), 20.8 (4xCH3C=O), 21.5 
(2xCHCH3), 22.6 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.4 (2xCH2(CH2)2), 29.4 (2xCH2(CH2)2), 29.5 
(2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 47.8 (CH3N), 60.7 (2xCH2N), 62.2 (2xCH2OAc), 62.3 (2xCH2OAc), 
65.1 (CaromCH2N), 68.5 (2xCHOC), 68.8 (2xCHOC), 71.3 (2xCHOC), 71.5 (2xCHOC), 71.7 (2xCHOC), 72.9 
(2xCHOC), 74.7 (2xCHOC), 77.7 (2xCHOC), 77.9 (2xCHOC), 100.4 (2xCH(O)2), 101.2 (2xCH(O)2), 127.0 
(Carom), 129.3 (2xCHarom), 130.8 (CHarom), 133.1 (2xCHarom), 169.6 (4xCH3C=O), 169.7 (2xCH3C=O), 170.0 
(2xCH3C=O), 170.0 (2xCH3C=O), 170.6 (2xCH3C=O), 170.6 (2xCH3C=O). 
N-methyl,N-octadecyl,N,N-bis((S)-8-[(2”,3’,3”,4’,4”,6’,6”-heptaacetoxy-2’-O--D-glucopyranosyl--
D-glucopyranosyl)-oxy])nonyl ammonium iodide (242d): (0.18 g, 97%), light yellow powder. 1H-NMR 
(400 MHz, CDCl3): H 0.88 (3H, t, J=6.8 Hz, CH2CH3), 1.22 
(6H, d, J=6.2 Hz, 2xCHCH3), 1.24-1.47 (48H, m, 
22xCH2(CH2)2, 2xCHaHbCHCH3, CH2CH3), 1.52-1.62 (2H, 
m, 2xCHaHbCHCH3), 1.71-1.81 (6H, m, 3xCH2CH2N), 1.99 
(6H, s, 2xCH3C=O), 2.00 (6H, s, 2xCH3C=O), 2.03 (12H, s, 
4xCH3C=O), 2.06 (6H, s, 2xCH3C=O), 2.08 (6H, s, 2xCH3C=O), 2.09 (6H, s, 2xCH3C=O), 3.31 (3H, s, 
CH3N), 3.41-3.52 (6H, m, 3xCH2N), 3.66-3.75 (8H, m, 4xCHCH2OAc, 2xCH3CHO, 2xCHOC), 4.05-4.11 
(4H, m, 4xCHCHaHbOAc), 4.23-4.28 (4H, m, 4xCHCHaHbOAc), 4.49 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.72 (2H, 
d, J=8.0 Hz, 2xCH(O)2), 4.87 (2H, dxd, J=9.5 Hz, J=8.1 Hz, 2xCHOC), 4.92 (2H, dxd, J=9.7 Hz, J=9.7 Hz, 
2xCHOC), 5.01 (2H, dxd, J=9.6 Hz, J=9.6 Hz, 2xCHOC), 5.12 (2H, dxd, J=9.5 Hz, J=9.5 Hz, 2xCHOC), 5.18 
(2H, dxd, J=9.5 H, J=9.5 Hz, 2xCHOC). 13C-NMR (100 MHz, CDCl3): C 14.0 (CH2CH3), 20.4 (2xCH3C=O), 
20.5 (2xCH3C=O), 20.6 (4xCH3C=O), 20.6 (2xCH3C=O), 20.7 (2xCH3C=O), 20.7 (2xCH3C=O), 21.4 
(2xCHCH3), 22.4 (2xCH2CH2N), 22.5 (CH2CH2N), 22.6 (CH2CH3), 24.6 (2xCH2(CH2)2), 26.3 (CH2(CH2)2), 
26.3 (2xCH2(CH2)2), 29.2-29.6 (16xCH2(CH2)2), 31.8 (CH2(CH2)2), 36.4 (2xCH2CHCH3), 49.0 (CH3N), 61.7 
(3xCH2N), 62.1 (2xCH2OAc), 62.2 (2xCH2OAc), 68.4 (2xCHOC), 68.8 (2xCHOC), 71.2 (2xCHOC), 71.4 
(2xCHOC), 71.6 (2xCHOC), 72.9 (2xCHOC), 74.6 (2xCHOC), 77.7 (2xCHOC), 77.8 (2xCHOC), 100.4 
(2xCH(O)2), 101.1 (2xCH(O)2), 169.5 (4xCH3C=O), 169.6 (2xCH3C=O), 169.9 (4xCH3C=O), 170.4 
(2xCH3C=O), 170.5 (2xCH3C=O). 
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General procedure for the synthesis of deprotected monocationic bolaamphiphilic sophorolipids 
(243): In a 50 mL flask, peracetylated monocationic bolaamphiphilic sophorolipid 242 (0.45 mmol, 
1 eq) was dissolved in a methanol/water mixture (1:1) and 13 mL Et3N (0.90 mmol, 2 eq) was added. 
The mixture was stirred for 2 h at reflux temperature and concentrated under reduced pressure to 
yield pure deprotected monocationic bolaamphiphilic sophorolipid 243. 
N,N-dimethyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl ammonium 
iodide (243a): (0.069 g, 80%), yellow powder. 1H-NMR (400 MHz, MeOD): H 1.31 (6H, d, J=6.1 Hz, 
2xCHCH3), 1.34-1.59 (18H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3), 1.60-1.70 (2H, m, 2xCHaHbCHCH3), 1.80-
1.88 (4H, m, 2xCH2CH2N), 3.15 (6H, s, 2xCH3N), 3.26-3.42 
(14H, m, 10xCHOC, 2xCH2N), 3.45 (2H, dxd, J=8.3 Hz, 
J=8.3 Hz, 2xCHOC), 3.51-3.56 (2H, m, 2xCHOC), 3.63 (2H, 
dxd, J=8.5 Hz, J=8.5 Hz, 2xCHOC), 3.69-3.73 (4H, m, 4xCHCHaHbOH), 3.86-3.93 (6H, m, 4xCHCHaHbOH, 
2xCHOC), 4.51 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.74 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, 
MeOD): C 20.7 (2xCHCH3), 22.3 (2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.0 (2xCH2(CH2)2), 29.0 
(2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 50.0 (2xCH3N),61.4 (2xCH2OH), 61.6 (2xCH2OH), 
64.2 (2xCH2N), 70.2 (2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.8 (2xCHOC), 77.0 
(2xCHOC), 77.7 (2xCHOC), 80.0 (2xCHOC), 101.6 (2xCH(O)2), 103.0 (2xCH(O)2). 
N-butyl,N-methyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl 
ammonium iodide (243b): (0.082 g, 96%), yellow powder. 1H-NMR (400 MHz, MeOD): H 1.06 (3H, t, 
J=7.4 Hz, CH2CH3), 1.28 (6H, d, J=6.2 Hz, 2xCHCH3), 1.32-
1.56 (20H, m, 8xCH2(CH2)2, 2xCHaHbCHCH3, CH2CH3), 1.58-
1.67 (2H, m, 2xCHaHbCHCH3), 1.70-1.80 (6H, m, 
3xCH2CH2N), 3.06 (3H, s, CH3N), 3.24 (2H, dxd, J=9.3 Hz, 
J=7.8 Hz, 2xCHOC), 3.25-3.35 (14H, m, 8xCHOC, 3xCH2N), 
3.41 (2H, dxd, J=8.8 Hz, J=8.8 Hz, 2xCHOC), 3.50 (2H, dxd, J=9.1 Hz, J=7.8 Hz, 2xCHOC), 3.58 (2H, dxd, 
J=8.7 Hz, J=8.7 Hz, 2xCHOC), 3.66-3.70 (4H, m, 4xCHCHaHbOH), 3.82-3.90 (6H, m, 4xCHCHaHbOH, 
2xCHOC), 4.47 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.70 (2H, d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, 
MeOD): C 12.7 (CH2CH3), 19.4 (CH2CH3), 20.7 (2xCHCH3), 22.0 (2xCH2CH2N), 23.9 (CH2CH2N), 24.7 
(2xCH2(CH2)2), 26.1 (2xCH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 (2xCH2CHCH3), 47.6 
(CH3N), 61.2 (CH2N), 61.4 (2xCH2OH), 61.5 (2xCH2N), 61.6 (2xCH2OH), 70.2 (2xCHOC), 70.4 (2xCHOC), 
74.6 (2xCHOC), 76.3 (4xCHOC), 76.8 (2xCHOC), 76.9 (2xCHOC), 77.6 (2xCHOC), 80.1 (2xCHOC), 101.5 
(2xCH(O)2), 103.1 (2xCH(O)2). 
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N-benzyl,N-methyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl 
ammonium iodide (243c): (0.14 g, 96%), yellow powder. 1H-NMR (400 MHz, MeOD): H 1.33 (6H, d, 
J=6.1 Hz, 2xCHCH3), 1.37-1.61 (18H, m, 8xCH2(CH2)2, 
2xCHaHbCHCH3), 1.64-1.73 (2H, m, 2xCHaHbCHCH3), 1.87-
2.02 (4H, m, 2xCH2CH2N), 3.08 (CH3N), 3.29-3.44 (14H, m, 
10xCHOC, 2xCH2N), 3.49 (2H, dxd, J=8.6 Hz, J=8.6 Hz, 
2xCHOC), 3.56 (2H, dxd, J=8.4 Hz, J=8.4 Hz, 2xCHOC), 
3.66 (2H, dxd, J=8.3 Hz, J=8.3 Hz, 2xCHOC), 3.71-3.77 (4H, m, 4xCHCHaHbOH), 3.87-3.95 (6H, m, 
4xCHCHaHbOH, 2xCHOC), 4.54 (2H, d, J=7.7 Hz, 2xCH(O)2), 4.67 (2H, s, CaromCH2N), 4.75 (2H, d, J=7.7 
Hz, 2xCH(O)2), 7.59-7.69 (5H, m, 5xCHarom). 
13C-NMR (100 MHz, MeOD): C 20.7 (2xCHCH3), 22.2 
(2xCH2CH2N), 24.7 (2xCH2(CH2)2), 26.1 (2xCH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.3 (2xCH2(CH2)2), 36.5 
(2xCH2CHCH3), 47.2 (CH3N), 61.0 (2xCH2N), 61.4 (2xCH2OH), 61.7 (2xCH2OH), 65.3 (CH2N), 70.2 
(2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.3 (4xCHOC), 76.8 (2xCHOC), 76.9 (2xCHOC), 77.6 
(2xCHOC), 80.1 (2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2), 127.6 (Carom), 129.0 (2xCHarom), 130.5 
(CHarom), 132.8 (2xCHarom). 
N-methyl,N-octadecyl,N,N-bis((S)-8-[(2’-O--D-glucopyranosyl--D-glucopyranosyl)-oxy])nonyl 
ammonium iodide (243d): (0.099 g, 95%), yellow powder. 1H-NMR (400 MHz, MeOD): H 0.95 (3H, t, 
J=6.7 Hz, CH2CH3), 1.31 (6H, d, J=6.2 Hz, 2xCHCH3), 1.33-
1.59 (48H, m, 22xCH2(CH2)2, 2xCHaHbCHCH3, CH2CH3), 
1.61-1.70 (2H, m, 2xCHaHbCHCH3), 1.75-1.84 (6H, m, 
3xCH2CH2N), 3.10 (CH3N), 3.26-3.40 (22H, m, 10xCHOC, 
6xCH2N), 3.45 (2H, dxd, J=8.4 Hz, J=8.4 Hz, 2xCHOC), 3.53 
(2H, dxd, J=8.3 Hz, J=8.3 Hz, 2xCHOC), 3.63 (2H, dxd, J=8.5 Hz, J=8.5 Hz, 2xCHOC), 3.70-3.73 (4H, m, 
4xCHCHaHbOH), 3.85-3.93 (6H, m, 4xCHCHaHbOH, 2xCHOC), 4.51 (2H, d, J=7.6 Hz, 2xCH(O)2), 4.73 (2H, 
d, J=7.8 Hz, 2xCH(O)2). 
13C-NMR (100 MHz, MeOD): C 13.1 (CH2CH3), 20.7 (2xCHCH3), 21.9 (CH2CH2N), 
22.0 (2xCH2CH2N), 22.4 (CH2CH3), 24.7 (2xCH2(CH2)2), 26.0 (CH2(CH2)2), 26.1 (2xCH2(CH2)2), 28.9 
(CH2(CH2)2), 29.0 (2xCH2(CH2)2), 29.1 (2xCH2(CH2)2), 29.2 (CH2(CH2)2), 29.3 (CH2(CH2)2), 29.4 
(9xCH2(CH2)2), 31.7 (CH2(CH2)2), 36.5 (2xCH2CHCH3), 47.6 (CH3N), 61.4 (2xCH2OH), 61.5 (3xCH2N), 61.7 
(2xCH2OH), 70.2 (2xCHOC), 70.4 (2xCHOC), 74.6 (2xCHOC), 76.4 (4xCHOC), 76.8 (2xCHOC), 76.9 
(2xCHOC), 77.6 (2xCHOC), 80.0 (2xCHOC), 101.5 (2xCH(O)2), 103.1 (2xCH(O)2). 
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5. Summary 
Sophorolipids, a class of glycolipid biosurfactants, are promising renewable-based building blocks for 
chemical derivatization. They are produced by micro-organisms through fermentation, with the yeast 
Starmerella bombicola being the preferred producing organism. Sophorolipids meet all the criteria to 
be successful renewable building blocks for chemical derivatization since they comprise a complex 
structure and can be produced in high quantities and quality. An output of around 400 g/L can be 
obtained at an estimated production price of 2 to 5 €/kg. Via fermentation, multiple sophorolipid 
derivatives can be produced and selective production of one single sophorolipid derivative can be 
obtained with genetically modified S. bombicola strains. Natural sophorolipids already possess 
interesting biological and physico-chemical properties. They feature anti-cancer, antimicrobial, 
dermatological, immunoregulatory, spermicidal and antiviral activities. They also possess 
self-assembly properties, with a high variety in the type of nanostructures formed for different 
sophorolipid derivatives. 
In this work the major sophorolipid fermentation product, i.e. the diacetylated sophorolipid lactone, 
was used for the synthesis of a wide range of innovative sophorolipid derivatives. The first goal was 
to synthesize short-chained intermediate sophorolipid derivatives, in particular a sophorolipid 
aldehyde, via an ozonolysis reaction. A synthetic pathway towards the desired sophorolipid aldehyde 
intermediate iv was successfully developed (Scheme I). Sophorolipid lactone i was transformed into 
sophorolipid methyl ester ii and, subsequently, into the peracetylated analogue iii according to 
literature procedures. Cleavage of the double bond through ozonolysis resulted in sophorolipid 
aldehyde iv via reductive work-up. Ozonolysis of the diacetylated sophorolipid lactone i and the 
sophorolipid methyl ester ii was also evaluated, but proved to be not successful for the synthesis of 
the desired sophorolipid aldehyde intermediate.  
 
Scheme I. Optimized synthetic pathway towards sophorolipid aldehyde iv 
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The fermentation conditions and the concomitant purity of the starting product proved to have a big 
influence on the chemical derivatization. Diacetylated sophorolipid lactones i obtained from 
fermentations with the Starmerella bombicola oe sble strain, which produces selectively sophorolipid 
lactones, using oleic acid and yeast extract as substrates were most suitable as starting product. The 
synthetic pathway was extended to the production of the sophorolipid alcohol intermediate v by 
adjusting the reductive work-up of the ozonolysis reaction (Scheme II). 
 
Scheme II. Synthesis of intermediate sophorolipid alcohol v 
Moreover, the synthesis of the C12 sophorolipid aldehyde vii was accomplished via the incorporation 
of petroselinic acid in the sophorolipid structure (Scheme III). The CMC value and the corresponding 
surface tension of the petroselinic acid based diacetylated sophorolipid lactone vi and sophorolipid 
acid viii were determined and compared to their oleic acid based counterparts. Much lower CMC 
values were obtained for the petroselinic acid based sophorolipids compared to their oleic acid based 
counterparts, indicating a less compact geometry for the petroselinic acid based sophorolipids. 
 
Scheme III. Synthesis of C12 sophorolipid aldehyde vii and sophorolipid acid viii 
The intermediate sophorolipid aldehyde iv was used for the synthesis of a broad set of innovative 
sophorolipid derivatives. The first step in this modification pathway comprised the synthesis of 
sophorolipid amines ix via reductive amination with secondary amines (Scheme IV). This reductive 
amination was extended to sophorolipid aldehyde vii for the synthesis of N-methyl,N-octadecyl 
sophorolipid amine x (Scheme V). 
 
Scheme IV. Reductive amination of sophorolipid aldehyde iv towards sophorolipid amines ix 
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Scheme V. Reductive amination of sophorolipid aldehyde vii towards sophorolipid amine x 
The reductive amination was extended to primary amines for the synthesis of secondary sophorolipid 
amines (Scheme VI). The mixture of sophorolipid aldehyde iv and the primary amine had to be stirred 
1 hour at room temperature prior to the addition of sodium cyanoborohydride and acetic acid to 
avoid the dual reductive amination towards bolaamphiphilic sophorolipids. 
 
Scheme VI. Selective synthesis of sophorolipid methyl amine xi 
The purity of the sophorolipid amines after reductive amination proved to be highly dependent on 
the quality of the sophorolipid aldehyde. No extra purification step was needed after reductive 
amination with highly pure sophorolipid aldehyde iv which was derived from ozonolysis reactions 
with dichloromethane as solvent. However, in the optimized reaction procedure of the ozonolysis 
reaction, methanol is used as solvent instead of dichloromethane to increase the green character of 
the synthetic pathway. In this case, further purification proved to be necessary due to the slightly 
lower purity of this ozonolysis product. Therefore, the ozonolysis reaction can be addressed as the 
major bottleneck of the overall synthetic pathway. A balance should be found between the green 
character of the ozonolysis solvent and its influence on the purity and concomitant purification steps 
of the sophorolipid amine derivatives after reductive amination. 
The sophorolipid tertiary amines ix were used for the synthesis of a varied set of peracetylated and 
deprotected quaternary ammonium sophorolipids (Scheme VII). Sophorolipid amines ix were 
quaternized with alkyl iodides in pressure vials towards the peracetylated quaternary ammonium 
sophorolipids xii. Subsequent deprotection of the sugar head groups with sodium methoxide yielded 
the deprotected quaternary ammonium sophorolipids xiii. This quaternization and deprotection 
procedure was extended to N-methyl,N-octadecyl sophorolipid amine x for the synthesis of 
peracetylated and deprotected quaternary ammonium sophorolipids xiv and xv (Scheme VIII). 
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Scheme VII. Synthesis of peracetylated and deprotected sophorolipid amines xii and xiii 
 
Scheme VIII. Synthesis of peracetylated and deprotected sophorolipid amines xiv and xv 
The sophorolipid tertiary amines ix were also used for the synthesis of a varied set of peracetylated 
and deprotected sophorolipid amine oxides (Scheme IX). Sophorolipid amines ix were oxidized with 
mCPBA towards the peracetylated sophorolipid amine oxides xvi. Subsequent deprotection of the 
sugar head groups with triethylamine in a water/methanol mixture yielded the deprotected 
sophorolipid amine oxides xvii. 
 
Scheme IX. Synthesis of peracetylated and deprotected sophorolipid amine oxides xvi and xvii 
Two different sets of bolaamphiphilic sophorolipid amines were synthesized from sophorolipid 
aldehyde iv (Scheme X). Peracetylated N,N’-dialkyl bolaamphiphilic sophorolipids xviii were 
synthesized via reductive amination with different N,N’-dialkyl diamines. Several attempts to 
synthesize N,N’-dioctadecyl bolaamphiphilic sophorolipids were unsuccessful. Peracetylated N-alkyl 
bolaamphiphilic sophorolipids xix were synthesized via reductive amination with different primary 
amines. 
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Scheme X. Synthesis of peracetylated N,N'-dialkyl and N-alkyl bolaamphiphilic sophorolipids xviii and xix 
The peracetylated bolaamphiphilic sophorolipid amines xviii and xix were transformed into a broad 
set of bolaamphiphilic sophorolipid derivatives (Scheme XI, Scheme XII). Deprotection with 
triethylamine in a water/methanol mixture yielded deprotected bolaamphiphilic sophorolipid amines 
xx and xxiii. Quaternization with methyl iodide in a pressure vial resulted in the synthesis of cationic 
bolaamphiphilic sophorolipids xxi and xxiv. Finally, these cationic bolaamphiphilic sophorolipids were 
deprotected with triethylamine in a water/methanol mixture into deprotected cationic 
bolaamphiphilic sophorolipids xxii and xxv. 
 
Scheme XI. Modification of N,N’-dialkyl bolaamphiphilic sophorolipids xviii via quaternization and deprotection 
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Scheme XII. Modification of N-alkyl bolaamphiphilic sophorolipids xix via quaternization and deprotection 
All derivatives have been evaluated for their antimicrobial activity against a set of Gram-positive and 
Gram-negative strains (Table I). None of the derivatives displayed significant activity against any of 
the Gram-negative strains. The quaternary ammonium sophorolipids, monocationic bolaamphiphilic 
sophorolipids and dicationic bolaamphiphilic sophorolipids proved to be the most active derivatives. 
The best results were obtained for the deprotected quaternary ammonium sophorolipids xiii(h) and 
xiii(i). These derivatives were even more active than the antibiotic gentamicin sulfate against the 
four Gram-positive strains S. aureus, E. faecium, B. subtilis and S. pneumoniae in in vitro evaluations. 
Moreover, evaluation of the deglycosylated derivatives of these two quaternary ammonium 
sophorolipids demonstrated that the presence of the carbohydrate head has a positive effect on the 
antimicrobial activity. 
Evaluation of the quaternary ammonium sophorolipids on their suitability as gene delivery vectors 
indicated that the same two quaternary ammonium sophorolipids xiii(h) and xiii(i) were the most 
effective derivatives. Moreover, evaluation of their deglycosylated derivatives demonstrated that the 
presence of the carbohydrate head highly increased the cell viability of the evaluated cell lines and 
concomitant biocompatibility of these quaternary ammonium sophorolipids. Small-angle X-ray 
scattering (SAXS) analysis demonstrated that only the two quaternary ammonium sophorolipids 
xiii(h) and xiii(i) formed spherical micelles. These specific self-assembly properties and increased 
transfection efficiency may be attributed to the presence of the long aliphatic chain in the quaternary 
ammonium sophorolipids. 
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Table I. Overview of the minimum inhibitory concentrations (µM) of the different sophorolipid derivatives 
 S. aureus S. aureus 
Mu50 
E. faecium B. subtilis S. pneumoniae 
i 45.4 90.79    
vi 45.4 363.2    
viii >1607 >1607    
xii(b) >101  >101 >101 >101 
xii(c) >97  >97 24 97 
xii(d) >93  >93 >93 >93 
xii(e) 489  >977 977 977 
xii(f) >94  >94 >94 >94 
xii(g) 45  >91 45 91 
xii(h) 6.59-8 26.36 8 8 8 
xii(i) 6.36-8 50.91 8 8 8 
xiii(b) >144  >144 >144 >144 
xiii(h) 2.18-6 4.37 6 6 6 
xiii(i) 2.09-5 4.18 5 5 5 
xiv(a) 12.73 815    
xiv(b) 12.31 394    
xv(a) 66.9 66.9    
xv(b) 23.03 64.1    
xviii(b) 375 1501    
xxi(a) 165 660    
xxi(b) 80 321    
xxi(c) 20 158    
xxi(d) 38 38    
xxii(b) 392 >1569    
xxiv(a) 92 184    
xxiv(b) 45 45    
xxiv(c) 44 44    
xxv(c) 132 >2114    
xxv(d) 116 232    
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6. Samenvatting 
Sophorolipiden, een klasse van glycolipide biosurfactants, zijn uitermate interessante hernieuwbare 
bouwstenen voor chemische derivatisering. Ze worden fermentatief geproduceerd door micro-
organismen waarbij de gist Starmerella bombicola bij voorkeur gebruikt wordt als productie 
organisme. Sophorolipiden voldoen aan alle criteria om beschouwd te worden als hernieuwbare 
bouwstenen voor chemische derivatisering aangezien ze beschikken over een complexe structuur in 
combinatie met hoge productiehoeveelheden en zuiverheid. Een opbrengst rond 400 g/L kan worden 
verkregen aan een geschatte productieprijs van 2 tot 5 €/kg. Verschillende sophorolipide derivaten 
kunnen geproduceerd worden via fermentatie en met genetisch gemodificeerde S. bombicola 
stammen kan de selectieve productie van één sophorolipide derivaat verkregen worden. Natuurlijke 
sophorolipiden bezitten zelf reeds interessante biologische en fysico-chemische eigenschappen. Ze 
beschikken over anti-kanker, antimicrobiële, dermatologische, immunoregulatorische, spermicidale 
en antivirale eigenschappen. Ze bezitten ook self-assembly eigenschappen met een grote variatie in 
de aard van de nanostructuren die gevormd worden door de verschillende sophorolipiden. 
In dit werk werd het belangrijkste fermentatieproduct, namelijk het digeacetyleerde sophorolipide 
lacton, gebruikt voor de synthese van een uitgebreide reeks aan innovatieve sophorolipide derivaten. 
Het eerste doel omsloot de synthese van korte keten intermediaire sophorolipide derivaten, meer 
bepaald een sophorolipide aldehyde, via een ozonolyse reactie. Met succes werd een synthetische 
pathway voor het gewenste sophorolipide aldehyde intermediair iv ontwikkeld (Schema I). Het 
sophorolipide lacton i werd omgezet naar het sophorolipide methyl ester ii en vervolgens naar het 
pergeacetyleerde analoog iii volgens bestaande procedures. Het sophorolipide aldehyde iv werd 
verkregen door splitsing van de dubbele binding via ozonolyse gevolgd door reductieve opwerking. 
Ozonolyse van het digeacetyleerd sophorolipide lacton i en het sophorolipide methyl ester ii werd 
ook geëvalueerd, maar leidde niet tot de synthese van het gewenste aldehyde intermediair. 
 
Schema I. Geoptimaliseerde synthetische pathway naar sophorolipide aldehyde iv 
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De fermentatie condities en de daaruit volgende zuiverheid van het startproduct hebben een grote 
invloed op de chemische derivatisering. Digeacetyleerd sophorolipide lacton i verkregen uit 
fermentaties met de S. bombicola oe sble stam, die selectief sophorolipide lactonen produceert, zijn 
het meest geschikt als startproduct wanneer oleïnezuur en gistextract gebruikt worden als substraat. 
De synthetische pathway werd uitgebreid naar de productie van het sophorolipide alcohol 
intermediair v door de reductieve opwerking van de ozonolyse reactie aan te passen (Schema II). 
 
Schema II. Synthese van het intermediaire sophorolipide alcohol v 
Daarnaast werd ook de synthese van een C12 sophorolipide aldehyde vii verkregen door het 
inbouwen van petroselinezuur in de sophorolipide structuur (Schema III). De CMC waarde en 
bijhorende oppervlaktespanning van de petroselinezuur gebaseerde digeacetyleerde sophorolipide 
lacton vi en het zure sophorolipide viii werden bepaald en vergeleken met de overeenkomstige 
oleïnezuur derivaten. De petroselinezuur gebaseerde sophorolipiden hebben een veel lagere CMC 
waarde dan hun oleïnezuur gebaseerde tegenhangers, wat wijst op een minder compacte geometrie 
voor de petroselinezuur gebaseerde sophorolipiden. 
 
Schema III. Synthese van een C12 sophorolipide aldehyde vii en zuur sophorolipide viii 
Het intermediaire sophorolipide aldehyde iv werd gebruikt voor de synthese van een brede waaier 
aan innovatieve sophorolipide derivaten. Als eerste stap in de modificatie pathway werden 
sophorolipide amines ix gevormd via reductieve aminering met secundaire amines (Schema IV). Deze 
reductieve aminering werd ook toegepast op sophorolipide vii voor de synthese van 
N-methyl,N-octadecyl sophorolipide amine x (Schema V). 
 
Schema IV. Reductieve aminering van sophorolipide aldehyde iv naar sophorolipide amines ix 
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Schema V. Reductieve aminering van sophorolipide aldehyde vii naar sophorolipide amine x 
Reductieve aminering werd ook toegepast voor de synthese van secundaire sophorolipide amines 
aan de hand van primaire amines (Schema VI). Het roeren van sophorolipide aldehyde iv en het 
primaire amine gedurende 1 uur bij kamertemperatuur voor het toevoegen van natrium 
cyanoboorhydride en azijnzuur bleek noodzakelijk om een extra reductieve aminering tot 
bolaamfifiele sophorolipiden te voorkomen. 
 
Schema VI. Selectieve synthese van sophorolipide methyl amine xi 
De zuiverheid van de sophorolipide amines na de reductieve aminering was sterk afhankelijk van de 
kwaliteit van het sophorolipide aldehyde. Na de reductieve aminering met zeer zuiver sophorolipide 
aldehyde iv, verkregen uit ozonolyse reactie met dichloormethaan als solvent, was er geen extra 
opzuiveringsstap nodig. In de geoptimaliseerde reactieprocedure van de ozonolyse reactie wordt er 
echter methanol gebruikt in de plaats van dichloormethaan om het groene karakter van de 
synthetische pathway te verhogen. In dit geval was verdere opzuivering noodzakelijk door de 
verminderde zuiverheid van het ozonolyse product. Hierdoor kan de ozonolyse reactie aangeduid 
worden als knelpunt van de synthetische pathway. Er moet een balans worden gevonden tussen het 
groene karakter van het solvent voor de ozonolyse en zijn invloed op de zuiverheid en de 
daaruitvolgende opzuiveringsstappen van de sophorolipide amines na de reductieve aminering. 
De tertiaire sophorolipide amines ix werden gebruikt voor de synthese van een gevarieerde set aan 
pergeacetyleerde en ontschermde sophorolipide quaternaire ammoniumzouten (Schema VII). De 
sophorolipide amines ix werden gequaterniseerd met alkyl iodides in drukvaten tot de 
pergeacetyleerde sophorolipide quaternaire ammoniumzouten xii. De daaropvolgende ontscherming 
van de suikerkop werd uitgevoerd met natrium methoxide tot de ontschermde sophorolipide 
quaternaire ammoniumzouten xiii. Deze quaternisering en ontscherming werden uitgebreid naar het 
N-methyl,N-octadecyl sophorolipide amine x voor de synthese van de pergeacetyleerde en 
ontschermde sophorolipide quaternaire ammoniumzouten xiv en xv (Schema VIII). 
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Schema VII. Synthese van pergeacetyleerde en ontschermde sophrolipide amines xii en xiii 
 
Schema VIII. Synthese van pergeacetyleerde en ontschermde sophorolipide amines xiv en xv 
De tertiaire sophorolipide amines ix werden ook gebruikt voor de synthese van een uitgebreide set 
aan pergeacetyleerde en ontschermde sophorolipide amine oxides (Schema IX). De sophorolipide 
amines ix werden geoxideerd met mCPBA tot de pergeacetyleerde sophorolipide amine oxides xvi. 
De daaropvolgende ontscherming van de suikergroepen werd uitgevoerd met triethylamine in een 
water/methanol mengsel tot de ontschermde sophorolipide amine oxides xvii. 
 
Schema IX. Synthese van pergeacetyleerde en ontschermde sophorolipide amine oxides xvi en xvii 
Twee verschillende klassen aan bolaamfifiele sophorolipide amines werden gevormd uit 
sophorolipide aldehyde iv (Schema X). Pergeacetyleerde N,N’-dialkyl bolaamfifiele sophorolipiden 
xviii werden verkregen via reductieve aminering met verschillende N,N’-dialkyl diamines. 
Verschillende pogingen voor de synthese van N,N’-dioctadecyl bolaamfifiele sophorolipiden waren 
niet succesvol. Pergeacetyleerde N-alkyl bolaamfifiele sophorolipiden xix werden gevormd via 
reductieve aminering met verschillende primaire amines. 
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Schema X. Synthese van pergeacetyleerde N,N'-dialkyl en N-alkyl bolaamfifiele sophorolipiden xviii en xix 
De pergeacetyleerde bolaamfifiele sophorolipide amines xviii en xix werden omgezet in een 
uitgebreide groep aan bolaamfifiele sophorolipide derivaten (Schema XI, Schema XII). De 
ontscherming werd uitgevoerd met triëthylamine in een water/methanol mengsel tot de 
ontschermde bolaamfifiele sophorolipide amines xx en xxiii. De quaternisering werd uitgevoerd met 
methyl iodide in een drukvat tot de kationische bolaamfifiele sophorolipiden xxi en xxiv. Tot slot 
werden de kationische bolaamfifiele sophorolipiden ontschermd met triëthylamine in een 
water/methanol mengsel tot de ontschermde kationische bolaamfifiele sophorolipiden xxii en xxv. 
 
Schema XI. Modificatie van N,N'-dialkyl bolaamfifiele sophorolipiden xviii via quaternisering en ontscherming 
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Schema XII. Modificatie van N,N'-dialkyl bolaamfifiele sophorolipiden xix via quaternisering en ontscherming 
Alle derivaten werden geëvalueerd op hun antimicrobiële activiteit tegen een groep Gram-positieve 
en Gram-negatieve stammen (Tabel I). Geen enkele van de derivaten vertoonde significante activiteit 
tegen één van de Gram-negatieve stammen. De sophorolipide quaternaire ammoniumzouten, 
monokationische bolaamfifiele sophorolipiden en dikationische bolaamfifiele sophorolipiden zijn de 
meest actieve derivaten. De beste resultaten werden verkregen voor de ontschermde sophorolipide 
quaternaire ammoniumzouten xiii(h) en xiii(i). Deze derivaten waren zelfs actiever dan het 
antibioticum gentamicine sulfaat tegen de vier Gram-positieve stammen S. aureus, E. faecium, 
B. subtilis en S. pneumoniae in een in vitro evaluatie. Daarnaast toonde de evaluatie van de 
gedeglycosyleerde derivaten van deze sophorolipide quaternaire ammoniumzouten aan dat de 
aanwezigheid van de suikerkop een positief effect heeft op de antimicrobiële activiteit. 
De evaluatie van de quaternaire ammoniumzouten als gene delivery vectoren toonde aan dat 
dezelfde twee sophorolipide quaternaire ammoniumzouten xiii(h) en xiii(i) de hoogste activiteit 
vertoonden. Daarnaast toonde de evaluatie van hun gedeglycosyleerde derivaten aan dat de 
aanwezigheid van de suikerkop de levensvatbaarheid van de cellen en de daaruitvolgende 
bio-compatibiliteit met de geëvalueerde cellijnen sterk verhoogde. Small-angle X-ray scattering 
(SAXS) analyse toonde aan dat enkel de sophorolipide quaternaire ammoniumzouten xiii(h) en xiii(i) 
sferische micellen vormen. Deze specifieke self-assembly eigenschappen en verhoogde 
transfectie-efficiëntie kunnen toegewezen worden aan de aanwezigheid van de lange alifatische 
keten in deze sophorolipide quaternaire ammoniumzouten. 
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Tabel I. Overzicht van de minimale inhibitie concentraties (µM) voor de verschillende sophorolipide derivaten 
 S. aureus S. aureus 
Mu50 
E. faecium B. subtilis S. pneumoniae 
i 45.4 90.79    
vi 45.4 363.2    
viii >1607 >1607    
xii(b) >101  >101 >101 >101 
xii(c) >97  >97 24 97 
xii(d) >93  >93 >93 >93 
xii(e) 489  >977 977 977 
xii(f) >94  >94 >94 >94 
xii(g) 45  >91 45 91 
xii(h) 6.59-8 26.36 8 8 8 
xii(i) 6.36-8 50.91 8 8 8 
xiii(b) >144  >144 >144 >144 
xiii(h) 2.18-6 4.37 6 6 6 
xiii(i) 2.09-5 4.18 5 5 5 
xiv(a) 12.73 815    
xiv(b) 12.31 394    
xv(a) 66.9 66.9    
xv(b) 23.03 64.1    
xviii(b) 375 1501    
xxi(a) 165 660    
xxi(b) 80 321    
xxi(c) 20 158    
xxi(d) 38 38    
xxii(b) 392 >1569    
xxiv(a) 92 184    
xxiv(b) 45 45    
xxiv(c) 44 44    
xxv(c) 132 >2114    
xxv(d) 116 232    
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